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Zusammenfassung
Lassopeptide sind eine Klasse von Naturstoffen, die der Familie der ribosomal-synthetisierten und 
posttranslational-modifizierten  Peptide  zugehörig  sind.  Sie  sind  gekennzeichnet  durch  das 
einzigartige Strukturmotiv des Lassoknotens, dessen Name sich von der Beobachtung ableitet, dass 
diese Topologie an den Knoten in einer Lassoschlinge erinnert. Diese Struktur wird durch einen 
N-terminalen Makrolactamring verwirklicht, der von dem C-terminalen Peptidschwanz durchfädelt 
ist.  Die  Faltung  dieser  Moleküle  wird  durch  nicht-kovalente  Wechselwirkungen  sterisch 
anspruchsvoller  Aminosäuren,  die  über  und  unter  dem Ring  lokalisiert  sind,  aufrecht  erhalten, 
wodurch  der  C-terminale  Bereich  des  Peptids  im  Inneren  des  Ringes  fixiert  wird.  Was  diese 
Verbindungen interessant für die Forschung macht ist, dass ihre Struktur trotz ihrer rein sterischen 
Stabilisierung  oft  eine  außergewöhnliche  Resistenz  gegenüber  thermischer,  chemischer  und 
proteolytischer Degradation aufweist. Dennoch ist bisher wenig über die allgemeine Funktion dieser 
Stoffe  in  der  Natur  bekannt,  obwohl  es  einige  zuvor  beschriebene  Lassopeptide  gibt,  für  die 
interessante biologische Aktivitäten beobachten wurden.
Um mehr  Information  über  ihre  physiko-chemischen  Eigenschaften,  ihre  Biosynthese  und  ihre 
mögliche Rolle in der Natur zu erhalten, war das primäre Ziel dieser Arbeit das gezielte  Genome 
Mining und  die  darauffolgende  Isolierung  und  Charakterisierung  neuartiger  Lassopeptide.  Die 
Ergebnisse dieser Untersuchungen wurden in mehreren Studien publiziert,  die im Verlauf dieser 
Doktorarbeit präsentiert und diskutiert werden sollen. Neben der Isolierung einer Vielzahl neuer 
Lassopeptide,  konnten  durch  die  sorgfältige  Untersuchung  und  Charakterisierung  dieser  neuen 
Verbindungen zusätzlich einige bisher vorherrschende Vorstellungen aus diesem Forschungsgebiet 
widerlegt  und  aktualisiert  werden.  Ferner  hat  die  Auswertung  der  Daten  aus  unseren 
Genome-Mining-Studien interessante Beobachtungen über das Vorkommen von Lassopeptiden in 
Bakterien  und  über  die  Existenz  verschiedener  Subgruppen  von  Biosynthesegencluster-
andordnungen zugelassen. Diese Informationen könnten zukünftige Untersuchungen erleichtern, die 
auf die Identifizierung der konkreten Funktionen dieser Verbindung ausgelegt sind.
Des Weiteren wurde untersucht ob Lassopeptide geeignete Gerüste für die Wirkstoffentwicklung 
durch  Epitope-Grafting-Ansätze  sind.  In  dieser  Hinsicht  wurde  eine  vorher  veröffentlichte, 
bioaktive Lassopeptidvariante als Basis genommen, um zu zeigen, dass solche Verbindungen in der 
Tat durch rationale Ansätze optimiert und verbessert werden können. Dieses Vorgehen basierte auf 
Forschungsergebnissen,  die  aus  Studien  mit  linearen  und zyklischen  Peptiden erhalten  wurden, 
welche, im Gegensatz zu Lassopeptiden, leicht durch chemische Synthese zugänglich sind.
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Summary
Lasso peptides are a class of natural products that belong to the family of ribosomally-assembled 
and posttranslationally-modified peptides. They are defined by an unique structural motif referred 
to as the so-called lariat knot, whose name is derived from the fact that this topology is reminiscent 
of the knot found in the noose of a lasso. This structure is achieved by the presence of an N-terminal 
macrolactam ring that is threaded by the C-terminal tail of the peptide. The fold in these molecules 
is then conserved by non-covalent interactions in the form of bulky amino acids located above and 
below the macrolactam ring, in this way entrapping the tail inside of the ring. What makes these 
compounds of interest for research is that their structure, even though it is maintained merely by 
sterical interactions, often exhibits a tremendous stability against thermal, chemical and proteolytic 
degradation. Still, up to now little is known about the general function of these compounds for their 
producing organisms, although there are some interesting biological activities attributed to some of 
the previously reported lasso peptides.
To obtain more information about their physico-chemical properties, their biosynthesis and to get an 
idea what role they might play in nature, the primary subject of this thesis was the directed genome 
mining for and the subsequent isolation and characterization of novel lasso peptides. The results of 
these projects were published in several studies that will be shown and discussed in the course of 
this thesis. Amongst other findings, these studies not only include the discovery of a multitude of 
novel lasso peptides, but through the thorough analysis and characterization of these compounds, 
several former assumptions of this research area could be overhauled and updated. In addition to 
this,  the  bioinformatic  data  gathered during our  genome mining studies  furthermore  uncovered 
interesting facts about the distribution of lasso peptides amongst bacteria and about the existence of 
different subgroups of biosynthetic gene cluster arrangements, which could facilitate future research 
directed towards identifiying the concrete functions of these compounds.
Furthermore,  it  was  also  investigated  if  these  compounds  are  suitable  scaffolds  for  drug 
development via epitope grafting approaches. In this regard, a previously reported bioactive lasso 
graft  was used as the basis to show that such compounds can indeed be further optimized and 
improved upon by rational approaches that utilize the information obtained from research done with 
simple linear or cyclic peptides that are, in contrast to lasso peptides, easily accessible by synthetic 
means.
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1. Introduction
1.1 Ribosomally Produced Peptides
Natural products can originate from many sources both in regard to the producing organisms as well 
as to the way they are synthesized. A lot of well known examples of natural products belong to the 
groups of non-ribosomal peptides,  polyketides, alkaloids, terpenoids or cyclic dipeptides. All  of 
these compounds have in common that they are synthesized by enzymes utilizing the chemical 
building blocks available to the producing organisms. Therefore, alterations in these scaffolds by 
biosynthetic  means can be difficult  to  introduce and depend on the availability of  the building 
blocks and chemical variations thereof as well as on the ability of the corresponding enzymes to 
recognize and modify slightly different substrates.1 In contrast to these groups of natural products, 
there is  the class of so-called ribosomally-synthesized and posttranslationally-modified peptides 
(RiPPs), which utilizes gene encoded precursor peptides in combination with processing enzymes 
that transform them into diverse compounds with interesting biological properties.2 Even though 
their  genetic  origin  limits  the  precursor  peptides  to  contain  only  proteinogenic  amino  acids, 
posttranslational modifications can introduce such dramatic changes to these peptide scaffolds that 
the resulting products may only barely resemble anything that was originally synthesized by the 
ribosome.3-8 Nevertheless, although drastic changes may occur during the processing of a precursor 
peptide,  some classes of  RiPPs are also maintaining the majority of  their  original  amino acids 
unaltered and introduce only slight changes that primarily alter the three-dimensional structure of 
the peptide scaffold and through these rather simple means generate a desired functionality and a 
high compound stability. Interestingly, there are also examples of RiPPs that in their mature form 
are  not  even  peptides  anymore,  but  only  mere  small  organic  molecules  like  pyrroloquinoline 
quinone (PQQ), even though their synthesis still starts with the ribosomal assembly of a precursor 
peptide.3-5,7 Typically,  all  precursor  peptides  contain  a  core  peptide  that  gets  modified  during 
maturation and is usually flanked by a sequence on at least one side that is needed for enyzmatic 
recognition, although it will not be present in the final natural product (Figure 1.1).2
In this work, the focus was directed upon representatives of the still young RiPP family of lasso 
peptides. Even though they have little complexity on a chemical level, they are a very interesting 
family of natural products as they feature unique and so far synthetically completely inaccessible 
three-dimensional structures combined with high sequence and functional diversity.
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Figure 1.1. Schematic depiction of RiPP maturation. The different regions of the peptide during the different steps of  
the maturation are represented by colored boxes. Not every RiPP precursor features all of these regions, but may indeed 
contain only some of them, e.g. only a leader peptide and core peptide region. In general, only the core peptide gets 
posttranslationally modified. Most modifications are introduced while the precursor peptide is  still  intact,  but final  
modification reactions, like macrocyclizations, may require prior proteolysis of the precursor peptide. Macrocyclization 
reactions and/or subsequent export of the mature compound is known to occur for some RiPPs, but is not observed for 
all of these natural products.
1.2 Lasso Peptides
1.2.1 Characteristics of Lasso Peptides
The RiPP family of lasso peptides is predominantly defined by their unique structural motif, the 
so-called  lasso  fold.  This  name  was  coined  by  the  observation  that  the  three-dimensional 
appearance of lasso peptides is reminiscent of a lariat knot (Figure 1.2).9-30
In general,  the lasso fold is  defined by the presence of  a  macrolactam ring through which the 
C-terminal tail is threaded. The tail is kept in place by two bulky residues, the so-called plugs, 
positioned above and below the macrolactam ring, stabilizing the structure merely by non-covalent 
interactions.  Nevertheless,  this  steric  fold  conservation  confers  tremendous  stability  against 
chemical,  proteolytical  as  well  as  in  some  cases  also  thermal  degradation.9,10,15,17,22,25-27,31-39 The 
macrolactam ring itself is generated by the formation of an isopeptide bond between the N-terminal 
α-amino group and a carboxylic acid side chain of an aspartate or glutamate residue that can be 
located at positions 7 to 9 of the lasso peptide. Generally, lasso peptides can be divided into three 
classes, which are defined by the number of disulfide bonds present. Class I lasso peptides have two 
disulfide  bonds,  of  which  one  is  formed  with  the  for  this  class  conserved  cysteine  residue  at 
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position 1. Class II lasso peptides, which currently comprise the largest number of known lasso 
peptides, feature no disulfide bonds and therefore rely only on the non-covalent fold conservation 
conferred by the plug amino acids. The third and youngest class of lasso peptides contains a single 
disulfide bond and currently has only one known representative. An overview over all known lasso 
peptides, their primary structures and their class designation can be found in Table 1.1.
Figure 1.2. Backbones of representative lasso peptides belonging to the three different classes known for this group of 
natural products. The ring forming residues are shown in red, the remaining residues of the macrolactam in yellow and 
the amino acids of the tail region in blue. The disulfide bonds between two cysteine residues are highlighted in green.  
The shown lasso peptides are RP 71955 (PDB code 1RPB),9 capistruin (BMRB code 20014)18 and BI-32169 (PDB code 
3NJW).19,20
The majority of three-dimensional structures of lasso peptides were solved via NMR spectroscopy,9-
19,21-26,28,30,49,50 while only two lasso peptide crystal structures were published so far.20,26 Nonetheless, 
the NMR based structure elucidation of a lasso peptide is far from trivial.21 This may explain how 
both the structures of microcin J25 (MccJ25)50-53 and BI-3216948 were first  wrongly reported as 
head-to-tail  cyclized  or  dicyclic  peptides,  respectively.  Additionally,  the  recently  published 
non-threaded  structure  of  lassomycin28 is  highly  debatable  in  regard  to  the  facts  that  a 
branched-cyclic peptide should be rather susceptible towards proteolytic degradation and that such a 
defined solution structure is  very unlikely for  a  compound with such a  mobile  C-terminal  tail. 
Furthermore,  it  now appears  that  the  first  published  solution  structure  of  astexin-130 was  also 
flawed, but in the opposite way and that indeed unthreaded astexin-1 was probed by NMR in this 
case.  These  assumptions  are  founded on subsequent  experiments  that  showed  that  astexin-1  is
3
Table 1.1. Overview over all known lasso peptides with their host organisms, primary structures 
and class designations.
lasso peptide source primary structure class lasso peptide source primary structure class
aborycin10 Streptomyces 
griseoflavus TÜ 4072
I lariatin*,17 Rhodococcus jostii 
K01-B0171
II
MS-271*,34 Streptomyces sp. 
MS-271
I lassomycin*,28 Lentzea kentuckyensis II
NP-0627 Streptomyces sp. I microcin J25*,32 Escherichia coli AY25 II
RP71955*,40 Streptomyces sp. 
SP9440
I propetin41,42 Microbispora sp. 
SNA-115
II
siamycin I*,43 Streptomyces sp. 
AA6532
I RES-701-144 Streptomyces sp. RE-701 II
siamycin II*,43 Streptomyces sp. 
AA3891
I RES-701-245 Streptomyces sp. RE-701 II
SSV208329 Streptomyces sviceus 
ATCC 20983
I RES-701-345 Streptomyces sp. RE-896 II
anantin46 Streptomyces 
coerulescens
II RES-701-445 Streptomyces sp. RE-701 II
astexin-1*,25,30 Asticcacaulis 
excentricus CB48
II rhodanodin37 Rhodanobacter 
thiooxydans LCS2
II
astexin-2*,23,25 Asticcacaulis 
excentricus CB48
II rubrivinodin37 Rubrivivax gelatinosus 
IL44
II
astexin-323 Asticcacaulis 
excentricus CB48
II sphingonodin I37 Sphingobium japonicum 
UT26
II
burhizin37 Burkholderia 
rhizoxinica HKI 454
II sphingonodin II37 Sphingobium japonicum 
UT26
II
capistruin*,18 Burkholderia 
thailandensis E264
II sphingopyxin I37 Sphingopyxis alaskensis 
RB2256
II
caulonodin I37 Caulobacter sp. K31 II sphingopyxin II37 Sphingopyxis alaskensis 
RB2256
II
caulonodin II37 Caulobacter sp. K31 II SRO15-200529 Streptomyces roseosporus 
NRRL 15998
II
caulonodin III37 Caulobacter sp. K31 II sungsanpin24 Streptomyces sp. II
caulonodin IV*,47 Caulobacter sp. K31 II syanodin I37 Sphingobium yanoikuyae 
XLDN2-5
II
caulonodin V47 Caulobacter sp. K31 II xanthomonin I*,26 Xanthomonas gardneri 
ATCC 19865
II
caulonodin VI47 Caulobacter sp. K31 II xanthomonin II*,26 Xanthomonas gardneri 
ATCC 19865
II
caulonodin VII47 Caulobacter sp. K31 II xanthomonin III26 Xanthomonas citri pv. 
magniferaeindicae LM941
II
caulosegnin I*,22 Caulobacter segnis 
ATCC21756
II zucinodin37 Phenylobacterium 
zucineum HLK1
II
caulosegnin II22 Caulobacter segnis 
ATCC21756
II BI-32169*,48 Streptomyces sp. DSM 
14996
III
caulosegnin III22 Caulobacter segnis 
ATCC21756
II
7OHTrp stands for 7-hydroxy-tryptophan.
* The three-dimensional structure is reported for all lasso peptides marked with an asterisk.
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thermally labile and that the plug amino acids suggested by the previous NMR structure were easily 
exchangeable with alanine. In contrast, a newly elucidated NMR structure of astexin-1 showed that 
the lower plug amino acid is indeed not R19 but Y15, which is in complete agreement with other 
observations that arose from a thorough mutational analysis.25
Concerning the origin and prevalence of lasso peptides, it is interesting to note that genome mining 
studies30,54 revealed that putative lasso peptide biosynthetic gene clusters are broadly distributed 
amongst many bacterial phyla. Still, their actual role in nature remains elusive up to now.
1.2.2 Lasso Peptide Biosynthesis
Lasso peptide biosynthetic gene clusters consist of at least three genes encoding a precursor peptide 
A, a cysteine protease B and a macrocyclase C (Figure 1.3).2 While in Gram-negative bacteria the 
majority  of  known  and  putative  lasso  peptide  biosynthetic  gene  clusters  have  an  ABC 
arrangement,18,22,23,25,26,30,37,55,56 in Gram-positive bacteria an ACB formation is more prevalent,28-30,57 
suggesting a common predecessor that diverged in parallel with the development of Gram-negative 
and Gram-positive cell walls. 
Figure 1.3. Schematic representation of the organization of known functional lasso peptide biosynthetic gene clusters  
with examples for host organisms they were found in. On the left side, organizations that are typical for proteobacterial  
lasso peptide biosynthetic gene clusters are shown. On the right side, typical organizations for actinobacterial lasso 
peptide biosynthetic gene clusters are depicted. 
Other  known  lasso  peptide  biosynthetic  gene  clusters  are  complementing  this  three  gene 
arrangement by a gene encoding an ATP binding cassette (ABC-) transporter D18,28,29,37,57,58 and in 
one  instance  a  cluster  also  featured  a  so  far  uncharacterized  O-methyltransferase,  which  was 
proposed  to  be  responsible  for  the  methylated  C-terminus  of  lassomycin  that  was  produced 
homologously by fermentation of a Lentzea strain.28 As previous genome mining studies revealed a 
number of lasso peptide biosynthetic gene clusters that comprised a variety of different enzymes so 
far  unknown  for  these  kind  of  clusters  (amongst  others  kinases,  sulfotransferases  or 
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acyltransferases),30,37 it seems reasonable to assume that these enyzmes could analogously modify 
their  respective target  lasso peptides.  Indeed,  the lasso peptides RES-701-2 and RES-701-4 are 
carrying another chemical modification in form of the hydroxylation of the aromatic moieties of 
their  C-terminal  tryptophan  residues.  As  these  two  lasso  peptides  are  otherwise  identical  with 
RES-701-1 and RES-701-3, respectively, this observation could suggest the presence of an enzyme 
in the producing strains that catalyzes the modification of tryptophan to 7-hydroxy-tryptophan for 
these lasso peptide scaffolds.38,45 Still,  because of the lack of genetic information this is merely 
speculative at the moment, even though such a selective chemical modification of these residues 
during  the  extraction  and  purification  procedures  appears  to  be  rather  unlikely.  Another  quite 
peculiar observation was made for the biosynthetic gene clusters of lassomycin and lariatin as their 
cysteine proteases is split into two separate enzymes, which we dubbed, based on their origin, B1 
and  B2.28,37,57 The  bigger  of  the  two  resulting  enzymes,  B2,  is  composed  of  the  normally 
C-terminally  located  protease  domain,  while  the  smaller  enzyme,  B1,  features  the  conserved 
N-terminal domain of the B proteins and shows homology to PqqD, an enzyme that is suggested to 
mediate the interaction of the PQQ precursor peptide PqqA and its processing enzymes.3-5,7,23,37,57 A 
similar  function  could  be  conceivable  for  B1,  as  previous  in  vitro studies  revealed  the 
ATP-dependency of McjB from the MccJ25 biosynthesis  system, which is  rather unusual for a 
cysteine protease.59 Thus, an ATP-consuming chaperone-like function could be proposed for B1 and 
the N-terminal domains of non-split B proteins. Interestingly, a genome mining study also revealed 
some putative lasso peptide biosynthetic gene clusters in which the encoded B2 protein is directly 
fused to an ABC-transporter domain, which suggests that in these systems, precursor processing and 
export of the mature compound could be directly coupled.23 The aforementioned  in vitro studies 
furthermore confirmed the role of McjB as a protease that cleaves off the leader sequence of the 
McjA precursor peptide and the role of  McjC as an ATP-dependent macrocyclase.59 Surprisingly, 
these experiments also showed that McjB and McjC are interdependent, as they were proven to be 
unable to catalyze their corresponding functions on their own, but were capable to perform their 
catalytic  functions  when  assayed  with  an  inactive  variant  of  the  respective  other  enzyme. 
Combined,  these  results  led  to  the  postulation  of  a  maturation  mechanism  for  lasso  peptides 
(Figure 1.4). The in vitro and an additional in vivo study also confirmed residues that are crucial for 
the activities of McjB and McjC, while another study provided data that suggested McjB and McjC 
to be at least partially associated with the membrane.59-61 Nevertheless, the characterization of the 
MccJ25 processing enzymes was accompanied by extensive problems during their expression and 
isolation,  which  is  emphasized  by  the  fact  that  the  modification  assays  required  almost 
stochiometric amounts of the isolated enzymes as well as that the isolated McjB protein was still
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Figure 1.4. Lasso peptide maturation and conserved motifs of the processing enzymes. (a) Schematic depiction of the 
putative mechanism of lasso peptide biosynthesis. In the first step, the B protein cleaves off the leader peptide under 
ATP-consumption, which may also mediate the prefolding of the core peptide. In the next step, the C protein activates 
the carboxyl side chain in an ATP-dependent manner and subsequently catalyzes the macrocyclyzation, yielding the 
mature lasso peptide.37,59 (b) Conserved motifs of B proteins.37 The N-terminal domain may be needed for interaction 
with ATP, while the  C-terminal domain features a catalytical Cys-His-Asp triad typical for cysteine proteases. In B1 
proteins  only the N-terminal  domain is  present,  while  B2 proteins  only contain the cysteine  protease domain.  (c) 
Conserved motifs of C proteins.37 Previous studies59,61 based on homology comparisons and mutational analysis suggest 
motifs 1 and 2 to be involved in ATP-binding.
accompanied  by  significant  amounts  of  impurities.59 These  and  similar  problems  were  so  far 
encountered  for  all  maturation  enzymes  that  were  tested  in  our  group,  suggesting  that  these 
enzymes are generally very challenging to produce and isolate. This currently limits the further in  
vitro investigation of the lasso peptide biosynthesis and has so far foiled the possibility to crystallize 
these enzymes and hence to learn more about their three-dimensional arrangement and how they 
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actually interact with each other and the precursor peptide. Fortunately,  in vivo studies involving 
several lasso peptide biosynthetic gene clusters made it possible to get at least some information 
about residues of a lasso peptide precursor that are essential for either the recognition by or the 
activities of the processing enzymes. Besides obvious positions in the lasso peptide sequence itself,  
like the amino acid at position 1, the ring forming aspartate or glutamate residue and the plug amino 
acids,22,25,26,36,47,62 several residues in the C-terminal part of the leader sequence have been shown to 
play a major role for efficient maturation.22,25,26,36,47,63,64 The most conserved residue in this regard is 
the threonine at the penultimate position of the leader peptide, which seems so far to be conserved 
throughout all lasso peptide precursors and shows only restricted tolerance to substitutions, which is 
then again limited to structurally similar amino acids.22,25,26,36,47,63,64 A general recognition motif in the 
C-terminal region of the leader peptide, which is at least widely distributed amongst clusters of 
proteobacterial origin, was also identified very recently47 and is shown in Figure 1.5. Unlike for the 
T-2 residue there are also naturally occurring exceptions for this motif known in proteobacterial 
systems like in the precursor peptides of capistruin and MccJ25. Furthermore, this motif seems to 
be only loosely conserved in Gram-positive lasso peptide biosynthetic gene clusters.
Figure 1.5. On the  left,  the  conserved  motif  found in  the C-terminal  regions  of  the  leader  peptides  of  all  known 
functional lasso peptide precursors is shown.47 The result of the analysis with the MEME algorithm is depicted above, 
while the derived consensus sequence is shown below. On the right, an alignment of the last 15 amino acids of all leader  
peptides used for the MEME analysis is shown next to the names of the corresponding lasso peptides. Residues in 
accordance with the conserved motif are highlighted using the same color code.
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It is also interesting to mention that the proteobacterial distribution of precursor peptides that show 
any alterations  in  this  motif  are  more  or  less  limited  to  systems where  an  ABC-transporter  is 
present.37,47 This  observation  may suggest  that  clusters  with  D proteins  and clusters  without  D 
proteins diverged early on in proteobacteria and because of this could be regarded as two subgroups 
of proteobacterial lasso peptide biosynthetic gene clusters that are only loosely related to each other. 
With regard to the lasso sequence, several mutational studies were performed in vivo with different 
biosynthetic machineries.22,25,26,36,47,62,65-69 Taken together, it appears that most of the lasso sequence 
can  be  easily  exchanged  to  at  least  some  extent,  which  speaks  for  a  high  promiscuity  of  the 
processing enzymes. Still, there are also some residues that show very limited tolerance towards 
substitution. These are on the one hand some positions that appear to be specific for each individual 
lasso scaffold and on the other hand some generally crucial residues like the ring forming and the 
plug  amino  acids.  If  such  a  sensitivity  towards  substitutions  of  certain  positions  arises  from 
problems during the enyzmatic recognition or from factors negatively affecting the stability of the 
lasso fold can not be satisfyingly concluded by in vivo experiments alone, but in a lot of cases the 
cause for the low or complete lack of production can at least be speculated about based on the 
nature of the modified residue.
In general, lasso peptides are good targets for genome mining approaches for mainly two reasons. 
The first is that the ribosomal origin of the precursor peptides allows an easy identification of the 
amino  acid  sequences  of  the  mature  lasso  peptides  and  hence  an  accurate  prediction  of  the 
molecular masses that are to be expected upon lasso peptide production. The second is that the B 
proteins share little homology to enzymes outside of lasso peptide biosynthetic gene clusters and as 
such constitute an ideal input for BLAST homology searches to identify so far uncharacterized lasso 
peptide biosynthetic gene clusters.
1.2.3 Biological Functions of Lasso Peptides
The  answer  about  the  function  of  lasso  peptides  in  nature  remains  mostly elusive  so  far.  The 
majority of lasso peptides for which a biological activity is known were identified in culture screens 
for exactly these functions and therefore most targets identified in this way are of human origin.  
Even though these activities are interesting from a medicinal perspective, they most likely do not 
represent the original function of these compounds as these lasso peptides predominantly originated 
from bacteria  living in  environments  that  lack  direct  contact  to  humans.  An overview over  all 
biological activities known for lasso peptides is shown in Table 1.2.
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Table 1.2. Overview over all biological activities known for lasso peptides.
class lasso peptide biological activity
I aborycin, MS-271,  
NP-06, siamycin I/II, 
RP7195510,27,34,40,43
inhibitor of HIV-replication, inhibitor of calmodulin-activated myosin light chain kinase, 
antimicrobial  activity against  Bacillus subtilis,  Bacillus brevis,  Enterococcus faecium, 
Micrococcus luteus,  Pseudomonas  saccharophila, Staphylococcus  aureus and 
Streptomyces viridochromogenes
II anantin46 antagonist of  atrial natriuretic factor
II astexin-130 weak antimicrobial activity against Caulobacter crescentus CB15
II capistruin18 antimicrobial activity against Burkholderia and Pseudomonas spp.
II lariatin17 antimicrobial activity against Mycobacteria spp. (including M. tuberculosis)
II lassomycin28 antimicrobial  activity  against  Mycobacterium tuberculosis,  M. avium subsp. 
paratuberculosis and M. smegmatis
II microcin J2532 antimicrobial activity against different Escherichia, Salmonella and Shigella spp.
II propeptin41 inhibitor  of  prolyl  endopeptidase,  weak  antimicrobial  activity  against  Pseudomonas 
aeruginosa, Mycobacterium phlei and Xanthomonas oryzae
II RES-701-1/345 antagonist of endothelin type-B receptor
II sungsanpin24 inhibitor of cell invasion for the human cancer cell line A549
III BI-3216948 antagonist of glucagon receptor
Besides  the  most  likely  off  target  activities,  several  lasso  peptides  are  known  to  exhibit 
antimicrobial activities against certain species of bacteria. Interestingly, these activities are mostly 
found  against  strains  closely  related  to  or  living  in  the  same  environment  as  the  producing 
organisms. It is additionally known that the lasso peptide MccJ25 is not produced before the host 
organism enters  stationary growth phase,  at  which  point  nutrients  in  the  culture  are  becoming 
scarce.32,70 Furthermore, the production of MccJ25 was shown to be triggered by ppGpp production, 
which also correlates with nutrient starvation.70 Taken together, these observations suggest that such 
lasso peptides could be produced as a response to onsetting starvation or other stress conditions 
with  the  aim  to  kill  off  competitors  and  hence  to  ensure  the  survival  of  the  host  organism. 
Interestingly, all known biosynthetic gene clusters that produce lasso peptides with an antimicrobial 
activity,18,28,55,57,58 namely the clusters of MccJ25, capistruin, lariatin and lassomycin, also carry a 
gene encoding a dedicated ABC-transporter,  which in  case of McjD was directly proven to be 
essential for conferring immunity to the host organism against MccJ25 by mediating the export of 
the mature lasso peptide.55,58 In contrast, the majority of recently reported lasso peptides that were 
discovered by directed genome mining approaches did not exhibit antimicrobial activities against 
closely related organisms, but at the same time all of them also lacked an ABC-transporter encoding 
gene  as  part  of  their  biosynthetic  gene  clusters.22,26,30 This  suggests  that  the  presence  of  an 
ABC-transporter  could  be  directly  linked  to  the  presence  of  an  antimicrobial  activity  of  the 
produced compound. From all reported lasso peptides with known antimicrobial function, the actual 
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targets  were  only  found  for  MccJ25,  capistruin  and  lassomycin.28,71-77 The  in  this  regard  best 
investigated lasso peptide is MccJ25, whose target was identified by total  sequencing of single 
clones of prior sensitive bacteria that spontaneously developed a resistance against this compound. 
Thus unsurprisingly, the first uncovered mutations were all located in genes encoding parts of a 
dedicated import system, namely the enzymes involved in the FhuA-TonB complex that normally 
mediates the uptake of the iron loaded siderophore ferrichrome.76,77 Hence, it  was proposed that 
MccJ25 enters the cell in a likewise manner, which was recently confirmed by the elucidation of the 
co-crystal structure of FhuA and MccJ25 (Figure 1.6) that shows how MccJ25 mimics the binding 
mode of iron loaded ferrichrome.78
Figure 1.6. Co-crystal structure of the TonB-dependent receptor FhuA with MccJ25 (PDB code 4CU4).78 (a) Overview 
of the complete structure.  FhuA is depicted in orange as cartoon with overlay of a transparent surface map, while  
MccJ25 is colored by elements (carbon in gray, nitrogen in blue, oxygen in red). (b) Stereoview of a close -up of the 
FhuA binding pocket. Ionic interactions are highlighted by black dotted lines. The residues involved in key interactions 
are shown in light gray for FhuA and in dark gray for MccJ25.
Still, the actual target was only later identified in a more thorough approach and was shown to be 
the Gram-negative RNA polymerase, which is also true for capistruin.74,75 Further studies revealed 
that the antimicrobial activity of MccJ25 is derived from its the ability to inhibit the NTP uptake of 
the RNA polymerase. The fact that the observed resistance-conferring mutations were all clustered 
in the secondary channel of the RNA polymerase and the results of subsequent in silico modelling 
experiments both suggest that the lasso peptide is binding to the secondary channel and in this way 
obstructs the NTP uptake.72,73 Nonethless, in addition to this activity, a second mode of action for 
MccJ25 was also found for some highly sensitive Salmonella species. In these strains, it was first 
observed that MccJ25 is apparently able to depolarize the cell membrane and at the same time is 
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able to both increase cell permeability and decrease oxygen consumption.79,80 This could later also 
be shown for  E. coli strains that overexpressed the FhuA receptor.81 Interestingly, both modes of 
action appear to be independent of each other, since it was shown that E. coli strains overexpressing 
FhuA were  still  susceptible  for  MccJ25,  even  when  they  produced  a  MccJ25-resistant  RNA 
polymerase or when they were treated with C-terminal amidated MccJ25, which was shown to be 
unable to inhibit the RNA polymerase  in vitro.81,82 Further studies revealed that the antimicrobial 
activity in these cases is conferred by MccJ25 triggering superoxide production in an yet unknown 
fashion.  This  was  proven  by  the  fact  that  strains  which  both  overexpressed  FhuA and  had  a 
MccJ25-resistant RNA polymerase were sensitive towards MccJ25 under aerobic conditions, but 
resistant  towards  MccJ25  under  anearobic  conditions.81,83 Furthermore,  in  vitro assays  with 
membrane  fractions  from  E. coli showed  that  in  the  presence  of  MccJ25  NADH  and  lactate 
dehydrogenase activity was inhibited. This effect could be negated by the addition of a superoxide 
scavenger  molecule,  directly  linking  the  observed  enzyme  inhibition  to   MccJ25-triggered 
superoxide formation.81 In addition, it was shown that for both inhibiting the RNA polymerase and 
triggering the superoxide formation, MccJ25 had to pass both the periplasmic and the cytoplasmic 
membranes,  as  an  E. coli  strain overexpressing FhuA remained resistant  towards  MccJ25 when 
carrying a  mutation  in  the  SbmA protein,  which is  proposed to  be  crucial  for  the  transport  of 
MccJ25 from the periplasm into the cytosol.77,81,83 Interestingly, a single conserved mutation of Tyr9 
to  Phe  completely  abolishes  the  capability  of  MccJ25  to  cause  superoxide  production,  which 
strongly suggests Tyr9 to play a crucial role in the underlying mechanism.83
The target of lassomycin was detected in a likewise manner to the one of MccJ25. In this case, the 
resistance-conferring  alterations  in  Mycobacterium  tuberculosis mutants  were  clustered  in  the 
coding sequence for the  N-terminal region of ClpC1, an ATPase that interacts with the ClpP1P2 
complex and in this way mediates the degradation of proteins by ClpP1P2.28 Here, the antimicrobial 
function  is  achieved  by  uncoupling  of  the  ATP-hydrolysis  activity  of  ClpC1  from  the 
ClpP1P2-dependent proteolysis, thus not only wasting the cells energy, but at the same time also 
obstructing the ClpP1P2 activity, which is essential for the viability of M. tuberculosis. This shows 
that even though both MccJ25 and lassomycin have an antimicrobial activity, their mode of action is 
completely different, highlighting that although all lasso peptides share a common topology, they 
may  indeed  be  quite  diverse  in  regard  to  their  biological  functions.  The  co-occurrence  of 
antimicrobially  active  lasso  peptides  with  D protein  encoding  genes  in  their  biosynthetic  gene 
clusters  furthermore  suggests  that  lasso  peptides  lacking  such  an  ABC-transporter  system may 
instead have a completely different function, which could be revealed by closer inspection of the 
surroundings of corresponding gene clusters.
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1.2.4 Lasso Peptide Isopeptidases and TonB-dependent Receptors
Closer  inspection  of  the  surroundings  of  the  ABC-type  caulosegnin  biosynthetic  gene  cluster 
revealed that downstream to it another reverse facing gene cluster was present that contained four 
genes. These genes putatively encode a σ-factor, an anti-σ-factor, a TonB-dependent receptor and a 
peptidase.22,37 Analogous gene clusters were also found adjacent to both lasso peptide biosynthetic 
gene  clusters  from  Asticaccaulis  excentricus.22,23,25,37 Based  on  these  observations,  Link  and 
co-workers inspected the predicted peptidases from  A. excentricus more closely and showed that 
these  enzymes  were  indeed  dedicated  lasso  peptide  isopeptidases.23 In  vitro studies  with  the 
isopeptidase close to the second astexin biosynthetic gene cluster revealed that this enzyme cleaved 
the isopeptide bonds in the macrolactam rings of astexin-2 and  -3 with high specificity, while a 
branched-cyclic  peptide  with  the  same primary structure  as  astexin-2  was  completely  resistant 
towards this enzyme. Interestingly, the isopeptidase showed no activity against astexin-1. Based on 
a  bioinformatic  sequence  analysis,  a  catalytic  triad  consisting  of  Ser527-Glu610-His638  was 
identified and it was proven that a S527A mutation disrupts the catalytic activity of this enyzme, 
providing a strong evidence that these isopeptidases indeed belong to the family of serine proteases. 
Additionally,  in  vivo studies  could  confirm  that  astexin-1  was  selectively  degraded  by  the 
isopeptidase adjacent to its own biosynthetic gene cluster. Taken together, these experiments show 
that these isopeptidases recognize and degrade only the lasso peptides that are produced by the 
corresponding adjacent ABC-type biosynthetic gene clusters with a very high specificity, suggesting 
a general involvement of the other enzymes from the isopeptidase gene cluster with lasso peptides 
as well.23 This is especially intriguing considering that FhuA, which was shown to mediate the 
MccJ25  uptake  in  strains  sensitive  towards  this  lasso  peptide,  also  belongs  to  the  family  of 
TonB-dependent receptors.76-78 Interestingly, the similarities between lasso peptide and FhuA-like 
systems  do  not  end  here,  as  the  σ- and  anti-σ-factors  show  homology  to  FecI  and  FecR, 
respectively.22,23,37 FecI  and  FecR  are  regulatory  enzymes  associated  with  another  siderophore 
uptake system similar to the one FhuA belongs to (Figure 1.7).84-86
Hence, it is reasonable to assume that the enzymes encoded by the isopeptidase gene clusters could 
have similar functions involving the respective lasso peptides. While the σ- and anti-σ-factors could 
regulate  the  transcription  of  certain  promoters  in  response  to  the  presence  or  absence  of  the 
corresponding lasso peptide, the TonB-dependent receptor could mediate the uptake of this lasso 
peptide into the cell,  where it then would be linearized by the isopeptidase. Based on this, two 
possible  functions for lasso peptides from a proteobacterial  ABC-type biosynthetic gene cluster 
seem plausible. Either, they could have a scavenging function likewise to siderophores and would
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Figure 1.7. Schematic representation of the ferric citrate uptake in E. coli K12 mediated by the Fec proteins.84-86 First, 
extracellular ferric citrate (red spheres) binds to the TonB-dependent receptor FecA. FecA then mediates both the uptake 
of ferric citrate into the periplasm by interaction with the TonB protein complex (black arrow) as well as the activation 
of FecR (red arrow). Subsequently, activated FecR binds FecI and thus allows interaction of the FecI σ-factor with the 
RNA polymerase, which initiates a strong transcription of the  fecABCDE operon. In the periplasm, ferric citrate can 
interact with a protein complex consisting of the perisplasmic binding protein FecB, the transmembrane proteins FecC  
and FecD and the cytoplasmic ATPase FecE. The complex then facilitates the transport of ferric citrate through the 
cytoplasmic membrane under ATP-consumption.
release their scavenged molecules or ions upon degradation by the isopeptidases, or they could play 
a role as signaling molecules. From these proposed functions, the scavenging role is rather unlikely 
as all lasso peptides may share their basic three-dimensional appearance, but have a highly diverse 
primary structure showing no conservation of any particular  residues that  could be involved in 
selective binding of a target molecule or ion. Therefore, a signaling function seems more feasible. 
In this scenario, the linearization of the lasso peptide by the isopeptidase would either function as a 
way to slowly diminish the signal in case no new lasso peptide is internalized or, on the contrary, 
the signaling function would not be conferred by the lasso peptide itself, but only by the resulting 
linear peptide. Of course, all of this is purely speculative at the moment and needs further testing to 
conclusively reveal the real function of these lasso peptides. Nevertheless, these or similar functions 
would be in agreement with the observed lack of antimicrobial activities of the lasso peptides from 
proteobacterial ABC-type biosynthetic gene clusters, which points to a different role in nature as 
merely  killing  off  competing  organisms  under  nutrient  limiting  conditions.  The  fact  that  two 
separate genome mining studies could furthermore show that most of the ABC-type clusters from 
proteobacteria  have  a  neighboring  isopeptidase  gene  cluster,  additionally  points  out  that  the 
corresponding lasso peptides probably all fulfill a similar function in their native hosts.23,37
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1.3 Epitope Grafting
1.3.1 Advantages and Drawbacks of Peptides in Medicinal Applications
In nature, there are many instances known where peptides act as signaling molecules, e.g. hormones 
like somatostatin, somatropin or insulin. Targeting the corresponding receptors, of which some use 
only small peptide epitopes for substrate recognition, can induce or inhibit certain cell functions, 
which can be of special medicinal interest for affecting pathogens, but also for affecting cancerous 
and  non-cancerous  human  cell  lines.  Additionally,  peptides  became  of  interest  for  potential 
therapeutic applications in the context of other targets, e.g. as inhibitors of specific enzymes or for 
disturbing  certain  protein-protein  interactions  and  thus  the  functions  of  the  corresponding 
multienzyme  complexes.87-111 For  discovery  of  peptides  with  such  activities,  methods  for 
high-throughput  generation and screening of vast  compound libraries have been developed and 
successfully  employed  for  the  identification  of  peptide  based  drug-leads.8,96-98,101,102,104,106,112 
Nonetheless, the major drawback of linear peptides is that they are highly susceptible to proteolytic 
degradation, which results in a very low half-life in the human body, making them unsuitable for 
therapeutic applications.65,87,88,91,105,108,110,113 A solution for this problem is to incorporate the peptide 
pharmacophore into more stable scaffolds.  These can be as simple as small,  constrained cyclic 
peptides,  whose  stability  against  proteolytic  degradation  can  be  further  improved  by  the 
incorporation  of  D-amino  acids.  Prominent  examples  of  this  are  cilengitide  and  octreotide.87-
89,91,94,100,104,106,109,112-116 The former compound is an anti-cancer agent currently under investigation in 
clinical trials that selectively binds to the αvβ3 integrin receptor and through this is able to inhibit 
angiogenesis, which is a crucial factor for tumor growth and metastasis. The latter compound is a 
somatostatin  receptor  antagonist  that  is  approved  as  a  drug for  either  tumor  therapy or  tumor 
imaging, depending on which chelator moiety and corresponding complexed radionuclide is linked 
to the peptide scaffold. Nevertheless, there are more and more examples known, were complex and 
highly  stable  natural  peptide  scaffolds  were  successfully  employed  for  presenting  a  bioactive 
peptide epitope to an interaction partner.
1.3.2 Cyclotides as Potent Scaffolds for Epitope Grafting Approaches
The most prominent examples for natural scaffolds used in epitope grafting efforts are probably the 
cyclotides.93,95,105,108,110,117-124  These natural products are plant-derived, consist of around 30 amino 
acids and feature the unique structural motif of the so-called cyclic cystine knot (CCK), which 
consists of macrocyclized C- and N-termini combined with three disulfide bonds that form a knotted 
and very compact structure. This structural motif has a very promiscuous primary structure and at 
15
the same time confers a high stability against proteolytic and thermal degradation, therefore making 
cyclotides ideal candidates for the delivery and presentation of peptide epitopes to protein targets in  
vivo.  The  general  appearance  of  such  a  structure  is  shown  exemplary  for  the  first  cyclotide 
discovered, namely kalata B1,117 in Figure 1.8.
Figure 1.8. Stereoview of the three-dimensional structure of the cyclotide kalata B1 (PDB code 1KAL).117 Depicted 
below is the primary structure of this natural product using the same color scheme for the corresponding residues as  
above.
State of the art research employs solid phase synthesis, native chemical ligation and heterologous 
expression utilizing intein chemistry for production of novel cyclotide variants. These methods not 
only  provide  efficient  ways  to  access  a  large  cyclotide  diversity,  but  also  generally  allow the 
incorporation of unnatural amino acids. So far, cyclotide grafts were generated that were able to act 
as inhibitors for proteases like  β-tryptase and the human leukocyte elastase,119,120 as  agonists or 
antagonists for the vascular endothelial  growth factor,118 melanocortin 4,121 bradykinin B1123 and 
several  integrin  receptors105,122 or  to  negate  the  binding  of  Hdm2 and  HdmX to  p53  and  thus 
reactivating  the  p53  tumor  suppressor  pathway in  certain  cancer  cell  lines.108 These  results  in 
combination  with  the  easy  access  to  cyclotide  scaffolds  by  synthetic  approaches  as  well  as 
biosynthesis highlights the potential of cyclotides in epitope grafting endeavors and explains why 
the cyclotide scaffold is so prominent in this research area.
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1.3.3 Lasso Peptides as Potent Scaffolds for Epitope Grafting Approaches 
Similar to cyclotides, the extraordinary stability of the lasso fold9,10,15,17,22,25-27,31-39 predisposes these 
compounds for use in epitope grafting efforts. In contrast to cyclotides, up to now the potential of 
lasso peptides as scaffolds in this field of research was only barely investigated.65 From all lasso 
peptides  discovered  so  far,  MccJ25 is  probably the  most  suitable  scaffold  for  epitope  grafting 
approaches (Figure 1.9). 
Figure 1.9. MccJ25 as scaffold for epitope grafting approaches. The ring forming glutamate residue is colored in red,  
the remaining ring amino acids in yellow and the tail amino acids in blue. (a) Stereoview of the three-dimensional 
structure  of  MccJ25  (PDB code  1Q71).14-16 (b)  Schematic  representation  of  MccJ25.  The  red  arrow indicates  the 
thermolysin cleavage site. (c) Stereoview of the three-dimensional structure of thermolysin cleaved MccJ25 (PDB code 
1S7P).49 (d) Schematic representation of the grafting of the fictional XXX peptide epitope into the loop of MccJ25  
replacing Gly12, Ile13 and Gly14. The incorporated mutation is highlighted in green.
One reason for this is the extraordinary high stability of MccJ25, as it was reported that this lasso 
peptide retains its antimicrobial activity even after autoclaving.32 Furthermore, MccJ25 is the only 
lasso  peptide  known that  can  be  converted  into  a  stable  two-chain  peptide  complex  by either 
thermolysin treatment (Figure 1c)35,39,49,50 or gas phase fragmentation.15,16,50,67 In this state, the tail and 
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the ring of the lasso peptide are no longer covalently linked, but are still interlocked so tightly that 
they  form  a  single  molecular  unit  that  retains  its  ability  to  inhibit  the  Gram-negative  RNA 
polymerase.39 The fact that the biosynthetic gene cluster of MccJ25 originated from an E. coli strain 
additionally facilitates the heterologous production of  this  lasso peptide and variants  thereof  in 
standard E. coli lab strains, which provides an efficient way to access modified MccJ25 scaffolds by 
biosynthesis. This is especially important as until now lasso peptides remain inaccessible by means 
of chemical synthesis. Another important criterion that qualifies MccJ25 as promising scaffold for 
epitope grafting efforts is its large and exposed loop region, which is important for the incorporation 
and presentation of a peptide pharmacophore. With eleven tail amino acids above the macrolactam 
ring,  this  is  by far  the  largest  loop of  all  lasso  peptides  with  so  far  known three-dimensional 
structures.Compared  to  cyclotides,  lasso  peptides  may  appear  inferior  as  scaffolds  for  epitope 
grafting endeavors as their limitation to biosynthetic production complicates the incorporation of 
unnatural amino acids as well as the production of large compound libraries, which necessitates a 
more  rational  approach  to  the  epitope  grafting  with  these  kind  of  scaffolds.  Besides  these 
limitations, lasso peptides also have advantages over cyclotides for medicinal applications. Namely, 
they are smaller and have a more compact structure and since their fold does not rely on disulfide 
bonds, they are in contrast to cyclotides resistant towards reductive conditions.
Before this thesis, only one example of epitope grafting employing a lasso peptide scaffold was 
reported.65 In this study, the integrin recognition sequence RGD was incorporated into the loop of 
MccJ25. This lasso graft was shown to be able to bind the αvβ3 integrin in vitro as well as being 
able to inhibit the capillary formation of human umbilical vein endothelial cells (HUVECs) in cell 
culture assays. Still, even though the compound had a promising affinity in the nanomolar range for 
binding to αvβ3 in vitro, the selectivity for this integrin receptor was rather poor, making the lasso 
peptide unsuitable for therapeutic use.  Nonetheless, this study served as a proof-of-concept that 
established lasso peptides as promising epitope grafting scaffolds and the reported lasso graft can 
serve as a starting point for the development of a more potent and more selective lasso peptide 
based integrin inhibitor.
18
2. Motivation and Objectives
Lasso peptides are a family of RiPPs that were first discovered in the beginning of the 1990s. For 
more than a decade after their discovery, the isolation of new representatives of this natural product 
family  was  decided  by  chance  and  because  of  this,  little  was  initially  known  about  their 
biosynthesis,  characteristics  and  functions.  This  changed  with  the  emergence  of  increasingly 
inexpensive  sequencing  techniques  through  which  a  vast  amount  of  genomic  data  became 
accessible  to  the  scientific  community.  With  this  steadily  growing  wealth  of  information, 
bioinformatic  analysis  of  genetic  data  allowed  an  efficient  way  to  assess  the  distribution  and 
prevalence of certain genes and their corresponding proteins in nature. Furthermore, it allowed the 
genome mining for natural product biosynthetic gene clusters in the sum of the available genomic 
data and in this way facilitated the targeted search for systems producing novel representatives of 
natural product families. Amongst many others, this approach can be employed for lasso peptides 
and thus  in  2008 the first  lasso peptide isolated in  the  course  of  a  genome mining study was  
reported.18 After this initial  proof-of-principle,  the next logical step was to optimize the overall 
procedure to allow a fast and efficient way for the isolation and subsequent characterization of 
novel lasso peptides. This was the primary objective of this thesis and was targeted at not only 
increasing the overall number of known representatives of this natural product family, but at the 
same  time  these  studies  should  also  yield  new  information  about  their  biosynthesis, 
physcio-chemical properties and their role in nature.
The second objective of this thesis was to show that the extraordinary stability of these compounds 
could  be  combined  with  specific  peptide  epitopes  that  confer  medicinal  relevant  biological 
activities. In this regard, the aim was to use a previously reported lasso graft that acted as inhibitor 
of the αvβ3 integrin receptor65 and to improve its bioactivity by rational means. 
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3. Results
This  section  contains  an  overview over  all  studies  published in  the  course  of  this  thesis.  This 
overview includes a description of the author contributions and a short background and summary 
for each study alongside the publications themselves. The corresponding Supporting Information 
can be found in the appendix.
3.1  Caulosegnins  I-III:  A  Highly  Diverse  Group  of  Lasso  Peptides 
Derived From a Single Biosynthetic Gene Cluster
Julian D. Hegemann, Marcel Zimmermann, Xiulan Xie, and Mohamed A. Marahiel, Caulosegnins 
I-III: A Highly Diverse Group of Lasso Peptides Derived From a Single Biosynthetic Gene Cluster, 
J. Am. Chem. Soc. 2013, 135(1), 210-222.
doi: 10.1021/ja308173b 
Author contributions:
The project was designed by Julian D. Hegemann and Mohamed A. Marahiel  with the help of 
Marcel Zimmermann. All experiments were carried out by Julian D. Hegemann with the exception 
of the NMR structure elucidation of caulosegnin I, which was done by Xiulan Xie. Analysis and 
interpretation of the experimental data was done by Julian D. Hegemann with assistance provided 
when needed by Marcel Zimmermann. The manuscript was written by Julian D. Hegemann and 
revised with the support of Mohamed A. Marahiel and Marcel Zimmermann. Mohamed A. Marahiel 
was furthermore responsible for the project supervision in general.
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Background and Summary:
Several lasso peptides were known prior to this work, but information about the genetic background 
of  their  biosynthetic  machineries  were  scarce.  At  this  point,  only four  functional  lasso peptide 
biosynthetic  gene  clusters  were  known,  namely  the  ones  producing  MccJ25,55,56,58 capistruin,18 
lariatin57 and  astexin-1.30 The  major  problems  preceding  this  publications  persisted  since  the 
isolation and characterization of capistruin by Marahiel and co-workers.18 Capistruin was the first 
lasso peptide that was isolated using a genome mining approach that was directed at finding and 
isolating a novel lasso peptide, while lasso peptides that were isolated before, where just found in 
screenings  for  compounds  with  specific  bioactivities.  What  makes  capistruin  special  is  that  its 
homologous production by cultivating  Burkholderia thailendenis  E264 in M20 minimal medium 
was  already sufficient  for  allowing  the  isolation  of  this  lasso  peptide  in  amounts  suitable  for 
characterization and NMR structure elucidation. At the same time, the heterologous production of 
this lasso peptide in  E. coli only provided trace amounts, which could only be used for basic MS 
analysis.  Since  then,  no  other  lasso  peptide  investigated  in  this  group  showed  a  homologous 
production anywhere close to capistruin, which necessitated the optimization of the heterologous 
lasso peptide production in E. coli. In this work, results from Link and co-workers64,125 were used as 
a  starting  point  to  develop  a  robust  and  efficient  way  for  generally  optimizing  the  yields  of 
heterologous lasso peptide production by expression of proteobacterial gene clusters in E. coli. This 
not only allowed the isolation and characterization of caulosegnins I-III in this study, but at the 
same time this was the basis that made all the subsequent genome mining studies of lasso peptides 
that were performed in our group possible.26,37,47 Additionally, this work showed for first time that a 
single lasso peptide biosynthetic gene cluster could contain more than one precursor encoding gene 
and that it had the capability to produce a quite diverse set of lasso peptides, which even differed in  
the sizes of their  macrolactam rings.  A thorough mutational  analysis  furthermore provided new 
information about the lasso peptide biosynthesis and surprisingly revealed that smaller amino acids 
as previously assumed are suitable to maintain the lasso fold of caulosegnin I. In addition to these 
results, this study also disproved the former notion that, as it is true for MccJ25,32 all lasso peptide 
would have an instrinsic thermal stability, which was made even more intriguing by the fact that  
caulosegnins I and III were shown to be heat labile, while caulosegnin II was proven to be a heat 
stable lasso peptide. Thus, this study was the first to come that made way to revising the former 
paradigms of lasso peptide research.
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3.2 The Astexin-1 Lasso Peptides: Biosynthesis, Stability, and Structural 
Studies
Marcel Zimmermann, Julian D. Hegemann, Xiulan Xie, and Mohamed A. Marahiel, The Astexin-1 
Lasso Peptides: Biosynthesis, Stability, and Structural Studies,
Chem. Biol. 2013, 20(4), 558-569.
doi: 10.1016/j.chembiol.2013.03.013 
Author contributions:
The project was designed by Marcel Zimmermann and Mohamed A. Marahiel with assistance of 
Julian D. Hegemann. All  experiments were carried out by Marcel Zimmermann, except for the 
structure  revision  of  astexin-1  by  NMR  spectroscopy  which  was  done  by  Xiulan  Xie.  The 
experimental data was evaluated and interpreted by Marcel Zimmermann with the aid of Julian D. 
Hegemann. The manuscript was written by Marcel Zimmermann and its revision was done together 
with  Julian  D.  Hegemann  and  Mohamed  A.  Marahiel,  of  whom  the  latter  was  additionally 
responsible for the project supervision in general.
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Background and Summary:
During the initial experimental work for this study, the isolation of the lasso peptide astexin-1 and 
the elucidation of its three-dimensional structure were published by Link and co-workers.30 Still, the 
structure postulated was in strong disagreement with information that we had already obtained from 
mutational studies, namely that the plug residues proposed by Link and co-workers were easily 
interchangeable  with  alanine,  while  the  exchange  of  Y14  and  F15  with  alanine  dramatically 
decreased the lasso peptide production. Encouraged by this, we elucidated the three-dimensional 
structure of a truncated variant of astexin-1 ourselves and indeed could prove that the previously 
published structure was flawed. We subsequently started to search for reasons for this discrepancy 
and characterized the stability properties of astexin-1. Besides probing the proteolytic stability of 
this  lasso  peptide,  the  thermal  stability  of  astexin-1  was  also  assessed,  revealing  that  it  was, 
similarly to the previously published caulosegnins I and III,22 a heat sensitive lasso peptide. Based 
on this, it could be reasoned that a too careless purification of astexin-1 in the work done by Link 
and  co-workers  led  to  the  unthreading  of  the  lasso  fold  and  that  they  merely  analyzed  a 
branched-cyclic peptide by NMR that was falsely assigned as lasso peptide, which might explain 
the  poor  quality  of  the  presented  NMR structure.  In  addition  to  these  results,  this  study was 
substantiated by a thorough mutational analysis of the astexin-1 precursor peptide. The most notable 
result of these investigations was that astexin-1 could be transformed into a heat stable lasso peptide 
by simple exchange of the lower plug amino acid F15 with the more bulky residue tryptophan.
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3.3  Lasso  Peptides  From Proteobacteria:  Genome Mining  Employing 
Heterologous Expression and Mass Spectrometry
Julian D. Hegemann, Marcel Zimmermann, Shaozhou Zhu, Dennis Klug, Mohamed A. Marahiel, 
Lasso Peptides From Proteobacteria: Genome Mining Employing Heterologous Expression and 
Mass Spectrometry,
Biopolymers Pept. Sci. 2013, 100(5), 527-542.
doi: 10.1002/bip.22326
Author contributions:
The project was designed by Julian D. Hegemann and Mohamed A. Marahiel with the aid of Marcel 
Zimmermann. The experiments were performed predominantly by Julian D. Hegemann himself. 
Additional  experimental  assistance  was  received  by  Marcel  Zimmermann,  Shaouhou  Zhu  and 
Dennis  Klug  in  regard  to  the  cloning  of  some  of  the  constructs  as  well  as  help  during  the 
heterologous  expression  of  the  lasso  peptides.  The  data  obtained  this  way  was  analyzed  and 
interpreted by Julian D. Hegemann with feedback of Marcel Zimmermann. The manuscript was 
written by Julian D. Hegemann and its revision was done together with Mohamed A. Marahiel and 
Marcel Zimmermann. In addition to this, Mohamed A. Marahiel was further responsible for the 
project supervision.
49
Background and Summary:
After it had previously been shown that lasso peptide production could already be significantly 
increased by simple incorporation of an E. coli  optimized ribosomal binding site in the intergenic 
region between the precursor peptide and the B protein encoding genes,22,64 the applicability of this 
approach  was  assessed  for  ten  other  putative  lasso  peptide  biosynthetic  gene  clusters.  These 
clusters were identified by a B-protein centric genome mining approach and all of them were of 
proteobacterial  origin.  The  heterologous  production  of  all  twelve  predicted  lasso  peptides  was 
successful, even though the overall yields strongly differed between the different systems. Besides 
showing that the incorporation of the ribosomal binding site was beneficial in most of the tested 
systems, this study was also concerned with providing fast and simple means, with which it would 
be possible to provide strong evidence for the presence of a lasso fold without having to rely on an 
NMR or X-ray based three-dimensional structure elucidation. Thus, a general procedure that used 
thermal  stability  assays  in  combination  with  protease  treatment  and  high  resolution  MS-based 
analysis  was developed,  which allowed to quickly and efficiently gain strong evidence for  the 
presence or absence of a lasso fold and at the same time was able to prove if the lasso peptide in  
question was heat sensitive.  In light of the expansion of the number of known functional lasso 
peptide biosynthetic gene clusters from five to fifteen, the corresponding processing enzymes were 
also successfully analyzed for the presence of any conserved motifs, which can not only facilitate 
future  genome  mining  approaches,  but  also  substantiated  previous  studies  about  the  catalytic 
activity  of  these  kinds  of  enzymes.30,59-61 Finally,  a  thorough  bioinformatic  analysis  of  the  98 
identified  putative  lasso  peptide  biosynthetic  gene  clusters  from  proteobacteria  and  their 
surroundings allowed us to identify several distinct groups of cluster organizations. The largest of 
these groups where the ABCD arrangement known from the capistruin system and the plain ABC 
arrangement that is predominantly found adjacent to an inverse facing gene cluster comprising of 
four  conserved  genes  encoding  a  σ-factor,  an  anti-σ-factor,  a  TonB-dependent  receptor  and  a 
peptidase. The significance of the latter observation was later shown by a study done by Link and 
co-workers, who proved that the peptidase of such a gene cluster is indeed a lasso peptide specific  
isopeptidase.23
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3.4  Xanthomonins I-III:  A  New  Class  of  Lasso  Peptides  With  a 
Seven-Residue Macrolactam Ring
Julian D. Hegemann, Marcel Zimmermann, Shaozhou Zhu, Holger Steuber, Klaus Harms, Xiulan 
Xie, Mohamed A. Marahiel, Xanthomonins I-III: A New Class of Lasso Peptides With a 
Seven-Residue Macrolactam Ring,
Angew. Chem. Int. Ed. Engl. 2014, 53(8), 2230-2234.
doi: 10.1002/anie.201309267 
Angew. Chem. 2014, 126(8), 2262-2266.
doi: 10.1002/ange.201309267 
Author contributions:
The project was designed by Julian D. Hegemann and Mohamed A. Marahiel  with the help of 
Marcel Zimmermann. Experimental work was done almost exclusively by Julian D. Hegemann. 
The exception to this were the NMR based structure elucidation of xanthomonin II, performed by 
Xiulan Xie,  and the cloning of the xanthomonin III gene cluster as well  as the isolation of the 
corresponding  lasso  peptide,  which  was  carried  out  by Shaozhou  Zhu.  The  crystallization  and 
crystal structure elucidation of xanthomonin I was done in a collaboration of Julian D. Hegemann, 
Klaus Harms and Holger Steuber. The remaining data was evaluated and interpreted by Julian D. 
Hegemann  with  assistance  of  Marcel  Zimmermann.  The  manuscript  was  written  by  Julian  D. 
Hegemann and revised after consultation with Mohamed A. Marahiel and Marcel Zimmermann. 
Mohamed A. Marahiel was also responsible for the overall  project supervision.
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Background and Summary:
Since the first lasso peptides were isolated and since their intriguing and unique three-dimensional 
structures were recognized, only lasso peptides with eight- or nine-residue macrolactam rings were 
discovered.10,17,18,22-25,27-30,32,34,37,40,41,43-46,48,126 Consequently, it was proposed that lasso peptides could 
be limited to these ring sizes. In this regard, it was assumed that a ten-residue ring would be too big 
to  allow  the  steric  maintenance  of  the  lariat  knot,  while  it  was  doubted  that  the  inside  of  a 
seven-residue ring would be big enough to allow the threading by the C-terminal tail. At least the 
latter  assumption  was  proven  wrong  by  this  study,  where  three  novel  lasso  peptides, 
xanthomonins I-III, were reported that for first time combined the lasso fold with a seven-residue 
macrolactam ring. Subsequent structure elucidations of xanthomonin I by X-ray crystallography and 
xanthomonin II by NMR spectroscopy indeed showed how small the opening in such a ring truly is. 
Complementary mutational studies additionally confirmed that the residues threading the ring are 
limited to glycine. At the same time, this small opening allowed that the lasso fold in these scaffolds 
can be maintained in a heat stable manner by plug amino acids as small as threonine or valine. 
Indeed, every amino acid bigger than serine, even when located in some distance to the position of 
the  ring-threading,  was  shown  to  be  able  to  maintain  a  thermally  stable  lasso  fold  in 
xanthomonin II.  A comparison  to  the  chemically  accessible  class  of  [2]rotaxanes,  whose  most 
compact representatives have a threaded ring consisting of merely 20 atoms,127-129 shows that the 23 
atom comprising macrolactam rings of the xanthomonins are only slightly bigger. This observation 
further emphasizes that these lasso peptides are close to the limit of what appears to be chemically 
possible, which makes the existence of lasso peptides with six-residue macrolactam rings rather 
unlikely. Still, the question for the possibility of both lasso peptides with six-residue and ten-residue 
macrolactam rings can only be conclusively answered by future studies.
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3.5  Characterization  of  Caulonodin  Lasso  Peptides  Revealed 
Unprecedented N-Terminal Residues and a Precursor Motif Essential for 
Peptide Maturation
Marcel Zimmermann, Julian D. Hegemann, Xiulan Xie, and Mohamed A. Marahiel, 
Characterization of Caulonodin Lasso Peptides Revealed Unprecedented N-Terminal Residues and 
a Precursor Motif Essential for Peptide Maturation,
Chem. Sci. 2014, Epub ahead of print.
doi: 10.1039/c4sc01428f
Author contributions:
The project was designed by Marcel Zimmermann and Mohamed A. Marahiel with the assistance of 
Julian D. Hegemann.  The experiments  were carried out  by Marcel  Zimmermann with the only 
exceptions  being  the  NMR  based  structure  elucidation  of  caulonodin V  and  the  NMR  based 
structural  investigation  of  caulonodin VI,  which  both  were  performed  by  Xiulan  Xie.  Data 
evaluation  and   interpretation  was  done  by  Marcel  Zimmermann  with  the  aid  of  Julian  D. 
Hegemann. The manuscript was written by Marcel Zimmermann and revised with the support of 
Julian D. Hegemann and Mohamed A. Marahiel, the latter of whom was also responsible for the 
overall project supervision.
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Background and Summary:
Before this  study,  every known lasso peptide featured either  a  cysteine or  a  glycine residue at 
position 1, depending on it being either a class I or a class II/III lasso peptide.10,17,18,22-30,32,34,37,40,41,43-
46,48,126 As this observation held true since the discovery of the first lasso peptide in 1991,46 it was 
assumed that the conservation of the position 1 residue was a general criteria valid for all lasso 
peptides. In this work, two gene clusters from Caulobacter sp. K31 were tested for heterologous 
lasso peptide production in  E. coli. In contrast to all lasso peptide biosynthetic gene clusters that 
were investigated before, the four corresponding lasso peptides of these two gene clusters would 
carry either an alanine or serine residue at their N-terminus. Through this, we tried to assess if these 
biosynthetic systems were indeed able to produce class II lasso peptides with macrolactam rings 
formed between a carboxylic acid side chain and an N-terminal residue different than glycine. This 
was proven to be true for all four proposed lasso peptides, allowing us to revise another paradigm of 
lasso  peptide  research.  To substantiate  these  findings,  the  NMR structure  of  caulonodin V was 
elucidated and the long-range NOE contacts in caulonodin VI were investigated in order to clarify 
the identity of its upper and lower plug amino acids. To prove that the plugs of caulonodins IV and 
VII  were  at  the  corresponding  positions  as  the  ones  of  their  sibling  compounds,  a  thorough 
mutational and stability analysis was performed. Finally, these new results were put into context of 
our previous genome mining study37 and a bioinformatic analysis  of all  known functional lasso 
peptide precursors was done that led to the identification of a C-terminal leader peptide motif that 
appears to be highly conserved among ABC-type proteobacterial lasso peptide biosynthetic gene 
clusters. The importance of this conserved motif  was proven in two ways.  Firstly,  a mutational 
study with  caulonodin V confirmed  the  significance  of  different  residues  in  this  motif  as  any 
non-conserved mutations of these positions drastically reduced the overall lasso peptide production. 
Secondly,  we noticed  that  the  leader  peptide  of  the  previously  reported  rhodanodin37 naturally 
featured a serine residue at position -8 instead of the highly conserved glycine of the identified 
motif. By exchanging this serine with a glycine residue, thereby restoring the original motif, the 
heterologous production of rhodanodin was increased significantly, emphasizing the importance of 
this motif for (proteobacterial) lasso peptide maturation.
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3.6  Rational  Improvement  of  the  Affinity  and  Selectivity  of  Integrin 
Binding of Grafted Lasso Peptides
Julian D. Hegemann, Mariarosaria De Simone, Marcel Zimmermann, Thomas A. Knappe, Xiulan 
Xie, Francesco Saverio Di Leva, Luciana Marinelli, Ettore Novellino, Stefan Zahler, Horst Kessler, 
and Mohamed A. Marahiel, Rational Improvement of the Affinity and Selectivity of Integrin 
Binding of Grafted Lasso Peptides,
J. Med. Chem. 2014, 57(13), 5829-5834.
doi: 10.1021/jm5004478
Author contributions:
The project was designed by Julian D. Hegemann together with Thomas A. Knappe, Horst Kessler, 
Marcel  Zimmermann and Mohamed A.  Marahiel.  Generation  of  the  MccJ25 variants  and their 
isolation was done by Julian D. Hegemann. Integrin binding studies were done and evaluated in 
collaboration  with  Mariarosaria  De Simone  and  Horst  Kessler,  while  cell  culture  studies  were 
performed  and  interpreted  by  Stefan  Zahler.  The  NMR  spectroscopic  elucidation  of  the 
three-dimensional  structure  of  MccJ25(RGDF)  was  done  by  Xiulan  Xie  and  the  molecular 
dynamics simulations were carried out by Francesco Saverio Di Leva, Luciana Marinelli and Ettore 
Novellino. Project coordination was done predominantly by Julian D. Hegemann and Mohamed A. 
Marahiel. The manuscript was written by Julian D. Hegemann and revised after thorough exchange 
with  all  parties  involved  in  this  project.  The  general  project  supervision  was  performed  by 
Mohamed A. Marahiel.
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Background and Summary:
Due to their extraordinary stability, genetic accessibility and their promiscuous primary structures, 
lasso peptides are interesting scaffolds for epitope grafting approaches. Still, so far only one study 
was  carried  out  to  assess  the  applicability  of  lasso  peptides  in  this  field.65 Even  though  this 
proof-of-principle study was able to verify that a peptide epitope can be grafted into a lasso scaffold 
and still retains its original bioactivity, the resulting compound had only a moderate binding affinity 
and an even worse binding selectivity to the target integrin receptor. Based on this result, we set out 
to  optimize  the  grafted  lasso  peptide  by  applying  findings  from  the  research  that  led  to  the 
development of cilengitide, a highly potent and selective inhibitor of the  αvβ3 integrin receptor. 
The newly generated lasso grafts were then probed in  in vitro integrin binding studies, revealing 
that MccJ25(RGDF) had a significantly improved αvβ3 binding behavior, both in regard to affinity 
and selectivity of the interaction. This result was further substantiated by cell culture studies that 
confirmed that this compound indeed conferred the desired inhibitory activity. To shed light upon 
the structure-activity relationship of this novel compound, its structure was elucidated by NMR 
spectroscopy and then employed in a molecular dynamics simulation using the co-crystal structure 
of a cilengitide-αvβ3 complex (PDB code 1L5G)130 as a basis. In this way, it was revealed which 
moieties  of  MccJ25(RGDF)  are  important  for  receptor  recognition  and  of  which  nature  the 
inhibitor-receptor interactions are on a molecular level.
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4. Discussion
4.1 Breaking the Paradigms of Lasso Peptide Research
At the beginning, the target of this work was the genome mining driven discovery, isolation and 
characterization  of  novel  lasso  peptides.  Back  then,  capistruin  was  still  the  only lasso  peptide 
discovered in this way and the repetition of such a discovery was hindered by several inherent 
problems. These were predominantly the poor homologous production of lasso peptides by newly 
chosen  strains  that  carried  lasso  peptide  biosynthetic  gene  clusters,  the  poor  heterologous 
production when cloning these clusters into a plasmid and subsequently expressing them in E. coli 
and the inexperience in regard to the criteria for choosing putative lasso peptide biosynthetic gene 
clusters for investigation in this way. Because of this, five years had passed since the discovery of 
capistruin before the next example of successful genome mining of a lasso peptide was reported in 
this group.22 In the meantime, research was focused on obtaining deeper knowledge about how lasso 
peptides can be efficiently produced in and isolated from  E. coli,  about which sources of lasso 
peptide biosynthetic gene clusters are most promising for heterologous production and about what 
conditions can positively or negatively effect the lasso peptide production in general. Alongside our 
own research, further intriguing information was obtained by studies that were published in the 
meanwhile. Especially works of Link and co-workers64,125 steered us in the right direction in this 
regard. The ideas derived from these studies ultimately led us to establish methods to significantly 
increase the heterologous production of lasso peptides in E. coli by simple genetic alterations of the 
corresponding  biosynthetic  gene  clusters.  By these  means,  we  were  finally  able  to  report  the 
isolation of three new lasso peptides, caulosegnins I-III, by a directed genome mining approach.22 
Based on this  success,  we revisited  all  the biosynthetic  gene clusters  that  had been previously 
cloned into expression vectors in our group, which before showed no or only trace lasso peptide 
production in  E. coli.  By employing our new set of genetic tools,  two things became apparent. 
Firstly, the genetic modification of the intergenic region in these clusters seems to be almost always 
beneficial for overall lasso peptide production and of general applicability. Secondly, when using 
E. coli as a heterologous host, the biosynthetic gene clusters from proteobacterial origin work best. 
These findings led to a comprehensive genome mining study that culminated in the description and 
characterization of twelve novel lasso peptides.37 In general, the work done in this group in the 
recent years greatly increased the number of both known lasso peptides and known lasso peptide 
biosynthetic gene clusters as emphasized by Figure 4.1. Nevertheless, the results obtained in our 
recent publications about lasso peptides22,25,26,37 also subtly hint at another still persisting problem. 
Namely, that gene clusters from organisms not belonging to the phylum Proteobacteria often still  
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Figure 4.1. Discoveries  of  (a)  lasso  peptides  and  (b)  functional  lasso  peptide  biosynthetic  gene  clusters. 17,18,22-26,28-
30,32,37,40,41,44,46,48,55,57 For the left graph, practically identical lasso peptides belonging to the siamycin or RES-701 families 
were counted as one single entity, even though they were rediscovered several times. As 2014 is still in progress, the red 
line was not expanded to this year.
cause  problems  when  expressed  heterologously  in  E. coli  and  that  at  the  same  time  the  host 
organisms of these gene clusters are not producing the corresponding lasso peptides homologously. 
Thus, even though the problem of isolating proteobacterial lasso peptides appears to be solved, a 
rich  reservoir  of  novel  and  interesting  biosynthetic  systems  remains  currently  more  or  less 
inaccessible  for  us.  This  furthermore  explains  why  all  lasso  peptides  described  in  recent 
publications22,25,26,37 of our group were of proteobacterial origin.
Nonetheless, the studies presented here not only yielded a plethora of novel lasso peptides, but also 
vastly  increased  the  general  knowledge  about  these  compounds  and  their  physico-chemical 
properties. Especially in regard to the paradigms established before this work, new information was 
obtained that  either  put  prior  assumptions  in  question  or  completely overhauled  these  notions. 
Namely, these were as follows:
- All lasso peptides have an exceptional instrinsic thermal stability.
- Only the biggest amino acids are able to fulfill the role as plug amino acids.
- Only lasso peptides with eight- or nine-residue macrolactam rings can be produced.
- All lasso peptides carry either a glycine or cysteine residue at position 1 of their sequence.
- The only conserved essential residue in a lasso peptide leader sequence is the threonine at the 
penultimate position.
- All lasso peptides are antimicrobial agents.
These ideas, and how they were proven wrong, will be discussed in the subsequent sections.
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4.1.1 The Thermal Stability of Lasso Peptides
The notion of an intrinsic thermal stability of lasso peptides goes back to the isolation of MccJ25.32 
There, it was reported that even after autoclaving, MccJ25 still exhibited its antimicrobial activity, 
revealing the tremendous heat resistance of this compound. Due to the presence of the general lasso 
fold and the basic similarities of all lasso peptides, such a behavior was assumed to be found for all 
members of this natural compound family. It came as quite a surprise that this assumption held not 
true for caulosegnins I and III. Indeed, the thermal sensitivity of caulosegnin I was only uncovered 
upon the first attempts of purifying this compound. This was due to the fact that after the first round 
of HPLC, the solvent was removed under reduced pressure in a water bath at 40 °C. Even though 
only  the  fractions  corresponding  to  a  single  distinct  peak  were  pooled  and  evaporated,  the 
subsequent  second  HPLC  purification  step  suddenly  again  revealed  the  presence  of  two 
well-resolved,  distinct  peaks.  What  was  even  more  peculiar  was  that  both  peaks  belonged  to 
compounds with the exact same molecular mass. The combination of all of these observations led to 
the assumption that caulosegnin I most likely was partially thermally unthreaded upon the solvent 
evaporation at 40 °C. As a consequence, the solvent was subsequently removed more carefully and 
afterwards small samples of the obtained pure lasso peptide were exposed to different temperatures 
for different time intervals. Ensuing LC-MS analysis confirmed our initial hypothesis and revealed 
the appearance of a second peak featuring the same molecular mass but a different retention time 
(Figure 4.2).
Figure 4.2. Thermally induced unthreading of caulosegnin I.22 Even the incubation for only 1 h at 95 °C causes the 
almost complete unthreading of this heat sensitive lasso peptide.
Furthermore,  it  was  shown that  the  intensity of  this  new peak directly correlated to  the tested 
temperature and the duration of the incubation.22 Since then, the assessment of the thermal stability 
became one of the benchmarks for characterizing a newly isolated lasso peptide in our group. By 
this,  we  were  able  to  report  several  instances  of  thermally  sensitive  lasso  peptides,  namely 
astexin-1,  caulonodin IV,  caulonodin V,  caulonodin VI,  caulonodin VII,  caulosegnin I, 
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caulosegnin III,  rhodanodin,  rubrivinodin,  sphingonodin II,  sphingopyxin I and syanodin I.22,25,37,47 
This is of especial interest for astexin-1, as in light of these observations, it becomes likely that the 
wrongfully elucidated structure of astexin-1 that was presented by Link and co-workers30 could 
possibly be traced back to a thermally induced unthreading during the isolation and purification 
procedures of this compound and maybe even during the NMR measurements themselves. Testing 
the thermal stability of a new lasso peptide straight away, thus can help to avoid problems during 
the isolation and characterization of such a compound and can help to adjust the conditions for 
NMR analysis in advance to avoid unthreading during the measurements. Hence, the observation 
that not all lasso peptides necessarily have a high thermal stability not only overhauls a wrong belief 
about these compounds, but is also an important factor to consider when working with these natural 
products.
Additionally,  our studies also helped to unveil  criteria that decide upon the thermal stability or 
sensitivity of a lasso peptide. In this regard, the present ring size in combination with the lower plug 
amino  acid  seem  to  be  important  factors  that  decide  how  a  compound  reacts  at  elevated 
temperatures. While the very small seven-residue macrolactam rings are able to form a heat stable 
lasso fold with all lower plug amino acids bigger than serine,26 even a tyrosine residue can in some 
cases  be  inadequate  for  stabilizing  the  fold  of  a  nine-residue  ring  lasso  peptide  at  increased 
temperatures.22,25 Yet,  the  ring  size  and  the  character  of  the  lower  plug  amino  acid  alone  are 
insufficient  parameters  to  predict  the  thermal  stability  of  a  lasso  peptide  as  the  comparison of 
caulosegnins II and III emphasizes.22 While both lasso peptides have a nine-residue macrolactam 
ring, use a tyrosine residue as lower plug amino acid and have a similar amino acid composition, 
only caulosegnin II is heat stable. The definite reason for this difference is not known so far and is 
still a subject of research. Nevertheless, it is known that the distance of the lower plug amino acid to 
the macrolactam ring itself seems to already affect the thermal stability of a lasso peptide. This was 
shown for both the capistruin and caulosegnin I scaffolds, as mutational studies revealed that amino 
acids that are generally suitable for maintaining the lasso fold can loose this ability if positioned 
farther  away  from  the  point  where  the  tail  threads  the  macrolactam  ring.  In  the  case  of 
caulosegnin I, isoleucine was shown to be able to maintain the fold when replacing the naturally 
occurring  plug  amino  acid  E16,  while  the  mutation  E16A resulted  in  a  mere  branched-cyclic 
peptide,  even though another isoleucine residue was present at  position 17 of the caulosegnin I 
scaffold.22 For capistruin, it was shown that the simultaneous alanine exchange of the lower plug 
amino acid R15 and the adjacent F16 transformed this heat stable lasso peptide in a heat sensitive 
compound, where the remaining bulky F18 residue is still able to maintain the lasso fold at room 
temperature,  but  cannot  stop  thermally  induced  unthreading  of  the  lasso  fold.36 Hence,  this 
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capistruin variant was the first reported heat sensitive lasso peptide, while caulosegnin I was the 
first  naturally occurring lasso peptide reported that showed a temperature sensitive behavior. In 
general,  investigations of the thermal stability can give an insight on how stable and rigid a lasso 
scaffold is,  ranging from a rather loose arrangement like the mentioned R15A F16A capistruin 
variant to the very tight lasso fold in  xanthomonin II, where even amino acids in some distance to 
the naturally occurring plug amino acid can maintain a thermally stable fold.26,36 Interestingly, it was 
also shown that the thermal properties of a lasso peptide can be inverted by rational means. As such, 
we have reported that the thermally sensitive astexin-1 can be transformed into a heat stable lasso 
peptide by introducing the single point mutation F15W.25 This proves that both thermal stability and 
sensitivity are subject to change and suggests that this fact could be employed by organisms in 
dependence of their  needs,  e.g.  for generating compounds that degrade at  certain temperatures, 
allowing them to be used as temperature dependent switches. On the other hand, probing how easy 
a  heat sensitive lasso peptide degrades,  could reveal that an organism is  adopted to a life in  a 
temperature range where the thermally induced unthreading of a lasso peptide is so slow that it is of 
no relevance to the producing strain.
4.1.2 The Plug Amino Acids of Lasso Peptides
In addition to revealing the existence of heat sensitive lasso peptides in nature, caulosegnin I also 
showed that smaller amino acids as formerly believed can act as plug amino acids. In prior studies, 
especially in cases of the mutational analyses of the MccJ25 and capistruin scaffolds,36,62 it seemed 
like only the biggest and bulkiest amino acid side chains, namely arginine, phenylalanine, tyrosine 
and tryptophan, were suitable for the sterical maintenance of the lasso fold. Again, caulosegnin I 
was the first lasso peptide proving this statement to be wrong, as it was revealed that it  used a 
surprisingly small glutamate residue as lower plug amino acid.22 Encouraged by this observation, 
we looked further into the nature of amino acids that could act as a plug. In case of caulosegnin I, 
we saw that the lower limit for a plug amino acid in this eight-residue macrolactam ring carrying 
lasso peptide was asparagine. This amino acid was only barely able to maintain the fold under the 
expression and isolation conditions, as it was observed that the majority of the corresponding lasso 
peptide variant was already unthreaded upon the actual LC-MS analysis (Figure 4.3).26 
Reducing the size of the macrolactam ring, unsurprisingly also reduces the needed size of an amino 
acid side chain for stabilizing the lasso fold.  Following this  reasoning, it  makes sense that the 
xanthomonin II scaffold can be maintained in a completely heat stable manner by all amino acids 
that  exceed  serine  in  size.26 Of  course,  as  demonstrated  by  the  difference  in  thermal  stability 
properties of the very similar lasso peptides caulsegnin II and III,22 the plug amino acid alone is not
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Figure 4.3. Thermal treatment of an extract of caulosegnin I variant E16N.22 The chromatograms shown belong to an 
extracted ion current for the singly (1905.9935) and doubly (953.5006) charged ions of the lasso peptide before and 
after  treatment  at  95 °C for  1 h.  The  peaks  are  labeled  as  branched-cyclic  or  lasso  peptide,  respectively,  and  the 
observed masses for the doubly protonated species are shown adjacent to them. 
the  only  factor  affecting  the  general  stability  of  a  lasso  peptide,  even  when  identically  sized 
macrolactam rings are present. Therefore, future studies will focus on both unveiling other criteria 
important for the maintenance of the lasso fold and on characterizing the range of amino acids that 
are suitable for stabilizing a lasso peptide with a nine-residue macrolactam ring.
4.1.3 The Allowed Sizes of the Macrolactam Rings in Lasso Peptides
Since the isolation of anantin until very recently, the only macrolactam rings found in lasso peptides 
were eight- and nine-residues in size.10,17,18,22-25,27-30,32,34,37,40,41,43-46,48,126 Thus, it is of little surprise that 
this observation led to the idea that these are the only ring sizes possible for lasso peptides. The 
fundamental argumentation for this assumption was that ten-residue macrolactam rings would be 
too big to allow the steric maintenance of the lasso fold,  while the opening in a seven-residue 
macrolactam ring was deemed to be too small to allow the threading by the  C-terminal tail. The 
latter assumption was proven wrong by the report of the xanthomonins I-III, which are extremely 
stable lasso peptides with seven-residue macrolactam rings.26 Nevertheless, the first indications for 
the possibility of seven-residue macrolactam rings in lasso peptides were already found in an earlier 
genome mining study.37 In this investigation, several instances became apparent, where putative 
lasso peptide sequences contained a glutamate residue suitable for ring formation at position 7. In 
some cases,  like xanthomonins I-II,  an additional  glutamate or  aspartate  residue was present  at 
positions  8  or  9  of  the  predicted  lasso  peptide,  while  in  the  remaining  instances,  like 
xanthomonin III, only the position 7 residue of the putative lasso sequence featured a carboxylic 
acid side chain. Indeed, during the first investigations of the heterologous expression of the gene 
cluster producing xanthomonins I and II, we still expected the production of ordinary eight-residue 
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macrolactam ring containing lasso peptides.  Conversely,  the first  tandem MS analyses  of these 
compounds already included strong hints for the presence of seven-residue macrolactam rings, as 
the fragmentation spectra showed strong signals corresponding to the first seven amino acids minus 
the one molecule of water that is lost during the cyclization reaction (Figure 4.4).26 
Figure 4.4. Fragmentation  spectrum  of  xanthomonin I.26 The  b- and  y-fragments  are  depicted  in  blue  or  red, 
respectively. The b7 fragment is furthermore highlighted by a red arrow.
Subsequent  generation  and  expression  of  E7A  and  E8A mutants  of  xanthomonin II  already 
conclusively proved the ring size predicted by MS, as the E7A variant was not produced, while the 
E8A  variant  was  produced  on  wild  type  level.26 Finally,  the  structure  elucidations  of  both 
xanthomonin I  and  II  revealed  the  spacial  organizations  of  these  small  rings.  Due  to  these 
structures, it also became apparent how small the ring openings really were and that they could 
barely be threaded by the  C-terminal tails.26 This observation was further substantiated by results 
from the mutational studies on xanthomonin II, which confirmed that the only amino acid tolerated 
at the two positions that thread the ring was glycine and that even the introduction of a barely larger 
alanine  residue  at  these  positions  completely or  almost  completely abolished  the  lasso  peptide 
production.26 Combining this information with what is known for the chemically accessible class of 
the [2]rotaxanes,127-129 it becomes likely that seven-residues compose the lower limit possible for 
threaded macrolactam rings. In regard to ten-residue macrolactam rings, research has yet to prove or 
disprove their occurrence in nature. Still, so far no hints for lasso peptides with such an arrangement 
were found, but then again, this held true for lasso peptides featuring seven-residue rings until it 
was recently proven otherwise.
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4.1.4 The N-terminal Amino Acids of Lasso Peptides
Similarly to the presence of seven-residue macrolactam rings, the presence of an N-terminal amino 
acid  different  to  cysteine  or  glycine  was  assumed  unlikely  due  to  the  lack  of  previous 
observations.10,17,18,22-30,32,34,37,40,41,43-46,48,126 Nonetheless,  several  putative  class II  lasso  peptide 
precursors were recently identified that featured the conserved threonine residue at the penultimate 
position  of  the  leader  peptide,  but  lacked  the  usual  glycine  residue  at  position  1  of  the  lasso 
sequence.  In  some  of  these  instances,  a  glycine  was  present  one  amino  acid  closer  to  the 
C-terminus.37 These precursors rose the question, if they were really matured into a lasso peptide 
featuring a so far unobserved amino acid at their first position or if they indeed contained a change 
of the the TxG cleavage motif to TxxG (Figure 4.5).
Figure 4.5. Schematic depiction of  the precursor  peptides of caulonodins I-VII.37,47 While the precursor  peptides of 
caulonodins I-III (CK31_A 5194/5193/519x) fulfill all  previously postulated criteria of lasso peptide precursors, the 
precursor peptides of caulonodins IV/V (CK31_A 1984/198x) and caulonodins VI/VII (CK31_A 2238/2239) feature an 
unusual amino acid at position 1 of the lasso sequence. The T-2 residue is highlighted in blue, the position 1 residues 
and ring forming glutamates in red, while all glycines at position 2 of a lasso sequence are shown in orange.
Additionally, it could not be excluded that in these instances a simple random mutation event had 
occurred,  altering the glycine at  position 1 to a  different  amino acid and thus  abolishing lasso 
peptide production in the corresponding organism. Due to the availability of genetic tools and the 
gathered experience for significant improvement of heterologous production of proteobacterial lasso 
peptides  in  E. coli,  it  was  decided  upon  investigation  of  two  gene  clusters  from  Caulobacter 
sp. K31  that  contained  four  precursor  peptides  with  this  peculiar  feature.47 The  subsequent 
experiments not only proved that these lasso peptides could be produced in good yields in E. coli, 
but also showed that a glycine exchange of the serine or alanine residues at position 1 of these lasso  
peptides drastically decreased the overall lasso peptide production.47 These results are converse to 
previously reported mutational studies for lasso peptides carrying a glycine at position 1. In these 
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cases, it was shown that the glycine could not or only poorly be exchanged to any other amino acid 
(Figure 4.6).22,25,36,62,67 Taken together, these different studies show that lasso peptides do not appear 
to be generally restricted to carry either a glycine or cysteine residue at position 1, but at the same  
time also reveal that the present position 1 amino acid seems to be recognized with high specificity 
by its corresponding biosynthetic machinery. Thus, in highlight of these results, the scope of small 
open  reading  frames  that  could  encode  class II  lasso  peptide  precursors  was  extended  to 
theoretically allow every canonical amino acid at position 1 of the lasso sequence, even though the 
predominant amino acid at this position still appears to be glycine.
Figure 4.6. Production of all reported position 1 lasso peptide variants.22,25,36,47,62 The bars are highlighted in different 
colors corresponding to the observed relative production. A green bar represents a production of >50%, a yellow bar a 
production of 50-15% and an orange bar a production of 15-1% relative to the respective wild type production levels.  
Variants that were only detectable by MS are marked with a red cross, while variants that showed no production at all  
are highlighted with a black minus sign. In case of microcin J25, the G1X refers to this residue being exchanged against 
all other canoncial amino acids of which non of the corresponding variants showed any production.
4.1.5 The Threonine at the Penultimate Position of the Leader Peptide as Essential  
Residue in Lasso Peptide Precursors
The importance of the threonine residue at the penultimate position of the leader sequence for lasso 
peptide maturation was first recognized for the MccJ25 and the capistruin systems.63-65 Since then, 
closer inspection of this residue revealed that its exchange against another amino acid practically 
always negatively affects the overall  lasso peptide production. This effect is weakest,  when the 
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newly introduced amino acid shares some structural similarity to threonine, which is the case for 
serine,  cysteine,  valine  and  isoleucine.64 In  subsequent  mutational  studies  with  different  lasso 
peptide  processing  systems,  it  was  furthermore  shown  that  the  tolerance  for  such  structurally 
conserved  mutations  of  T-2  differs  from  system  to  system.22,25,26 Apparently,  some  processing 
enzymes, like the ones that transform McjA to MccJ25, tolerate these alterations rather well, while 
other systems, like the one maturing xanthomonins I and II, react very poorly to such a substitution 
with regard to the overall efficiency of lasso peptide production (Figure 4.7).22,25,26,63-65 
Figure 4.7. Lasso peptide production levels that correspond to all assayed T-2 lasso peptide precursor variants reported 
in the literature.22,25,26,47,64 The bars are highlighted in different colors corresponding to the observed relative production. 
A green bar represents a production of >50%, a yellow bar a production of 50-15% and an orange bar a production of  
15-1% relative to the respective wild type production levels. Variants that were only detectable by MS are marked with  
a red cross, while variants that showed no production at all are highlighted with a black minus sign.
Thus, the recognition of the T-2 residue seems to be of an universal nature and to be conserved for 
all lasso peptide processing enzymes, even though some show at least a basic tolerance towards 
changes. This observation holds true until today with no known example of a functional, natural 
occurring lasso peptide precursor that does not feature a threonine at this position. Still, on basis of 
the first  McjA precursor peptide studies,  it  was assumed that T-2 is the only strictly conserved 
leader peptide residue that is crucial for enzymatic recognition.63 This assumption turned out to be at 
least  partially  wrong,  as  we  recently  reported  a  generally  conserved  recognition  motif  in  the 
C-terminal section of a lasso peptide leader sequence.47 The reason for calling this assumption only 
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partially and not generally wrong is  that this  motif  seems to be only strictly conserved for the 
precursor peptides encoded by ABC-type proteobacterial lasso peptide biosynthetic gene clusters, 
which  explains  why it  is  not  present  in  the MccJ25 or  capistruin precursors.  Nonetheless,  this 
finding suggests that corresponding motifs may be found in one form or the other in each of the 
different subgroups of lasso peptide biosynthetic gene cluster arrangements. At the same time, it 
also shows that even though a large number of the conserved positions and residues may vary in 
between these different subgroups, the threonine at the penultimate position of the leader peptide 
seems to be conserved in all or at least most of them. Therefore, the notion that only T-2 is essential 
for enzymatic recognition appears to be flawed and should be considered accordingly in future 
mutational studies of and genome mining searches for novel lasso peptides.
4.1.6 The Antimicrobial Activity of Lasso Peptides
There are several instances known, where lasso peptides show a significant antimicrobial activity 
against certain bacteria10,17,18,28,32,34,41,43 and interestingly most of these compounds were identified in 
studies that were not focused on the discovery of a new lasso peptide itself. The only exceptions to 
this are capistruin18 and maybe astexin-1,30 even though the latter exhibits such a weak antimicrobial 
activity against  Caulobacter crescentus that it is unclear if this activity is of any real relevance. 
Because of the occurrence of an antimicrobial activity of such lasso peptides in combination with 
the observation that MccJ25 is only produced by its host under nutrient-limitation, it was reasoned 
that lasso peptides generally could be antimicrobial agents that ensure their hosts survival under 
stressful environmental conditions. Hence, it was surprising that a large number of recently isolated 
lasso peptides  that  were tested  for  such an activity,  appeared to  be  completely inactive  in  this 
regard. Although a more thorough screening might reveal sensitive organisms, it may be that these 
compounds  just  generally  do  not  exhibit  an  antimicrobial  activity.  Interestingly,  all  known 
biosynthetic gene clusters producing antimicrobially active lasso peptides, with exception of the 
questionably active astexin-1, contain a gene encoding an ATP-dependent transporter (Figure 4.8), 
while gene clusters that produce supposedly non-antimicrobial lasso peptides lack such a gene. 
Due  to  the  low  number  of  known  examples  in  both  cases,  this  observation  might  just  be 
coincidental, but from a logical point of view it makes sense to reason that expression of a dedicated 
ABC-transporter  is  only  necessary  in  presence  of  an  antimicrobially  active  compound.  In 
conclusion, this new data puts the assumption of a general role of lasso peptides as antimicrobial 
agents in question and suggests that this is more likely only true for a subgroup of this natural 
product family. The implications of this observation is discussed in more detail in the following 
section.
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Figure 4.8. Schematic representation of all known biosynthetic gene clusters that produce highly active antimicrobial 
lasso peptides.18,28,55,57,58 The names of the genes from the lariatin and lassomycin biosynthesis systems were altered to fit  
the  established  nomenclature  for  lasso  peptide  biosynthetic  gene  clusters  according  to  the  previously  described 
reasoning.37
4.2 New Genome Mining Studies Hint at the Possible Functions of Lasso 
Peptides in Nature
Before 2008, lasso peptides were but a mere curiosity in the field of natural product research. Their 
discovery was  left  to  chance  and limited  to  the  few examples  where  they were  both  strongly 
produced by their hosts and coincidentally also conferred a bioactivity, which was looked for by the 
researchers.10,17,27,32,34,40,41,43-46,48 This all changed with the report of capistruin, the first lasso peptide 
found by genome mining efforts intended to actually discover a new representative of this natural 
product family.18 Since then, the coincidental isolation of novel lasso peptides became scarce24,28,29 
and was more and more replaced by directed, systematic approaches with the aim to isolate new 
examples of as well as to learn more about this unique class of RiPPs.18,22,23,26,30,37 Through these 
efforts, it became clear that lasso peptides are distributed amongst almost all bacterial phyla and in 
some cases even constitute one of the only few secondary metabolites produced by a particular 
organism.22,30,37,47 Nevertheless, the overall role of these compounds in nature remains enigmatic. 
With some instances known where they can act as antimicrobials10,17,18,27,28,32,34,40,41,43 and others were 
they confer an interesting, but most likely off-target activity,10,24,27,34,40,41,43-46,48 the assumption became 
prevalent that these compounds were generally produced to kill off competitors and ensure survival 
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of  their  hosts  under  stressful  environmental  conditions.  The  general  truth  of  this  notion  was 
dispelled as more and more examples of lasso peptides were reported that lack any antimicrobial 
activity.22,23,26,37 Of course, it cannot be ruled out that in these instances merely the wrong organisms 
were tested for sensitivity, but still it seems likely that at least some lasso peptides could have a 
completely different function. The idea of no general role for lasso peptides that is true independent 
from where they originated is underlined by the observation that the corresponding biosynthetic 
gene  clusters  can  be  separated  into  different  subgroups,  depending  on  the  respective  cluster 
organization and their genetic surroundings.23,30,37 Thus, it  may be possible that for example the 
antimicrobial fraction of lasso peptides always occurs together with dedicated immunity conferring 
enzymes like McjD, while the lack of such an enzyme could be a direct proof of a lasso peptide not  
exhibiting  a  bactericidal  activity.  Of  course,  at  this  point  it  is  completely  unclear  if  only 
ABC-transporters can fulfill the role as lasso peptide immunity factors. On the contrary, it would be 
rather peculiar if different clades of bacteria with different kinds of lasso peptide biosynthetic gene 
clusters would not at least in some cases have developed alternative mechanisms to ensure survival 
of  the  host  organism  when  it  is  producing  an  antimicrobial  active  lasso  peptide.  Still, 
ABC-transporters remain the only known examples for this so far, highlighting that the eyes of the 
researchers should be kept pried open for alternative ways and mechanisms for bacteria to deal with 
this subclass of bioactive lasso peptides. In this regard, it should be mentioned that there is at least 
one known instance where an organism encodes enzymes which can specifically degrade the lasso 
peptides it produces. These enzymes  are the isopeptidases produced by  Asticcacaulis extrenticus 
CB48,  which  were  shown  to  cleave  the  isopeptide  bonds  of  lasso  peptides  produced  by  this 
organism and in this way transform them back into linear peptides that are easily degraded by other 
proteases. Furthermore, these enzymes are highly specific, i.e. they only recognize peptides in a 
lasso fold and not their branched-cyclic analogues and each isopeptidase just degrades the lasso 
peptides produced by one single biosynthetic machinery.23 Interestingly, the genes encoding these 
isopeptidases are part of a gene cluster adjacent to the respective biosynthetic gene clusters that 
produce  the  recognized  lasso  peptides.  Genome  mining  studies  furthermore  revealed  that  the 
co-occurrence of an ABC-type lasso peptide biosynthetic gene cluster and an adjacent isopeptidase 
encoding gene cluster seems to be highly conserved throughout proteobacteria.23,37 Still, it remains 
doubtful that these isopeptidases are indeed immunity factors. The reason for this notion is the lack 
of a significant antimicrobial activity of any of the newly isolated lasso peptides that were tested in 
this regard. In addition to this observation, a closer inspection of the other genes next to the ones 
encoding  the  respective  isopeptidases  also  suggests  a  different  function  for  these  systems 
(Figure 4.9).
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Figure 4.9. Schematic depiction of the basic organization of an ABC-type lasso peptide biosynthetic gene cluster and an 
adjacent isopeptidase gene containing cluster.37
Normally,  the first  two genes  in  these clusters encode a putative  σ-factor  and an anti-σ-factor, 
respectively. The next gene then usually encodes a putative TonB-dependent receptor and the fourth 
and last gene of these kind of cluster arrangements encodes the actual isopeptidase. Especially the 
presence of a TonB-dependent receptor, a protein that practically has the exact opposite function to 
an ATP-dependent exporter, suggests that the gene products of these clusters more likely play a role 
in  sensing,  uptake  and  subsequent  degradation  of  the  corresponding  lasso  peptides  instead  of 
conferring a resistance against supposedly antimicrobially active compounds. In this context, the 
question arises, why an organism should selectively take up a compound that it  also just could 
produce itself. The most likely answer for this would be that these molecules either act as signaling 
or as scavenger molecules. To resolve this, future studies need to address the function and role of 
the complete isopeptidase gene clusters, either by heterologously producing and characterizing the 
remaining three gene products adjacent to the isopeptidase gene or by incorporating mutations in 
the corresponding genomes with subsequent probing what differences occur if the complete or at 
least parts of such a cluster are knocked-out. In addition to this, supplemental studies should be 
performed on clusters that differ from both the well-known ABC- or ABCD-type arrangements, as 
this  could  reveal  yet  another  subclass  of  lasso  peptides  that  could  possibly  also  have  another 
biological function.
4.3 Potential of Modified Lasso Peptides for Medicinal Applications
Prior to the experiments presented here, a proof-of-concept study was published, detailing that it is 
generally possible to incorporate a bioactive peptide epitope into a lasso scaffold and thus creating a 
hybrid  compound  with  both  the  bioactivity  conferred  by  the  peptidic  pharmacophore  and  the 
physiological  stability  of  the  lasso  fold.65 Even  though  this  study  demonstrated  the  general 
possibility of such an endeavor, the resulting lasso graft had only an unsatisfactory binding affinity 
and selectivity for its target. Thus, we wanted to assess, if the basic bioactivity this graft exhibited 
could be improved. For this, a rational approach based on previous studies that were involved in the 
development of the peptidic drug cilengitide was chosen. Indeed, both consequently generated lasso 
peptide variants had an improved binding selectivity and in one case additionally a higher binding 
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affinity towards the target αvβ3 integrin receptor. The subsequent NMR based structure elucidation 
of MccJ25(RGDF) and molecular dynamics simulations with this structure furthermore confirmed 
that  the  improved  binding  behavior  most  likely  relates  to  direct  interactions  of  the  newly 
incorporated  phenylalanine  with  the  receptor  binding  pocket.69 Taken  together,  these  results 
demonstrate  that  grafted  lasso  peptides  can  indeed  be  optimized  by  rational  approaches. 
Nonetheless, this study also revealed some still existing drawbacks of the use of lasso peptides in 
epitope  grafting  efforts.  Besides  the  obvious  limitation  to  canonical  amino  acids  due  to  the 
persisting  lack  of  a  chemical  route  to  lasso  peptide  synthesis,  the  incorporation  of  the  desired 
mutations in the lasso peptide itself can already prove to be problematic. For example, although a 
manifold of unpublished mutants was generated in the course of the work on the improvement of 
the MccJ25(RGD) graft and even though their maturation was confirmed by LC-MS analysis, the 
alterations introduced in these variants reduced the lasso peptide yields so much that their isolation 
was not possible. In these attempts, the improved binding behavior should be achieved by either 
switching the position of the peptide epitope or by increasing the structural rigidity of the binding 
motif by incorporation of two cysteines that were able to form a disulfide bond. Thus, even though 
these variants were generated on a sound reasoning, the unsuccessful isolation of these compounds 
prohibited  the  assessment  of  them  in  regard  to  their  αvβ3  binding  behavior.  Therefore,  the 
introduction of a phenylalanine adjacent to the RGD binding motif was chosen, which finally not 
only yielded lasso grafts that were produced in amounts suitable for isolation, but which at the same 
time also showed the desired improved binding behavior. So, even though a positive result was 
obtained in  the end of  this  project,  in  future studies  the  aforementioned problems could either 
completely  prevent  the  incorporation  of  other  peptide  epitopes  or  at  least  prohibit  the  further 
improvement of an established, active lasso graft. Additionally, this problem also causes a challenge 
in regard to the high-throughput generation of diverse compound libraries for activity assessments. 
Although a general approach for this was shown in a study where randomly generated MccJ25 
variants were screened for an improved bactericidal activity, this was only possible due to the fact 
that  the  target  activity  allowed  a  very  straightforward  live-and-death-screening  of  the  newly 
generated  variants.66 Thus,  every other  target  activity would  require  the  prior  development  and 
establishment of another, more sophisticated system that allows a screening in this or a similar way,  
which is not always possible. In conclusion, lasso peptides generally do show potential in the field 
of epitope grafting approaches and for the development of drug leads. Nevertheless, the results 
obtained so far, though promising, emphasize that more work has to be done to increase the tool set  
to facilitate both the screening and development of novel bioactive lasso grafts and thus allowing an 
access to more efficient and more extensive ways to produce compound diversity.
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5. Outlook
5.1 The Next Obstacles in Lasso Peptide Research
Lasso peptide research has made big advances in recent years. Not only has the number of known 
lasso peptides and corresponding biosynthetic gene clusters drastically increased, but also more and 
more information about the biosynthesis, physico-chemical properties and distribution in nature of 
these interesting compounds has come to light. Nevertheless, since the isolation of the first lasso 
peptides many questions still remain unresolved, which have to be addressed in future research. The 
new research tasks derived from these questions include, but are not limited to, the search for novel 
and  so  far  uncharacterized  types  of  lasso  peptide  biosynthetic  gene  clusters,  getting  a  deeper 
understanding of the maturation enzymes including the underlying mechanism of the lasso peptide 
biosynthesis itself, studying their physico-chemical behaviors as well as finding out the reasons for 
differences of such properties for different lasso peptides and finding out more about their role in 
nature.  For this,  we can apply the lessons we already learned about lasso peptides and how to 
produce them, but we will also have to face new challenges when moving away from the familiar 
proteobacterial systems and have to start to find new solutions for upcoming problems. 
One  of  the  biggest  problems  in  this  regard  will  be  the  incompatibility  of  some  of  the 
non-proteobacterial  biosynthetic  gene  clusters  with  E. coli expression.  This  may be  caused  by 
obvious reasons like a different codon bias, but can also include more complex problems like the 
processing enzymes being adapted to a biochemical environment different to the one present inside 
E. coli cells. In these cases, several approaches could be pursued and future studies have to reveal 
which of them are most efficient for obtaining positive results. These approaches range from the de 
novo gene synthesis after optimization of the nucleotide sequence in respect to E. coli codon usage, 
over the complete change of the heterologous expression system to the thorough screening of a 
multitude  of  homologous  fermentation  conditions  to  find  conditions  favoring  the  lasso  peptide 
production by the original host organism. At least in the case of switching the heterologous host, 
there is one report where this was already done successfully. In this study, the biosynthetic gene 
cluster responsible for the lariatin production was identified in the genome of  Rhodococcus jostii  
K01-B0171, cloned in a suitable vector system and finally heterologously produced in a lariatin 
deficient Rhodococcus mutant strain.57 Of course, in this case the heterologous host was almost 
completely identical with the producing strain and as the authors did not comment on the yields of 
their heterologous lasso peptide production, it most likely was not too impressive, but still this study 
can be seen as a proof-of-principle that encourages the application of a similar methodology for 
future research. Such approaches are nowadays furthermore facilitated by the fact that more and 
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more  genetically  engineered  subspecies  of  organisms  like  Bacillus  subtilis,131 Streptomyces  
coelicolor132 or  Lactococcus  lactis133 are  established  as  heterologous  expression  hosts.  These 
systems additionally become increasingly attractive due to the steady optimization of corresponding 
genetic tools, which leads to the continuous improvement of the overall expression efficiency in 
these organisms. Still,  even though it  most likely would be beneficial to change the expression 
system from E. coli to a host that is more closely related to the strain the biosynthetic gene cluster in 
question  originated  from,  this  could  also  necessitate  the  development  of  a  completely  new 
optimization approach than the one we successfully employed for the proteobacterial lasso peptide 
biosynthetic gene clusters. Nevertheless, once established, such a new approach could hopefully be 
applied to all  or at  least  most of the clusters found in bacteria  belonging to  the corresponding 
phylum. As such, the development of this would be greatly desirable as it then could provide access 
to a so far mostly untapped source for lasso peptides, in particular when they are derived from 
clusters with more unusual genetic arrangements. In this regard, biosynthesis systems like the ones 
involved  in  the  production  of  the  RES-701  family  lasso  peptides  or  lassomycin  seem  to  be 
especially  interesting,  as  they  may provide  information  about  lasso  peptide  tailoring  enzymes, 
which is something research utterly neglected so far.
Still, future studies should not solely focus on the isolation of new lasso peptides, but also try to 
unveil more information about the mechanism of lasso peptide biosynthesis in general. So far, the 
research  in  this  area  is  proceeding  very  slowly  as  the  lasso  peptide  maturation  enzymes  are 
generally very challenging to work with. This notion is emphasized by all the unsuccessful attempts 
of getting soluble, active proteins from a manifold of different clusters that were made in all the 
years where lasso peptide research was conducted in this group. Then again, this general problem 
only means that a success in this regard would be even more interesting, as it may finally allow 
access to not only a more detailed characterization of the processing enzymes, but maybe also could 
lead to structural investigations of these enzymes and their interactions with the precursor peptides 
by means of X-ray crystallography, H-D exchange experiments and the likes.
Finally,  future research should strive to  establish the role  of  lasso peptides in  nature.  For  this, 
current leads like the proteobacterial lasso peptide isopeptidase containing gene clusters as well as 
the systems that produce antimicrobial lasso peptides should be primarily pursued, but at the same 
time completely new and unknown systems should not be completely ignored either.
In summary, even though plenty of new information about lasso peptides was obtained in recent 
years, many more insights about this intriguing family of natural products are just waiting to be 
uncovered.
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5.2 Epitope Grafting of Lasso Peptides
Since it was both shown to be possible to successfully graft peptide epitopes into lasso peptide 
scaffolds65 as well as to furthermore improve these bioactive grafts by rational means,69 the next 
goal should be to apply these techniques to new epitopes and new biological targets. For this, all 
peptide epitopes that use canonical amino acids and have a size of up to five residues seem to be 
promising starting points at the moment. Still, for this research to excel, additional studies assessing 
the use of lasso peptide scaffolds different to MccJ25 as well as testing ways to utilize methods for 
the  in vivo incorporation of non-canonical amino acids and the chemical modification of isolated 
lasso peptides should be conducted simultaneously.  These complementary studies could help to 
emphasize  the  potential  of  lasso peptides  as  grafting  scaffolds  and could  facilitate  an  efficient 
access to new and more diverse lasso peptide variants.
As such, it becomes clear that epitope grafting with lasso peptides is still in its infancy and currently 
cannot  rival  already  well-established  grafting  platforms  like  cyclotides.  Nonetheless,  some 
characteristics of lasso peptides would nicely complement these well-known systems and thus it 
seems promising to further pursue the use of lasso peptides in drug development.
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Protease Stability Assays Highlight the Resistance of the Lasso Fold Against Proteolytic 
Degradation. The stability of the caulosegnins against proteolytic degradation by trypsin, 
chymotrypsin, elastase, proteinase K and carboxypeptidase Y was tested. These assays were also 
performed with samples of caulosegnin I and III which were mostly unthreaded by heating them to 
95 °C for 1 h. This was done to allow a comparison of the lasso fold to the branched cyclic 
analogues in regard to their protease sensitivity and to further proof their proposed topologies. 
In general these experiments showed the high stability of caulosegnins against proteolytic 
degradation with caulosegnin I and III being only slightly digested in some cases, while 
caulosegnin II was not affected at all by any of the tested proteases. On the other hand, the 
unthreaded caulosegin I and III were highly sensitive against all tested proteases (Figure S11-S13, 
Table S8). 
As carboxypeptidase Y cleaves off amino acids from the C-terminus of a peptide chain, these 
assays were of particular interest as they could provide information about the present topology of the 
digested compound. The branched cyclic analogue of caulosegnin I was readily digested to a point 
where only four amino acids after the macrolactam ring remained, while the branched cyclic 
analogue of caulosegnin III was digested until only one additional amino acid after the macrolactam 
ring was present, thus proving the proposed topology in both cases. In contrast the assays of 
caulosegnin I and III showed that even after 16 h of incubation only trace amounts of these 
degradation products were present, which were most likely formed by the digestion of branched 
cyclic peptide formed during the course of these assays because of the heat lability of both lasso 
peptides. These observations are in accordance with the notion that the macrolactam ring is able to 
sterically shield amino acids positioned inside or close by the ring from proteolytic degradation. 
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Mass Spectrometric Analysis Supports the Suggested Plugs of Caulosegnin II and III. MS
2
 
analysis was used to confirm the primary structures of the investigated lasso peptides, their variants 
and their branched cyclic analogues. MS
2
 spectra, independent from the present topology, contained 
all fragments corresponding to the predicted amino acid sequence (lacking a water molecule) up to 
the position of the proposed macrolactam ring. This is not only a strong hint for the presence of a 
macrolactam ring, but also indicates that it has to be formed between the suggested residues. Tandem 
mass spectrometry thus confirms the predicted primary structure, indicates that the proposed position 
and presence of a macrolactam ring is correct and shows a difference between the proposed lasso 
and branched cyclic topologies. This is, in combination with the facts that the predictions were all 
based on information derived from the biosynthetic gene cluster and that NMR structure elucidation 
confirmed the lasso topology of caulosegnin I, strong evidence of all caulosegnins being true lasso 
peptides. With a similar set of MS data, but lacking a biochemical link between the compound and 
the proposed biosynthetic gene cluster, any mutational analysis, protease assays, thermal stability 
assays and without any 3D structural proof of the biosynthetic gene cluster being generally able to 
produce lasso peptides, the discovery of two new lasso peptides was recently reported (Kersten, R. 
D.; Yang, Y. L.; Xu, Y.; Cimermancic, P.; Nam, S. J.; Fenical, W.; Fischbach, M. A.; Moore, B. S.; 
Dorrestein, P. C. Nat. Chem. Biol. 2011, 7, 794-802), which further emphasizes the potency of mass 
spectrometric analysis in this regard. 
Additionally comparison of signal intensities of a lasso peptide and its branched cycled analogue 
yields interesting information about the lasso fold. In case of caulosegnin I (Figure S15) relative 
signal intensities for both the single and double charged b17 fragment ions increased drastically for 
the branched cyclic compared to the lasso peptide. This fragment corresponds to a bond breakage 
after Ile17, which is located one amino acid after the lower plug Glu16. In a similar fashion the 
intensities of the b17 fragment ions of caulosegnin II (Figure S16) and caulosegnin III (Figure S17) 
show a significant increase for the branched cylic analogues, which corresponds to bond breakages 
in the same distance to the suggested plugs and thus supports the idea of Tyr16 sterically trapping the 
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tail inside the ring of the lasso peptides. 
For caulosegnin II it can additionally be observed, that the lasso peptide fragmentation yields 
much more intensive signals for the fragments formed by bond breakage before the Pro13 (namely 
the y7 and b12 fragment ions). This suggests a constrained conformation of Pro13 in the lasso fold, 
leading to the notion of Pro13 possibly being the turning point of the loop of caulosegnin II similar 
to Pro12 being the turning point of the loop of caulosegnin I. Not surprisingly a similar observation 
is not found for caulosegnin I, as the additional amino acid in the loop would lead to a more relaxed 
conformation. 
In the case of caulosegnin III bond breakages before the Ala14 (leading to the y6 and b13 fragment 
ions) are also more intensive for the lasso peptide, which suggests that because of the lacking proline 
residue, a slightly different, but still constrained, loop conformation is present. Furthermore the 
fragmentation spectrum of the branched cyclic analogue of caulosegnin III exhibits much stronger 
signals for the b14, b15, b16 and y5 fragment ions. These are all ions formed by a bond breakage in 
the area where the tail supposedly passes the ring in the lasso peptide. As it can be expected that 
bond breakages occur more often if the peptide bond is not shielded by the macrolactam ring, these 
are additional hints for the caulosegnin III plug being in the assumed area of the peptide's tail. 
 
NMR Spectroscopic Analysis: Torsion Angles and Side Chain Stereospecific Assignment. 
Distinct values of vicinal coupling constants (6.0 and 9.7 Hz) were observed for Gly1, Gly5, and 
Gly14, thus the torsion angles  were unequivocally assigned to -120 ± 15° (Güntert, P.; Braun, W.; 
Billeter, M.; Wüthrich, K. J. Am. Chem. Soc. 1989, 111, 3997-4004). The torsion angles  were 
restrained to -70°  30° for Gln6, Glu8, Ala9, Asn11, Leu13, Glu16, Ile17, and Gln18 with 
3
JHN < 9 
Hz, and -120°  30° for the remaining residues with 
3
JHN  9 Hz. Stereospecific assignment of the 
following prochiral methylene protons were fulfilled by measuring 3J and analyzing patterns of 
the intraresidual NOE interactions d and dN(Wagner, G. Prog. NMR Spec. 1990, 22, 101-139.): 
Phe3, Glu8, Leu13, Glu16, and Gln18 in (t
2
g
3
); Gln6 and Arg15 in (g
2
g
3
), and Asn11 in (g
2
t
3
). For 
S5 
t
2
g
3
, g
2
g
3
, and g
2
t
3
 conformations around the CC bond the torsion angle 
1
 was constrained in 
the range of -60  30°, 60  30°, and 150  30°, respectively. 
 
 
Supplementary Figures and Tables 
 
Supplementary Figure S1. Chromatograms of the HPLC purification of caulosegnin I. (a) First 
purification with water/0.05% formic acid and MeOH/0.045% formic acid. (b) Second purification 
with water/0.1% TFA and MeCN/0.1% TFA. 
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Supplementary Figure S2. Chromatograms of the HPLC purification of caulosegnin II. (a) First 
purification with water/0.05% formic acid and MeOH/0.045% formic acid. (b) Second purification 
with water/0.1% TFA and MeCN/0.1% TFA. 
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Supplementary Figure S3. Chromatograms of the HPLC purification of caulosegnin III. (a) First 
purification with water/0.05% formic acid and MeOH/0.045% formic acid. (b) Second purification 
with water/0.1% TFA and MeCN/0.1% TFA. 
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Supplementary Figure S4. DQF-COSY spectrum in the fingerprint region of caulosegnin I in 
methanol-d3 at 288 K. 
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Supplementary Figure S5. Section of the TOCSY spectrum (mixing time 140 ms) of caulosegnin I 
in methanol-d3 at 288 K. 
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Supplementary Figure S6. Section of the NOESY spectrum (mixing time 300 ms) of caulosegnin I 
in methanol-d3 at 288 K. 
 
S11 
 
Supplementary Figure S7. 
1
H, 
15
NHSQC spectrum of caulosegnin I in methanol-d3 at 288 K. 
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Supplementary Figure S8. 
1
H variable temperature spectra in NH region of cauloesegnin I in 
methanol-d3. 
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Supplementary Figure S9. 
1
H variable delay spectra in NH region of caulosegnin I in methanol-d4. 
Spectrum in methanol-d3 is shown as reference. The spectra were recorded at 288 K. 
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Supplementary Figure S10. Interactions between the C-terminal tail and the macrocyclic ring of 
caulosegnin I shown in stereoview. The surface of the ring is colored in orange, the surface of the 
side chains from Arg15 and Glu16 are colored by elements. Steric hindrance caused by the depicted 
side chains traps the tail within the ring. (a) Shown from below, (b) from the side and (c) from above 
the ring. 
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Supplementary Figure S11. Chromatograms of the heat stability assays of caulosegnin IIII. (a) 
Incubation of caulosegnin I at 95 °C for different time intervals. (b) Incubation of caulosegnin I at 
different temperatures for 4 h. (c) Incubation of caulosegnin II at 95 °C for different time intervals. 
(d) Incubation of caulosegnin II at different temperatures for 4 h. (e) Incubation of caulosegnin III at 
95 °C for different time intervals. (f) Incubation of caulosegnin III at different temperatures for 4 h. 
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Supplementary Figure S12. Chromatograms of the protease stability assays of caulosegnin I. The digests of 
lasso peptide is shown in blue, the digest of thermally unthreaded caulosegnin I ist shown in red. (a) 
Chymotrypsin, 4 h, 25 °C. (b) Trypsin, 4 h, 25 °C. (c) Elastase, 4 h, 37 °C. (d) Proteinase K, 4 h, 37 °C. (e) 
Carboxypeptidase Y, 16 h, 25 °C. Signals marked with an asterisk could not be assigned to a specific 
fragment. 
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Supplementary Figure S13. Chromatograms of the protease stability assays of caulosegnin III. The digests of 
lasso peptide is shown in blue, the digest of thermally unthreaded caulosegnin I is shown in red. (a) Chymotrypsin, 
4 h, 25 °C. (b) Trypsin, 4 h, 25 °C. (c) Elastase, 4 h, 37 °C. (d) Proteinase K, 4 h, 37 °C. (e) Carboxypeptidase Y, 
16 h, 25 °C. Signals marked with an asterisk could not be assigned to a specific fragment. 
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Supplementary Figure S14. Extracted ion chromatograms of (a) caulosegnin I P12A and (b) 
caulosegnin I E16A prior and after heating at 95 °C for 1 h. For caulosegnin I P12A the increase of 
the amount of unthreaded lasso peptide is observable, while heating does not affect caulosegnin I 
E16A at all. The lack of formation of a second peak would be due to the fact that the variant is either 
a heat stable lasso peptide or is already a branched cyclic peptide which can not further unthread. As 
it would make no sense that replacing the plug with a much smaller amino acid would lead to a heat 
stable variant, the latter must be the case. This behaviour was observed for every variant being 
designated as a branched cyclic peptide. 
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Supplementary Figure S15. MS
2
 fragmentation of caulosegnin I and its branched cyclic analogue. 
Fragments of the b-series are highlighted in blue, fragments of the y-series in red. 
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Supplementary Figure S16. MS
2
 fragmentation of caulosegnin II and its branched cyclic analogue. 
Fragments of the b-series are highlighted in blue, fragments of the y-series in red. 
 
S21 
 
Supplementary Figure S17. MS
2
 fragmentation of caulosegnin III and its branched cyclic analogue. 
Fragments of the b-series are highlighted in blue, fragments of the y-series in red. 
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Supplementary Figure S18. Comparison of class II lasso peptide structures. The ring forming 
aspartate/glutamate is shown in red, the remaining amino acids of the macrolactam ring are shown in 
yellow, the tail amino acids are shown in blue and the side chains of the amino acids which were 
proposed to sterically trap the tail inside the ring are highlighted in green. The shown lasso peptides 
(as sticks on the left and overlayed with surface maps on the right) are MccJ25
18
 (a), caulosegnin I 
(b), capistruin
12
 (c) and lariatin A
11
 (d). 
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Supplementary Table S1. M9 Vitamin Mix. 
component amount 
choline chloride 1.0 g 
folic acid 1.0 g 
pantothenic acid 1.0 g 
nicotinamide 1.0 g 
myo-inositol 2.0 g 
pyridoxal hydrochloride 1.0 g 
thiamine 1.0 g 
riboflavin 0.1 g 
disodium adenosine 5'-triphosphate 0.3 g 
biotin 0.2 g 
 ad 300 mL ddH2O
a
 
a
10 M NaOH were added to the resulting suspension until everything was dissolved. Afterwards 
solution was sterile filtered and stored at 4 °C until needed. 
 
 
 
 
Supplementary Table S2. Cloning primers. Introduced restriction sites are underlined. 
name sequence 
Cseg_A1_NdeI_FP
a GGATTAC CAT ATG ACC AAG AAG AAC GCC ACC CAA G 
Cseg_C_HindIII_RP
a ATAT AAG CTT TCA ACG GGT GTT CGC CTT CCT CG 
LambdaTerm_McjProm_KpnI_FP
b ATAT GGT ACC AGC TTA ATT AGC TGA GCT TGG ACT CCT GTT GAT 
AG 
LambdaTerm_McjProm_EcoRI_RP
b TATAT GAA TTC CAC TCC CTC CTG TAG TTA TGC CTT TAC ACT CAA 
TTG G 
CsegBC-pET41a_EcoRI_FP
c ATATA GAA TTC ATG GAC CTG TGG CTC AGC GCC GGC GTG TAC 
CsegA1-pET41a_KpnI_RP
c ATAT GGT ACC TCA GCC TTG GAT TTC GCG GCC GAG CGG ATT G 
a
C. segnis chromosomal DNA was used as template 
b
pJP3 was used as template (Pan, S. J.; Cheung, W. L.; Link, A. J. Prot. Expr. Purif. 2010, 71, 
 200-206). 
cCseg AAABC pET41a was used as template 
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Supplementary Table S3a. Caulosegnin I mutagenesis primers. 
All primers were 5'-phosphorylated. Mutated sequences are marked in bold. A mutant was generated 
via PCR with a FP or RP carrying the desired mutation and a respective WT RP or FP. CsegA1_T-
P_BC pET41a was used as template for all PCRs. 
name sequence 
CsegA1_WT_FP AAT CCG CTC GGC CGC GAA ATC CAA GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA1_WT_RP GAC CGC TTC GGG CTG GCC GAC GAA CGC GCC  TTG CGT CAG GCG ATG GGC 
GTC GCC GAC GC 
CsegA1_T-2A_RP GAC CGC TTC GGG CTG GCC GAC GAA CGC GCC  TTG CGC CAG GCG ATG GGC 
GTC GCC GAC GC 
CsegA1_T-2C_RP GAC CGC TTC GGG CTG GCC GAC GAA CGC GCC  TTG GCA CAG GCG ATG GGC 
GTC GCC GAC GC 
CsegA1_T-2I_RP GAC CGC TTC GGG CTG GCC GAC GAA CGC GCC  TTG AAT CAG GCG ATG GGC 
GTC GCC GAC GC 
CsegA1_T-2S_RP GAC CGC TTC GGG CTG GCC GAC GAA CGC GCC  TTG GCT CAG GCG ATG GGC 
GTC GCC GAC GC 
CsegA1_T-2V_RP GAC CGC TTC GGG CTG GCC GAC GAA CGC GCC  TTG AAC CAG GCG ATG GGC 
GTC GCC GAC GC 
CsegA1_G1A_RP GAC CGC TTC GGG CTG GCC GAC GAA CGC GGC  TTG CGT CAG GCG ATG GGC 
GTC GCC GAC GC 
CsegA1_G1C_RP GAC CGC TTC GGG CTG GCC GAC GAA CGC GCA  TTG CGT CAG GCG ATG GGC 
GTC GCC GAC GC 
CsegA1_G1F_RP GAC CGC TTC GGG CTG GCC GAC GAA CGC AAA  TTG CGT CAG GCG ATG GGC 
GTC GCC GAC GC 
CsegA1_E8D_RP GAC CGC ATC GGG CTG GCC GAC GAA CGC GCC  TTG CGT CAG GCG ATG GGC 
GTC GCC GAC GC 
CsegA1_P12A_FP AAT GCG CTC GGC CGC GAA ATC CAA GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA1_L13_FP AAT CCG GGC CGC GAA ATC CAA GGC TGA GGT ACC AGC TTA ATT AGC TGA 
GCT TGG ACT CCT GTT G 
CsegA1_R15A_FP AAT CCG CTC GGC GCG GAA ATC CAA GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA1_E16A_FP AAT CCG CTC GGC CGC GCG ATC CAA GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA1_E16D_FP AAT CCG CTC GGC CGC GAT ATC CAA GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA1_E16K_FP AAT CCG CTC GGC CGC AAA ATC CAA GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
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Supplementary Table S3b. Caulosegnin I mutagenesis primers. 
All primers were 5'-phosphorylated. Mutated sequences are marked in bold. A mutant was generated 
via PCR with a FP or RP carrying the desired mutation and a respective WT RP or FP. CsegA1_T-
P_BC pET41a was used as template for all PCRs. 
name sequence 
CsegA1_E16L_FP AAT CCG CTC GGC CGC CTG ATC CAA GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA1_E16M_FP AAT CCG CTC GGC CGC ATG ATC CAA GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA1_E16N_FP AAT CCG CTC GGC CGC AAC ATC CAA GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA1_E16Q_FP AAT CCG CTC GGC CGC CAG ATC CAA GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA1_E16A_I17A_FP AAT CCG CTC GGC CGC GCG GCC CAA GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA1_I17A_FP AAT CCG CTC GGC CGC GAA GCG CAA GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA1_I17STOP_FP AAT CCG CTC GGC CGC GAA TAA CAA GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA1_Q18STOP_FP AAT CCG CTC GGC CGC GAA ATC TAA GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA1_G19STOP_FP AAT CCG CTC GGC CGC GAA ATC CAA TAA TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
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Supplementary Table S4. Caulosegnin II mutagenesis primers. 
All primers were 5'-phosphorylated. Mutated sequences are marked in bold. A mutant was generated 
via PCR with a FP carrying the desired mutation and a WT RP. CsegA1-QG-A2_T-P_BC pET41a 
was used as template for all PCRs. 
name sequence 
CsegA2_WT_RP ATC CTC CGG CAG GCC CGG AGT GAG CGT GCC  TTG CGT CAG GCG ATG GGC 
GTC GCC GAC GC 
CsegA2_P13A_FP TTC CTG GCG GGC CAC TAC ATG CCG GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA2_H15A_FP TTC CTG CCT GGC GCG TAC ATG CCG GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA2_Y16A_FP TTC CTG CCT GGC CAC GCG ATG CCG GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA2_M17A_FP TTC CTG CCT GGC CAC TAC GCG CCG GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA2_P18A_FP TTC CTG CCT GGC CAC TAC ATG GCG GGC TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
 
Supplementary Table S5. Caulosegnin III mutagenesis primers. 
All primers were 5'-phosphorylated. Mutated sequences are marked in bold. A mutant was generated 
via PCR with a FP carrying the desired mutation and a WT RP. CsegA1-QG-A3_T-P_BC pET41a 
was used as template for all PCRs. 
name sequence 
CsegA3_WT_RP GTC CTC GAG CAG CAG GCC CAC CAG CGC GCC  TTG CGT CAG GCG ATG GGC 
GTC GCC GAC GC 
CsegA3_V13P_FP ATC ACC CCG GCC CGC TAC GAC CCG ATG TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA3_R15A_FP ATC ACC GTG GCC GCG TAC GAC CCG ATG TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA3_Y16A_FP ATC ACC GTG GCC CGC GCG GAC CCG ATG TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA3_D17A_FP ATC ACC GTG GCC CGC TAC GCG CCG ATG TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA3_P18A_FP ATC ACC GTG GCC CGC TAC GAC GCG ATG TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
CsegA3_M19A_FP ATC ACC GTG GCC CGC TAC GAC CCG GCG TGA GGT ACC AGC TTA ATT AGC 
TGA GCT TGG ACT CCT GTT G 
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Supplementary Table S6. Primers for modification of plasmid via deletion, insertion or 
replacement of DNA sequences. All primers were 5'-phosphorylated. Inserted sequences are 
underlined. 
name sequence 
CsegA1BC_FP
a TGA GAC GGC GGC CTT GGC CCC GAG CGC CGG G 
CsegA1BC_RP
a GCC TTG GAT TTC GCG GCC GAG CGG ATT GAC CGC TTC GG 
CsegA1A2BC_FP
a TGA GAC GGC GGC CTT GGC CCC GAG CGC CGG G 
CsegA1A2BC_RP
a GCC CGG CAT GTA GTG GCC AGG CAG GAA ATC CTC CGG CAG G 
CsegA2BC_FP
b ATG ACC AAG ACC CAT CGC CTG ATC CGC CTG GGC GAC GCC C 
CsegA2BC_RP
b ATG TAT ATC TCC TTC TTA AAG TTA AAC AAA ATT ATT TCT AGA GGG GAA 
TTG TTA TCC GCT C 
CsegA3BC_FP
a ATG ACG TCT AGG TTT CAA CTG CTG CGA TTG GGC AAG GCC 
CsegA3BC_RP
a ATG TAT ATC TCC TTC TTA AAG TTA AAC AAA ATT ATT TCT AGA GGG GAA 
TTG TTA TCC GCT C 
CsegA1-QG-A2BC_FP
b GGC ACG CTC ACT CCG GGC CTG CCG GAG GAT TTC CTG CC 
CsegA1-QG-A2BC_RP
b TTG CGT CAG GCG ATG GGC GTC GCC GAC GCG C 
CsegA1-QG-A3BC_FP
a GGC GCG CTG GTG GGC CTG CTG CTC GAG GAC ATC AC 
CsegA1-QG-A3BC_RP
a TTG CGT CAG GCG ATG GGC GTC GCC GAC GCG C 
CsegA1_RBS_FP
a AGAGGAGAAATTAACC ATG GAC CTG TGG CTC AGC GCC GGC GTG TAC G 
CsegA1_RBS_RP
a TCA GCC TTG GAT TTC GCG GCC GAG CGG ATT GAC 
CsegA1-QG-A2-T-P-BC FP
c TTC CTG CCT GGC CAC TAC ATG CCG GGC TGA GGT ACC AGC TTA ATT 
AGC TGA GCT TGG ACT CCT GTT G 
CsegA1-QG-A2-T-P-BC RP
c ATC CTC CGG CAG GCC CGG AGT GAG CGT GCC TTG CGT CAG GCG ATG 
GGC GTC GCC GAC GC 
CsegA1-QG-A3-T-P-BC FP
c ATC ACC GTG GCC CGC TAC GAC CCG ATG TGA GGT ACC AGC TTA ATT 
AGC TGA GCT TGG ACT CCT GTT G 
CsegA1-QG-A3-T-P-BC RP
c GTC CTC GAG CAG CAG GCC CAC CAG CGC GCC TTG CGT CAG GCG ATG 
GGC GTC GCC GAC GC 
aCseg AAABC pET41a was used as template 
bCseg A1A2BC pET41a was used as template 
cCseg A1_T-P_BC pET41a was used as template 
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Supplementary Table S7. Production of different constructs used for optimization of caulosegin IIII 
production. Presented absolute values are the integrals of the UV peaks of the lasso peptides from 
LCMS measurements of 100 L of the respective extracts. 
name UV peak 
area test 1 
UV peak 
area test 2 
UV peak 
area test 3 
UV peak 
area test 4 
mean value 
cseg AAABC  
pET41a
a
 
2534249 2898494 2124794 2560477 2529504 
cseg A1BC  
pET41a 
47671898 32481826 47204768 28266509 38906251 
cseg A1_RBS_BC 
 pET41a 
406593390 454829558 377863698 426010521 416324292 
cseg A1_TP_BC 
 pET41a 
518756822 433002760 719951408 885837566 639387139 
cseg A2BC  
pET41a 
2206210 1839511 1411016 2252130 1927217 
cseg A1-QG-A2BC 
 pET41a 
10840516 18858142 6480280 16528542 13176870 
cseg A1-QG-A2_ 
TP_BC pET41a 
239859039 403669011 308412837 336169281 322027542 
cseg A3BC  
pET41a 
1985625 2510361 233457 1419537 1537245 
cseg A1-QG-A3BC  
pET41a 
5242645 4489823 3627624 3917621 4319428 
Cseg A1-QG-A3_ 
TP_BC pET41a 
276867510 156550224 161126313 273336172 216970055 
a
Only caulosegnin I was produced in amounts big enough to yield an UV signal and thus was the 
only lasso peptide which production could be determined by UV peak integration. 
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Supplementary Table S8. Overview of the sensitivity against proteolytic degradation of the 
caulosegnins and their branched cyclic analogues. If more than one degradation product was 
detected, the main product is shown in bold. (see also figure S5-S6) 
 trypsin chymotrypsin elastase proteinase K carboxy-
peptidase Y 
caulosegnin I full length, 
 traces of -4 aa 
full length, 
traces of -6 aa 
full length, 
traces of -6 aa 
only full length full length, 
traces of -2 aa, -
3 aa, -7 aa 
caulosegnin I, 
unthreaded 
-4 aa
a
 -4 aa, -6 aa
a
 -6 aa
a
 -11 aa
a
 -2 aa, -3 aa, 
-7 aa
a
 
caulosegnin II only full length only full length only full length only full length only full length 
 
caulosegnin III only full length only full length full length, 
traces of -7 aa 
only full length full length, 
 traces of -9 aa 
caulosegnin III, 
unthreaded 
-4 aa, -9 aa, 
-2 aa 
-3 aa, -6 aa, 
- 9aa 
-7 aa, -9 aa complete 
degradation 
-9 aa 
a
Full length peptide was still detectable 
 
 
Supplementary Table S9. Structural Statistics for the Family of 15 Structures Selected to Represent 
the Solution Structure of caulosegnin I. 
Restraining Constraints Constraints Violations 
Total: 181 Distance violations, >0.5 Å: 0 
distance, i=j: 74 RMS deviations: 0.02 Å 
distance, |i-j|=1: 36 Dihedral violations, > 5°: 0 
distance, |i-j|>1: 38 RMS deviation: 2.4° 
dihedral: 33 Average pairwise RMS deviation (Thr
2
-Phe
18
) 
hydrogen bond: 0 Backbone atoms: 0.03 Å 
Constraints/residue: 9.5 All heavy atoms: 0.35 Å 
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Supplementary Table S10. Assignment of 
1
H and 
15
N Signals (ppm) of caulosegnin I in 
methanol-d3 at 288 K. 
AA NH H H others 
15
N 
Gly1 7.778 4.415; 3.378 / / 108.9 
Ala2 8.501 4.324 1.589 / 125.7 
Phe3 7.979 4.922 2.797; 3.419  115.1 
Val4 7.031 4.367 1.905 CH3: 0.937 114.8 
Gly5 8.465 4.343; 3.396  / 108.0 
Gln6 8.161 4.650 2.079; 2.318 CH2: 2.138; 2.550 
NH2: 7.674; 7.061 
121.9 
NH2: 
108.8 
Pro7 / 4.802 2.562; 1.753 CH2: 1.880; 2.135 
CH2: 3.592; 3.847 
/ 
Glu8 7.945 4.029 1.683; 2.696 CH2: 2.135; 2.013 123.7 
Ala9 8.444 3.940 1.376 / 124.1 
Val10 7.432 4.099 2.348 CH3: 0.874; 0.936 106.2 
Asn11 6.985 4.972 3.037; 2.594 NH2: 7.565; 6.971 113.0 
NH2: 
108.7 
Pro12 / 4.672 2.319; 1.934 CH2: 1.996 
CH2: 3.587; 3.821 
/ 
Leu13 7.514 4.345 1.832; 1.619 CH: 1.682 
CH3: 0.975; 0.894 
115.1 
Gly14 8.188 4.315; 3.807  / 108.0 
Arg15 7.855 5.061 0.635; 0.963 CH2: 1.036; 1.241 
CH2: 3.186; 2.885 
NH: 7.247 
117.0 
Glu16 9.322  4.882 2.006; 2.226 CH2: 2.366 118.8 
Ile17 9.059 4.179 1.830 CH2: 1.755; 1.081 
CH3: 0.970 
CH3: 0.910 
126.6 
Gln18 8.889 4.543 2.195; 1.836 CH2: 2.318 
NH2: 7.263; 6.708 
127.0 
NH2: 
111.1 
Gly19 8.384 3.979; 3.870  / 108.3 
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Supplementary Table S11. Production of the different caulosegin I variants. Presented absolute 
values are the integrals of the UV peaks of the lasso peptides from LCMS measurements of 100 L 
of the respective extracts. 
name UV peak area relative production retention time branched cyclic peptide / 
retention time lasso peptide 
WT 389998258 1.00 24.5 min / 27.0 min 
T2A 1318633 >0.01 24.5 min / 27.0 min 
T2C 137451137 0.35 24.5 min / 27.0 min 
T2I 11431440 0.03 24.5 min / 27.0 min 
T2S 13727351 0.04 24.5 min / 27.0 min 
T2V 34381092 0.09 24.5 min / 27.0 min 
G1A only mass >0.01 23.8 min / 26.3 min 
G1C 2560643 >0.01 24.5 min / 25.7 min 
G1F - - - 
E8D - - - 
P12A 27804733 0.07 23.6 min / 25.6 min 
L13 15503862 0.04 20.1 min / 23.5 min 
R15A 146869268 0.38 22.7 min / 24.4 min 
E16A 3967317 0.01 23.6 min / - 
E16D 300678905 0.77 22.7 min / 25.7 min 
E16K 213060796 0.55 25.0 min / 26.7 min 
E16L 42339595 0.11 25.8 min / 26.5 min 
E16N 13363270
a
 0.03 22.4 min / 26.1 min 
E16Q 95537464 0.25 22.5 min / 25.9 min 
E16A/I17A 10207088 0.03 21.9 min / - 
I17A 285451281 0.73 21.3 min / 24.5 min 
I17STOP only mass >0.01 21.7 min / 24.7 min 
Q18STOP 170273857 0.44 24.3 min / 27.1 min 
G19STOP 423351745 1.09 23.2 min / 25.9 min 
a
UV peak area was integrated for the branched-cyclic analogue as it greatly exceeded the signal of 
the original lasso peptide.
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Supplementary Table S12. Production of the different caulosegin II variants. Presented absolute 
values are the integrals of the UV peaks of the lasso peptides from LCMS measurements of 100 L 
of the respective extracts. 
name UV peak area relative production retention time branched cyclic peptide / 
retention time lasso peptide 
WT 251781008 1.00 26.0 min
a
 / 27.5 min 
P13A 104604208 0.42 26.1 min
a
 / 26.9 min 
H15A 126115859 0.50 25.4 min
a
 / 26.6 min 
Y16A only mass >0.01 25.6 min
b
 / - 
M17A 110407726 0.44 25.4 min
a
 / 26.8 min 
P18A 355436554 1.41 25.8 min
a
 / 27.3 min 
a
Determined by incubating the extracts at 95 °C for 8 h to generate trace amounts of unthreaded 
lasso peptide. 
b
Retention time did not change after incubating the extract at 95 °C for 8 h. 
 
 
Supplementary Table S13. Production of the different caulosegin III variants. Presented absolute 
values are the integrals of the UV peaks of the lasso peptides from LCMS measurements of 100 L 
of the respective extracts. 
name UV peak area relative production retention time branched cyclic peptide / 
retention time lasso peptide 
WT 135593658 1.00 29.5 min / 28.3 min 
V13P 265951883 1.96 28.7 min / 27.8 min 
R15A - - - 
Y16A - - - 
D17A 15218857 0.11 29.9 min / 29.2 min 
P18A 65873784 0.49 29.7 min / 28.3 min 
M19A 227569542 1.68 29.0 min / 27.5 min 
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Supplementary Figure S 1, related to Figure 1. Purification of astexin-1 products. A Preparative HPLC chromatogram. 1 Astexin-
1(18), (19), (21), (22) and (23), 2 Astexin-1(20). B Chromatogram of the first analytical HPLC. 3 Astexin-1((19), 4 Astexin-1(18) and 
(23), 5 Astexin-1(21) and (22), 6 Astexin-1(20). C Chromatogram of the second analytical HPLC. 7 Astexin-1((18), 8 Astexin-1(23) 
4 
Supplementary Figure S 2, related to Figure 2. Exemplary heat stability of three different astexin-1 variants. A astexin-1(16) Δ7 
variant as an example of a heat labile variant, B astexin-1(19) Y14A variant as an example of an already unfolded variant, C astexin-
1(19) F15W variant as the only heat stable variant. Each sample is shown as TIC and EIC on the left, MS and MS² spectra in the middle 
5and on the right. MS and MS² spectra in the middle correspond to the peaks before, while those on the right correspond to the peaks 
after heat treatment. 
 
Supplementary Figure S 3, related to Figure 3. Stability of native astexin-1 and variants against proteolytic degradation shown as 
HPLC chromatograms (A – J) or EIC (K – M). Trypsin digestion of WT astexin-1(19) A before and B after heat treatment. 1 astexin-
1(19) lasso, 2 astexin-1(19) unfolded. Trypsin digestion of WT astexin-1(23) C before and D after heat treatment. 3 astexin-1(23) lasso, 
4 astexin-1(23) unfolded, 5 astexin-1(19) lasso, 6 astexin-1(19) unfolded. Carboxypeptidase Y digestion of the astexin-1 Δ7(16) variant 
E before and F after heat treatment. 7 astexin-1(16) lasso, 8 astexin-1(16) unfolded, 9 astexin-1(11) and (13), 10 astexin-1(10). 
Carboxypeptidase Y digestion of the astexin-1 Δ6(17) variant G before and H after heat treatment. 11 astexin-1(17) lasso, 12 astexin-
1(17) unfolded, 13 astexin-1(14), 14 astexin-1(12) and (13). Carboxypeptidase Y digestion of the R19W astexin-1 variants (19) and (21) 
I before and J after heat treatment. 15 astexin-1(19), 16 astexin-1(21), 17 astexin-1(19) unfolded, 18 astexin-1(21) unfolded. 
Carboxypeptidase Y digestion of variants K D9E, L Y14A and M F15W shown as EIC.  
6 
 
 
Supplementary Figure S 4, related to Figure 5. Variable temperature 1H spectra in the region 9.65 – 6.75 ppm of astexin-1(19) in 
H2O/D2O (9:1). The labels are signal assignments of the amide protons, whereby x stands for an impurity. 
  
7 
Supplementary Figure S 5, related to Figure 6. Section of NOESY spectrum (mixing time 300 ms) of astexin-1(19) in H2O/D2O at 
283 K. 
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Supplementary Figure S 6, related to Figure 7. Quality comparison of the here presented and the recently published structure 
(Maksimov, et al., 2012). A Ramachandran Plot of the 20 lowest energy structures of astexin-1(19) created by PROCHECK NMR. B 
Ramachandran plot of the 20 lowest energy structures of astexin-1(23) from Maksimov et al. 2012. C Superimposition of the 20 
minimum energy structures of astexin-1(19) in the same color code as Figure 6A. D Superimposition of the 20 minimum energy 
structures of astexin-1(23) in the same color code created with PyMol from the PDB file 2LTI (Maksimov, et al., 2012). 
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Additional Figure 1 Section of DQF-COSY spectra of A lasso astexin-1(23) and B unfolded astexin-1(19) in DMSO-d6 at 295 K 
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Supplementary Table S 1, related to Figure 4. Summary of the results of the mutational analysis of the 
astexin-1 system including production, heat stability and stability against carboxypeptidase Y. 
 
mutant rel. production by 
Integration of UV in % 
thermostable stability against 
carboxypeptidase Y digestion 
WT 100 ± 23 no unfolded unstable 
T-2A detected my MS * * 
T-2V not detected by MS - - 
T-2S detected by MS * * 
R-1A 20 ± 6 * * 
G1C not detected by MS - - 
D9E detected by MS already unfolded unstable 
I10A 4.1 ± 0.2 no - 
G11A 19 ± 2 no - 
Q12A 72 ± 34 no - 
T13A 85 ± 3 no - 
Y14A detected by MS already unfolded unstable 
F15A not detected by MS - - 
E16A 14.0 ± 0.8 no - 
E17A 33 ± 5 no - 
S18A 44 ± 8 no - 
R19A 72 ± 8 no - 
I20A 2.5 ± 0.6 no - 
N21A 22.3 ± 1.6 no - 
Q22A 67 ± 9 no - 
D23A 10.4 ± 1.3 no - 
Δ1 aa 33 ± 3 no - 
Δ2 aa 28.8 ± 0.9 no - 
Δ3 aa 1.9 ± 0.2 no - 
Δ4 aa 0.7 ± 0.2 no - 
Δ5 aa 16.7 ± 0.6 no - 
Δ6 aa 18.1 ± 0.3 no unfolded unstable 
Δ7 aa 2.3 ± 0.2 no unfolded unstable 
Δ8 aa detected by MS already unfolded - 
11 
 
mutant rel. production by 
Integration of UV in % 
thermostable stability against 
carboxypeptidase Y digestion 
Δ9 aa not detected by MS - - 
Y14W 2.7 ± 0.3 no - 
F15W 24 ± 5 yes stable 
R19W 18 ± 4 no unfolded unstable 
* = sequence equals the WT; - = was not tested 
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Supplementary Table S 2. Assignment of 1H Signals (ppm) of astexin-1 (23) in H2O/D2O (9:1) at 288 K 
AA NH αH βH others 
Gly1 7.531 3.789; 3.307 / / 
Leu2 8.835 5.174 2.082; 1.684 γCH: 1.637 
δCH3: 1.090; 0.980 
Ser3 9.033 5.074 4.292; 3.811  
Gln4 8.670 4.809 2.283; 2.184 γCH2: 2.642 
εNH2: 7.920; 7.323 
Gly5 7.434 4.327; 4.077 / / 
Val6 8.704 4.297 2.262 γCH3: 1.036; 1.009 
Glu7 9.386 5.355 2.694; 2.493 γCH2: 2.889; 2.816 
Pro8 / 3.974 2.478; 2.083 γCH2: 2.396; 2.183 
δCH2: 4.115; 4.697 
Asp9 8.082 4.808 2.489; 1.146 / 
Ile10 7.268 4.285 1.736 γCH2: 1.408; 1.044 
γCH3: 0.924; δCH3: 0.886 
Gly11 8.762 3.930; 3.813 / / 
Gln12 9.233 4.626 2.060 γCH2: 2.589; 2.527 
εNH2: 7.809; 7.085 
Thr13 8.728 4.794 4.730 γCH3: 1.174 
Tyr14 9.109 4.965 3.000; 2.352 δCH: 6.957; εCH: 6.884 
Phe15 8.661 4.848 3.494; 2.930 δCH: 7.433; εCH: 7.536 
Glu16 9.345  4.567 2.399; 2.339 γCH2: 2.824 
Glu17 9.246 4.627 2.352; 2.250 γCH2: 2.779; 2.744 
Ser18 8.762 4.641 4.062 / 
Arg19 8.692 4.582 1.947 γCH2: 2.069; 1.809; 
δCH2: 3.383; εNH: 7.386 
Ile20 8.409 4.328 2.029 γCH2: 1.626; 1.364 
γCH3: 1.077; δCH3: 1.046 
Asn21 8.776 4.873 3.040; 2.930 δNH2: 7.854; 7.134 
Gln22 8.605 4.538 2.331; 2.156 γCH2: 2.544 
εNH2: 7.766; 7.105 
Asp23 8.620 4.867 3.135; 3.084 / 
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Supplementary Table S 3. Assignment of 1H Signals (ppm) of astexin-1 (19) in H2O/D2O (9:1) at 283 K 
AA NH αH βH others 
Gly1 7.555 3.786; 3.308 / / 
Leu2 8.885 5.177 2.059; 1.683 γCH: 1.637 
δCH3: 1.083; 0.970 
Ser3 9.059 5.060 4.307; 3.801 / 
Gln4 8.670 4.804 2.270; 2.174 γCH2: 2.641 
εNH2: 7.963; 7.370 
Gly5 7.452 4.307; 4.074 / / 
Val6 8.731 4.284 2.254 γCH3: 1.031; 0.999 
Glu7 9.449 5.352 2.698; 2.501 γCH2: 2.892; 2.807 
Pro8 / 3.967 2.476; 2.081 γCH2: 2.389; 2.179 
δCH2: 4.109; 4.705 
Asp9 8.094 4.803 2.470; 1.132 / 
Ile10 7.286 4.281 1.729 γCH2: 1.388; 1.045 
γCH3: 0.924; δCH3: 0.877 
Gly11 8.799 3.907; 3.804 / / 
Gln12 9.290 4.618 2.053 γCH2: 2.593; 2.523 
εNH2: 7.849; 7.117 
Thr13 8.753 4.800 4.752 γCH3: 1.161 
Tyr14 9.147 4.959 3.000; 2.345 δCH: 6.953; εCH: 6.874 
Phe15 8.660 4.843 3.500; 2.930 δCH: 7.430; εCH: 7.527 
Glu16 9.379  4.561 2.407; 2.330 γCH2: 2.828 
Glu17 9.308 4.64 2.360; 2.248 γCH2: 2.797; 2.751 
Ser18 8.803 4.659 4.077 / 
Arg19 8.689 4.556 1.961 γCH2: 2.113; 1.822; 
δCH2: 3.380; εNH: 7.400 
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Supplementary Table S 4. Structural statistics for the family of 20 structures selected to represent the structure 
of astexin-1(19) in H2O/D2O (9:1) 
Restraining Constraints Constraints Violations 
Total: 202 Distance violations, >0.5 Å: 0 
distance, i=j: 105 RMS deviations: 0.02 Å 
distance, |i-j|=1: 40 Dihedral violations, > 5°: 0 
distance, |i-j|>1: 24 RMS deviation: 1.8° 
dihedral: 33 Average pairwise RMS deviation (Leu2-Ser18) 
hydrogen bond: 0 Backbone atoms: 0.03 Å 
Constraints/residue: 10.6 All heavy atoms: 0.30 Å 
 
 
 
 
Supplementary Table S 5. M9 Vitamin Mix 
component amount 
biotin 0.2 g 
choline chloride 1.0 g 
disodium adenosine 5’-triphosphate 0.3 g 
folic acid 1.0 g 
myo-inositol 2.0 g 
nicotinamide 1.0 g 
panthothenic acid 1.0 g 
pyridoxal hydrochloride 1.0 g 
riboflavin 0.1 g 
thiamine 1.0 g 
H2O ad 300 mL 
10 M NaOH were added to the resulting suspension until everything was dissolved. 
The solution was then sterile filtered and stored at 4°C 
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Supplementary Table S 6. Oligonucleotide Primers 
name sequence 
Astex0830A_NdeI_FP GGATTAC CAT ATG CAT ACC CCC ATT ATT TCG GAA 
ACG GTC 
Astex0832C_XhoI_RP ATAT CTC GAG TTA GGT CCG CGG ACG GCG C 
Astex3626A1_NdeI_FP GGATTAC CAT ATG ACC AAG CGT ACG ACC ATC GCC 
Astex3623C_XhoI_RP ATAT CTC GAG CTA GGG TGG CCC CGC CCG AG 
AE08_rth_tail_all_FP TGA CGA CGG GAA GGC GCG CAC AC 
AE08_-9aa_RP GTA GGT CTG GCC GAT ATC GGG CTC GAC AC 
AE08_-8aa_RP GAA GTA GGT CTG GCC GAT ATC GGG CTC G 
AE08_-7aa_RP TTC GAA GTA GGT CTG GCC GAT ATC GGG C 
AE08_-6aa_RP CTC TTC GAA GTA GGT CTG GCC GAT ATC GGG 
AE08_-5aa_RP AGA CTC TTC GAA GTA GGT CTG GCC GAT ATC G 
AE08_-4aa_RP GCG AGA CTC TTC GAA GTA GGT CTG GCC G 
AE08_-3aa_RP GAT GCG AGA CTC TTC GAA GTA GGT CTG GCC 
AE08_-2aa_RP GTT GAT GCG AGA CTC TTC GAA GTA GGT CTG G 
AE08_-1aa_RP CTG GTT GAT GCG AGA CTC TTC GAA GTA GGT C 
AE08_R19A_RP GTC CTG GTT GAT GGC AGA CTC TTC GAA GTA GGT 
CTG GCC 
AE08_F15A_RP GTC CTG GTT GAT GCG AGA CTC TTC GGC GTA GGT 
CTG GCC 
AE08_Y14A_RP GTC CTG GTT GAT GCG AGA CTC TTC GAA GGC GGT 
CTG GCC 
AE08_R19W_RP GTC CTG GTT GAT CCA AGA CTC TTC GAA GTA GGT 
CTG GCC 
AE08_F15W_RP GTC CTG GTT GAT GCG AGA CTC TTC CCA GTA GGT 
CTG GCC 
AE08_ring_all_FP GGC CAG ACC TAC TTC GAA GAG TCT CGC ATC 
AE08_G1C_RP GAT ATC GGG CTC GAC ACC CTG GCT GAG ACA GCG 
GGT 
AE08_D9E_RP GAT CTC GGG CTC GAC ACC CTG GCT GAG ACC GCG 
GGT 
AE08_Leader_all_FP GGT CTC AGC CAG GGT GTC GAG CCC GAT ATC 
Astex0830_R-1A_RP GGC GGT CTC AGC TGA AGC CTT GCC CAG AAC 
16 
 
name sequence 
Astex0830_T-2A_RP GCG GGC CTC AGC TGA AGC CTT GCC CAG AAC 
AE08_T-2S_RP GCG GCT CTC AGC TGA AGC CTT GCC CAG AAC 
AE08_T-2V_RP GCG GAC CTC AGC TGA AGC CTT GCC CAG AAC 
AE08SLIMTail1FP GAG TCT CGC ATC AAC CAG GAC TGA CGA CG 
AE08SLIMTail1RP ATC GGG CTC GAC ACC CTG GCT GAG ACC 
AE08SLIM_I10A_FP GCC GGC CAG ACC TAC TTC GAA GAG TCT CGC ATC 
AAC CAG GAC TGA CGA CG 
AE08SLIM_I10A_RP TTC GAA GTA GGT CTG GCC GGC ATC GGG CTC GAC 
ACC CTG GCT GAG ACC 
AE08SLIM_G11A_FP ATC GCC CAG ACC TAC TTC GAA GAG TCT CGC ATC 
AAC CAG GAC TGA CGA CG 
AE08SLIM_G11A_RP TTC GAA GTA GGT CTG GGC GAT ATC GGG CTC GAC 
ACC CTG GCT GAG ACC 
AE08SLIM_Q12A_FP ATC GGC GCG ACC TAC TTC GAA GAG TCT CGC ATC 
AAC CAG GAC TGA CGA CG 
AE08SLIM_Q12A_RP TTC GAA GTA GGT CGC GCC GAT ATC GGG CTC GAC 
ACC CTG GCT GAG ACC 
AE08SLIM_T13A_FP ATC GGC CAG GCC TAC TTC GAA GAG TCT CGC ATC 
AAC CAG GAC TGA CGA CG 
AE08SLIM_T13A_RP TTC GAA GTA GGC CTG GCC GAT ATC GGG CTC GAC 
ACC CTG GCT GAG ACC 
AE08SLIM_Y14W_FP ATC GGC CAG ACC TGG TTC GAA GAG TCT CGC ATC 
AAC CAG GAC TGA CGA CG 
AE08SLIM_Y14W_RP TTC GAA CCA GGT CTG GCC GAT ATC GGG CTC GAC 
ACC CTG GCT GAG ACC 
AE08SLIM_E16A_FP ATC GGC CAG ACC TAC TTC GCC GAG TCT CGC ATC 
AAC CAG GAC TGA CGA CG 
AE08SLIM_E16A_RP GGC GAA GTA GGT CTG GCC GAT ATC GGG CTC GAC 
ACC CTG GCT GAG ACC 
AE08SLIMTail2FP TGA CGA CGG GAA GGC GCG CAC ACT G 
AE08SLIMTail2RP TTC GAA GTA GGT CTG GCC GAT ATC GGG CTC 
AE08SLIM_E17A_FP GCG TCT CGC ATC AAC CAG GAC TGA CGA CGG GAA 
GGC GCG CAC ACT G 
17 
 
name sequence 
AE08SLIM_E17A_RP GTC CTG GTT GAT GCG AGA CGC TTC GAA GTA GGT 
CTG GCC GAT ATC GGG CTC 
AE08SLIM_S18A_FP GAG GCT CGC ATC AAC CAG GAC TGA CGA CGG GAA 
GGC GCG CAC ACT G 
AE08SLIM_S18A_RP GTC CTG GTT GAT GCG AGC CTC TTC GAA GTA GGT 
CTG GCC GAT ATC GGG CTC 
AE08SLIM_I20A_FP GAG TCT CGC GCC AAC CAG GAC TGA CGA CGG GAA 
GGC GCG CAC ACT G 
AE08SLIM_I20A_RP GTC CTG GTT GGC GCG AGA CTC TTC GAA GTA GGT 
CTG GCC GAT ATC GGG CTC 
AE08SLIM_N21A_FP GAG TCT CGC ATC GCC CAG GAC TGA CGA CGG GAA 
GGC GCG CAC ACT G 
AE08SLIM_N21A_RP GTC CTG GGC GAT GCG AGA CTC TTC GAA GTA GGT 
CTG GCC GAT ATC GGG CTC 
AE08SLIM_Q22A_FP GAG TCT CGC ATC AAC GCG GAC TGA CGA CGG GAA 
GGC GCG CAC ACT G 
AE08SLIM_Q22A_RP GTC CGC GTT GAT GCG AGA CTC TTC GAA GTA GGT 
CTG GCC GAT ATC GGG CTC 
AE08SLIM_D23A_FP GAG TCT CGC ATC AAC CAG GCC TGA CGA CGG GAA 
GGC GCG CAC ACT G 
AE08SLIM_D23A_RP GGC CTG GTT GAT GCG AGA CTC TTC GAA GTA GGT 
CTG GCC GAT ATC GGG CTC 
Introduced restriction sites are underlined; introduced mutations are shown in bold. 
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Supplementary Methods 
 
Strains and general methods. Asticcacaulis excentricus CB48 (DSM 4724) was purchased from the 
German Collection for Microorganisms and Cell Cultures (DMSZ). E. coli TOP10, which was used 
for cloning, and E. coli BL21 (DE3), which was used for heterologous expression, were purchased 
from Invitrogen. Oligonucleotides and carboxypeptidase Y were purchased from Sigma Aldrich. 
Trypsin was purchased from Promega. Restriction enzymes, Phusion polymerase and T4 DNA Ligase 
were purchased from New England Biolabs. DNA Sanger Sequencing was performed by GATC 
Biotech AG (Konstanz) to determine the identity of constructed plasmids and mutants.  
 
Cloning of the astexin-1 biosynthesis cluster. Genomic DNA of Asticcacaulis excentricus CB48 
was used to amplify the atxABC gene cluster with PCR with the first two primers of Supplementary 
Table S6. PCR was performed with Phusion Polymerase following the instructions of the 
manufacturer. PCR was subjected to gel electrophoresis and amplicons with the correct size were 
excised, purified and subsequently digested with NdeI and XhoI. pET41a vector was digested in the 
same way and the fragments were ligated with T4 DNA Ligase. Transformation was performed with 
TOP10 cells for cloning and BL21(DE3) for expression. 
 
Construction of astexin-1 mutants. The astex222xABCpET41a plasmid was used as template for all 
performed mutations. Mutagenesis was either done with a modified protocol of the site directed 
mutagenesis with inverse PCR (Hemsley, et al., 1989) or with the site-directed-ligation-independent-
mutagenesis (SLIM) protocol (Chiu, et al., 2008). Primers for each mutant or mutant group are shown 
in Supplementary Table S6. 
 
Heterologous expression of the WT and mutated astexin-1 biosynthesis cluster. E. coli 
BL21(DE3) cells were transformed with the plasmid astex222xABCpET41 or mutants thereof and 
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grown overnight at 37°C in LB medium containing kanamycin (50 μg/mL). M9 minimal medium 
supplemented with M9 vitamin mix (Supplementary Table S5) and containing kanamycin (50 µg/mL) 
was inoculated with the overnight culture to an OD600 of 0.01. The culture was grown at 37 °C to an 
OD600 of 0.6 and the expression was induced with the addition of IPTG to a final concentration of 
0.1 mM. Expression was continued overnight and the cells were harvested by centrifugation. Pellets 
were extracted as stated in the purification section and extracts were subsequently applied to HPLC 
for purification or analyzed by a HPLC-MS system. 
 
Torsion angle constraints for NMR structure elucidation. Only those unambiguous coupling 
constants were used. Thus, 3JHNα ≥ 9 Hz was observed for Leu2, Ser3, Val6, Glu7, Asp9, Ile10, and 
Glu12 – Phe15. The torsion angles ϕ of these residues were restrained to -120° ± 30°. For the residues 
Gly1, Gln4, Gly5, Gly11, and Glu16 – Arg19, 3JHNα < 9 Hz was detected. Thus their torsion angles 
ϕ were restrained to -70° ± 30°. Stereospecific assignment of the following prochiral β-methylene 
protons were fulfilled by measuring 3Jαβ and analyzing patterns of the intraresidual NOE interactions 
dαβ and dNβ (Wagner, 1990): Leu2, Ser3, Asp9, Try14, and Phe15 in (t2g3); Gln4, Glu7, and Glu17 in 
(g2g3). For t2g3and g2g3 conformations around the Cα-Cβ bond the torsion angle χ1 was constrained 
in the range of -60 ± 30°and 60 ± 30° respectively. 
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S2 
Supporting Information 
Supplementary Table S1. Primers for the cloning of the investigated gene clusters. Introduced 
restriction sites are underlined. 
name sequence 
BurhA_NdeI_FP GGATTAC CAT ATG AAC AAG CAA CAA CAA GAG TCG GGC CTG C 
BurhC_SpeI_RP ATAT ACT AGT TAT TGC CAA CTT TGA ATA AAC AGC TCG GCA GC 
CK31_A1_NdeI_FP GGATTAC CAT ATG GAA CGG ATC GAA GAC CAC ATC GAC GAC GAA CTG ATC 
GAC CTG GGC G 
CK31_C_EcoRI_RP ATAT GAA TTC TCA GAC ATC CTC CCA GGA TCG CAC CCA GGA CTC GAC GTC 
GGC C 
PzucA_NdeI_FP GGATTAC CAT ATG ACC AGG CTT CTC AAT CTG ATG AGC GTT CGG CTG 
PzucC_HindIII_RP ATAT AAG CTT TCA GGC CGA CCA CCG CCG GAC CCA GGC 
RhotA_NdeI_FP GGGAATTC CAT ATG ACG CAA TCG CAG GAG ACT GAG ATG GAC ACG AAC GAG 
AAC 
RhotC_HindIII_RP ATAT AAG CTT TTA GGG GTA TTG GGA CTG CTG CCG TAC CCA GTT CTC CAA 
GGC 
RugeA_NdeI_FP GGGAATTC CAT ATG AAG GAG TTC GCC ATG GAC GAA GAG CTG GAA CTG GAG 
ATC GTC GAC C 
RugeC_HindIII_RP ATAT AAG CTT TCA AGC GAG CGG ACG AGG CGC GGC CGC G 
Sjap1_A_NdeI_FP GGGAATTC CAT ATG GAA CGT GAC AAT GAC GTG ATC GAA CTC GGC GCG GTC 
AGC GTG 
Sjap1_C_XhoI_RP ATAT CTC GAG CTA ATC CTG GGT CTG CCC CGC CAC CCA TGC CTC GAC ATC 
GGC 
Sjap2_A_NdeI_FP GGGAATTC CAT ATG GAT CGT CAT GAC AAC TCC GAG GTC GAT GAG ATC ATC 
GAC CTC GGC ACC 
Sjap2_C_HindIII_RP ATAT AAG CTT CTA GGC AGG TTG CGA CCT GGC CCA CGC CTC GAC GTC G 
SyanA_NdeI_FP GGGAATTC CAT ATG GAA CGC AAC AGC GAA GAC CGC CGT GAC GAC GTC GTC 
G 
SyanC_HindIII_RP ATAT AAG CTT TCA GCC GCG ACG GGC AGC GAG CCA GGC TTC GAC 
Sala1_A_NdeI_FP GGAATTC CAT ATG AAA GAC TTC AAC GAA CTG ATC GAC C 
Sala1_C_XhoI_RP CCG CTC GAG TCA ATT TCC CTC CCA ATA TCG GGC C 
Sala2_A_NdeI_FP GGAATTC CAT ATG GAA CGC ACC GAA GTA ATC GAG G 
Sala2_C_EcoRI_RP GGC GAA TTC TTA TCG GCC CAA TGC GCT ATC G 
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Supplementary Table S2. Primers for the introduction of the E. coli optimized RBS in between the 
precursor genes and the genes encoding the processing enzymes. All primers were 
5'-phosphorylated and the RBS sequence is underlined. 
name sequence 
Burh_RBS_FP AGAGGAGAAATTAACC ATG CAG CAT GGC GCT TGG AGA CAA AGT CAG 
CTA TG 
Burh_RBS_RP TTA TTC GTC GTC GGA GTC AAT GCG ATC ACT CCA GCG 
CK31_A1A2A3_RBS_FP AGAGGAGAAATTAACC ATG CGC GTA GCC GTT CCC GAT CAT CTC GCA TAC 
CK31_A1A2A3_RBS_RP CTA GTC TTC CGA CAG GCC CAT GGG CGG GCG 
CK31_A1_RBS_FPa AGAGGAGAAATTAACC ATG CGC GTA GCC GTT CCC GAT CAT CTC GCA TAC 
CK31_A1_RBS_RPa TTA GTC CCG GGA CAG GCC CGT GGG CTC CCG G 
CK31_A2_RBS_FPa ATG CAA CGG ATC ATC GAC GAG ACC ACG GAC GGT CTG 
CK31_A2_RBS_RPa ATG TAT ATC TCC TTC TTA AAG TTA AAC AAA ATT ATT TCT AGA GGG GAA 
TTG 
CK31_A3_RBS_FPa ATG GAA TTT GAA GGC ATC CCT TCC CCG GAC GCG CGG ATC GAT CTC 
CK31_A3_RBS_RPa ATG TAT ATC TCC TTC TTA AAG TTA AAC AAA ATT ATT TCT AGA GGG G 
Pzuc_RBS_FP AGAGGAGAAATTAACC ATG CCC GCG CTG CAC CCG AAA TCC TTT CTC GTC 
Pzuc_RBS_RP TCA GAC GTC GAA CGG CTT GTT CAG GTC TTC GAA GTC ACC 
Rhot_RBS_FP AGAGGAGAAATTAACC ATG ACC AGC TAT TGG CTA CAC GAC GAC CTC TCA 
TTC TGC C 
Rhot_RBS_RP TTA CTC GGT GAT TCC CGG AGT GGC GGC GTG GCC 
Ruge_RBS_FP AGAGGAGAAATTAACC ATG TCG GCA ACG ACA CGC CGT CTA CAC CCG 
AGG CCG ATC TTG 
Ruge_RBS_RP TCA GAC GCG CTG CGG GAA GGC CGG GTT GTC TTC CGA G 
Sjap1_RBS_FP AGAGGAGAAATTAACC ATG ACC GGC TTT ACA CTG CGC GAT GGT CTG AGC 
Sjap1_RBS_RP TCA GTC GTC GGA AAG ACC GAA ATT ATT TTC ACC AAG CCC GAC ATC 
Sjap2_RBS_FP AGAGGAGAAATTAACC ATG GCG CTG GCA CTG CGT GAC CAG CTC TC 
Sjap2_RBS_RP TCA GTC GTC AGA AAT GCC GCC GAT CAG GTT TTT GGG C 
SyanA_RBS_FP AGAGGAGAAATTAACC ATG GCC CGC GCG GAC ATA AAT TGG TGC GAT GTC 
GGA GGG C 
SyanC_RBS_RP TCA GTC GTC GAG GAT ACC GGC AAG GCC CTG GCC GGC AG 
Sala1_RBS_FP AGAGGAGAAATTAACC ATG TCC GCC ATG CTG CGA TCG GGC CTG CAC 
Sala1_RBS_RP TCA GTC GTC GGC CGT GAT GCC GCC GGC 
Sala2_RBS_FP AGAGGAGAAATTAACC ATG CCT GCA ATG CAC TAT AGG ACG GCA CCC GGC 
Sala2_RBS_RP TCA GTC CTG CGC GAT TCC GGT GAG GAA CTG C 
aCK31_A1A2A3BC pET41a was used as template 
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Supplementary Table S3. M9 Vitamin Mix. 
component amount 
choline chloride 1.0 g 
folic acid 1.0 g 
pantothenic acid 1.0 g 
nicotinamide 1.0 g 
myo-inositol 2.0 g 
pyridoxal hydrochloride 1.0 g 
thiamine 1.0 g 
riboflavin 0.1 g 
disodium adenosine 5'-triphosphate 0.3 g 
biotin 0.2 g 
 ad 300 mL ddH2O
a
 
a10 M NaOH was slowly added to the resulting suspension until everything was dissolved (pH ~12). 
Afterwards the solution was sterile filtered and stored at 4 °C until needed. 
 
 
 
S5 
Supplementary Table S4a. Genome mining results I. Overview over identified gene clusters. 
strain cluster organization GntR 
present? 
TonB 
present? 
GenBank accession no. 
of the B/B2 protein 
Asticaccaulis excentricus CB48 ABC yes yes YP_004088036.1 
Asticaccaulis excentricus CB48 AABC yes yes ADU14097.1 
Breviundimonas diminuta ATCC 11568 ABC yes yes ZP_08267984.1 
Burkholderia gladioli BSR3 ABCD no no YP_004361612.1 
Burkholderia mallei ATCC23344 ABC no no YP_102882.1 
Burkholderia oklahomensis C6786 ABCCD no no ZP_02362859.1 
Burkholderia oklahomensis EO147 ABCCD no no ZP_02355720.1 
Burkholderia pseudomallei 1106A ABCD no no YP_001066181.1 
Burkholderia pseudomallei 1710b ABCD no no YP_333463.1 
Burkholderia pseudomallei 668 ABCD no no YP_001058938.1 
Burkholderia pseudomallei 7894 ABCD no no ZP_02481751.1 
Burkholderia pseudomallei DM98 ABCD no no ZP_02402883.1 
Burkholderia pseudomallei K96243 ABCD no no YP_108394.1 
Burkholderia rhizoxinica HKI454 ABCD no no YP_004027714.1 
Burkholderia thailandensis E264 ABCD no no YP_442959.1  
Candidatus Odysella thessalonicensis L13 AABCD no no ZP_08778228.1 
Candidatus Odysella thessalonicensis L13 ABCD no no ZP_08778197.1 
Caulobacter crescentus CB15 ABC no yes NP_421509.1 
Caulobacter segnis ATCC 21756 AAABC yes yes YP_003593637.1 
Caulobacter sp. AP07 AABC yes yes ZP_10749588.1 
Caulobacter sp. K31 AABC yes yes YP_001683611.1 
Caulobacter sp. K31 AABC yes yes YP_001683865.1 
Caulobacter sp. K31 AAABC yes yes YP_001676626.1 
Chitinophaga pinensis DSM 2588 XB1KB2CAA no no YP_003124540.1 
Citromicrobium bathyomarinum JL354 ABC no no ZP_06863107.1 
Citromicrobium sp. JLT1363 CA*B2SKB1DD no no ZP_08702804.1 
Citromicrobium sp. JLT1363 B2XXB1KSCX no no ZP_08702964.1 
Escherichia coli AY25 ABCD no no AAD28495.1 
Escherichia coli MS 196-1 BC no no ZP_07192991.1 
Erythrobacter sp. NAP1 DBKACBX no no ZP_01040581.1 
Francisella cf. novicida 3523 XDB1B2CXX no no YP_005823896.1 
Francisella cf. novicida Fx1 XDB1B2CXXX no no YP_005825876.1 
Francisella novicida U112 XDB1B2CXX no no YP_898576.1 
Gallionella capsiferriformans ES-2 XB2XCXXB1XD no no YP_003846630.1 
Geobacter uraniireducens Rf4 A*CKKSB1B2D no no YP_001230130.1 
Hahella chejuensis KCTC 2396 BC no no YP_432495.1 
Haliangium ochraceum DSM 14365 ABC no no YP_003265873.1 
Legionella pneumophila 2300/99 Alcoy A*XCB1B2DK no no YP_003620325.1 
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Supplementary Table S4b. Genome mining results I. Overview over identified gene clusters. 
strain cluster organization GntR 
present? 
TonB 
present? 
GenBank accession no. 
of the B/B2 protein 
Legionella pneumophila str. Corby A*XCB1B2DDK no no YP_001252493.1 
Legionella pneomophila subsp. pneumophila 
ATCC 43290 
XCB1B2DK no no YP_005187270.1 
Legionella pneumophila subsp. pneumophila XCB1B2DK no no YP_006507101.1 
Magnetospirillum magneticum AMB-1 A*BCD no no YP_420827.1 
Marine gamma proteobacterium HTCC2148 KXXXCADBX no no ZP_05094211.1 
Marinomonas mediterranea MMB-1 ACKSXBDD no no YP_004312360.1 
Mesorhizobium amorphea CCNWGS0123 AB1B2CKD no no ZP_09090636.1 
Mesorhizobium australicum WSM2073 AB1B2CKD no no EHB69037.1 
Mesorhizobium ciceri biovar biserrulae WSM1271 AB1B2CKD no no YP_004139467.1 
Mesorhizobium loti MAFF303099  AB1B2CKD no no NP_105951.1 
Mesorhizobium opportunistum WSM2075 AB1B2CKD no no YP_004608836.1 
Novosphingobium aromaticivorans DSM 12444 KB1B2CDX no no YP_498511.1 
Novosphingobium sp. AP12 ABC no yes ZP_10744725.1 
Novosphingobium sp. PP1Y ABC no yes YP_004532633.1 
Novosphingobium sp. PP1Y ABC yes yes YP_004534330.1 
Novosphingobium sp. Rr 2-17 ABC yes yes ZP_10362270.1 
Oligotropha carboxidovorans OM5 ACBD no no YP_002290457.1 
Phenylobacterium zucineum HLK1 ABC yes yes YP_002131237.1 
Phenylobacterium zucineum HLK1 ABC yes yes YP_002131016.1 
Photorhabdus asymbiotica ATCC 43949 BCD no no YP_003041097.1 
Pseudomonas geniculata N1 ABC yes yes ZP_11209434.1 
Psychromonas ingrahamii 37 B2DXB1XXC no no YP_943976.1 
Rhodanobacter sp. 115 ABC yes yes ZP_10191822.1 
Rhodanobacter sp. 116-2 ABC yes yes ZP_10201279.1 
Rhodanobacter sp. 2APBS1 ABC yes yes ZP_08950893.1 
Rhodanobacter thiooxydans LCS2 ABC yes yes ZP_10205116.1 
Rhodobacter sphaeroides 2.4.1 AB1B2CKD no no YP_352615.1 
Rhodobacter sphaeroides ATCC 17025 AB1B2CKD no no YP_001168162.1 
Rhodobacter sphaeroides ATCC 17029 AB1B2CKD no no YP_001043097.1 
Rhodobacter sphaeroides KD131  AB1B2CKD no no YP_002525230.1 
Rhodospirillum rubrum ATCC 11170 XB2XB1KSC no no YP_428105.1 
Rhodospirillum rubrum ATCC 11170 B1B2XC no no YP_425910.1  
Roseobacter denitrificans OCh 114 AB1B2CK no no YP_683998.1 
Roseobacter litoralis Och 149 AB1B2CK no no YP_004689588.1 
Rubrivivax benzoalyticus JA2 ABC no yes ZP_08403836.1 
Rubrivivax gelatinosus IL44 ABC no yes YP_005435542.1 
Shewanella sp. HN-41 B2XXDAB1KSC no no ZP_08567205.1 
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Supplementary Table S4c. Genome mining results I. Overview over identified gene clusters. 
strain cluster organization GntR 
present? 
TonB 
present? 
GenBank accession no. 
of the B/B2 protein 
Sphingobium chlorophenolicum L-1 ABC yes yes YP_004554865.1 
Sphingobium japonicum UT26 ABC yes yes YP_003546448.1 
Sphingobium japonicum UT26 ABC yes yes YP_003547070.1 
Sphingobium sp. AP49 ABC yes yes ZP_10544572.1 
Sphingobium sp. SYK-6 ABC no yes YP_004835823.1 
Sphingobium yanoikuyae ATCC 51230 AB1B2CKD no no EKU73221.1 
Sphingobium yanoikuyae ATCC 51230 ABC yes yes EKU73624.1 
Sphingobium yanoikuyae XLDN2-5 AB1B2CKD no no ZP_09906630.1 
Sphingobium yanoikuyae XLDN2-5 ABC yes yes ZP_09907189.1 
Sphingobium yanoikuyae XLDN2-5 ABC yes yes ZP_09906533.1 
Sphingomonas sp. LH128 ABC yes yes ZP_10870859.1 
Sphingomonas sp. LH128 XKB1CXB2X no no ZP_10874239.1 
Sphingomonas sp. SKA58 ABC yes yes ZP_01301928.1 
Sphingopyxis alaskensis RB2256 ABC no yes YP_617574.1 
Sphingopyxis alaskensis RB2256 ABC no yes YP_617642.1 
Stenotrophomonas maltophilia R551-3 ABC no yes YP_002028439.1 
Sulfurovum sp. AR DBKCA* no no ZP_10062210.1 
Sulfurovum sp. NBC37-1 ACKDXXB1B2 no no YP_001359375.1 
Uncultured marine bacterium 463 KXXXCADBX no no AAS07978.1 
Xanthomonas axonopodis 
pv. malvacearum str. GSPB1386 
ACB1B2DD no no ZP_13082330.1 
Xanthomonas axonopodis 
pv. citri str. 306 
ACB1B2DD no no XAC0058 
Xanthomonas axonopodis 
pv. malvacearum str. GSPB1386 
ACB1B2DD no no ZP_13082330.1 
Xanthomonas axonopodis 
pv. malvacearum str. GSPB2388 
ACB1B2DD no no ZP_13087953.1 
Xanthomonas axonopodis 
pv. punicae str. LMG 859 
ACB1B2DD no no ZP_10261507.1 
Xanthomonas citri pv. magniferaeindicae ABC yes yes ZP_09881129.1 
Xanthomonas citri pv. magniferaeindicae ACB1B2DD no no ZP_09878744.1 
Xanthomonas gardneri ATCC 19865 AABC yes yes ZP_08185024.1 
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Supplementary Table S5a. Genome mining results II. Overview over putative lasso peptide 
precursors. Numbers on the right side represent the number of amino acids of the precursor 
peptides, the putative lasso peptides and the macrolactam rings, in this order. The threonine residue 
at the penultimate position of the leader peptide is highlighted in blue, while the amino acid at 
position 1 of the lasso peptide sequence and the corresponding ring forming amino acid are marked 
in red. 
strain precursor     
Asticcacaulis excentricus CB48 (2228) MHTPIISETVQPKTAGLIVLGKASAETR GLSQGVEPDIGQTYFEESRINQD 51 23 9 
Asticcacaulis excentricus CB48 (2448) MRTYNRSLPARAGLTDLGKVTTHTK GPTPMVGLDSVSGQYWDQHAPLAD 49 24 9 
Asticcacaulis excentricus CB48 (2447) MTKRTTIAARRVGLIDLGKATRQTK GLTQIQALDSVSGQFRDQLGLSAD 49 24 9 
Breviundimonas diminuta ATCC 11568 MMNTFKLRLVSFGSAKALTRD GMGEEFI-EGLVRDSLYPPAG 41 20 8 
Burkholderia gladioli BSR3 MSAIIKKLFRNRASNQAHRFDVVSVTH GQPGYQTIDFRVVTRLGGR 46 19 9 
Burkholderia mallei ATCC 23344 MVRFLAKLLRSTIHGSNGVSLDAVSSTH GTPGFQTPDARVISRFGFN 47 19 9 
Burkholderia oklahomensis C6786 MVRFLAKLLRSTIHGSNGVSLDAVSSTH GTPGFQTPDARVISRFGFN 47 19 9 
Burkholderia oklahomensis EO147 MVRFLAKLLRSTIHGSNGVSLDAVSSTH GTPGFQTPDARVISRFGFN 47 19 9 
Burkholderia pseudomallei 1106A MVRFLAKLLRSTIHGSNGVSLDAVSSTH GTPGFQTPDARVISRFGFN 47 19 9 
Burkholderia pseudomallei 1710b MVRFLAKLLRSTIHGSNGVSLDAVSSTH GTPGFQTPDARVISRFGFN 47 19 9 
Burkholderia pseudomallei 668 MVRFLAKLLRSTIHGSNGVSLDAVSSTH GTPGFQTPDARVISRFGFN 47 19 9 
Burkholderia pseudomallei 7894 MVRFLAKLLRSTIHGSNGVSLDAVSSTH GTPGFQTPDARVISRFGFN 47 19 9 
Burkholderia pseudomallei DM98 MVRFLAKLLRSTIHGSNGVSLDAVSSTH GTPGFQTPDARVISRFGFN 47 19 9 
Burkholderia pseudomallei K96243 MVRFLAKLLRSTIHGSNGVSLDAVSSTH GTPGFQTPDARVISRFGFN 47 19 9 
Burkholderia rhizoxinica HKI454 MNKQQQESGLLLAEESLMELCASSETL GGAGQYK-EVEAGRWSDRIDSDDE 50 23 8 
Burkholderia thailandensis E264 MVRLLAKLLRSTIHGSNGVSLDAVSSTH GTPGFQTPDARVISRFGFN 47 19 9 
Candidatus odyssella thessalonicensis L13(8821) MKYLKKSIMVKSFFNKLDKNEHAGLINISQSASTITA GGCGAKF-EQGGVTSLQKFDA 57 20 8 
Candidatus odyssella thessalonicensis L13(8986) MENIEITTKTSTVLDTNLVVVLEESASSLTQ GCCGGWL-EQWGGYSRP 47 16 8 
Candidatus odyssella thessalonicensis L13(8991) MENIEITTEISAILDTNLGVVLEESASSLTR GLVGTGK-EGFCVGFRY 47 16 8 
Caulobacter crescentus CB15 MTPTTPRPTLLRLGAAKTLTR SLEDGTIKEAGSSQYYFV 39 18 9 
Caulobacter segnis ATCC 21756 (2568) MTKKNATQAPRLVRVGDAHRLTQ GAFVGQP-EAVNPLGREIQG 42 19 8 
Caulobacter segnis ATCC 21756 (2567) MTKTHRLIRLGDAQRLTQ GTLTPGLPEDFLPGHYMPG 37 19 8 
Caulobacter segnis ATCC 21756 (2566) MTSRFQLLRLGKADRLTR GALVGLLLEDITVARYDPM 37 19 8 
Caulobacter sp. AP07 (619)  MERTEHRIDDLIELGAASVETK GADLPTS-EVGIGRQPAGITED 43 21 8 
Caulobacter sp. AP07 (620) MSKETAMRQVENQTEELVELGRASDETQ GPDMPTS-EVGIGRAPFGITED 49 21 8 
Caulobacter sp. K31 (2238) MNTLKTRLIRFGSAKRLTR AGTGVLLPETNQIKRYDPA 38 19 9 
Caulobacter sp. K31 (2239) MTTPKFRLIRLGSAKRLTR SGIGDVFPEPNMVRRWD 36 17 9 
Caulobacter sp. K31 (1984) MTPIQSKFCLLRVGSAKRLTQ SFDVGTIKEGLVSQYYFA 39 18 9 
Caulobacter sp. K31 (198x) MTQVSPSPLRLIRVGRALDLTR SIGDSGLRESMSSQTYWP 40 18 9 
Caulobacter sp. K31 (5194) MERIEDHIDDELIDLGAASVETQ GDVLNAP-EPGIGREPTGLSRD 44 21 8 
Caulobacter sp. K31 (5193) MQRIIDETTDGLIELGAASVETQ GDVLFAP-EPGVGRPPMGLSED 44 21 8 
Caulobacter sp. K31 (519x) MEFEGIPSPDARIDLGLASEETC GQIYDHP-EVGIGAYGCEGLQR 44 21 8 
Chitinophaga pinensis DSM 2588 (4903) MKNETTQQKTTWETPDMTVLPINDVTL GAGAAGT-DFASEISV 42 15 8 
Chitinophaga pinensis DSM 2588 (4902) MKNNTSQQPLTWETPDMIVLPIDKVTL GKAGSGS-DFAAEWEVST 44 17 8 
Citromicrobium bathyomarineum MKEFDHNQNEVIDLGKASVETK GAVGFYI-DASGGQLANSPGLLDE 45 23 8 
Citromicrobium sp. JLT1363 MNQPHETLPTNAGKRAWSTPQVVDLDDRRAIA GGAVNAP-EYFAPTFYSVS 50 18 8 
Desulfobacca acetoxidans DSM 11109 MMICFPAVTRYLAIVLSLRRKASELTWK QTPCRWT-DSRPSGTVP 44 16 8 
Escherichia coli AY25 (Microcin J25) MIKHFHFNKLSSGKKNNVPSPAKGVIQIKKSASQLTK GGAGHVP-EYFVGIGTPISFYG 58 21 8 
Erythrobacter sp. NAP1 MTKVTEKVKYEAPKLTVFGSVRNLTG GSGTSFR-DGAVTNTRF 43 16 8 
Geobacter uraniireducens Rf4 MDRDKQSCPDSSVISGESVAASTRSAWSAPTITRIEIKRTMA GASVAL--DSSLFTTH 56 14 7 
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Supplementary Table S5b. Genome mining results II. Overview over putative lasso peptide 
precursors. Numbers on the right side represent the number of amino acids of the precursor 
peptides, the putative lasso peptides and the macrolactam rings, in this order. The threonine residue 
at the penultimate position of the leader peptide is highlighted in blue, while the amino acid at 
position 1 of the lasso peptide sequence and the corresponding ring forming amino acid are marked 
in red. 
strain precursor     
Haliangium ochraceum DSM 14365 MAKKKTDTKKTFLQDLGKATEETK SDGPPERYDNLVFRTKGPYLG 45 21 9 
Legionella pneumophila 2300/99 Alcoy MDKLDWELPEVCAIPIDSVTADQD GNLKSDGPDSSGLSSSSSSSGG 46 22 9 
Legionella pneumophila str. Corby MDKLDWELPEVCAIPIDSVTADQY GNKKNDGPDSSGLSSSSSPSG 45 21 9 
Magnetospirillum magneticum AMB-1 MSDQSPPATEDAPARKPWHKPEITTLAVEET ATNGSTGNDGSGATTFS 48 17 9 
Marine gamma proteobacterium MSGEQSVSRREENPQISISAGSGRKYKTPRLERFGEISHVTQ GSFGKKK-DAEGDEVAIIPK 61 19 8 
Marinomonas mediterranea MBP1 MSDIDVNTLLSEDKNSKKSLGDKLIWVAPVLEELETDKTRS GGGTAT--ETPFNPGVSS 57 16 7 
Mesorhizobium amorphae CCNWGS0123 MEQNVEKHEYETPSLTVHGSIETITQ GGGGSTALDASFPAHTPIGELTFS 50 24 9 
Mesorhizobium australicum WSM2073 MEQNVEKHEYETPNLTVHGSIETITQ GGGGSTAIDASFPAHTPIGDLTFS 50 24 9 
Mesorhizobium ciceri biovar biserrulae MEQNVEKHEYETPSLTVHGSIETITQ GGGGSTAIDASFPAHTPIGDLTFS 50 24 9 
Mesorhizobium loti MAFF303099 MEQNVEKHEYETPSLTVHGSIETITQ GGGGSTAIDASFPAHTPIGDLTFS 50 24 9 
Mesorhizobium opportunistum WSM2075 MEQNVEKHEYETPSLTVHGSIETITQ GGGGNTAIDASFPAHTPIGDLTFS 50 24 9 
Novosphingobium sp. AP12 MKEREHNESDVIELGIAHIETR GNALFGRDDTQTGMKYGVAGISSED 47 25 8/9 
Novosphingobium sp. PP1Y (Lpi3xx) MESRSRMEKIMEKTIDTLEDKVVDLGSVTEETR GIVGAL-EDQQGGQRAALGLTDD 55 22 7/8 
Novosphingobium sp. PP1Y (AT163xx) MKEVIMTVIDEHRDDELIDLGAVSAATK GAVQGEA-DLEGQPRQIFGAISDD 51 21 8 
Novosphingobium sp. Rr 2-17 MDRLHDIIDLGAASVETK GPIGEGS-DLVLGQNPAGLSDD 39 19 8 
Oligotropha carboxidovorans OM5 MQRVAGREGIHAVTRTRDAMKATARDPTI GPLLIEH-EFENVRDGGRRGGDNQEMFGGRL 59 30 8 
Phenylobacterium zucineum HLK1 (217x) MNTRLHPPVSRLICLGGAKASTN QGVGIRQ-ELNPDEGFDD 40 17 8 
Phenylobacterium zucineum HLK1 (239x) MTRLLNLMSVRLLGFGSAKAATN GGIGGDFEDLNKPFDV 39 16 8/9 
Pseudomonas geniculata N1 MFMNELIELGVVAGEQNHEDQSELIELGSVVSETK AHNHGTLWDGVFPTTSP 52 17 9 
Rhodanobacter sp. 115 MTQTQEIVMNTNENIRNNASEDVIVLGVASVETQ GGPGSN--EAVGFGGPVIPGISEE 56 22 7 
Rhodanobacter sp. 116-2 MTRPQETEMNTNENIRNDTPEDVIVLGVASVETK GPMGSTEPEGGLGRPVIPGISEE 57 23 7/9 
Rhodanobacter sp. 2APBS1 MNTNENIRTNAPEDVIELGIASVETK GEFGVT--EGGGQGKPMIPGISEE 48 22 7 
Rhodanobacter thiooxydans LCS2 MTQSQETEMDTNENIRSNAQDDVIELSVASVETK GVLPIGN-EFMGHAATPGITE 54 20 8 
Rhodobacter sphaeroides 2.4.1 MANNIQTLAYEAPVLRVHGTLEAMTH GATDGWALDASFPVDTPKGDLTFS 50 24 9 
Rhodobacter sphaeroides ATCC 17025 MLRIFDVANNIQTLAYQAPVLRAHGTLEAMTH GASTGHVTDAAFPSGTAIADMTFS 56 24 9 
Rhodobacter sphaeroides ATCC 17029 MANNIQTLAYEAPVLRVHGTLEAMTH GATDGWALDASFPVDTPKGDLTFS 50 24 9 
Rhodobacter sphaeroides KD131 MLRVHGTLEAMTH GATDGWALDASFPVDTPKGDLTFS 37 24 9 
Roseobacter denitrificans Och 114 MTKAVYEAPVLRSHGKVEAVTK GGSTGSSLDAAFPAGTPFTDLTLS 46 24 9 
Roseobacter litoralis Och 149 MTKAVYEAPVLRSHGKVEAVTK GGSTGSSLDAAFPAGTPFADLTLS 46 24 9 
Rubrivivax benzoalyticus MDEETELDIVDLGDAKDTTK GILLPGSEDNVTMPGRQIA 39 19 8/9 
Rubrivivax gelatinosus IL144 MKEFAMDEELELEIVDLGDAKELTQ GAPSLINSEDNPAFPQRV 43 18 9 
Shewanella sp. HN-41 MQQDNMNKSGLAVEQTVKAAWSKPEIEEINIAGYTE GKATGTN-ESFLSAPS 51 15 8 
Sphingobium chlorophenolicum L-1 MHIPYVKSGREPGRPLVKLGKARHQTR ASMNEIAPELVGDKTQRFGG 47 20 9 
Sphingobium japonicum UT26 (C1-3001x) MERDNDVIELGAVSVETK GPGGITG-DVGLGENNFGLSDD 39 21 8 
Sphingobium japonicum UT26 (P1-00960) MDRHDNSEVDEIIDLGTASAVTQ GMGSGST-DQNGQPKNLIGGISDD 46 23 8 
Sphingobium sp. AP49 MERDAHSQDIVDLGDAVELTR GVLLIGQDDGNGTLYKASGISDED 44 24 8/9 
Sphingobium sp. SYK-6 MNHEHETDDLIELGNASTDTK GGAFIVE-DNEGSLSLQTGLTDD 43 22 8 
Sphingobium yanoikuyae ATCC 51230 (4094) MEREEEIMRIDLGAATEQTQ GPGGIDGDEFLQQDRVGLADD 41 21 8/9 
Sphingobium yanoikuyae ATCC 51230 (4584) MEKESYESPELVELGSFESLTQ GTSYGESLDATFPDGTPRGELTFS 46 24 9 
Sphingobium yanoikuyae XLDN2-5 (284x) MERNSEDRRDDVVELGAVSVETK GISGGTV-DAPAGQGLAGILDD 44 21 8 
Sphingobium yanoikuyae XLDN2-5 (616x) MEREYEATDDGVVELGVGSELTN GVGRGGI-DSPDRQPLTGLLDD 44 21 8 
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Supplementary Table S5c. Genome mining results II. Overview over putative lasso peptide 
precursors. Numbers on the right side represent the number of amino acids of the precursor 
peptides, the putative lasso peptides and the macrolactam rings, in this order. The threonine residue 
at the penultimate position of the leader peptide is highlighted in blue, while the amino acid at 
position 1 of the lasso peptide sequence and the corresponding ring forming amino acid are marked 
in red. 
strain precursor     
Sphingobium yanoikuyae XLDN2-5 (3348) MEKESYESPELVELGSFESLTQ GTSYGESLDATFPDGTPRGELTFS 46 24 9 
Sphingomonas sp. LH128 MSQQRRNVMEHVEEDTMVELGAVSTETK GGQVGIN-DFERGLQLTGSGLTDD 51 23 8 
Sphingomonas sp. SKA58 MEMKMNNINEHEDSVVDLGVASVETK GAALDDS-DNIGGQVRQLGIADD 48 22 8 
Sphingopyxis alaskensis RB2256 (253x) MKDFNELIDLGAISVETR GIEPLGPVDEDQGEHYLFAGGITADD 44 26 9 
Sphingopyxis alaskensis RB2256 (260x) MERTEVIEEVIDLGKASVETK GEALIDQ-DVGGGRQQFLTGIAQD 44 23 8 
Stenotrophomonas maltophilia R551-3 MNELIELGVVAGQQNPEDQGVGGELIELGSVVSETK AHNHGTLWDGVFPTTSP 53 17 9 
Sulfurovum sp. AR MRVRMKKNFSIKKYNKPEIKNLGKIGTKTQYNKSTAGADGTS STHYNKGQDTGFGGAGTVTP 62 20 9 
Sulforovum sp. NBC37-1 MIEKNHSDFSGETERQKKPYSSPKIEIIANVRMATK GSTIGGT-DSGGQSANVPSDPGGW 59 23 8 
Uncultured marine bacterium MSGEQSVSRREENPQISISAGSGRKYKTPRLERFGEISHVTQ GSFGKKK-DAEGDEVAIIPK 61 19 8 
Xanthomonas axonopodis pv. citri str..306 MHENQPAVLSDTSIEGGRKAWSAPVVSFLSIDETA SNATVG-DDGNGTFTGS 51 16 7/8 
Xanthomonas axonopodis pv. malvercearum 
str. GSPB1386 
MHENQPAVLSDTSIEGGRKAWSAPVVSFLSIDETA NNATVG-DDGNGTFTGS 51 16 7/8 
Xanthomonas axonopodis pv. malvercearum 
str. GSPB2388 
MHENQPAVLSDTSIEGGRKAWSAPVVSFLSIDETA NNATVG-DDGNGTFTGS 51 16 7/8 
Xanthomonas axonopodis pv. punicae 
str. LMG 859 
MHENQPAVLSDTSIEGGRKAWSAPVVSFLSIDETA SNATVG-DDGNGTFTGS 51 16 7/8 
Xanthomonas citri pv. mangiferaindicae (260x) MKTFVDSAPSQEDHGKDIIVLGIASVETQ GGAGAG--EVNGMSPIAGISEE 49 20 7 
Xanthomonas citri pv. mangiferaindicae (18x) MHENQPAVLSDTSIEGGRKAWSAPVVSFLSIDETA SNATVG-DDGNGTFTGS 51 16 7/8 
Xanthomonas gardneri ATCC 19865 (4058) MNSNDTTHSDASNEITVLGVASTDTK GGPLAG-EEIGGFNVPGISEE 46 20 7/8 
Xanthomonas gardneri ATCC 19865 (4059) MDTSNNDARTTALDQDLIVLGVASLDTQ GGPLAG-EEMGGITTLGISQD 48 20 7/8 
 
 
Supplementary Table S6. Comparison of the processing enzymes from different gene clusters of 
the same organism with ABC organization and promising precursor peptides. Identity and similarity 
were determined using the BLOSUM62 algorithm. 
 identity / similarity B identity / similarity C 
S. japonicum UT26 37% / 52% 34% / 49% 
S. yanoikuyae XLDN2-5 33% / 49% - 
S. alaskensis RB2256 34% / 49% 33% / 48% 
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Supplementary Table S7. Production values of the investigated lasso peptides using the WT 
constructs or the modified constructs carrying an E. coli optimized RBS. 
construct / fermentation condition UV peak area (main product) production increase  
through RBS incorporation 
burhABC pET41a / 1 d 37 °C 41399295a (-6 aa) - 
burhA_RBS_BC pET41a / 1 d 37 °C 513371242a (-6 aa) 12.4-fold 
ck31_A1A2A3BC pET41a / 3 d 20 °C 36664950 (only caulonodin I, -4 aa) - 
ck31_A1_RBS_BC pET41a / 3 d 20 °C 3099721597 (-4 aa) 84.5-fold 
ck31_A2_RBS_BC pET41a / 3 d 20 °C 2594419029 (-4 aa) nd 
ck31_A3_RBS_BC pET41a / 3 d 20 °C 158874664 (-4 aa) nd 
pzucABC pET41a / 3 d 20 °C - - 
pzucA_RBS_BC pET41a / 3 d 20 °C 156292239a (full length) nd 
rhotABC pET41a / 3 d 20 °C 6976504 (-3 aa) - 
rhotA_RBS_BC pET41a / 3 d 20 °C 5087403 (-3 aa) no increase 
rugeABC pET41a / 1 d 37 °C 53597497 (full length) - 
rugeA_RBS_BC pET41a / 1 d 37 °C 1339158610 (full length) 25.0-fold 
sjap1_ABC pET41a / 3 d 20 °C 166128796 (-4 aa) - 
sjap1_RBS_BC pET41a / 3 d 20 °C 295433797 (-4 aa) 1.8-fold 
sjap2_ABC pET41a / 3 d 20 °C 35147323 (-4 aa) - 
sjap2_RBS_BC pET41a / 3 d 20 °C 85936911 (-4 aa) 2.5-fold 
syan1_ABC pET41a / 3 d 20 °C 187078501 (-4 aa + -5 aa) - 
syan1_RBS_BC pET41a / 3 d 20 °C 1664150210 (-4 aa + -5 aa) 8.9-fold 
sala1_ABC pET41a / 3 d 20 °C 242675653 (-5 aa) - 
sala1_RBS_BC pET41a / 3 d 20 °C 1851952312 (-5 aa) 7.6-fold 
sala2_ABC pET41a / 3 d 20 °C 18517684 (-4 aa) - 
sala2_RBS_BC pET41a / 3 d 20 °C 265940664 (-4 aa) 14.4-fold 
nd = not determined 
aas no UV peak was observable, the peak area of the EIC of the respective singly and doubly charged ions of the 
investigated compound was used instead. 
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Supplementary Table S8. Alignment of the first motif of the B proteins from the 15 known, 
functional lasso peptide biosynthetic gene clusters identified by use of the MEME algorithm. 
protein position of the 
first aligned 
amino acid 
sequence position of the 
last aligned 
amino acid 
AtxB 2 YELNDGVGLALVDQHPIFLDLKTDRYLSLSP 32 
BurhB 33 HHLMPHVFGACFAQQIILLDVVRDRYAVLTE 63 
CapB 1 MTPASHCHIAVFDQAIVALDMQRSRYFLYDE 31 
CK31_B 3 VAVPDHLAYCVKQGGVTFLDVRGDRYFGLPP 33 
CsegB 3 LWLSAGVYAVMIDDDVVFLDVATNAYFCLPA 33 
LarB1 3 LRLRKNVIITPTEYGAVALDERSGDYYQLNS 33 
PzucB 2 PALHPKSFLVAVDADLVLLQVDRDRYLCLPD 32 
RhotB 5 YWLHDDLSFCLVDGHPIFLDMGSDRYFRLSG 35 
RugeB 12 LSLAPHVRACATGGQVILLDLRSGTYLGLAG 42 
Sjap1_B 4 FTLRDGLSFCRTEGQVIFLDLHADRYFGLRP 34 
Sjap2_B 3 LALRDQLSFCIIEQHVLFLDVANDRYFGVRE 33 
SyanB 1 MA.RADINWCDVGGRIVVIDVARDIYLQLPQ 30 
Sala1_B 3 AMLRSGLHYCQFDSGFVLFDLSADRYFLLTD 33 
Sala2_B 6 YRTAPGIFYCRAGSRVIFLDMNRDRYFQLGA 36 
 
Supplementary Table S9. Alignment of the second motif of the B proteins from the 15 known, 
functional lasso peptide biosynthetic gene clusters identified by use of the MEME algorithm. 
protein position of the 
first aligned 
amino acid 
sequence position of the 
last aligned 
amino acid 
AtxB 152 CLPDAFAIATHLRRR.GVDAKLVFGV..R.LPFAAHAWVQVDDIVVGDRPDRI 200 
BurhB 209 CLEWSVAL.TVLCARAGLALKLVIGV..QSFPFYAHAWSEAGGAVIGDSPLRR 258 
CapB 169 CLQMSFALATHLRRE.NVPAQLVIGV..RPMPFVAHAWVEIDGRVCGDEPELK 218 
CK31_B 161 CLLDSLALLDFLHRR.GLYPHIVFGVI.R.QPFAAHCWVQADDVVLNDRLDHV 210 
CsegB 158 CLFRSQMLRDYLLAL.GHRVDWIFGV..RTWPFGAHCWLQAGDLVLDDEAERL 207 
LarB2 80 CLQRSISV.CILMRLDGRWPTWCVGVPSK.PPFRAHAWIEAGGQIVA.ELGDM 129 
McjB 150 CLTYSYALKRILNSR.NIDAHLVIGV..RTQPFYSHSWVEVGGQVINDAPNMR 199 
PzucB 154 CLVRSFVLRRFLRR.SGVDADWVFGV..RTWPFSAHCWLQVGDRALDDYAERL 203 
RhotB 164 CLLDSLAMAKFLKRR.RMRVNVIVGV..TGDPFSAHCWVQAGDMVLNDALGNV 213 
RugeB 183 CLYDSLALLLFLASE.GHCPRWVVGV..RTRPFAAHSWVQSGSLVLNDQAEHV 232 
Sjap1_B 160 CLPTALSLASWLIAL.DIRPDLVLGV..KLNPFQAHSWVEVDGMIVADDPDQV 209 
Sjap2_B 159 CLLYSLALAKLLLSS.GTSPTLIFGV..KLAPFAAHCWVQDGDCVLNDDLDHT 208 
SyanB 162 CLPDSMALLHFLRSR.NMACRLVLGV..RLDPFEAHCWVQDHDMILGDTHERV 211 
Sala1_B 156 CLVRGIAMARMLGCR.GVAASLVFGV..T.MPFAAHSWVQVGDTVLTDSLDMV 204 
Sala2_B 161 CLSRSIALVQRLAAQ.GCAAHLVIGV..RVIPFAAHSWAQIGDVVLNDSPEEV 210 
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Supplementary Table S10. Alignment of the first motif of the C proteins from the 15 known, 
functional lasso peptide biosynthetic gene clusters identified by use of the MEME algorithm. 
protein position of the 
first aligned 
amino acid 
sequence position of the 
last aligned 
amino acid 
AtxC 204 ELRALILRSIKAYASDFPHVVVSFSGGLDSSVVAAGLAQ 242 
BurhC 210 TPFDILKHYLNRFVSFSDRPVLELSGGLESSSVLLAMRA 248 
CapC 204 SCAAALDDVYSRIAHSHPNVCAALSGGVDSSAGAIFLRK 242 
CK31_C 215 AVRQAVEVSVRKWADQSSPVLLELSGGLDSSIIACCLDE 253 
CsegC 221 DLRRTIDATVAALASDAGPIVCEISGGLDSAIVATSLAA 259 
LarC 209 ETAAALFSVVRNQLSDHSAASCDISGGLDSSSIAAIAAN 247 
McjC 176 STIDSIIDNI.EMMRDNRKIALLFSGGLDSALIFHTLKE 213 
PzucC 204 ALAASLDDVCATWTGAYGALMAEVSGGFDSALVAVTARR 242 
RhotC 221 AIRSSVETVVKSLADLDQLTLLELSGGLDSSIIGACLKR 259 
RugeC 227 ALRETVQACASAWAGCHDRVLFRLSGGVDSSILLSCLSR 265 
Sjap1_C 216 MIRRAVSTATRASTMGTKRALLMLSGGIDSSVLAAALGT 254 
Sjap2_C 216 RVRRVTLNSVHAWASCYRNILIQISGGLDSSILAAALRG 254 
SyanC 218 EVAQAVDSACHHWSRQVGPVALTLSGGLDSSVLAAALPG 256 
Sala1_C 203 ALRRTIADCVGAWATCFPSIMVGVSGGLDSSIVAASAAN 241 
Sala2_C 203 RLRDTVFASVGALASDYQNIIVGVSGGLDSSIVCAALTR 241 
 
Supplementary Table S11. Alignment of the second motif of the C proteins from the 15 known, 
functional lasso peptide biosynthetic gene clusters identified by use of the MEME algorithm. 
protein position of the 
first aligned 
amino acid 
sequence position of the 
last aligned 
amino acid 
AtxC 316 S.QTRT.G.GAI.FSGNGGDSVFCFMH..SA 340 
BurhC 324 SQFERQEH.TPL.ISGHGGDALFLAPPPCSA 352 
CapC 319 A.LGPS...SVL.LEGQGGDLLFRAVP..DA 342 
CK31_C 324 AELAPQLGARSF.FSGLGGDNVFCSIA..TA 351 
CsegC 334 A.LEAI.DARAL.FTGHGGDTVFYQVAA.SA 360 
LarC 329 N.VARSKGSQVH.LTGFGGDELFIGSP..T. 354 
McjC 285 G.QPPIDD.DLLYLCGHGGDHIFGQNP..S. 310 
PzucC 318 GELNRHK.ADAL.LTGYGGDAVFFQMP..SA 344 
RhotC 332 S.AARCE.ANSF.FSGAGGDAVFGYLT..SA 357 
RugeC 337 AELAAEYGSGAL.FTGAGGDQLFFEFG..R. 363 
Sjap1_C 327 A.VGAS.GADLS.IDGGGGDNVFFSLR..S. 351 
Sjap2_C 327 A.AKAV.GAEVV.FNGNAGDAVFCFLQ..SA 352 
SyanC 325 A.VAHEVGARAI.AYGSGGDNVFCFLR..SA 351 
Sala1_C 316 G.QLPV...DAF.FSGNGGDGILCGVR..SA 339 
Sala2_C 313 AEICKT.GADAI.FTGNGGDNVFCFLH..SA 339 
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Supplementary Table S12. Alignment of the third motif of the C proteins from the 15 known, 
functional lasso peptide biosynthetic gene clusters identified by use of the MEME algorithm. 
protein position of the 
first aligned 
amino acid 
sequence position of the 
last aligned 
amino acid 
AtxC 444 P.PVVHPLMAKPIQAFCLSLPSWMWVSGGKDRSLVRDAFEGLLP 486 
BurhC 460 P.KH.YPFLCQPMVEFALSTPSYDHFEGAHNRIVLRKSVAAATG 501 
CapC 451 S.RL.NPYLAQPVVEAAFGLHSYDSFDHRNDRIVLREIASAHTP 492 
CK31_C 458 AVRF..PLLTQPVMEACLRVPTWMANHQGRNRAVARDAFFDRLP 499 
CsegC 462 A.RIVHPLLAQPVVEACLAIPAPILSAGEGERSFAREAFADRLP 504 
LarC 482 GVLLVAPMLEQAVVEAAISVRTPERLTPHKYKPVLTHATRGLLP 525 
PzucC 448 A.DLLYPLLSQPLVETALAIPSWKHLDGGRDRALARSVAADRLP 490 
RhotC 461 PIRM..PLLSQPVIETCLRVPSWMWFHNGQNRAVARQAFSDLLP 502 
RugeC 473 P.ELVNPLLSQPLIELCLRLPTWVLTHGGRGRALARRAFADELP 515 
Sjap1_C 459 PVRHVTPLASQPVVEACLRIPSWWWFRQGQNRVVARDAFRDRLP 502 
Sjap2_C 458 PIFMVSPLLSQPLVELCLAVPSWMWCAGGVNRALARAAFERDLP 501 
SyanC 458 GLPVIYPLLSQPVMEACLRQPTWLWYEDGMNRAIARRAYAPKLP 501 
Sala1_C 448 P.PHIAPLMSQPIIEACLAIPTWDWIAGGQNRAVARKAFEGCLP 490 
Sala2_C 447 P.PMFPVLLAQPIVETCLRISSWQWCEGGINRSVARRAFGGFLP 489 
 
Supplementary Table S13. Alignment of the fourth motif of the C proteins from the 15 known, 
functional lasso peptide biosynthetic gene clusters identified by use of the MEME algorithm. 
protein position of the 
first aligned 
amino acid 
sequence position of the 
last aligned 
amino acid 
AtxC 480 AFEGLLPDSVRLRKSKGSPAGFLHALYRAKGRQMIERIRHGYLRREGIID 529 
BurhC 498 AATGY.PN..LWRRNKGETSGIDLLGLRDHREHVMAVCLEGWLAKAGYID 544 
CapC 487 ASAHT.PVDVLWRRTKGSFGIGFVKGIVSHYDALRELIRDGVLMRSGRLD 535 
CK31_C 493 AFFDRLPPRVRDRQTKGGLNAFMGVAFERNRQALARHLLDGRLVQRGLID 542 
CsegC 498 AFADRLPPSIVGRRSKGEISVFLNRSLAASAPFLRGFLLEGRLAARGLID 547 
LarC 519 ATRGLLPAVVAERQTKGGEDTDAAIGFSENISAIRELWDESRLASLGIVD 568 
PzucC 485 A.ADRLPPEIVARRSKGMLTSYYARQVCESLGFLRAYLLDGRLAAEGVLD 533 
RhotC 496 AFSDLLPQKIIARKSKGTLTAYLGALHRRRKHEITDFLADGQLQAHGLVD 545 
RugeC 509 AFADELPPEIRTRRAKGGMEELLQAVLLRNLGFAKELLLDGELARRGLLD 558 
Sjap1_C 496 AFRDRLPAAVVDRRTKGTPDSYIAEIFTANRSVIRSMLLDGNLRRAGLLD 545 
Sjap2_C 495 AFERDLPRQIIQRRSKGSPDSLLLAILELNRPALIKWLCDGLLASRNIID 544 
SyanC 495 AYAPKLPARIVQRASKGGFTSLVRSLYLRNLAAIRAMLLEGELCARGILD 544 
Sala1_C 484 AFEGCLPELITARTQKGGPGDFHLSIYRAHRSALHDRLRGGILAESGILD 533 
Sala2_C 483 AFGGFLPRQVVHRTSKAGPDSVTAAAFESGRPKLRELLLDGLLRQNRIID 532 
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Supplementary Figure S1 - Comparison of suitable precursor peptides found in the same organism and/or in the same 
gene cluster. In cases of the precursor peptides found in C. sp. K31 and S. yanoikuyae XLDN2-5 two alignments are 
shown, one for the highly similar precursor peptides and one for all that were compared from these organisms. 
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fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity fragment 
ion 
charg
e 
predicted 
mass 
observed 
mass 
intensity 
b17 +2 915.4 915.8 717000 b10-H2O +1 983.5 983.5 14800 
b17-H2O +2 906.4 906.9 134000 b10-2H2O +1 965.5 965.5 3780 
b16 +2 837.4 837.7 45900 b9 +1 872.4 872.5 24400 
b16 +1 1673.8 1673.7 146000 b8 +1 773.4 773.5 13100 
c15 +1 1575.8 1575.8 4230 b8-H2O +1 755.4 755.4 13900 
b15 +1 1558.7 1558.8 1030 y2 +1 290.2 290.2 693 
b15-H2O +1 1540.7 1540.8 1930 y3-H2O +1 359.2 359.3 1030 
b14 +1 1471.7 1471.7 2350 y3 +1 377.2 377.3 1590 
b14-H2O +1 1453.7 1453.7 654 y4-H2O +1 545.3 545.4 5070 
b13 +1 1285.6 1285.7 4100 y4 +1 563.3 563.4 5660 
b13-H2O +1 1267.6 1267.7 906 y6-H2O +1 758.4 758.5 28700 
b12 +1 1129.5 1129.6 565 y6 +1 776.4 776.5 5500 
b11 +1 1072.5 1072.5 18000 y7 +1 847.4 847.5 24300 
b11-H2O +1 1054.5 1054.5 6680 y8 +1 976.5 976.6 2030 
b10 +1 1001.5 1001.5 36500 y9 +1 1075.5 1075.6 995 
 
Supplementary Figure S2 - Mass analysis of burhizin. On top the total ion current (TIC), extracted ion current (EIC) 
for the singly and doubly charged ions of the main product (-6 aa truncation) and the UV signal of the 1 d 37 °C pellet 
extract are shown. Depicted in the middle is the fragmentation spectrum of the doubly charged main product. All 
detectable fragment ions with their predicted masses, observed masses and signal intensities are listed on the bottom. 
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fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity fragment 
ion 
charg
e 
predicted 
mass 
observed 
mass 
intensity 
b17-NH3 +2 813.4 813.5 52800 b10-NH3 +1 915.4 915.5 26900 
b16 +2 793.4 793.7 67200 b8 +1 778.4 778.4 459000 
b14 +2 694.4 694.7 8420 b8-NH3 +1 761.4 761.4 159000 
b14 +1 1387.7 1387.7 76700 y3-H2O +1 256.1 256.2 1460 
b14-NH3 +1 1370.7 1370.7 11700 y3 +1 274.1 274.2 17000 
b13 +1 1258.7 1258.7 30200 y4-H2O +1 385.2 385.3 2630 
b13-NH3 +1 1241.6 1241.8 3160 y4 +1 403.2 403.3 6760 
b12 +1 1102.6 1102.6 5150 y5-H2O +1 541.3 541.4 21300 
b12-NH3 +1 1085.5 1085.6 2070 y5 +1 559.3 559.4 13300 
b11 +1 1045.5 1045.5 1420000 y6-H2O +1 598.3 598.5 22000 
b11-NH3 +1 1028.5 1028.5 250000 y6 +1 616.3 616.4 2750000 
a11 +1 1017.5 1017.5 128000 y7 +1 729.4 729.5 101000 
a11-NH3 +1 1000.5 1000.5 32300 y9-H2O +1 865.5 865.6 26200 
b10 +1 932.5 932.5 86800 y9 +1 883.5 883.6 294000 
 
Supplementary Figure S3 - Mass analysis of caulonodin I. On top the total ion current (TIC), extracted ion current 
(EIC) for the singly and doubly charged ions of the main product (-4 aa truncation) and the UV signal of the 3 d 20 °C 
pellet extract are shown. Depicted in the middle is the fragmentation spectrum of the doubly charged main product. All 
detectable fragment ions with their predicted masses, observed masses and signal intensities are listed on the bottom. 
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fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity fragment 
ion 
charg
e 
predicted 
mass 
observed 
mass 
intensity 
b17 +2 830.4 830.6 22100 b10 +1 965.5 965.5 108000 
b17-H2O +2 821.4 821.8 11000 b9 +1 908.5 908.5 5510 
b16 +2 801.9 802.2 178000 b8 +1 811.4 811.5 1390000 
b15 +2 736.4 736.7 17100 b8-H2O +1 793.4 793.5 66000 
b14 +2 687.9 688.2 10300 y3 +1 304.1 304.2 9940 
b14 +1 1374.8 1374.8 3170 y4 +1 401.2 401.3 181000 
b13 +1 1277.7 1277.7 300000 y5-H2O +1 539.3 539.4 18400 
b13-H2O +1 1259.7 1259.7 7770 y5 +1 557.3 557.4 39700 
b12 +1 1121.6 1121.6 21300 y6 +1 614.3 614.4 3700000 
b12-H2O +1 1103.6 1103.6 2560 y7 +1 713.4 713.5 114000 
b11 +1 1064.6 1064.6 2030000 y8 +1 770.4 770.6 9870 
b11-H2O +1 1046.5 1046.6 57000 y9 +1 867.5 867.5 849000 
 
Supplementary Figure S4 - Mass analysis of caulonodin II. On top the total ion current (TIC), extracted ion current 
(EIC) for the singly and doubly charged ions of the main product (-4 aa truncation) and the UV signal of the 3 d 20 °C 
pellet extract are shown. Depicted in the middle is the fragmentation spectrum of the doubly charged main product. All 
detectable fragment ions with their predicted masses, observed masses and signal intensities are listed on the bottom. 
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fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity fragment 
ion 
charg
e 
predicted 
mass 
observed 
mass 
intensity 
b17 +2 886.4 886.7 5550 b10 +1 1078.5 1078.6 24600 
b16 +2 821.9 822.2 25600 b9 +1 1021.5 1021.5 94500 
b16-H2O +2 812.9 813.2 5990 a9 +1 993.5 993.6 3490 
b14 +2 741.9 742.1 9000 b8 +1 922.4 922.5 7810 
b13 +2 660.3 660.5 9330 y2 +1 251.1 251.1 1040 
b12 +2 624.8 625.0 9520 y3 +1 308.1 308.1 7660 
b16 +1 1642.7 1642.7 1940 y4 +1 471.2 471.2 61300 
b15 +1 1539.7 1539.7 5310 y5 +1 542.2 542.3 2900 
b14 +1 1482.7 1482.7 30300 y6-H2O +1 581.2 581.3 27500 
b13 +1 1319.6 1319.7 46900 y6 +1 599.2 599.3 372000 
b12 +1 1248.6 1248.6 8310 y7 +1 712.3 712.4 18200 
b11 +1 1191.6 1191.6 718000 y8 +1 769.3 769.4 32000 
b11-NH3 +1 1174.6 1174.7 14000 y9 +1 868.4 868.5 5580 
a11 +1 1163.6 1163.7 2640      
 
Supplementary Figure S5 - Mass analysis of caulonodin III. On top the total ion current (TIC), extracted ion current 
(EIC) for the singly and doubly charged ions of the main product (-4 aa truncation) and the UV signal of the 3 d 20 °C 
pellet extract are shown. Depicted in the middle is the fragmentation spectrum of the doubly charged main product. All 
detectable fragment ions with their predicted masses, observed masses and signal intensities are listed on the bottom. 
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fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity fragment 
ion 
charg
e 
predicted 
mass 
observed 
mass 
intensity 
b16 +2 822.4 822.7 1710 b10-H2O +1 925.4 925.4 3500 
b16-H2O +2 813.4 814.1 151000 b9 +1 830.3 830.5 120 
a16 +2 808.4 808.8 95100 b9-H2O +1 812.3 812.4 14200 
a16-H2O +2 799.4 800.1 32200 b8 +1 715.3 715.4 57900 
b15 +2 772.9 773.2 144050 b8-H2O +1 697.3 697.4 10600 
b15-H2O +2 763.9 764.4 108000 y2 +1 233.1 233.1 375 
b15 +1 1544.7 1544.7 10800 y3 +1 380.2 380.3 648 
b15-H2O +1 1526.7 1526.8 2850 x4-NH +1 488.2 488.4 15600 
b14 +1 1429.7 1429.6 3620 y4-H2O +1 459.2 459.3 5770 
b13 +1 1282.6 1282.7 459 y4 +1 477.2 477.3 35800 
b12 +1 1185.6 1185.5 15300 y5-H2O +1 587.3 587.4 11100 
b12-H2O +1 1167.5 1167.6 25200 y5 +1 605.3 605.4 76900 
b12-2H2
O 
+1 1149.5 1149.6 3030 y6 +1 719.4 719.5 3840 
b11 +1 1057.5 1057.4 23900 y7 +1 832.5 832.7 44 
b11-H2O +1 1039.4 1039.4 6640 y8 +1 947.5 947.6 4210 
b10 +1 943.4 943.4 54800      
 
Supplementary Figure S6 - Mass analysis of zucinodin. On top the total ion current (TIC), extracted ion current (EIC) 
for the singly and doubly charged ions of the main product (full length) and the UV signal of the 3 d 20 °C pellet extract 
are shown. Depicted in the middle is the fragmentation spectrum of the doubly charged main product. All detectable 
fragment ions with their predicted masses, observed masses and signal intensities are listed on the bottom. 
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fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity fragment 
ion 
charg
e 
predicted 
mass 
observed 
mass 
intensity 
b17 +2 816.4 816.7 4690 a10 +1 1012.5 1012.5 669 
b17-NH3 +2 807.9 808.0 3390 b9 +1 909.5 909.6 16100 
b15 +2 739.4 739.7 9550 a9 +1 881.5 881.6 1050 
b15-H2O +2 730.4 730.8 3760 c8 +1 779.3 779.2 4510 
b14 +2 688.8 689.2 1780 b8 +1 762.4 762.6 5510 
b13 +2 653.3 653.7 1090 y3 +1 274.2 274.2 1990 
b15 +1 1477.7 1477.8 24200 y4 +1 345.2 345.3 15 
b15-NH3 +1 1460.7 1460.8 2400 y5 +1 416.2 416.4 114 
b14 +1 1376.7 1376.8 9190 y6 +1 553.3 553.4 195 
b13 +1 1305.6 1305.8 685 y7-H2O +1 592.3 592.5 2090 
b12 +1 1234.6 1234.8 636 y7 +1 610.3 610.4 21600 
b11 +1 1097.6 1097.7 229 y8 +1 741.3 741.5 16100 
b10 +1 1040.5 1040.6 2040 y9 +1 888.4 888.6 1010 
b10-NH3 +1 1023.6 1023.6 914      
 
Supplementary Figure S7 - Mass analysis of rhodanodin. On top the total ion current (TIC), extracted ion current 
(EIC) for the singly and doubly charged ions of the main product (-3 aa truncation) and the UV signal of the 3 d 20 °C 
pellet extract are shown. Depicted in the middle is the fragmentation spectrum of the doubly charged main product. All 
detectable fragment ions with their predicted masses, observed masses and signal intensities are listed on the bottom. 
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fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity fragment 
ion 
charg
e 
predicted 
mass 
observed 
mass 
intensity 
b18-NH3 +2 930.0 930.0 199000 a11 +1 1052.5 1052.6 59300 
a18 +2 924.5 924.8 60200 a11-NH3 +1 1052.5 1035.6 39900 
b17 +2 888.9 889.3 264000 b10 +1 966.5 966.6 43800 
b16 +1 1620.8 1620.8 4600 a10 +1 938.5 938.8 23000 
b16-NH3 +1 1603.7 1603.8 6110 b9 +1 851.4 851.6 39600 
b15 +1 1492.7 1492.8 6020 y2 +1 274.2 274.2 13000 
b14 +1 1395.7 1395.7 2520000 y4-NH3 +1 481.3 481.4 83800 
b14-NH3 +1 1378.6 1378.7 248000 y4 +1 499.3 499.4 2450000 
a14 +1 1367.7 1367.6 93500 y5-H2O +1 628.4 628.6 28400 
a14-NH3 +1 1350.7 1350.7 58900 y5 +1 646.4 646.5 726000 
b13 +1 1248.6 1248.7 790000 y6 +1 717.4 717.6 13700 
b13-NH3 +1 1231.6 1231.7 110000 y7-H2O +1 796.5 796.7 13000 
b12 +1 1177.6 1177.7 31200 y7 +1 814.5 814.6 336000 
b11 +1 1080.5 1080.6 255000 y8 +1 928.5 928.7 82300 
b11-NH3 +1 1063.5 1063.7 43000 y9 +1 1043.5 1043.7 44700 
 
Supplementary Figure S8 - Mass analysis of rubrivinodin. On top the total ion current (TIC), extracted ion current 
(EIC) for the singly and doubly charged ions of the main product (full length) and the UV signal of the 1  d 37 °C pellet 
extract are shown. Depicted in the middle is the fragmentation spectrum of the doubly charged main product. All 
detectable fragment ions with their predicted masses, observed masses and signal intensities are listed on the bottom. 
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fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity 
b17 +2 762.9 762.8 2430 b9 +1 736.4 736.4 20800 
b17-H2O +2 753.9 754.6 63200 a9 +1 708.4 708.6 17200 
b16 +2 734.4 734.6 121000 c8 +1 654.3 654.3 702 
b16-H2O +2 725.3 725.8 36900 b8 +1 637.3 637.3 56800 
a16 +2 720.4 720.6 27200 b8-H2O +1 619.3 619.4 5280 
a16-H2O +2 711.4 711.9 7990 a8 +1 609.3 609.4 2120 
b15 +2 660.8 661.0 9350 y2 +1 223.1 223.1 2710 
b15-H2O +2 651.8 652.3 4390 y3 +1 337.2 337.2 1390 
b15 +1 1320.6 1320.6 17300 y4 +1 451.2 451.3 3090 
b15-NH3 +1 1303.6 1303.6 7770 y5-H2O +1 562.2 562.3 24300 
b14 +1 1206.6 1206.5 3520 y5 +1 580.2 580.3 1220 
b14-H2O +1 1188.6 1188.6 560 z6-H2O +1 602.2 602.3 2360 
b13 +1 1092.5 1092.4 5600 y6-H2O +1 619.3 619.4 56800 
b13-H2O +1 1074.5 1074.5 629 z6 +1 620.2 620.3 9230 
b12 +1 963.5 963.4 4010 y6 +1 637.3 637.3 5280 
b12--H2O +1 945.5 945.5 331 y7-2H2O +1 714.3 714.1 17600 
b11 +1 906.5 906.4 80700 y7-H2O +1 732.3 732.4 5420 
b11-H2O +1 888.5 888.5 1420 y8 +1 807.4 807.4 5310 
a11 +1 878.5 878.3 994 y9-H2O +1 906.4 906.4 80700 
b10 +1 793.4 793.4 27400 y9 +1 888.4 888.5 1420 
b10-H2O +1 775.4 775.5 135      
 
Supplementary Figure S9 - Mass analysis of sphingonodin I. On top the total ion current (TIC), extracted ion current 
(EIC) for the singly and doubly charged ions of the main product (-4 aa truncation) and the UV signal of the 3 d 20 °C 
pellet extract are shown. Depicted in the middle is the fragmentation spectrum of the doubly charged main product. All 
detectable fragment ions with their predicted masses, observed masses and signal intensities are listed on the bottom. 
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fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity 
b19 +2 891.4 891.6 337 b14-H2O +1 1309.6 1309.6 1980 b8-H2O +1 657.2 657.3 21700 
b19-H2O +2 882.4 882.8 47100 b14-2H2O +1 1291.6 1291.5 140 b8-2H2O +1 639.2 639.3 13100 
b19-2H2O +2 873.4 874.2 9650 b13 +1 1199.5 1199.5 793 y4-H2O +1 341.2 341.3 659 
b18 +2 862.9 863.3 4950 b13-H2O +1 1181.5 1181.5 385 y4 +1 359.2 359.3 327 
b18-H2O +2 853.9 854.5 12200 b12 +1 1102.4 1102.4 272000 y5 +1 473.3 473.4 1570 
b18-2H2O +2 844.9 845.7 2330 b12-H2O +1 1084.4 1084.4 125000 z6-H2O +1 566.3 566.5 11500 
b17 +2 834.4 834.6 13900 b12-2H2O +1 1066.4 1066.4 36900 y6 +1 601.4 601.5 1740 
b17-H2O +2 816.4 817.1 11600 b12-3H2O +1 1048.4 1048.5 7210 y7 +1 698.4 698.5 688000 
b16 +2 777.9 778.3 15000 c11 +1 991.4 991.5 9320 y8 +1 826.5 826.5 89700 
b16-H2O +2 768.9 769.5 19700 b11 +1 974.4 974.4 81900 y9 +1 883.5 883.6 64400 
b16 +1 1554.7 1554.7 1520 b11-H2O +1 956.4 956.4 25300 z10 +1 980.5 980.7 3130 
b16-H2O +1 1536.7 1536.7 4390 b11-2H2O +1 938.3 938.4 3640 y10 +1 997.5 997.6 28800 
b16-2H2O +1 1518.7 1518.5 532 b10 +1 917.3 917.4 53000 y11-H2O +1 1107.6 1107.7 10500 
b15 +1 1441.6 1441.7 342 b9 +1 803.3 803.4 81300 y11 +1 1125.6 1125.6 20300 
b15-H2O +1 1423.6 1423.8 751 b9-H2O +1 785.3 785.4 16200 y11 +2 563.3 563.5 782 
b14 +1 1327.6 1327.6 718 b8 +1 675.2 675.3 10700      
 
Supplementary Figure S10 - Mass analysis of sphingonodin II. On top the total ion current (TIC), extracted ion 
current (EIC) for the singly and doubly charged ions of the main product (-4 aa truncation) and the UV signal of the 3 d 
20 °C pellet extract are shown. Depicted in the middle is the fragmentation spectrum of the doubly charged main 
product. All detectable fragment ions with their predicted masses, observed masses and signal intensities are listed on 
the bottom. 
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fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity fragment 
ion 
charg
e 
predicted 
mass 
observed 
mass 
intensity 
b17 +2 696.4 696.6 1010 b12 +1 965.5 965.4 43 
b16 +2 667.8 668.1 32200 b11 +1 908.5 908.4 1830 
b16-H2O +2 658.8 659.0 7050 b10 +1 837.4 837.4 175 
a16 +2 653.8 654.1 9860 b9 +1 740.4 740.4 57700 
b15 +2 632.3 632.5 9180 b9-H2O +1 722.4 722.4 6110 
b15-H2O +2 623.3 623.5 4710 b8 +1 669.3 669.3 2970 
a15 +2 618.3 618.6 5230 y3 +1 260.2 260.1 94 
b15 +1 1263.6 1263.6 7810 y4 +1 317.2 317.2 316 
b15-H2O +1 1245.6 1245.6 880 y5 +1 445.2 445.6 99 
a15 +1 1235.6 1235.5 1410 y6 +1 502.3 502.3 2510 
b14 +1 1150.6 1150.6 530 y7 +1 573.3 573.4 450 
b14-H2O +1 1132.5 1132.5 181 y8 +1 670.4 670.5 62200 
b13 +1 1093.5 1093.5 3315 y9 +1 741.4 741.4 12000 
b13-H2O +1 1075.5 1075.5 246      
 
Supplementary Figure S11 - Mass analysis of syanodin I. On top the total ion current (TIC), extracted ion current 
(EIC) for the singly and doubly charged ions of the main product (-4 aa truncation) and the UV signal of the 3 d 20 °C 
pellet extract are shown. Depicted in the middle is the fragmentation spectrum of the doubly charged main product. All 
detectable fragment ions with their predicted masses, observed masses and signal intensities are listed on the bottom. 
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fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity 
b21 +2 1082.5 1082.6 392 c15 +2 786.9 786.7 3380 b11 +1 1104.5 1104.5 30000 
b21-H2O +2 1073.5 1073.8 23900 b15 +2 778.4 778.6 33400 a10 +1 961.5 961.2 16900 
a21 +2 1068.5 1068.8 6880 b18 +1 1978.9 1978.8 56100 b9 +1 860.5 860.2 242000 
b20 +2 1054.0 1054.3 129000 b18-H2O +1 1960.9 1960.9 3100 y4 +1 351.2 351.2 27800 
b20-H2O +2 1045.0 1045.2 22600 b17 +1 1831.9 1831.8 273000 y5 +1 464.3 464.4 14900 
b19 +2 1025.5 1025.8 443000 b17-H2O +1 1813.8 1813.8 25200 y6 +1 627.3 627.4 5310 
b19-H2O +2 1016.5 1016.8 73800 b16 +1 1718.8 1718.7 49400 z7 +1 747.4 747.4 20500 
a19 +2 1011.5 1011.8 23900 b16-H2O +1 1700.8 1700.7 8930 y7 +1 764.4 764.5 41900 
b18 +2 990.0 990.0 634000 b15 +1 1555.7 1555.6 24700 y8-H2O +1 875.4 875.5 18300 
b18-H2O +2 981.0 981.2 99900 b15-H2O +1 1537.7 1537.7 3660 y8 +1 893.4 893.6 25400 
a18 +2 976.0 976.3 59200 b14 +1 1418.6 1418.6 51200 y9 +1 950.4 950.5 153000 
a18-H2O +2 967.0 967.2 12100 b14-H2O +1 1400.6 1400.6 7680 y10 +1 1078.5 1078.8 31000 
c17 +2 924.9 925.6 16200 b13 +1 1289.6 1289.6 21500 z11-H2O +1 1158.5 1158.5 4580 
b17 +2 916.4 916.7 351000 b13-H2O +1 1271.6 1271.6 4130 z11 +1 1176.5 1176.6 5970 
b17-H2O +2 907.4 907.7 71000 b12 +1 1232.6 1232.5 120000 y11 +1 1193.5 1193.5 88100 
a17 +2 902.4 902.7 72000 b12-H2O +1 1214.6 1214.6 12400 y12-H2O +1 1304.6 1304.6 12000 
a16 +2 845.9 846.2 64800 c11 +1 1121.6 1121.6 7490 y12 +1 1322.6 1322.6 41800 
 
Supplementary Figure S12 - Mass analysis of sphingopyxin I. On top the total ion current (TIC), extracted ion current 
(EIC) for the doubly charged ions of the main product (-5 aa truncation) and the UV signal of the 3 d 20 °C pellet 
extract are shown. Depicted in the middle is the fragmentation spectrum of the doubly charged main product. All 
detectable fragment ions with their predicted masses, observed masses and signal intensities are listed on the bottom. 
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fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity 
b19-H2O +2 954.0 954.4 373000 b15-2H2O +2 735.9 736.5 3940 b9 +1 923.5 923.5 22400 
b19-2H2O +2 945.0 945.5 22900 b14 +2 698.4 689.7 2210 b8 +1 824.4 824.4 8550 
b18 +2 934.5 934.8 632000 b17 +1 1766.9 1766.8 42000 y3-H2O +1 272.2 272.2 1550 
b18-H2O +2 925.5 925.8 613000 b17-H2O +1 1748.9 1748.8 1750 y3 +1 290.2 290.2 5930 
b18-2H2O +2 916.5 916.8 145000 b16 +1 1653.8 1653.7 118000 y4-H2O +1 419.2 419.3 5760 
b18-3H2O +2 907.5 908.2 17300 b16-H2O +1 1635.8 1635.7 19500 y4 +1 437.2 437.3 2910 
b17 +2 884.0 884.2 640000 b15 +1 1506.7 1506.7 36600 y5-H2O +1 547.3 547.5 1350 
b17-H2O +2 874.9 875.2 245000 b15-H2O +1 1488.7 1488.8 5430 y5 +1 565.3 565.4 1550 
a17 +2 870.0 870.2 76000 b15-2H2O +1 1470.7 1470.7 251 y6-2H2O +1 657.3 657.4 1050 
a17-H2O +2 861.0 861.3 30500 b14 +1 1378.7 1378.6 10300 y6-H2O +1 675.4 675.5 1150 
b16 +2 827.4 827.7 437000 b14-H2O +1 1360.7 1360.7 1410 y6 +1 693.4 693.4 768 
b16-H2O +2 818.4 818.7 229000 b13 +1 1250.6 1250.7 5260 y7 +1 849.5 849.5 3980 
a16 +2 813.4 813.7 36700 b13-H2O +1 1232.6 1232.6 1170 y8 +1 906.5 906.2 6600 
b16-2H2O +2 809.4 809.9 16600 b12 +1 1094.5 1094.4 1830 y9 +1 963.5 963.2 32300 
a16-H2O +2 804.4 804.7 48100 b12-H2O +1 1076.5 1076.5 165 y10-H2O +1 1002.5 1002.6 12600 
c15 +2 762.4 762.1 1720 b11 +1 1037.5 1037.6 895 y10 +1 1020.5 1020.6 11000 
b15 +2 753.9 754.1 22400 b11-H2O +1 1019.5 1019.5 236 y11-H2O +1 1101.6 1101.6 2950 
b15-H2O +2 744.9 745.2 19600 b10 +1 980.5 980.5 451 y11 +1 1119.6 1119.7 2130 
 
Supplementary Figure S13 - Mass analysis of sphingopyxin II. On top the total ion current (TIC), extracted ion 
current (EIC) for the doubly charged ions of the main product (-4 aa truncation) and the UV signal of the 3 d 20 °C 
pellet extract are shown. Depicted in the middle is the fragmentation spectrum of the doubly charged main product. All 
detectable fragment ions with their predicted masses, observed masses and signal intensities are listed on the bottom. 
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Supplementary Figure S14 -Thermal stability assays for (a) burhizin, (b) caulonodin I, (c) caulonodin II, 
(d) caulonodin III, (e) zucinodin and (f) rhodanodin. The observed masses and an excerpt of the EIC of the respective 
lasso peptides are shown on the left. An excerpt of the EIC after incubation for 1 h at 95 °C is presented on the right. In 
cases where the formation of a second peak was detected, the observed mass of the new compound is shown on the far 
right. Theoretical m/z values are 924.4433 for burhizin, 830.9186 for caulonodin I, 839.4250 for caulonodin II, 
895.3966 for  caulonodin III, 831.9444 for zucinodin and 825.4093 for rhodanodin. 
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Supplementary Figure S14 - Thermal stability assays for (g) rubrivinodin, (h) sphingonodin I, (i) sphingonodin II, 
(j) syanodin, (k) sphingopyxin I and (l) sphingopyxin II. The observed masses and an excerpt of the EIC of the 
respective lasso peptides are shown on the left. An excerpt of the EIC after incubation for 1 h at 95 °C is presented on 
the right. In cases where the formation of a second peak was detected, the observed mass of the new compound is 
shown on the far right. Theoretical m/z values are 947.4769 for rubrivinodin, 771.8633 for sphingonodin I, 900.4212 for 
sphingonodin II, 1409.7024 for  syanodin, 1091.5085 for sphingopyxin I and 971.9850 for sphingopyxin II. 
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Supplementary Figure S15 – Comparison of the fragmentation spectra of the heat labile lasso peptides (left) and their branched 
cyclic analogs obtained by incubation for 1 h at 95 °C (right). (a) rhodanodin, (b) rubrivinodin, (c) sphingonodin II, (d) 
sphingopyxin I and (e) syanodin I. 
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Supplementary Figure S16 – Results of the carboxypeptidase Y digestion assays of the eight isolated lasso peptides (a) 
caulonodin I, (b) caulonodin II, (c) caulonodin III, (d) rubrivinodin, (e) sphingonodin I, (f) sphingopyxin I, (g) sphingopyxin II and 
(h) syanodin I. Shown in blue are measurements of the untreated lasso peptides, in red of the lasso peptides after treatment with 
carboxypeptidase Y for 4 h at 25 °C, in green of the lasso peptides after incubation for 4 h at 95 °C and in orange of the lasso 
peptides after incubation for 4 h at 95 °C and subsequent carboxypeptidase Y treatment for 4 h at 25 °C. 
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Supplementary Figure S17 – Results of the carboxypeptidase Y digestion assays with the extracts containing (a) 
burhizin and (b) zucinodin. The corresponding EIC chromatograms are shown before (blue) and after (red) treatment 
with carboxypeptidase Y for 4 h at 25 °C. Scales were chosen depending on the signal intensity of the corresponding 
EICs.   
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Supplementary Figure S18 – Results of the carboxypeptidase Y digestion assays with the extract containing 
sphingonodin II. Above, the corresponding EIC chromatograms of unheated extract are shown before (blue) and after 
(red) treatment with carboxypeptidase Y for 4 h at 25 °C. Below, the corresponding EIC chromatograms of extract after 
incubation for 4 h at 95 °C are shown before (green) and after (orange) treatment with carboxypeptidase Y for 4 h at 
25 °C. Scales were chosen depending on the signal intensity of the corresponding EICs.   
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Supplementary Figure S19 – Results of the carboxypeptidase Y digestion assays with the extract containing 
rhodanodin. Above, the corresponding EIC chromatograms of unheated extract are shown before (blue) and after (red) 
treatment with carboxypeptidase Y for 4 h at 25 °C. Below, the corresponding EIC chromatograms of extract after 
incubation for 4 h at 95 °C are shown before (green) and after (orange) treatment with carboxypeptidase Y for 4 h at 
25 °C. Scales were chosen depending on the signal intensity of the corresponding EICs.   
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Experimental Procedures 
Bacterial Strains and General Methods. Xanthomonas gardneri (DSM no. 19127, ATCC no. 19865)  
was purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ), while 
Xanthomonas citri pv. mangiferaeindicae (LMG no. 941, ATCC no. 11637) was purchased from the 
Belgian Co-Ordinated Collections of Micro-Organisms (BCCM/LMG). For cloning and mutagenesis 
Escherichia coli TOP10 was used, while E. coli BL21(DE3) was used for heterologous expression. 
Confirmation of the identity of the constructed plasmids and corresponding mutants was done via DNA 
dideoxy sequencing by GATC Biotech. Oligonucleotides, proteinase K and carboxypeptidase Y were 
purchased from Sigma Aldrich, while chymotrypsin was purchased from Promega. Restriction enzymes, 
Phusion polymerase and T4 DNA Ligase were ordered from New England Biolabs. 
 
Cloning, Modification and Mutagenesis of the Lasso Peptide Biosynthetic Gene Clusters from 
Xanthomonas gardneri and Xanthomonas citri pv. mangiferaeindicae. For the cloning of the gene 
clusters from X. gardneri and X. citri pv. mangiferaeindicae their DNA was amplified by PCR using 
Phusion polymerase and appropriate oligonucleotide primers (see Supplementary Table S1a). The ~2.9 kb 
PCR product from X. gardneri was digested with NdeI and SpeI, while the ~2.6 kb PCR product from 
X. citri was digested with NdeI and HindIII. Both clusters were cloned into a likewise digested pET41a 
vector. 
The resulting xgaA1A2BC pET41a construct was then modified by PCR using 5'-phosphorylated 
oligonucleotide primers (see Supplementary Table S1b) flanking the leftovers of the multiple cloning site 
(MCS). After the PCR reaction, the DNA was purified and subsequently treated with DpnI to remove 
residual template DNA. Then a blunt end ligation overnight at 16 °C was performed, yielding a variant of 
the plasmid lacking the remaining MCS. This construct was used for replacing the intergenic region 
between the xgaA1A2 and xgaBC genes with a terminator sequence followed by the mcjBCD-promoter. 
This was done via ligation of a PCR amplicon (see Supplementary Table S1b) for the corresponding 
primers) of the plasmid and an amplicon of the terminator-promoter (T-P) sequence (generated using 
csegA1_T-P_csegBC pET41a as template[1]) after digestion with EcoRI and KpnI. Single precursor 
variants of this construct were created via deletion of either one of the precursor genes by PCR using 5'-
phosphorylated oligonucleotide primers (see Supplementary Table S1b) that were flanking the gene to be 
deleted. The resulting amplicons were isolated and purified, treated with DpnI and finally ligated to yield 
the single precursor constructs xgaA1_T-P_xgaBC pET41a and xgaA2_T-P_xgaBC pET41a. (See 
Supplementary Table S3a). 
The xcitABC pET41a plasmid was also modified by PCR using 5'-phosphorylated oligonucleotide primers 
(see Supplementary Table S1b) to replace the intergenic region between xcitA and xcitBC with an E. coli 
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optimized ribosomal binding site (RBS). As the forward primer was carrying the RBS as a non-binding 
overhang on its 5'-end, a blunt end ligation, after DNA purification and a subsequent DpnI digestion, 
resulted in the desired xcitA_RBS_xcitBC pET41a construct (See Supplementary Table S3b). 
Site-directed ligase-independent mutagenesis (SLIM)[2-3] was used for the generation of xanthomonin II 
variants. Different sets of SLIM primers were used for introducing mutations either  between  positions -2 
to 9 (see Supplementary Table S1c) or between positions 10 to 20 (see Supplementary Table S1d-S1e) of 
the precursor peptide. In a similar manner xanthomonin III variants were generated (see 
Supplementary Table S1f). 
In all cases, the ligated or hybridized DNA was dialyzed and then E. coli TOP10 was transformed with 
the DNA via electroporation. After overnight incubation on LB agar plates containing 50 g/mL 
kanamycin, individual transformants were used to inoculate liquid LB overnight cultures for plasmid 
preparations. Isolated plasmids were analyzed by DNA sequencing and, if sequencing confirmed the 
correct sequences, E. coli BL21(DE3) was transformed with the correct constructs for expression. 
 
Production, Isolation and Purification of Xanthomonins I-III. For large scale expressions, M9 
minimal medium (17.1 g/L Na2HPO4∙12 H2O, 3 g/L KH2PO4, 0.5 g/L NaCl, 1 g/L NH4Cl, 1 mL/L MgSO4 
solution  (2 M), 0.2 mL/L CaCl2 solution (0.5 M), pH = 7.0, after autoclaving 10 mL/L glucose solution 
(40% w/v) and 0.2 mL/L vitamin mix (see Supplementary Table S2) were added) was inoculated to an 
OD600 of 0.01 with a LB overnight culture of E. coli BL21(DE3) carrying the corresponding construct. 
All cultures contained 50 g/mL kanamycin. 
After inoculation, the cells were grown at 37 °C until an OD600 of ~0.4 and then slowly cooled to 20 °C in 
the course of 1 h. Upon reaching an OD600 of ~0.6 the expression was induced by addition of IPTG to a 
final concentration of 0.05 mM. After 3 days of cultivation at 20 °C, cells were harvested by 
centrifugation and the supernatant was discarded. For extraction, the cell pellet was resuspended in pure 
methanol and shaken overnight at 4 °C. For each 1 L of culture fermented, 75 mL of pure methanol was 
used for extraction. The extract was centrifuged and the supernatant was evaporated at 40 °C and reduced 
pressure. Dried extract was resuspended in 50% methanol, cleared by centrifugation and filtration and 
subsequently applied to preparative HPLC (microbore 1100 HPLC system (Agilent) with a VP 250/21 
Nucleodur C18 Htec 5 m column (Macherey-Nagel) at room temperature and a flow rate of 18 mL/min). 
For xanthomonin I production, the construct xgaA1_T-P_xgaBC pET41a was expressed in E. coli 
BL21(DE3) and the lasso peptide was purified by two rounds of HPLC. For the first round, the following 
gradient of water/0.045% formic acid (solvent A) and MeOH/0.05% formic acid (solvent B) was used: 
Linear increase from 40% to 85% B in 30 min, followed by a linear increase from 85% to 95% B in 5 min 
and holding 95% B for an additional 3 min. The pooled fractions of the main product (-4 aa truncation of 
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the full length lasso peptide) were evaporated at 40 °C and reduced pressure and ~2 mg of the semipure 
compound were subsequently applied to a second round of purification using the following gradient of 
water/0.1% trifluoroacetic acid (solvent C) and MeCN/0.1% trifluoroacetic acid (solvent D): Linear 
increase from 20% to 50% D in 30 min, followed by a linear increase from 50% to 95% D in 5 min and 
holding 95% D for additional 2 min. The pure -4 aa truncation of xanthomonin I was obtained with a 
yield of 12.7 mg/L. 
For xanthomonin II production the construct xgaA2_T-P_xgaBC pET41a was expressed in E. coli 
BL21(DE3) and purified by two rounds of HPLC. For the first round, the following gradient was used: 
Linear increase from 25% to 85% B in 60 min, followed by a linear increase from 85% to 95% B in 5 min 
and holding 95% B for additional 3 min. The pooled fractions of the main product (-6 aa truncation of the 
full length lasso peptide) were evaporated at 40 °C and reduced pressure and ~2 mg of the semipure 
compound were applied to a second round of purification using the following gradient: Linear increase 
from 20% to 50% D in 30 min, followed by a linear increase from 50% to 95% D in 5 min and holding 
95% D for additional 2 min. The pure -6 aa truncation of xanthomonin II was obtained with a yield of 
4.1 mg/L. 
For xanthomonin III production the construct xcitA_RBS_xgaBC pET41a was expressed in E. coli 
BL21(DE3) and purified by two rounds of HPLC. For the first round, the following gradient was used: 
Linear increase from 20% to 30% B in 5 min, followed by a linear increase from 30% to 95% B in 25 min 
and holding 95% B for additional 3 min. The fractions containing the different main products (-4, -5 and -
7 aa truncations of the full length lasso peptide) were pooled separately and  evaporated at 40 °C and 
reduced pressure. Subsequently, ~2 mg of the semipure -7 aa truncation were applied to a second round of 
purification using the following gradient: Linear increase from 10% to 35% D in 30 min, followed by a 
linear increase from 35% to 95% D in 3 min and holding 95% D for additional 2 min. The pure -7 aa 
truncation of xanthomonin III was obtained with a yield of 0.3 mg/L. 
 
Expression of Xanthomonin Variants. Xanthomonin II variants were expressed for 3 days at 20 °C in 
M9 minimal medium as described above. The wild type and each variant were fermented as triplicate 
30 mL cultures and each pellet was extracted with 5 mL pure methanol by shaking over night at 4 °C. 
Afterward, the extracts were centrifuged and the supernatant was evaporated via freeze drying. The dried 
extracts were then resuspended in 1 mL 50% methanol each, cleared via centrifugation and analyzed for 
production via LC-FT-MS (see Supplementary Tables S4a-S4d). Xanthomonin III variants were 
expressed accordingly as triplicate 500 mL M9 minimal medium cultures. Pellets were extracted with 
25 mL MeOH by shaking over night at 4 °C. After centrifugation, the supernatant was evaporated via 
freeze drying and the dried extracts were resuspended in 1 mL 50% methanol and analyzed in a likewise 
manner to the Xanthomonin II variants (See Supplementary Table S5). 
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Mass Spectrometric Analysis. Mass spectrometric analysis of extracts was done using a LTQ-FT ultra 
instrument (Thermo Fisher Scientific) that was connected to a microbore 1100 HPLC system (Agilent). 
Separation of the extracts was achieved by using a CC 125/2 Nucleosil 300-8 C18 column (Macherey-
Nagel) and a gradient of water/0.1% trifluoroacetic acid (solvent A) and MeCN/0.1% trifluoroacetic acid 
(solvent B) at 40 °C and a flow rate of 0.2 ml/min, while UV absorption was recorded at 215 nm for 
detection: Holding 2% B for 2 min, followed by a linear increase from 2% to 30% B in 18 min, a 
subsequent increase from 30% to 90% B in 15 min and holding 95% B for an additional 2 min. For each 
measurement, 100 L of the respective samples were injected. Each sample was then analyzed for the 
presence of any possible truncation product, ranging from the full length product to the lone macrolactam 
ring. For quantification, the UV peak areas of all detectable truncations were integrated and added to 
determine the overall production. Relative production of variants was determined by comparison of their 
overall integral to the overall integral of the corresponding wild type samples. All data obtained this way 
is shown in Supplementary Tables S3-S5. 
Analysis of thermal stability and protease assays of the purified lasso peptides was done with a 
1100 series MSD (Hewlett-Packard) coupled with a microbore 1100 HPLC system (Agilent). For sample 
separation an EC 125/2 Nucleodur 100-3 C18ec column at room temperature and a flow rate of 
0.2 mL/min was used. For xanthomonin I,  the following gradient was used: Linear increase from 25% to 
35% B in 15 min, followed by a linear gradient from 35% to 95% B in 2 min and holding 95% B for 
additional 5 min. For xanthomonin II,  the following gradient was used: Linear increase from 20% to 35% 
B in 15 min, followed by a linear gradient from 35% to 95% B in 2 min and holding 95% B for additional 
5 min. For xanthomonin III,  the following gradient was used: Linear increase from 0% to 30% B in 
15 min, followed by a linear gradient from 30% to 95% B in 2 min and holding 95% B for additional 
5 min. 
Tandem mass spectrometry was performed by employing collision-induced dissociation fragmentation 
within the linear ion trap using online LC-MS. As the singly charged ions were the dominant species for 
all xanthomonins, they were selected for fragmentation studies. In all instances, the energy for 
fragmentation was set to 35%. 
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Protease Assays of Xanthomonins I and II. For testing the proteolytic stability of Xanthomonins I and 
II, assays with chymotrypsin, proteinase K and carboxypeptidase Y were performed. These assays were 
performed over the course of 4 h at either 25 °C (chymostrypsin and carboxypeptidase Y) or 37 °C 
(proteinase K), using 10 g of purified lasso peptide per assay. Chymotrypsin assays were done with 
0.5 g protease per reaction in a buffer containing 100 mM Tris-HCl and 10 mM CaCl2 at pH 8.5. 
Proteinase K assays were done with 1 U proteinase K per reaction in a buffer containing 50 mM Tris-HCl 
at pH 7.5. Carboxypeptidase Y assays were done with 0.5 U carboxypeptidase Y per reaction in a buffer 
containing 50 mM MES and 1 mM CaCl2 at pH 6.75. After theend of the incubation time, the samples 
were compared to an untreated sample via LC-MS. 
 
Thermal Stability Assays of Xanthomonins I and II. For testing the thermal stability of 
xanthomonins I-II, 100 L samples, containing each 10 g of the corresponding lasso peptide in water, 
were incubated at 95 °C for different time intervals and were then compared to an untreated sample via 
LC-MS. 
 
Crystallization and Data Collection. Saturated solutions of the -4 aa truncation of xanthomonin I and 
the -6 aa truncation of xanthomonin II in water were used for crystallization screenings using typical 
protein crystallization screens purchased from Qiagen. Crystals of xanthomonin I were obtained upon 
incubation at 277 K after mixing 300 nL peptide solution with 300 nL reservoir solution consisting of  
8.5 mM cobalt chloride, 85 mM sodium acetate at pH 4.6, 0.85 M 1,6-hexanediol and 15% (V/V) 
glycerol. Crystals of xanthomonin II were obtained upon incubation at 291 K after mixing 300 nL peptide 
solution with 300 nL reservoir solution consisting of  2 M sodium chloride and 10% (w/V) polyethylene 
glycol 6000. Crystals were harvested from mother liquor and frozen without cryoprotectant in liquid 
nitrogen. Data was collected at 100 K at Bessy II (Helmholtz-Zentrum Berlin, Germany), Beamline 14.1 
using a Dectris PILATUS detector.[4] In order to achieve high-resolution data for xanthomonin I, the 
wavelength was set to 0.800 Å and an oscillation range of 0.1° in order to improve the signal-to-noise 
ratio. Data processing and scaling was performed using the program XDS.[5] Data were prepared for 
solving the phase problem by direct methods using XPREP 
 
Crystal Structure Elucidation of Xanthomonin I. Xanthomonin I crystallizes in the monoclinic space 
group P21 with cell constants a = 13.804(3) Å, b = 45.096(9) Å, c = 13.890(3) Å, β = 91.42°, 
V = 8644(3) Å3, with two molecules, one bridging water molecule, 18 solvent water molecules and one 
molecule 1,6-hexanediol in the asymmetric unit, empirical formula 2(C65H97N17O21),C6H12O2,19(H2O), 
formula weight 3363.64 g/mol, calculated density 1.292 g/cm3. The structure has been solved using dual 
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space direct methods[6] and refined using the full matrix least squares procedure,[7] non-hydrogen atoms of 
the peptide and the bridging water molecule were anisotropically refined. Hydrogen atoms have been 
mostly included at calculated positions; some N- or O-bonded hydrogen atoms involved in hydrogen 
bonds were located and isotropically refined. Solvent water oxygen atoms were refined with a common 
isotropic temperature factor without adding hydrogen atoms and with split positions. 
The refinement of 2162 parameters converged to R1 = 0.0544 and R2 = 0.148 for all 24760 independent 
reflections.  The largest peak and hole in the difference Fourier density map was 0.51 and -0.32 e Å-3. 
The coordinates of the crystal structure of the -4 aa truncation of xanthomonin I have been submitted to 
the Protein Data Bank (PDB) and assigned the accession number 4NAG. 
 
NMR Structure Elucidation of Xanthomonin II. The sample for the NMR spectroscopic studies 
contained 2.8 mg of the -6 aa truncation of xanthomonin II in 250 L DMSO-d6 filled in a 3 mm Wilmad 
tube (Rototec Spintec). Spectra were recorded on a Bruker Avance 600 MHz spectrometer equipped with 
an inverse triple resonance 1H-13C-15N probe with z-gradient. Temperature influence on the sample was 
studied by recording 1H spectra at temperatures between 295 and 313 K with an increment of 5 K. The 
2D experiments DQF-COSY,[8] TOCSY,[9] and NOESY[10] were performed at 305 K in the standard way 
for sequential assignments.[11] The TOCSY spectra were recorded with a mixing time of 120 ms, while 
NOESY spectra were recorded with mixing times of 100 and 300 ms. 1D spectra were acquired with 
65536 data points, while 2D spectra were collected using 4096 points in the F2 dimension and 512 
increments in the F1 dimension. Both 1D and 2D spectra were recorded with 32 transients and relaxation 
delays of 3.0 s. Chemical shifts were referenced to the rest signal of DMSO-d6. All spectra were 
processed with Bruker TOPSPIN 3.1. NOE cross-peaks were analyzed within the program Sparky.[12] 
Structure calculations were performed on the -6 aa truncation of xanthomonin II in DMSO-d6 at 305 K. 
NOESY cross-peaks with a mixing time of 100 ms were used to create distance constraints. Constraints of 
the torsion angle ϕ were determined by analyzing the vicinal coupling constants 3JHNα, while those of χ
1 
were determined by fulfilling the stereospecific assignment on the basis of NOE contacts and 3Jαβ. These 
constraints were used in the simulated annealing protocol and the structure calculations were done with 
the program CYANA 2.1.[13] The coordinates of the 15 lowest energy structures of the -6 aa truncation of 
xanthomonin II have been submitted to the Protein Data Bank (PDB) and assigned the accession number 
2MFV. 
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Antibacterial Assays. Spot-on-lawn assays were used to assess a potential antibacterial activity of 
xanthomonins I and II. These assays were performed with Asticaccaulis excentricus, Bacillus subtilis, 
Burkholderia thailendensis, Burkholderia rhizoxinica, Caulobacter crescentus, Caulobacter sp. K31, 
Caulobacter segnis, Micrococcus flavus, Sphingobium japonicum, Sphingopyxis alaskensis and 
Xanthomonas gardneri.  
Soft agar was prepared by inoculation of soft agar medium (6 g/L agar) to an OD of ~0.01 with an 
culture of the corresponding bacterial strain during its exponential growth phase. These bacterial 
suspensions were then used for creating overlays on a 20 mL agar layer (15 g/L agar). Subsequently,  
several droplets of different volumes (0, 5, 10 or 20 L of an 1 mg/mL stock solution of the respective 
lasso peptide) were placed on marked spots on the agar overlay. LB medium was used as both liquid and 
solid medium for all strains with exception of Caulobacter crescentus and C. sp. K31. For the latter 
strains, PYEGR medium was employed. The plates were analyzed for the presence of inhibition halos 
after both 1 and 2 days of incubation at 30 °C. In no case, the formation of inhibition halos was observed, 
meaning that all tested strains are not sensitive towards xanthomonins I and II in the tested concentration 
range. 
 
Thermal Stability and Carboxypeptidase Y Assays of Xanthomonin II Variants and 
Xanthomonin III. For assessment of the topology and thermal stability of Xanthomonin II variants, 
220 L of the corresponding extracts were evaporated at 30 °C under reduced pressure and subsequently 
resuspended in 44 L MES buffer (50 mM MES, 1 mM CaCl2, pH 6.75). 22 L of these solutions were 
incubated at 95 °C for 4 h. From both the untreated and thermally treated samples, 10 L were mixed 
with 15 L carboxypeptidase Y solution (100 U/mL, 50 mM MES, 1 mM CaCl2, pH 6.75), incubated at 
25 °C for 4 h and were afterward diluted with 75 L water. As non-digested references, 10 L of each 
untreated and thermally treated samples were diluted with 15 L MES buffer and 75 L water. As control, 
these experiments were also done with extracts of wild type xanthomonin II. All samples were then 
analyzed via LC-FT-MS. 
Differentiation between a lasso peptide and an unthreaded branched cyclic peptide is possible via 
carboxypeptidase Y digestion. As the macrolactam ring shields the amino acids of the tail that are 
positioned inside of the ring against proteolytic digestion, a lasso peptide with a suitable plug amino acid 
at this position can only be degraded up or close to the plug amino acid. In contrast, a branched cyclic 
peptide can be digested up or close to the macrolactam ring. Analysis of the main products after 
carboxypeptidase Y digestion thus reveals the topology of the investigated variant. For a heat stable lasso 
peptide, carboxypeptidase Y digestion would show only degradation products up or close to the plug 
amino acid, independent of prior thermal treatment. On the other hand, a heat senstive lasso peptide 
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would show different degradation products, depending on the carboxypeptidase Y digestion being 
performed before or after thermal treatment. 
In a similar manner, the thermal stability and topology of Xanthomonin III was assessed. In this case, 
10 L of a solution of pure -7 amino acid truncation of xanthomonin III in water (1 mg/mL) was used for 
each assay and as reference. If necessary, samples were incubated for 4 h at 95 °C. For 
carboxypeptidase Y assays, 25 L of a carboxypeptidase Y solution (20 U/mL, 50 mM MES, 1 mM 
CaCl2, pH 6.75) were added, the samples were then incubated at 25 °C for 4 h and afterward diluted with 
75 L water. Samples that should not be treated with carboxypeptidase Y were directly diluted with 25 L 
MES buffer and 75 L water. All samples were analyzed via LC-MS. 
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Supplementary Table S1a. Oligonucleotide primers for cloning of the investigated gene clusters. 
Introduced restriction sites are underlined. 
name sequence 
XgaA1_NdeI_FP GGATTAC CAT ATG AAC AGC AAC GAC ACC ACC CAC AGC G 
XgaC_SpeI_RP ATAT ACT AGT TCA GCC TTG ATG ACG GAC CCA GTT CTC GAC 
XcitA_NdeI_FP GG GAA TTC CAT ATG AAA ACG TTC GTC GAT AGC GCT CCG AGC CAG GAA GAC C 
XcitC_HindIII_RP ATAT AAG CTT CTA GCC GTG ATT GCG GAT CCA GTT CTC GAT CAT GCA CAG GTC 
 
 
Supplementary Table S1b. Oligonucleotide primers for cluster optimization. Introduced restriction sites 
are underlined. Sequences introduced via mutagenesis are highlighted in bold. 
name sequence 
pET41mcsKO_FPa TAA TTG ATT AAT ACC TAG GCT GCT AAA CAA AGC CCG AAA GGA AGC TG 
pET41mcsKO_RPa CGG AGT GAT GGT GAT GGT GAT GAC CAG AAC CAC TAG TTC AGC 
XgaBC-pET41a_ 
EcoRI_FP 
ATATA GAA TTC ATG CAT CGC TAC ACA TTG CGC GAC GAC 
XgaA2-pET41a_ 
KpnI_RP 
ATAT GGT ACC TA GTC CTG GCT GAT GCC CAG GGT GGT G 
LambdaTerm_Mcj
Prom_KpnI_FP 
ATAT GGT ACC AGC TTA ATT AGC TGA GCT TGG ACT CCT GTT GAT AG 
LambdaTerm_Mcj
Prom_EcoRI_RP 
TATAT GAA TTC CAC TCC CTC CTG TAG TTA TGC CTT TAC ACT CAA TTG G 
Xcit_LinkRBS_FPa AGAGGAGAAATTAACC ATG GCT CGG CAT CTG AAC GAA GAC ATT TCG TAC TGC 
CAA C 
Xcit_LinkRBS_RP
a
 
TCA TTC TTC GGA GAT GCC GGC GAT GGG GGA CAT CCC 
a Primers were 5'-phosphorylated 
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Supplementary Table S1c. Oligonucleotide primers for mutation of the xanthomonin II precursor 
peptide in between positions -2 to 9. All mutations were introduced using SLIM.[2-3] SLIM overhang 
regions are underlined. Mutated positions are highlighted in bold. 
name sequence 
XgaA2_FP_-2-9 GGT GGC ATC ACC ACC CTG GGC ATC AGC CAG GAC TAG 
XgaA2_RP_-2-9 GCG CAG GGC GGG CCA TTG GCA GGC GAA GAA ATG GGT GGC ATC ACC ACC CTG GGC 
ATC AGC CAG GAC TAG 
XgaA2_T-2A 
_FPTail 
GCG CAG GGC GGG CCA TTG GCA GGC GAA GAA ATG GGT GGC ATC ACC ACC CTG GGC 
ATC AGC CAG GAC TAG 
XgaA2_T-2A 
_RPTail 
CAT TTC TTC GCC TGC CAA TGG CCC GCC CTG CGC GTC CAG GCT TGC GAC CCC TAG 
CAC GAT GAG ATC CTG 
XgaA2_T-2C 
_FPTail 
TGC CAG GGC GGG CCA TTG GCA GGC GAA GAA ATG GGT GGC ATC ACC ACC CTG GGC 
ATC AGC CAG GAC TAG 
XgaA2_T-2C 
_RPTail 
CAT TTC TTC GCC TGC CAA TGG CCC GCC CTG GCA GTC CAG GCT TGC GAC CCC TAG 
CAC GAT GAG ATC CTG 
XgaA2_T-2I 
_FPTail 
ATT CAG GGC GGG CCA TTG GCA GGC GAA GAA ATG GGT GGC ATC ACC ACC CTG GGC 
ATC AGC CAG GAC TAG 
XgaA2_T-2I 
_RPTail 
CAT TTC TTC GCC TGC CAA TGG CCC GCC CTG AAT GTC CAG GCT TGC GAC CCC TAG 
CAC GAT GAG ATC CTG 
XgaA2_T-2S 
_FPTail 
AGC CAG GGC GGG CCA TTG GCA GGC GAA GAA ATG GGT GGC ATC ACC ACC CTG GGC 
ATC AGC CAG GAC TAG 
XgaA2_T-2S 
_RPTail 
CAT TTC TTC GCC TGC CAA TGG CCC GCC CTG GCT GTC CAG GCT TGC GAC CCC TAG 
CAC GAT GAG ATC CTG 
XgaA2_T-2V 
_FPTail 
GTG CAG GGC GGG CCA TTG GCA GGC GAA GAA ATG GGT GGC ATC ACC ACC CTG GGC 
ATC AGC CAG GAC TAG 
XgaA2_T-2V 
_RPTail 
CAT TTC TTC GCC TGC CAA TGG CCC GCC CTG CAC GTC CAG GCT TGC GAC CCC TAG 
CAC GAT GAG ATC CTG 
XgaA2_P3A 
_FPTail 
ACA CAG GGC GGG GCG TTG GCA GGC GAA GAA ATG GGT GGC ATC ACC ACC CTG 
GGC ATC AGC CAG GAC TAG 
XgaA2_P3A 
_RPTail 
CAT TTC TTC GCC TGC CAA CGC CCC GCC CTG TGT GTC CAG GCT TGC GAC CCC TAG 
CAC GAT GAG ATC CTG 
XgaA2_E7A 
_FPTail 
ACA CAG GGC GGG CCA TTG GCA GGC GCG GAA ATG GGT GGC ATC ACC ACC CTG GGC 
ATC AGC CAG GAC TAG 
XgaA2_E7A 
_RPTail 
CAT TTC CGC GCC TGC CAA TGG CCC GCC CTG TGT GTC CAG GCT TGC GAC CCC TAG 
CAC GAT GAG ATC CTG 
XgaA2_E7D_E8A 
_FPTail 
ACA CAG GGC GGG CCA TTG GCA GGC GAT GCG ATG GGT GGC ATC ACC ACC CTG GGC 
ATC AGC CAG GAC TAG 
XgaA2_E7D_E8A 
_RPTail 
CAT CGC ATC GCC TGC CAA TGG CCC GCC CTG TGT GTC CAG GCT TGC GAC CCC TAG 
CAC GAT GAG ATC CTG 
XgaA2_E8A_ 
FPTail 
ACA CAG GGC GGG CCA TTG GCA GGC GAA GCG ATG GGT GGC ATC ACC ACC CTG GGC 
ATC AGC CAG GAC TAG 
XgaA2_E8A_ 
RPTail 
CAT CGC TTC GCC TGC CAA TGG CCC GCC CTG TGT GTC CAG GCT TGC GAC CCC TAG 
CAC GAT GAG ATC CTG 
XgaA2_E7A_E8D 
_FPTail 
ACA CAG GGC GGG CCA TTG GCA GGC GCG GAT ATG GGT GGC ATC ACC ACC CTG GGC 
ATC AGC CAG GAC TAG 
XgaA2_E7A_E8D 
_RPTail 
CAT ATC CGC GCC TGC CAA TGG CCC GCC CTG TGT GTC CAG GCT TGC GAC CCC TAG 
CAC GAT GAG ATC CTG 
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Supplementary Table S1d. Oligonucleotide primers for mutation of the xanthomonin II precursor peptide in between positions 10 to 
20. All mutations were introduced using SLIM.
[2-3]
 SLIM overhang regions are underlined. Mutated positions are highlighted in bold. 
name sequence 
XgaA2_FP_10-20 TAG GTA CCA GCT TAA TTA GCT GAG CTT GGA CTC CTG TTG ATA G 
XgaA2_RP_10-20 CAT TTC TTC GCC TGC CAA TGG CCC GCC CTG TGT GTC CAG 
XgaA2_G10A_ 
FPTail 
GCG GGC ATC ACC ACC CTG GGC ATC AGC CAG GAC TAG GTA CCA GCT TAA TTA GCT 
GAG CTT GGA CTC CTG TTG ATA G 
XgaA2_G10A_ 
RPTail 
GTC CTG GCT GAT GCC CAG GGT GGT GAT GCC CGC CAT TTC TTC GCC TGC CAA TGG 
CCC GCC CTG TGT GTC CAG 
XgaA2_G10L_ 
FPTail 
CTG GGC ATC ACC ACC CTG GGC ATC AGC CAG GAC TAG GTA CCA GCT TAA TTA GCT 
GAG CTT GGA CTC CTG TTG ATA G 
XgaA2_G10L 
_RPTail 
GTC CTG GCT GAT GCC CAG GGT GGT GAT GCC CAG CAT TTC TTC GCC TGC CAA TGG 
CCC GCC CTG TGT GTC CAG 
XgaA2_G10F_ 
FPTail 
TTT GGC ATC ACC ACC CTG GGC ATC AGC CAG GAC TAG GTA CCA GCT TAA TTA GCT 
GAG CTT GGA CTC CTG TTG ATA G 
XgaA2_G10F_ 
RPTail 
GTC CTG GCT GAT GCC CAG GGT GGT GAT GCC AAA CAT TTC TTC GCC TGC CAA TGG 
CCC GCC CTG TGT GTC CAG 
XgaA2_G11A_ 
FPTail 
GGT GCG ATC ACC ACC CTG GGC ATC AGC CAG GAC TAG GTA CCA GCT TAA TTA GCT 
GAG CTT GGA CTC CTG TTG ATA G 
XgaA2_G11A_ 
RPTail 
GTC CTG GCT GAT GCC CAG GGT GGT GAT CGC ACC CAT TTC TTC GCC TGC CAA TGG 
CCC GCC CTG TGT GTC CAG 
XgaA2_G11L_ 
FPTail 
GGT CTG ATC ACC ACC CTG GGC ATC AGC CAG GAC TAG GTA CCA GCT TAA TTA GCT 
GAG CTT GGA CTC CTG TTG ATA G 
XgaA2_G11L_ 
RPTail 
GTC CTG GCT GAT GCC CAG GGT GGT GAT CAG ACC CAT TTC TTC GCC TGC CAA TGG 
CCC GCC CTG TGT GTC CAG 
XgaA2_G11F_ 
FPTail 
GGT TTT ATC ACC ACC CTG GGC ATC AGC CAG GAC TAG GTA CCA GCT TAA TTA GCT 
GAG CTT GGA CTC CTG TTG ATA G 
XgaA2_G11F_ 
RPTail 
GTC CTG GCT GAT GCC CAG GGT GGT GAT AAA ACC CAT TTC TTC GCC TGC CAA TGG 
CCC GCC CTG TGT GTC CAG 
XgaA2_I12A_ 
FPTail 
GGT GGC GCG ACC ACC CTG GGC ATC AGC CAG GAC TAG GTA CCA GCT TAA TTA GCT 
GAG CTT GGA CTC CTG TTG ATA G 
XgaA2_I12A_ 
RPTail 
GTC CTG GCT GAT GCC CAG GGT GGT CGC GCC ACC CAT TTC TTC GCC TGC CAA TGG 
CCC GCC CTG TGT GTC CAG 
XgaA2_I12A_ 
T13A_FPTail 
GGT GGC GCG GCC ACC CTG GGC ATC AGC CAG GAC TAG GTA CCA GCT TAA TTA GCT 
GAG CTT GGA CTC CTG TTG ATA G 
XgaA2_I12A_ 
T13A_RPTail 
GTC CTG GCT GAT GCC CAG GGT GGC CGC GCC ACC CAT TTC TTC GCC TGC CAA TGG 
CCC GCC CTG TGT GTC CAG 
XgaA2_I12A_T13A
_T14A_FPTail 
GGT GGC GCG GCC GCA CTG GGC ATC AGC CAG GAC TAG GTA CCA GCT TAA TTA GCT 
GAG CTT GGA CTC CTG TTG ATA G 
XgaA2_I12A_T13A
_T14A_RPTail 
GTC CTG GCT GAT GCC CAG TGC GGC CGC GCC ACC CAT TTC TTC GCC TGC CAA TGG 
CCC GCC CTG TGT GTC CAG 
XgaA2_I12A_T13A
_T14A_L15A_ 
FPTail 
GGT GGC GCG GCC GCA GCG GGC ATC AGC CAG GAC TAG GTA CCA GCT TAA TTA GCT 
GAG CTT GGA CTC CTG TTG ATA G 
XgaA2_I12A_T13A
_T14A_L15A_ 
RPTail 
GTC CTG GCT GAT GCC CGC TGC GGC CGC GCC ACC CAT TTC TTC GCC TGC CAA TGG 
CCC GCC CTG TGT GTC CAG 
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Supplementary Table S1e. Oligonucleotide primers for mutation of the xanthomonin II precursor peptide in between positions 10 to 
20. All mutations were introduced using SLIM.
[2-3]
 SLIM overhang regions are underlined. Mutated positions are highlighted in bold. 
name sequence 
XgaA2_T13A_T14
A_L15A_FPTail 
GGT GGC ATC GCC GCA GCG GGC ATC AGC CAG GAC TAG GTA CCA GCT TAA TTA 
GCT GAG CTT GGA CTC CTG TTG ATA G 
XgaA2_T13A_T14
A_L15A_RPTail 
GTC CTG GCT GAT GCC CGC TGC GGC GAT GCC ACC CAT TTC TTC GCC TGC CAA 
TGG CCC GCC CTG TGT GTC CAG 
XgaA2_I12L_T13
A_T14A_L15A_ 
FPTail 
GGT GGC CTG GCC GCA GCG GGC ATC AGC CAG GAC TAG GTA CCA GCT TAA TTA 
GCT GAG CTT GGA CTC CTG TTG ATA G 
XgaA2_I12L_T13
A_T14A_L15A_ 
RPTail 
GTC CTG GCT GAT GCC CGC TGC GGC CAG GCC ACC CAT TTC TTC GCC TGC CAA 
TGG CCC GCC CTG TGT GTC CAG 
XgaA2_I12V_T13
A_T14A_L15A_ 
FPTail 
GGT GGC GTG GCC GCA GCG GGC ATC AGC CAG GAC TAG GTA CCA GCT TAA TTA 
GCT GAG CTT GGA CTC CTG TTG ATA G 
XgaA2_I12V_T13
A_T14A_L15A_ 
RPTail 
GTC CTG GCT GAT GCC CGC TGC GGC CAC GCC ACC CAT TTC TTC GCC TGC CAA 
TGG CCC GCC CTG TGT GTC CAG 
XgaA2_I12S_T13
A_T14A_L15A_ 
FPTail 
GGT GGC AGC GCC GCA GCG GGC ATC AGC CAG GAC TAG GTA CCA GCT TAA TTA 
GCT GAG CTT GGA CTC CTG TTG ATA G 
XgaA2_I12S_T13
A_T14A_L15A_ 
RPTail 
GTC CTG GCT GAT GCC CGC TGC GGC GCT GCC ACC CAT TTC TTC GCC TGC CAA 
TGG CCC GCC CTG TGT GTC CAG 
XgaA2_I12T_T13
A_T14A_L15A_ 
FPTail 
GGT GGC ACC GCC GCA GCG GGC ATC AGC CAG GAC TAG GTA CCA GCT TAA TTA 
GCT GAG CTT GGA CTC CTG TTG ATA G 
XgaA2_I12T_T13
A_T14A_L15A_ 
RPTail 
GTC CTG GCT GAT GCC CGC TGC GGC GGT GCC ACC CAT TTC TTC GCC TGC CAA 
TGG CCC GCC CTG TGT GTC CAG 
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Supplementary Table S1f. Oligonucleotide primers for mutation of the xanthomonin III precursor 
peptide in between positions 10 to 17. All mutations were introduced using SLIM.[2-3] SLIM overhang 
regions are underlined. Mutated positions are highlighted in bold. 
name sequence 
Xcit_10-17_SLIM 
_FP 
TCC GAA GAA TGA AGA GGA GAA ATT AAC CAT GGC TCG GCA TC 
Xcit_10-17_SLIM 
_RP 
ATT CAC CTC ACC GGC TCC CGC GCC GCC CTG GG 
Xcit_I14A_FPTail GGG ATG TCC CCC GCG GCC GGC ATC TCC GAA GAA TGA AGA GGA GAA ATT AAC 
CAT GGC TCG GCA TC 
Xcit_I14A_RPTail GAT GCC GGC CGC GGG GGA CAT CCC ATT CAC CTC ACC GGC TCC CGC GCC GCC 
CTG GG 
Xcit_P13A_I14A 
_FPTail 
GGG ATG TCC GCA GCG GCC GGC ATC TCC GAA GAA TGA AGA GGA GAA ATT AAC 
CAT GGC TCG GCA TC 
Xcit_P13A_I14A 
_RPTail 
GAT GCC GGC CGC TGC GGA CAT CCC ATT CAC CTC ACC GGC TCC CGC GCC GCC 
CTG GG 
Xcit_S12A_P13A_
I14A_FPTail 
GGG ATG GCT GCA GCG GCC GGC ATC TCC GAA GAA TGA AGA GGA GAA ATT AAC 
CAT GGC TCG GCA TC 
Xcit_S12A_P13A_
I14A_RPTail 
GAT GCC GGC CGC TGC AGC CAT CCC ATT CAC CTC ACC GGC TCC CGC GCC GCC 
CTG GG 
Xcit_M11A_S12A
_P13A_I14A 
_FPTail 
GGG GCC GCT GCA GCG GCC GGC ATC TCC GAA GAA TGA AGA GGA GAA ATT 
AAC CAT GGC TCG GCA TC 
Xcit_M11A_S12A
_P13A_I14A 
_RPTail 
GAT GCC GGC CGC TGC AGC GGC CCC ATT CAC CTC ACC GGC TCC CGC GCC GCC 
CTG GG 
 
 
Supplementary Table S2. M9 Vitamin Mix. 
component amount 
choline chloride 1.0 g 
folic acid 1.0 g 
pantothenic acid 1.0 g 
nicotinamide 1.0 g 
myo-inositol 2.0 g 
pyridoxal hydrochloride 1.0 g 
thiamine 1.0 g 
riboflavin 0.1 g 
disodium adenosine 5'-triphosphate 0.3 g 
biotin 0.2 g 
 ad 300 mL ddH2O
a
 
a10 M NaOH was slowly added to the resulting suspension until everything was dissolved (pH ~12). 
Afterward the solution was sterile filtered and stored at 4 °C until needed. 
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Supplementary Table S3a. Production of different constructs generated for production optimization of 
xanthomonins I and II. Truncations that were detectable by MS but not UV are marked with a “-”. 
name sample UV peak areas of all detectable compounds sum of UV peak areas relative production 
xgaA1A2BC 
pET41a 
1 8.8E+6 (xanthomonin I, -4 aa) 
- (xanthomonin II, -6 aa) 
8.8E+6  
 2 9.1E+6 (xanthomonin I, -4 aa) 
- (xanthomonin II, -6 aa) 
9.1E+6  
 3 8.6E+6 (xanthomonin I, -4 aa) 
- (xanthomonin II, -6 aa) 
8.6E+6  
 mean 8.8E+6 (xanthomonin I, -4 aa) 
- (xanthomonin II, -6 aa) 
8.8E+6 1.00 ± 0.02 
xgaA1_T-P_BC 
pET41a 
1 1.4E+6 (xanthomonin I, full) 
2.0E+6 (xanthomonin I, -3 aa) 
3.2E+8 (xanthomonin I, -4 aa) 
3.2E+8  
 2 1.4E+6 (xanthomonin I, full) 
2.1E+6 (xanthomonin I, -3 aa) 
3.2E+8 (xanthomonin I, -4 aa) 
3.3E+8  
 3 1.4E+6 (xanthomonin I, full) 
2.2E+6 (xanthomonin I, -3 aa) 
3.4E+8 (xanthomonin I, -4 aa) 
3.4E+8  
 mean 1.4E+6 (xanthomonin I, full) 
2.1E+6 (xanthomonin I, -3 aa) 
3.3E+8 (xanthomonin I, -4 aa) 
3.3E+8 37.27 ± 0.75 
xgaA2_T-P_BC 
pET41a 
1 1.6E+7 (xanthomonin II, -4 aa) 
6.0E+6 (xanthomonin II, -5 aa) 
6.6E+7 (xanthomonin II, -6 aa) 
8.8E+7  
 2 2.1E+7 (xanthomonin II, -4 aa) 
8.5E+6 (xanthomonin II, -5 aa) 
8.6E+7 (xanthomonin II, -6 aa) 
1.2E+8  
 3 1.5E+7 (xanthomonin II, -4 aa) 
5.3E+6 (xanthomonin II, -5 aa) 
6.0E+7 (xanthomonin II, -6 aa) 
8.0E+7  
 mean 1.7E+7 (xanthomonin II, -4 aa) 
6.6E+6 (xanthomonin II, -5 aa) 
7.1E+7 (xanthomonin II, -6 aa) 
9.5E+7 10.70 ± 1.69 
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Supplementary Table S3b. Production of different constructs generated for production optimization of 
xanthomonins III. Truncations that were detectable by MS but not UV are marked with a “-”. 
name sample UV peak areas of all detectable compounds sum of UV peak areas relative production 
xcitABC 
pET41aa 
1 1.4E+8 (xanthomonin III, -4 aa/-5 aa) 
- (xanthomonin III, -6 aa) 
1.0E+8 (xanthomonin III, -7 aa) 
2.4E+8  
 2 9.4E+7 (xanthomonin III, -4 aa/-5 aa) 
- (xanthomonin III, -6 aa) 
8.8E+7 (xanthomonin III, -7 aa) 
1.8E+8  
 3 1.1E+8 (xanthomonin III, -4 aa/-5 aa) 
- (xanthomonin III, -6 aa) 
8.0E+7 (xanthomonin III, -7 aa) 
1.8E+8  
 mean 1.1E+8 (xanthomonin III, -4 aa/-5 aa) 
- (xanthomonin III, -6 aa) 
8.9E+7 (xanthomonin III, -7 aa) 
2.0E+8 1.00 ± 0.13 
xcitA_RBS_BC 
pET41aa 
1 - (xanthomonin III, full) 
4.2E+8 (xanthomonin III, -4 aa/-5 aa) 
- (xanthomonin III, -6 aa) 
2.6E+8 (xanthomonin III, -7 aa) 
6.8E+8  
 2 - (xanthomonin III, full) 
4.9E+8 (xanthomonin III, -4 aa/-5 aa) 
- (xanthomonin III, -6 aa) 
3.3E+8 (xanthomonin III, -7 aa) 
8.2E+8  
 3 - (xanthomonin III, full) 
4.3E+8 (xanthomonin III, -4 aa/-5 aa) 
- (xanthomonin III, -6 aa) 
2.4E+8 (xanthomonin III, -7 aa) 
6.7E+8  
 mean - (xanthomonin III, full) 
4.5E+8 (xanthomonin III, -4 aa/-5 aa) 
- (xanthomonin III, -6 aa) 
2.8E+8 (xanthomonin III, -7 aa) 
7.2E+8 3.62 ± 0.34 
a  UV signals of -4 aa and -5 aa truncations strongly overlap. The intensity of their MS signals suggests an approximately 
equimolar ratio. 
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Supplementary Table S4a. Production of different xanthomonin II variants. Truncations that were 
detectable by MS but not UV are marked with a “-”. 
name sample UV peak areas of all detectable compounds sum of UV 
peak areas 
relative 
production 
wild type 1 1.6E+7 (-4 aa), 6.0E+6 (-5 aa), 6.6E+7 (-6 aa) 8.8E+7  
 2 2.1E+7 (-4 aa), 8.5E+6 (-5 aa), 8.6E+7 (-6 aa) 1.2E+8  
 3 1.5E+7 (-4 aa), 5.3E+6 (-5 aa), 6.0E+7 (-6 aa) 8.0E+7  
 mean 1.7E+7 (-4 aa), 6.6E+6 (-5 aa), 7.1E+7 (-6 aa) 9.5E+7 1.000 ± 0.158 
T-2A 1 - (-4 aa), - (-5 aa), 3.6E+5 (-6 aa) 3.6E+5  
 2 - (-4 aa), - (-5 aa), 4.8E+5 (-6 aa) 4.8E+5  
 3 - (-4 aa), - (-5 aa), 4.4E+5 (-6 aa) 4.4E+5  
 mean - (-4 aa), - (-5 aa), 4.3E+5 (-6 aa) 4.3E+5 0.005 ± 0.001 
T-2C 1 2.6E+6 (-4 aa), 1.4E+6 (-5 aa), 9.3E+6 (-6 aa) 1.3E+7  
 2 2.2E+6 (-4 aa), 8.7E+5 (-5 aa), 8.6E+6 (-6 aa) 1.2E+7  
 3 2.1E+6 (-4 aa), 9.6E+5 (-5 aa), 8.2E+6 (-6 aa) 1.1E+7  
 mean 2.3E+6 (-4 aa), 1.1E+6 (-5 aa), 8.7E+6 (-6 aa) 1.2E+7 0.128 ± 0.009 
T-2I 1 4.9E+5 (-4 aa), - (-5 aa), 5.3E+5 (-6 aa) 1.0E+6  
 2 4.5E+5 (-4 aa), - (-5 aa), 5.3E+5 (-6 aa) 9.9E+5  
 3 4.3E+5 (-4 aa), - (-5 aa), 5.1E+5 (-6 aa) 9.5E+5  
 mean 4.6E+5 (-4 aa), - (-5 aa), 5.2E+5 (-6 aa) 9.8E+5 0.010 ± 0.001 
T-2S  4.9E+5 (-4 aa), - (-5 aa), 4.3E+5 (-6 aa) 9.2E+5  
  4.9E+5 (-4 aa), - (-5 aa), 4.6E+5 (-6 aa) 9.6E+5  
  5.0E+5 (-4 aa), - (-5 aa), 4.1E+5 (-6 aa) 9.1E+5  
  4.9E+5 (-4 aa), - (-5 aa), 4.3E+5 (-6 aa) 9.3E+5 0.010 ± 0.001 
T-2V  7.3E+5 (-4 aa), - (-5 aa), 1.1E+6 (-6 aa) 1.8E+6  
  4.9E+5 (-4 aa), - (-5 aa), 9.8E+5 (-6 aa) 1.5E+6  
  3.6E+5 (-4 aa), - (-5 aa), 9.2E+5 (-6 aa) 1.3E+6  
  4.9E+5 (-4 aa), - (-5 aa), 1.0E+6 (-6 aa) 1.5E+6 0.016 ± 0.021 
P3A 1 - (full), 4.7E+6 (-4 aa), 2.0E+6 (-5 aa), 4.2E+7 (-6 aa) 4.8E+7  
 2 - (full), 3.6E+6 (-4 aa), 9.9E+5 (-5 aa), 4.0E+7 (-6 aa) 4.5E+7  
 3 - (full), 4.8E+6 (-4 aa), 1.7E+6 (-5 aa), 4.1E+7 (-6 aa) 4.8E+7  
 mean - (full), 4.7E+6 (-4 aa), 1.6E+6 (-5 aa), 4.1E+7 (-6 aa) 4.7E+7 0.495 ± 0.014 
E7A 1 - -  
 2 - -  
 3 - -  
 mean - - no production 
E7D E8A 1 - -  
 2 - -  
 3 - -  
 mean - - no production 
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Supplementary Table S4b. Production of different xanthomonin II variants. Truncations that were 
detectable by MS but not UV are marked with a “-”. 
name sample UV peak areas of all detectable compounds sum of UV peak areas relative production 
E8A 1 1.3E+7 (-4 aa), 6.7E+6 (-5 aa), 1.2E+7 (-6 aa) 3.1E+7  
 2 2.0E+7 (-4 aa), 1.0E+7 (-5 aa), 1.2E+7 (-6 aa) 4.2E+7  
 3 1.9E+7 (-4 aa), 9.2E+6 (-5 aa), 1.1E+7 (-6 aa) 3.9E+7  
 mean 1.7E+7 (-4 aa), 8.6E+6 (-5 aa), 1.2E+7 (-6 aa) 3.7E+7 0.395 ± 0.048 
E7A E8D 1 - -  
 2 - -  
 3 - -  
 mean - - no production 
G10A 1 - (-12 aa), - (-13 aa) -  
 2 - (-12 aa), - (-13 aa) -  
 3 - (-12 aa), - (-13 aa) -  
 mean - (-12 aa), - (-13 aa) - no UV 
G10L 1 - (-10 aa), - (-11 aa), - (-12 aa), - (-13 aa) -  
 2 - (-10 aa), - (-11 aa), - (-12 aa), - (-13 aa) -  
 3 - (-10 aa), - (-11 aa), - (-12 aa), - (-13 aa) -  
 mean - (-10 aa), - (-11 aa), - (-12 aa), - (-13 aa) - no UV 
G10F 1 - (-10 aa), - (-11 aa), - (-12 aa), - (-13 aa) -  
 2 - (-10 aa), - (-11 aa), - (-12 aa), - (-13 aa) -  
 3 - (-10 aa), - (-11 aa), - (-12 aa), - (-13 aa) -  
 mean - (-10 aa), - (-11 aa), - (-12 aa), - (-13 aa) - no UV 
G11A 1 6.6E+4 (-4 aa), - (-5 aa), 1.1E+6 (-6 aa), - (-10 aa), - (-13 aa) 1.2 E6  
 2 5.7E+4 (-4 aa), - (-5 aa), 9.7E+5 (-6 aa), - (-10 aa), - (-13 aa) 1.0 E6  
 3 5.9E+4 (-4 aa), - (-5 aa), 9.2E+5 (-6 aa), - (-10 aa), - (-13 aa) 9.8 E5  
 mean 6.0E+4 (-4 aa), - (-5 aa), 1.0E+6 (-6 aa), - (-10 aa), - (-13 aa) 1.1 E6 0.011 ± 0.001 
G11L 1 - (-5 aa), - (-6 aa), 
- (-9 aa), - (-10 aa), - (-11 aa), - (-12 aa), - (-13 aa) 
-  
 2 - (-5 aa), - (-6 aa), 
- (-9 aa), - (-10 aa), - (-11 aa), - (-12 aa), - (-13 aa) 
-  
 3 - (-5 aa), - (-6 aa), 
- (-9 aa), - (-10 aa), - (-11 aa), - (-12 aa), - (-13 aa) 
-  
 mean - (-5 aa), - (-6 aa), 
- (-9 aa), - (-10 aa), - (-11 aa), - (-12 aa), - (-13 aa) 
- no UV 
G11F 1 - (-6 aa), - (10 aa), - (-12 aa), - (-13 aa) -  
 2 - (-6 aa), - (10 aa), - (-12 aa), - (-13 aa) -  
 3 - (-6 aa), - (10 aa), - (-12 aa), - (-13 aa) -  
 mean - (-6 aa), - (10 aa), - (-12 aa), - (-13 aa) - no UV 
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Supplementary Table S4c. Production of different xanthomonin II variants. Truncations that were 
detectable by MS but not UV are marked with a “-”. 
name sample UV peak areas of all detectable compounds sum of UV peak areas relative production 
I12A 1 6.5E+6 (-4 aa), 2.8E+7 (-5 aa), 1.0E+8 (-6 aa) 1.4E+8  
 2 6.4E+6 (-4 aa), 2.7E+7 (-5 aa), 9.6E+7 (-6 aa) 1.3E+8  
 3 6.8E+6 (-4 aa), 2.7E+7 (-5 aa), 9.3E+7 (-6 aa) 1.3E+8  
 mean 6.6E+6 (-4 aa), 2.7E+7 (-5 aa), 9.7E+7 (-6 aa) 1.3E+8 1.382 ± 0.040 
I12A T13A 1 2.5E+7 (-4 aa), 4.5E+7 (-5 aa), 2.6E+7 (-6 aa), 
- (-11 aa), - (-12 aa), - (-13 aa) 
9.6E+7  
 2 2.5E+7 (-4 aa), 4.4E+7 (-5 aa), 2.6E+7 (-6 aa), 
- (-11 aa), - (-12 aa), - (-13 aa) 
9.4E+7  
 3 2.5E+7 (-4 aa), 4.5E+7 (-5 aa), 2.6E+7 (-6 aa), 
- (-11 aa), - (-12 aa), - (-13 aa) 
9.6E+7  
 mean 2.5E+7 (-4 aa), 4.5E+7 (-5 aa), 2.6E+7 (-6 aa), 
- (-11 aa), - (-12 aa), - (-13 aa) 
9.5E+7 1.008 ± 0.010 
12A T13A 
T14A 
1 3.0E+7 (-4 aa), 5.3E+7 (-5 aa), - (-6 aa), 
- (-8 aa), - (-10 aa), - (-11 aa), - (-12 aa), - (-13 aa) 
3.6E+7  
 2 3.0E+7 (-4 aa), 5.4E+7 (-5 aa), - (-6 aa), 
- (-8 aa), - (-10 aa), - (-11 aa), - (-12 aa), - (-13 aa) 
3.6E+7  
 3 3.0E+7 (-4 aa), 6.7E+7 (-5 aa), - (-6 aa), 
- (-8 aa), - (-10 aa), - (-11 aa), - (-12 aa), - (-13 aa) 
3.7E+7  
 mean 3.0E+7 (-4 aa), 5.8E+7 (-5 aa), - (-6 aa), 
- (-8 aa), - (-10 aa), - (-11 aa), - (-12 aa), - (-13 aa) 
3.6E+7 0.380 ± 0.005 
I12A T13A 
T14A L15A 
1 - (full), - (-4 aa), - (-8 aa), 
5.0E+6 (-10 aa), - (-11 aa), 6.9E+5 (-12 aa), - (13 aa) 
5.7E+6  
 2 - (full), - (-4 aa), - (-8 aa), 
4.1E+6 (-10 aa), - (-11 aa), 5.2E+5 (-12 aa), - (13 aa) 
4.7E+6  
 3 - (full), - (-4 aa), - (-8 aa), 
4.0E+6 (-10 aa), - (-11 aa), 5.7E+5 (-12 aa), - (13 aa) 
4.6E+6  
 mean - (full), - (-4 aa), - (-8 aa), 
4.4E+6 (-10 aa), - (-11 aa), 5.9E+5 (-12 aa), - (13 aa) 
5.0E+6 0.053 ± 0.005 
T13A 
T14A L15A 
1 9.7E+7 (-4 aa), 3.6E+6 (-5 aa), 1.7E+7 (-6 aa) 1.2E+8  
 2 1.0E+8 (-4 aa), 3.9E+6 (-5 aa), 1.8E+7 (-6 aa) 1.2E+8  
 3 1.0E+8 (-4 aa), 3.8E+6 (-5 aa), 1.8E+7 (-6 aa) 1.2E+8  
 mean 1.0E+8(-4 aa), 3.8E+6 (-5 aa), 1.8E+7 (-6 aa) 1.2E+8 1.280 ± 0.028 
I12L T13A 
T14A L15A 
1 - (full), - (-3 aa), 1.0E+8 (-4 aa), 8.3E+6 (-5 aa), 5.4E+6 (-6 aa) 1.1E+8  
 2 - (full), - (-3 aa),  1.1E+8 (-4 aa), 7.7E+6 (-5 aa), 6.6E+6 (-6 aa) 1.2E+8  
 3 - (full), - (-3 aa),  1.1E+8 (-4 aa), 7.3E+6 (-5 aa), 6.1E+6 (-6 aa) 1.2E+8  
 mean - (full), - (-3 aa),  1.1E+8 (-4 aa), 7.8E+6 (-5 aa), 6.0E+6 (-6 aa) 1.2E+8 1.253 ± 0.032 
I12V T13A 
T14A L15A 
1 - (full), 6.9E+7 (-4 aa), 2.0E+6 (-5 aa), 1.6E+7 (-6 aa) 8.7E+7  
 2 - (full), 7.4E+7 (-4 aa), 2.8E+6 (-5 aa), 1.7E+7 (-6 aa) 9.4E+7  
 3 - (full), 7.2E+7 (-4 aa), 3.7E+6 (-5 aa), 1.7E+7 (-6 aa) 9.3E+7  
 mean - (full), 7.1E+7 (-4 aa), 2.8E+6 (-5 aa), 176E+7 (-6 aa) 9.1E+7 0.964 ± 0.032 
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Supplementary Table S4d. Production of different xanthomonin II variants. Truncations that were 
detectable by MS but not UV are marked with a “-”. 
name sample UV peak areas of all detectable compounds sum of UV peak areas relative production 
I12S T13A 
T14A L15Aa 
1 - (full), 1.2E+7 (-4 aa/-10 aa), 
- (-8 aa), - (-11 aa), - (12 aa), - (-13 aa) 
1.2E+7  
 2 - (full), 9.3E+6 (-4 aa/-10 aa), 
- (-8 aa), - (-11 aa), - (12 aa), - (-13 aa) 
9.3E+6  
 3 - (full), 1.2E+7 (-4 aa/-10 aa), 
- (-8 aa), - (-11 aa), - (12 aa), - (-13 aa) 
1.2E+7  
 mean - (full), 1.1E+7 (-4 aa/-10 aa), 
- (-8 aa), - (-11 aa), - (12 aa), - (-13 aa) 
1.1E+7 0.119 ± 0.014 
I12T T13A 
T14A L15A 
1 1.1E+8 (-4 aa), 1.8E+6 (-5 aa), 8.4E+6 (-6 aa) 1.2E+8  
 2 1.0E+8 (-4 aa), 3.8E+6 (-5 aa), 7.9E+6 (-6 aa) 1.1E+8  
 3 1.0E+8 (-4 aa), 2.4E+6 (-5 aa), 7.0E+6 (-6 aa) 1.1E+8  
 mean 1.0E+8 (-4 aa), 2.7E+6 (-5 aa), 7.7E+6 (-6 aa) 1.2E+8 1.212 ± 0.037 
a  UV signals of -4 aa and -10 aa truncations strongly overlap. The intensity of their MS signals suggests an approximately 
equimolar ratio. 
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Supplementary Table S5. Production of different xanthomonin III variants. Truncations that were 
detectable by MS but not UV are marked with a “-”. 
name sample UV peak areas of all detectable compounds sum of UV peak areas relative production 
wild typea 1 - (full), 4.2E+8 ( -4 aa/-5 aa), - (-6 aa), 2.6E+8 ( -7 aa) 6.8E+8  
 2 - (full), 4.9E+8 (-4 aa/-5 aa), - (-6 aa), 3.3E+8 (-7 aa) 8.2E+8  
 3 - (full), 4.3E+8 (-4 aa/-5 aa), - (-6 aa), 2.4E+8 (-7 aa) 6.7E+8  
 mean - (full), 4.5E+8 (-4 aa/-5 aa), - (-6 aa), 2.8E+8 (-7 aa) 7.2E+8 1.000 ± 0.093 
I14Ab 1 - (full), - ( -4 aa) - (-5 aa), 8.0E+8 (-6 aa/-7 aa) 8.0E+8  
 2 - (full), - ( -4 aa) - (-5 aa), 7.4E+8 (-6 aa/-7 aa) 7.4E+8  
 3 - (full), - ( -4 aa) - (-5 aa), 7.1E+8 (-6 aa/-7 aa) 7.1E+8  
 mean - (full), - ( -4 aa) - (-5 aa), 7.5E+8 (-6 aa/-7 aa) 7.5E+8 1.035 ± 0.055 
P13A I14Ab 1 - ( -4 aa) - (-5 aa), 5.8E+8 (-6 aa/-7 aa) 5.8E+8  
 2 - ( -4 aa) - (-5 aa), 6.1E+8 (-6 aa/-7 aa) 6.1E+8  
 3 - ( -4 aa) - (-5 aa), 6.8E+8 (-6 aa/-7 aa) 6.8E+8  
 mean - ( -4 aa) - (-5 aa), 6.2E+8 (-6 aa/-7 aa) 6.2E+8 0.861 ± 0.054 
S12A P13A 
I14Ab 
1 - (full), - ( -4 aa) - (-5 aa), 8.5E+8 (-6 aa/-7 aa) 8.5E+8  
 2 - (full), - ( -4 aa) - (-5 aa), 8.3E+8 (-6 aa/-7 aa) 8.3E+8  
 3 - (full), - ( -4 aa) - (-5 aa), 8.7E+8 (-6 aa/-7 aa) 8.7E+8  
 mean - (full), - ( -4 aa) - (-5 aa), 8.5E+8 (-6 aa/-7 aa) 8.5E+8 1.173 ± 0.027 
M11A S12A 
P13A I14A 
1 - -  
 2 - -  
 3 - -  
 mean - - no production 
a  UV signals of -4 aa and -5 aa truncations strongly overlap. The intensity of their MS signals suggests an approximately 
equimolar ratio. 
b  UV signals of -6 aa and -7 aa truncations strongly overlap. The intensity of their MS signals suggests an approximately 
equimolar ratio. 
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Structural Investigations and Analysis of the Xanthomonins 
Comparison of All Previously Identified Lasso Peptide Precursors Containing Seven-Residue 
Macrolactam Rings. In a previously reported B-protein centric genome mining study,[14] we were able to 
identify a total of seven different putative lasso peptide precursor peptides that carry a glutamate residue 
suitable for macrolactam ring formation at position 7 of the proposed lasso peptide sequences. These 
precursor peptides were found in Novopshingobium sp. PP1Y, Rhodanobacter sp. 115, Rhodanobacter sp. 
116-2, Rhodanobacter sp. 2APBS1, Xanthomonas citri pv. mangiferaindicae and Xanthomonas gardneri. 
Interestingly, all strains, with exception of Novosphingobium sp. PP1Y, belong to the family of the 
Xanthomonadaceae, which suggests that most of the biosynthetic gene clusters that could produce 
seven-ring lasso peptides are closely related to each other. This is further highlighted when comparing the 
precursor peptides of these six Xanthomonadaceae precursor peptides to each other (see Supporting 
Information Figure S1). 
 
 
 
Supplementary Figure S1 - Comparison of all putative lasso peptide biosynthetic gene clusters that encode precursor peptides 
that could possibly be processed into lasso peptides with seven-residue macrolactam rings. The precursor peptides found in 
strains belonging to the Xanthomonadaceae family are shown in a direct sequence alignment, while the precursor peptide 
found in Novosphingobium sp. PP1Y is depicted below.  
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From all these proposed precursor peptides, four carry an additional amino acid that could be used for 
macrolactam ring formation, namely the precursor peptide of Novosphingobium sp. PP1Y (Asp8), the one 
of Rhodanobacter sp. 2APBS1 (Glu9) and both from Xanthomonas gardneri (Glu8 in both cases). 
 
 
Tandem Mass Spectrometry of Xanthomonins I-III. Tandem Mass Spectrometry was used to confirm 
the primary structure of all xanthomonins and the presence and location of the proposed macrolactam 
rings.[14] The latter is possible, as a single peptide bond breakage in the macrolactam ring would just open 
the ring without an alteration of the overall mass. Thus, fragment ions of the macrolactam rings are only 
detectable in case of a double bond breakage. Since double bond breakages occur with only a low 
probability for such small peptides when using CID, the corresponding signals can normally not be 
detected. Because of this, all b- and y-fragment ions that are detectable with high intensities are generally 
associated with single bond breakages in the C-terminal tail region of the lasso peptide. Based on this, 
one can determine the presence and location of a macrolactam ring by searching for the smallest 
detectable b-fragment (and in some cases for the biggest detectable y-fragment). In the case of a lasso 
peptide with a seven-residue macrolactam ring, this would be the b7-fragment ion, which was detected for 
all xanthomonins, while a signal corresponding to a b6-fragment ion could not be found. The 
fragmentation spectra of all xanthomonins alongside the assignments of all high intensity signals to the 
corresponding fragment ions are shown in Supplementary Figures S2a-S2c. 
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fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity 
b16 +1 1434.7 1434.6 5343 b11 +1 920.4 920.4 2370 
b16 - NH3 +1 1417.7 1417.5 1476 b10 +1 863.4 863.4 1840 
b15 +1 1377.7 1377.5 1166 b9 +1 806.4 806.4 28888 
b15 - NH3 +1 1360.7 1360.5 208 b9 - H2O +1 788.4 788.5 1270 
b14 +1 1280.6 1280.5 758070 b8 +1 693.3 693.3 17409 
b14 - H2O +1 1262.6 1262.6 9449 b8 - H2O +1 675.3 675.4 770 
a14 +1 1252.6 1252.5 20182 b7 +1 564.3 564.3 9108 
a14 - H2O +1 1234.6 1234.6 1265 b7 - H2O +1 546.3 546.4 2054 
a14 - NH3 +1 1235.6 1235.5 1923 a7 +1 536.3 536.3 1152 
b13 +1 1181.6 1181.5 30563 y8 +1 760.4 760.4 1432 
a13 +1 1153.6 1153.5 1622 y7 +1 647.3 647.3 4574 
b12 +1 1067.5 1067.4 5703 z7 +1 630.3 630.4 3900 
a12 +1 1039.5 1039.4 1191 y6 +1 590.3 590.3 124 
 
Supplementary Figure S2a - Mass analysis of the -4 aa truncation of xanthomonin I. The total ion current (TIC) is shown on 
the top, followed by the extracted ion current (EIC) of the fragmented singly charged ion and the UV trace of this 
measurement. In the middle, the actual fragmentation spectra is depicted with an inset schematic of the primary structure of the 
-4 aa truncation of xanthomonin I. In the table below, all detected fragment ions with their charge, their predicted masses, their 
observed masses and their signal intensities are listed. 
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fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity 
b14 +1 1253.6 1253.5 65631 b9 +1 824.4 824.3 95905 
b14 - H2O +1 1235.6 1235.4 52972 b9 - H2O +1 806.4 806.4 9993 
b14 - 2 H2O +1 1217.6 1217.4 2951 a9 +1 796.4 796.2 2126 
a14 +1 1225.6 1225.4 1049 b8 +1 693.3 693.3 211200 
a14 - H2O +1 1207.6 1207.6 1206 b8 - H2O +1 675.3 675.4 12914 
b13 +1 1152.5 1152.4 111249 a8 +1 665.3 665.3 2180 
b13 - H2O +1 1134.5 1134.4 51823 b7 +1 564.3 564.3 161058 
b13 - 2 H2O +1 1116.5 1116.5 3042 b7 - H2O +1 546.3 546.3 25017 
a13 +1 1124.5 1124.5 2306 a7 +1 536.3 536.3 15703 
b12 +1 1051.5 1051.4 165655 a7 - H2O +1 518.3 518.4 5938 
b12 - H2O +1 1033.5 1033.5 8923 y7 +1 708.3 708.3 1445 
a12 +1 1023.5 1023.4 26092 y6 +1 579.3 579.3 74982 
a12 - H2O +1 1005.5 1005.4 4293 y6 - H2O +1 561.3 561.3 4590 
b11 +1 938.4 938.3 49018 y6 - 2 H2O +1 543.3 543.3 6377 
b11 - H2O +1 920.4 920.5 3634 y5 +1 448.2 448.3 539 
b10 +1 881.4 881.3 14419 y4 +1 391.2 391.1 2399 
b10 - H2O +1 863.4 863.4 2600      
 
Supplementary Figure S2b - Mass analysis of the -6 aa truncation of xanthomonin II. The total ion current (TIC) is shown on 
the top, followed by the extracted ion current (EIC) of the fragmented singly charged ion and the UV trace of this 
measurement. In the middle, the actual fragmentation spectra is depicted with an inset schematic of the primary structure of the 
-6 aa truncation of xanthomonin II. In the table below, all detected fragment ions with their charge, their predicted masses, their 
observed masses and their signal intensities are listed. 
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fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity fragment 
ion 
charge predicted 
mass 
observed 
mass 
intensity 
full +1 1086.2 1086.4 46905 b9 +1 695.3 695.4 13067 
full - H2O +1 1068.2 1068.5 1098662 b9 - H2O +1 677.3 677.5 2637 
b13 - NH3 +1 1050.5 1050.6 2330 b8 +1 581.3 581.4 18863 
b12 +1 970.4 970.4 32987 b7 +1 482.2 482.3 26848 
b12 - NH3 +1 953.4 953.5 52945 b7 - H2O +1 464.2 464.4 15836 
b12 - H2O +1 952.4 952.6 4953 y5 +1 505.2 505.4 10601 
b11 +1 883.4 883.4 6115 y5 - H2O +1 487.2 487.4 1028 
b10 +1 752.3 752.5 4620      
 
Supplementary Figure S2c - Mass analysis of the -7 aa truncation of xanthomonin III. The total ion current (TIC) is shown on 
the top, followed by the extracted ion current (EIC) of the fragmented singly charged ion and the UV trace of this 
measurement. In the middle, the actual fragmentation spectra is depicted with an inset schematic of the primary structure of the 
-7 aa truncation of xanthomonin III. In the table below, all detected fragment ions with their charge, their predicted masses, 
their observed masses and their signal intensities are listed. 
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Protease Stability Assays for Xanthomonins I and II. Protease stability of xanthomonins I and II was 
assessed against carboxypeptidase Y, chymotrypsin and proteinase K and analyzed via LC-MS. In 
agreement with previous studies, both lasso peptides showed a high stability against proteolytic 
degradation.[1, 14-15] Only carboxypeptidase Y treatment of xanthomonin I resulted in the slow formation 
of trace amounts of the -5 and -6 aa truncation, of which the latter has the same length as the main 
product of the heterologous production of xanthomonin II. The recorded chromatograms of these assays 
are shown in Supplementary Figure S3. 
 
 
Supplementary Figure S3 - Protease stability assays of the -4 aa truncation of xanthomonin I (left side) and the -6 aa 
truncation of xanthomonin II (right side) against (a) carboxypeptidase Y, (b) chymotrypsin and (c) proteinase K. The UV traces 
of the untreated references are shown in blue, while the UV traces of the samples after protease treatment are shown in red. 
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Thermal Stability Assays for Xanthomonin I and II. To test the thermal stability of xanthomonins I 
and II, both lasso peptides were incubated for 1 h, 2 h, 4 h or 8 h at 95 °C and then compared to an 
unheated reference by LC-MS. In both cases, the thermal treatment showed no effect even after 8 h at 
95 °C. This highlights the high thermal stability of lasso peptides containing a seven-residue macrolactam 
ring. The recorded chromatograms of these assays are shown in Supplementary Figure S4. 
 
 
 
Supplementary Figure S4 - Thermal stability assays of (a) the -4 aa truncation of xanthomonin I (left side) and (b) the -6 aa 
truncation of xanthomonin II. In both cases, no change in molecular mass or retention time could be observed, even after 
incubation for 8 h at 95 °C. 
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Combined Carboxypeptidase Y and Thermal Stability Assays for Xanthomonin II Variants. As 
shown in previous studies,[1, 13-14] carboxypeptidase Y treatment can be used to differentiate between a 
lasso and a branched cyclic peptide. When combined with a thermal denaturation experiment, 
carboxypeptidase Y can also be used to determine if the lasso peptide unthreads during incubation at 
95 °C. Such assays were performed for the plug amino acid scan variants I12X/T13A/T14A/L15A of 
xanthomonin II and a wild type control (see Supplementary Tables S6a and S6b). 
For the wild type, carboxypeptidase Y digestion yielded the same results independent if the sample was 
incubated at 95 °C for 4 h or not. In both cases, the digestion could not produce any shorter main products 
than the -6 aa truncation of xanthomonin II. Similar results were obtained for the variants carrying an Ile, 
Leu, Thr or Val at position 12. For all these variants, the by far major product of the carboxypeptidase Y 
digestion was the -6 aa truncation, with only small traces of other truncations detectable. This data 
suggests that all these variants are indeed heat stable lasso peptides. 
In contrast, both variants carrying either Ala or Ser at position 12 yielded the -12 aa truncation as main 
products after the carboxypeptidase Y treatment. The fact that this was observed for both the thermally 
treated and untreated samples, suggests that they already had a branched cyclic topology to begin with. In 
case of the Ala variant this is not surprising, as all tail amino acids from positions 12 to 15 were replaced 
with Ala and this should allow an easy unthreading of the lasso peptide directly after its maturation. This 
is also reflected by the fact that after isolation, the -10 aa and -12 aa truncations were the only truncations 
that had an detectable UV peak. Interestingly, even though the variant carrying a Ser residue at position 
12 behaves similar when treated with carboxypeptidase Y, the main products after extraction are not only 
a -10 aa, but also a -4 aa truncation. Additionally, the overall amounts isolated of this variant were around 
twice as much when compared to the Ala variant. This may be a hint that with a Ser in the role of the plug 
amino acid, the lasso fold does not unthread as easily as it is the case with Ala. Hence, this variant could 
not be degraded as quickly in vivo, which is why significant amounts of the -4 aa truncation could still be 
isolated. Nonetheless, the carboxypeptidase Y assay shows that after isolation all truncations of the Ser 
variant were present in the branched cyclic topology, which leaves the question unresolved, if the 
compound was already completely unthreaded before isolation or if the  unthreading occurred during the 
isolation procedure. Nevertheless, the result shows that Ser is at best a very poor plug amino acid for  
xanthomonin II and in summary, these studies reveal that all amino acids bigger than Ser are suitable to 
maintain a heat stable lasso fold in the xanthomonin II scaffold. 
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Supplementary Table S6a. Results of the combined heat stability and carboxypeptidase Y assays of the 
extracts of the I12X T13A T14A L15A variants of xanthomonin II. The major signals of each 
measurement are highlighted in bold. 
name condition UV peak areas  and retention time of all detectable compounds 
wild type reference 1.8E+7  (22.1 min, -4 aa), 8.3E+6 (22.7 min, -5 aa), 6.2E+7 (21.6 min, -6 aa) 
 4 h, 95 °C 1.5E+7  (22.6 min, -4 aa), 6.2E+6 (23.2 min, -5 aa), 4.6E+7 (21.7 min, -6 aa) 
 carboxypeptidase Y 5.8E+7 (21.4 min, -6 aa) 
 4 h, 95 °C; 
carboxypeptidase Y 
6.0E+7 (21.5 min, -6 aa) 
I12A T13A 
T14A L15A 
reference - (19.4 min, full), - (17.6 min, -4 aa), – (17.6 min, -6 aa), - (17.4 min, -7 aa), 
- (17.5 min, -8 aa), - (16.7 min, -9 aa), 3.8E+6 (17.0 min, -10 aa), 
- (17.7 min, -11 aa), 6.4E+5 (14.3 min, -12 aa), - (13.9 min, -13 aa) 
 4 h, 95 °C - (19.4 min, full), - (17.6 min, -4 aa) – (17.7 min, -6 aa), - (17.5 min, -7 aa), 
- (17.5 min, -8 aa), - (16.7 min, -9 aa), 4.1E+6 (17.0 min, -10 aa), 
- (17.8 min, -11 aa), 6.3E+5 (14.2 min, -12 aa), - (13.9 min, -13 aa) 
 carboxypeptidase Y 1.9E+6 (14.3 min, -12 aa), - (14.1 min, -13 aa) 
 4 h, 95 °C; 
carboxypeptidase Y 
1.8E+6 (14.4 min, -12 aa), - (14.0 min, -13 aa) 
T13A 
T14A L15A 
reference 5.1E+7 (20.8 min, -4 aa), 3.5E+6 (21.1 min, -5 aa), 
9.9E+6 (21.7 min, -6 aa), - (14.2 min, -12 aa) 
 4 h, 95 °C 5.6E+7 (20.9 min, -4 aa), 3.2E+6 (21.2 min, -5 aa), 
9.8E+6 (21.8 min, -6 aa), - (14.2 min, -12 aa) 
 carboxypeptidase Y - (21.0 min, -4 aa), 6.0E+7 (22.0 min, -6 aa), - (21.9 min, -7 aa), 
- (14.3 min, -12 aa) 
 4 h, 95 °C; 
carboxypeptidase Y 
6.3E+7 (21.9 min, -6 aa), - (21.8 min, -7 aa), - (14.2 min, -12 aa) 
I12L T13A 
T14A L15A 
reference - (21.7 min, full), - (23.0 min, -3 aa), 5.9E+7 (21.3 min, -4 aa),   
5.6E+6 (21.6 min, -5 aa), 3.4E+6 (22.1 min, -6 aa) 
 4 h, 95 °C - (21.6 min, full), - (22.8 min, -3 aa), 5.5E+7 (21.2 min, -4 aa),   
7.0E+6 (21.6 min, -5 aa), 5.1E+6 (22.1 min, -6 aa) 
 carboxypeptidase Y - (21.3 min, -4 aa), 5.7E+7 (22.2 min, -6 aa), - (22.0 min, -7 aa), 
- (14.2 min, -12 aa) 
 4 h, 95 °C; 
carboxypeptidase Y 
5.6E+7 (22.1 min, -6 aa), - (21.9 min, -7 aa), - (14.3 min, -12 aa) 
I12V T13A 
T14A L15A 
reference - (20.6 min, full), 3.8E+7 (19.9 min, -4 aa), 4.2E+6 (20.4 min, -5 aa), 
9.9E+6 (20.9 min, -6 aa) 
 4 h, 95 °C - (20.6 min, full), 4.1E+7 (19.9 min, -4 aa), 4.8E+6 (20.3 min, -5 aa), 
1.1E+7 (20.9 min, -6 aa), - (14.2 min, -12 aa) 
 carboxypeptidase Y 4.4E+7 (20.9 min, -6 aa), - (14.2 min, -12 aa) 
 4 h, 95 °C; 
carboxypeptidase Y 
4.5E+7 (21.1 min, -6 aa), - (14.2 min, -12 aa) 
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Supplementary Table S6b. Results of the combined heat stability and carboxypeptidase Y assays of the 
extracts of the I12X T13A T14A L15A variants of xanthomonin II. The major signal(s) of each 
measurement are highlighted in bold. 
name condition UV peak areas  and retention time of all detectable compounds 
I12S T13A 
T14A L15Aa 
reference - (19.2 min, full), 4.4E+6 (17.2 min, -4 aa/-10 aa), - (17.3 min, -6 aa), 
2.7E+5 (16.5 min, -7 aa), - (17.0 min, -9 aa), - (18.2 min, -11 aa), 
- (14.3 min, -12 aa),  - (14.0 min, -13 aa) 
 4 h, 95 °C - (19.2 min, full), 4.2E+6 (17.2 min, -4 aa/-10 aa), 
2.0E+5 (16.5 min, -7 aa), - (17.0 min, -9 aa), - (18.0 min, -11 aa), 
- (14.3 min, -12 aa),  - (14.0 min, -13 aa) 
 carboxypeptidase Y 2.1E+6 (14.5 min, -12 aa),  - (14.0 min, -13 aa) 
 4 h, 95 °C; 
carboxypeptidase Y 
2.3E+6 (14.3 min, -12 aa),  - (14.0 min, -13 aa) 
I12T T13A 
T14A L15A 
reference 5.8E+7 (18.4 min, -4 aa), 4.1E+5 (18.9 min, -5 aa), 
4.3E+6 (19.6 min, -6 aa) 
 4 h, 95 °C 5.2E+7 (18.2 min, -4 aa), 2.0E+5 (18.9 min, -5 aa), 
4.3E+6 (19.8 min, -6 aa), - (16.9 min, -9 aa), - (17.1 min, -10 aa), 
- (14.2 min, -12 aa), - (14.0 min, -13 aa) 
 carboxypeptidase Y 6.1E+7 (19.6 min, -6 aa), 6.9E+5 (18.6 min, -7 aa), - (14.2 min, -12 aa) 
 4 h, 95 °C; 
carboxypeptidase Y 
- (18.9 min, -4 aa), 5.8E+7 (19.7 min, -6 aa), 6.9E+5 (18.8 min, -7 aa), 
- (14.4 min, -12 aa), - (14.0 min, -13 aa) 
a  UV signals of -4 aa and -10 aa truncations strongly overlap. The intensity of their MS signals suggests an approximately 
equimolar ratio. 
 
 
 S32 
 
Combined Carboxypeptidase Y and Thermal Stability Assays for Xanthomonin III. Combined 
carboxypetidase Y and thermal stability assays were performed with a purified sample of the -7 aa 
truncation of xanthomonin III. These assays revealed that xanthomonin III is resistant to both 
carboxypeptidase Y digestion and thermal denaturation, proving it to be as stable as xanthomonins I and 
II. Furthermore, these results, in combination with its heterologous origin and the data obtained from the 
tandem mass spectrometry analysis, give strong evidence of xanthomonin III being a true lasso peptide, 
even though its 3D structure was not elucidated. The recorded chromatograms of these assays are shown 
in Supplementary Figure S5. 
 
 
 
 
Supplementary Figure S5 - Combined carboxypeptpidase Y and thermal stability assays of the -7 aa truncation of 
xanthomonin III. 
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Analysis of the Xanthomonin III Variants Suggests that Met11 Acts as Plug Amino Acid. The 
generated and analysed variants of xanthomonin III provide two lines of evidence of Met11 acting as plug 
amino acid. This first indirect evidence is the lack of production of the M11A/S12A/P13A/I14A variant 
that suggests that this quadruple alanine mutation removes all tail amino acids that could act as plug for 
xanthomonin III, starting with Met11. The second evidence is provided by the fact that all other variants, 
namely S12A/P13A/I14A, P13A/I14A and I14A, are produced in comparable amounts to the wild type 
xanthomonin III. This suggests that these three amino acids are not needed for maintaining the lasso fold 
as long as Met11 is present, further emphasizing its proposed role as plug amino acid. Furthermore, the 
observation that all produced variants share the same truncation pattern with the wild type 
xanthomonin III, is an indication that all are present in the same lasso fold, limiting their truncation to 
points that are equidistant to the position where the tail threads through the macrolactam ring. Taking all 
this information together, this data is solid body of evidence for xanthomonin III being a true lasso 
peptide that uses Met11 as plug amino acid. 
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Structure Elucidation of Xanthomonin II Using NMR Spectroscopy. The primary structure of the -
6 aa truncation of xanthomonin II consists of 14 amino acids. The residue at position 1 is a Gly, while 
both amino acids at positions 7 and 8 are Glu. Therefore, the question arises if Glu7 or Glu8 is involved 
in the isopeptide bond formation needed for the macrocyclization. Both tandem mass spectrometry and 
mutational analysis suggest Glu7 to be the ring forming amino acid. Therefore, xanthomonin II represents 
not only one of the shortest lasso peptides known so far, but also features the smallest ring size for a lasso 
peptide yet. This reduces the minimal proven ring size to be seven amino acids and may be the minimum 
possible for lasso peptides. Determining its 3D structure with great care is thus of basic importance. 
The 1H spectra in DMSO-d6 at temperatures between 295 and 313 K with 5 K increments are shown in 
Supplementary Figure S6. 
 
 
Supplementary Figure S6 - Variable temperature 1H spectra in NH region of the -6 aa truncation of xanthomonin II in 
DMSO-d6 at 8.8 mM. 
 
For clarity, only the region of 9.10 to 6.30 ppm is shown in the spectra. Labels for the signal assignments 
of the amide protons are shown. Neat and well resolved single sets of signals were observed. A diverse 
distribution of the temperature response of these signals revealed a stable lasso fold of this compound. 
The best signal resolution was observed at 305 K and a full signal assignment (see 
Supplementary Table S7) was thus carried out at this temperature.   
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Supplementary Table S7. Assignment of 1H signals (in ppm) of the -6 aa truncation of xanthomonin II 
(14 amino acids in length) in DMSO-d6 at 305 K. 
AA NH H H others 
Gly1 7.2984 4.0945; 3.4672 / / 
Gly2 8.0857 4.3472; 3.6177 / / 
Pro3  4.487 2.010 CH2: 1.748; 2.003 
CH2: 3.546; 3.416 
Leu4 8.2800 4.3502 1.2942 CH: 1.323 
CH3: 0.7061; 0.6702 
Ala5 7.6705 4.5084 1.1242 / 
Gly6 8.2612 4.7757; 3.193 / / 
Glu7 8.3473 4.5977 1.936 CH2: 2.317; 2.052 
Glu8 7.9315 3.8321 1.9747 CH2: 2.333 
Met9 7.1098 4.4187 1.857; 1.785 CH2:2.373 
CH3:2.0433 
Gly10 8.759 4.2741; 3.660 / / 
Gly11 6.4984 4.1449; 3.1413 / / 
Ile12 8.2175 4.5916 2.2289 CH3: 0.9609 
CH2: 1.3180; 1.1330 
CH3 
Thr13 8.5749 4.6856 3.7190 CH3: 1.1574 
Thr14 8.0469 4.1649 4.1217 CH3: 1.0391 
 
 
All assignments of the 1H signals were obtained by standard procedures.[11] A combination of DQF-COSY 
and NOESY produced sequential assignments (i.e. all αH and NH and their sequences in the backbone), 
and a combination of DQF-COSY and TOCSY allowed the determination of the side chains. One pure 
conformation was observed. Full assignment of 1H signals was thus obtained (NOESY spectrum: 
Supplementary Figure S7, 1H chemical shifts: Supplementary Table S7). 
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Supplementary Figure S7 - NOESY spectrum of the -6 aa truncation of xanthomonin II in DMSO-d6 at 305 K with a mixing 
time of 300 ms. 
 
Strong NOE contacts between the NH of Gly1 and both the βH and H of Glu7 were observed, showing 
an internal linkage between these two residues. Strong sequential αH – δH NOESY cross-peaks between 
Gly2 and Pro3 were detected, which showed the trans-conformation of Pro3. The 1H spectra between 295 
and 313 K (Supplemtary Figure S6) show a low temperature coefficient of the NH of Gly1, Leu4, Ala5, 
Glu7, Glu8, Met9, Gly11, Leu12, and Thr13. A large number of long-range NOE contacts were observed. 
These are the dNN(i,j) connectivity between Gly1 – Gly11, Gly2 – Gly11, Leu4 – Gly11, and Ala5 – 
Thr13; the dαN(i,j) connectivity between Glu7 – Ile12, Gly11 – Glu7, and Thr14 – Ala5; the dβN(i,j) 
connectivity between Leu4 – Thr13 and Glu7 – Gly1; and the dαα(i,j) connectivity between Ala5 – Gly10. 
Furthermore, long-range contacts between residue side chains were observed for Pro3 – Ile12, Leu4 – 
Ile12, and Leu4 – Thr13. All this experimental evidence revealed a very compact 3D structure and is in 
favor of a lasso structure for xanthomonin II. 
Structure calculations were performed with the program CYANA 2.1.[13] The internal linkage was realized 
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by setting the distance constraints between N of Gly1 and C of Glu7 to be 1.33 Å. NOE cross-peaks 
observed in the 100 ms mixing time NOESY experiment were manually converted into distance 
constraints. In this way, 97 unambiguous distance constraints were obtained. 37 for the backbone, 25 for 
long-range interactions, and 35 for the side chains. Thus, there was an average of 7.5 distance constraints 
per residue. In addition, constraints of torsion angles ϕ and χ1 were determined by analyzing the vicinal 
coupling constants 3JHNα and 
3Jαα. Only unambiguous coupling constants were used. Thus, 
3
JHNα ≥ 9 Hz 
was observed for Gly2, Leu4, Ala5, Gly6, Glu7, Gly11, Ile12, and Thr13. The torsion angles ϕ of these 
residues were restrained to -120° ± 30°. For the residues Gly1, Glu8, Met9, and Gly10, 
3
JHNα < 9 Hz was 
detected. Thus their torsion angles ϕ were restrained to -70° ± 30°. Stereospecific assignment of the 
prochiral methylene protons was done for Gly1, Gly2, Pro3, Gly6, and Gly11. The side chain 
conformations of Met (t
2
g
3
), Thr13 (g2g3), and Thr14 (t2g3) were determined. For t
2
g
3
and g
2
g
3
 
conformations around the Cα-Cβ bond the torsion angle χ
1
 was constrained in the range of -60 ± 30°and 
60 ± 30°, respectively. 
The above mentioned constraints were used in the simulated annealing protocol for the calculation with 
the CYANA 2.1 program. The calculation was initiated with 50 random conformers and the resulting 
structures were processed with the program package Sybyl 7.3[16] to include the covalent linkage between 
the nitrogen of Gly1 and C of Glu7, followed by energy minimization under NMR constraints using 
TRIPOS force field within Sybyl. Thus, on the basis of low energies and minimal violations of the 
experimental data, a family of 15 structures was chosen. These 15 energy-minimized conformers show an 
average root-mean-square deviation (rmsd) of 0.02 Å and were chosen to represent the solution structure 
of the -6 aa truncation of xanthomonin II (Supplementary Figure S8). 
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Supplementary Figure S8 - Crossed-eyes stereoview of the superimposition of the 15 lowest energy structures of the -6 aa 
truncation of xanthomonin II (PDB code 2MFV). Structures are superimposed over all backbone atoms. The isopeptide bond 
forming Glu7 is highlighted in red, while the remaining ring amino acids are colored in yellow and the tail amino acids are 
shown in blue. 
 
The superimposition of the 15 lowest structures that are shown in Supplementary Figure S8 represents the 
lasso fold of xanthomonin II in DMSO-d6 at 32 ° C. This is verified by a quality comparison of the 15 
minimum energy structures and their Ramachandran plots (Supplementary Figure S9). The structural 
statistics for the 15 lowest energy structures are shown in Supplementary Table S8. 
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Supplementary Figure S9 - Ramachandran plot of the 15 lowest energy structures of the -6 aa truncation of xanthomonin II 
created by PROCHECK NMR. 
 
 
Supplementary Table S8. Structural statistics for the 15 lowest energy structures selected to represent 
the structure of the -6 aa truncation of xanthomonin II in DMSO-d6 at 32 °C. 
restraining constraints constraints violations 
total: 120 distance violations, >0.5 Å: 0 
distance, i=j: 30 RMS deviations: 0.02 Å 
distance, |i-j|=1: 39 dihedral violations, > 5°: 0 
distance, |i-j|>1: 28 RMS deviation: 2.8° 
dihedral: 15 average pairwise RMS deviation (Gly2-Thr13) 
hydrogen bonds: 0 backbone atoms: 0.03 Å 
constraints/residue: 8.6 all heavy atoms: 0.35 Å 
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Crystal Structure Elucidation of Xanthomonin I. 
Data collection and crystal structure elucidation were done as described in the Experimental Procedures. 
Xanthomonin I crystallizes as a dimer with one bridging water atom in between both monomeric units. 
Addtionally, the structure contains 18 solvent water molecules and one molecule 1,6-hexanediol. The 
dimeric crystal structure is shown in Supplementary Figure S10. Data collection and refinement statistics 
are shown in Supplementary Table S9. Coordinates, bond lengths, angles and displacement parameters 
are shown in Supplementary Tables S10-S15. 
 
Supplementary Figure S10 - Crossed-eyes stereoview of the crystal structure of xanthomonin I (PDB code 4NAG). The 
bridging water molecule is colored in green, while the 1,6-hexanediol and the xanthomin I molecules are colored by elements 
(nitrogen in blue, oxygen in red, carbon in magenta for the 1,6-hexanediol, in yellow for the first xanthomin I monomer and in 
gray for the second xanthomonin I monomer). The 18 solvent water molecules are not shown. 
 
Even though the structures of xanthomonin I and II were elucidated by different means, both appear to be 
very similar. This is not surprising, as their ring sequence is identical and the only major difference in 
their amino acid composition is found in the tail region below the ring. 
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Supplementary Table S9. Crystal data and structure refinement for the -4 aa truncation of xanthomonin I. 
 
Identification code  Xanthomonin I 
Empirical formula  C136 H244 N34 O63 
 2(C65H97N17O21),C6H12O2,19(H2O)' 
Formula weight  3363.64 g/mol 
Temperature  100(2) K 
Wavelength  0.8 Å 
Crystal system  Monoclinic 
Space group  P 21 
Unit cell dimensions a = 13.804(3) Å,  a= 90°. 
 b = 45.096(9) Å,   b= 91.42(3)°. 
 c = 13.890(3) Å,   g = 90°. 
Volume 8644(3) Å
3
 
Z 2 
Density (calculated) 1.292 mg/m
3
 
Absorption coefficient 0.102 mm
-1
 
F(000) 3604 
Theta range for data collection 0.903 to 25.935°. 
Index ranges -15<=h<=16, -54<=k<=54, -16<=l<=17 
Reflections collected 42090 
Independent reflections 24760 [R(int) = 0.0394] 
Completeness to theta = 25.242° 84.6%  
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 24760 / 111 / 2162 
Goodness-of-fit on F2 1045 
Final R indices [I>2sigma(I)] R1 = 0.0535, wR2 = 0.1470 
R indices (all data) R1 = 0.0544, wR2 = 0.1484 
Absolute structure parameter -0.1(3) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.508 and -0.321 e.Å
-3
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Supplementary Table S10a. Atomic coordinates ( x 104) and equivalent  isotropic displacement 
parameters (Å2x 103) for -4aa truncation of xanthomonin I.  U(eq) is defined as one third of  the trace of 
the orthogonalized Uij tensor. 
 x y z U(eq)  x y z U(eq) 
O(100) 9329(2) 6480(1) 6063(2) 32(1) C22 7121(3) 8145(1) 9750(3) 33(1) 
OH1 4722(3) 7698(1) 9979(3) 63(1) O13 6943(4) 8477(1) 5672(3) 69(1) 
C(100) 4299(6) 7906(2) 10577(6) 85(2) N13 7162(3) 8449(1) 8314(3) 34(1) 
C(101) 4237(9) 8209(2) 10036(8) 124(4) C13 7269(4) 8410(1) 6481(4) 38(1) 
C(102) 3941(12) 8465(2) 10658(9) 133(4) C23 6814(4) 8549(1) 7353(4) 40(1) 
C(103) 3973(14) 8758(3) 10083(17) 203(8) C33 7024(6) 8881(1) 7393(5) 65(2) 
C(104) 4849(19) 8925(7) 9650(30) 342(15) C43 7880(7) 8908(2) 8060(6) 75(2) 
C(105) 4760(30) 9230(6) 9145(13) 346(16) C53 7714(4) 8681(1) 8831(4) 45(1) 
OH2 4593(6) 9154(2) 8129(10) 151(4) O14 7746(2) 7626(1) 5849(2) 35(1) 
OW1 6338(2) 6342(1) 10399(2) 38(1) N14 8009(3) 8224(1) 6598(3) 31(1) 
OW2 14435(3) 8323(1) 5598(3) 54(1) C14 8532(3) 7760(1) 5876(3) 30(1) 
OW3 15755(3) 7868(1) 5777(3) 58(1) C24 8518(3) 8099(1) 5777(3) 33(1) 
OW4 14613(2) 7427(1) 5177(3) 45(1) C34 9508(4) 8245(1) 5643(4) 41(1) 
OW5 4356(2) 5164(1) 2598(3) 47(1) C44 9475(5) 8569(1) 5363(5) 55(1) 
OW6 14926(2) 6098(1) 1624(2) 36(1) C54 8906(7) 8625(2) 4416(6) 79(2) 
OW7 14003(3) 5576(1) 1088(3) 47(1) C64 10510(6) 8688(2) 5332(6) 76(2) 
OW8 11705(3) 7420(1) 9344(3) 53(1) C15 10272(3) 7221(1) 6746(3) 29(1) 
OW15 11550(3) 5390(1) 3002(3) 65(1) O15 10737(2) 7410(1) 7201(2) 36(1) 
OW23 14265(3) 4627(2) 6988(4) 94(2) C25 9516(3) 7302(1) 5956(3) 30(1) 
OW10 4141(5) 8592(2) 7404(5) 78(1) C35 9835(3) 7200(1) 4971(3) 34(1) 
OW11 5574(6) 9528(2) 6900(8) 78(1) N15 9388(3) 7626(1) 5958(3) 30(1) 
OW12 4365(5) 3764(2) 5300(9) 78(1) C16 10562(3) 6586(1) 8290(3) 29(1) 
OW13 3879(5) 4356(2) 5049(7) 78(1) O16 11056(2) 6386(1) 8663(2) 40(1) 
OW14 6438(9) 8476(3) 1858(9) 78(1) N16 10368(3) 6933(1) 6904(3) 31(1) 
OW16 6557(9) 8605(3) 2858(9) 78(1) C26 11019(3) 6810(1) 7637(3) 32(1) 
OW17 5487(12) 8897(4) 2704(12) 78(1) C17 8272(3) 7010(1) 10897(3) 26(1) 
OW18 3973(14) 4385(4) 4471(18) 78(1) O17 8433(2) 7062(1) 11764(2) 30(1) 
OW19 5969(17) 4285(5) -853(17) 78(1) C27 8920(3) 6803(1) 10337(3) 28(1) 
OW21 5732(14) 9567(4) 7422(19) 78(1) C47 8370(3) 6590(1) 9665(3) 27(1) 
OW22 3820(20) 8660(7) 7100(20) 78(1) O37 8247(2) 6304(1) 7441(2) 35(1) 
OW24 7220(30) 4870(7) -650(30) 78(1) C57 9023(3) 6416(1) 8983(3) 27(1) 
OW25 6310(20) 4773(7) -290(20) 78(1) C67 8341(3) 6240(1) 8304(3) 28(1) 
OW28 6290(20) 8838(8) 2290(20) 78(1) N17 9607(3) 6616(1) 8422(3) 28(1) 
OW29 4500(30) 3857(9) 4740(30) 78(1) O18 5985(3) 6110(1) 6834(2) 42(1) 
OW30 6160(30) 8639(9) 2230(30) 78(1) N18 7792(3) 6030(1) 8678(3) 29(1) 
OW31 5470(20) 4806(7) 140(20) 78(1) C18 6322(3) 6129(1) 7668(3) 32(1) 
OW32 5520(30) 9579(9) 8240(30) 78(1) O28 4876(4) 5416(2) 9385(3) 81(2) 
OW33 6500(20) 4814(7) 1240(20) 78(1) C28 7052(3) 5893(1) 8051(3) 32(1) 
OW34 4280(30) 3699(9) 5790(40) 78(1) O38 4176(3) 5357(1) 7959(3) 65(1) 
OW35 6326(12) 4382(4) -26(12) 78(1) C38 6555(4) 5649(1) 8600(4) 42(1) 
OW37 5250(40) 8803(11) 1950(40) 78(1) C48 5792(4) 5488(2) 7962(4) 52(1) 
OW38 12970(30) 4194(8) 6670(30) 78(1) C58 4918(4) 5417(1) 8512(4) 47(1) 
OW39 5860(40) 5056(12) -600(40) 78(1) O19 6140(2) 6948(1) 9025(2) 35(1) 
OW40 6920(30) 4938(11) -220(40) 78(1) N19 6048(3) 6333(1) 8288(3) 29(1) 
OW41 6700(30) 5088(11) -740(40) 78(1) C19 5942(3) 6865(1) 8200(3) 29(1) 
C11 7376(3) 7666(1) 10538(3) 30(1) C29 5388(3) 6574(1) 8030(3) 29(1) 
O11 8216(2) 7721(1) 10753(3) 41(1) C39 4466(3) 6569(1) 8631(4) 39(1) 
C21 6923(3) 7367(1) 10777(3) 29(1) C59 3940(4) 6269(1) 8587(4) 48(1) 
N11 7529(3) 7132(1) 10401(3) 29(1) C69 3545(4) 6172(1) 7625(5) 59(2) 
N22 6782(3) 7860(1) 10071(3) 32(1) C79 3803(4) 6828(1) 8345(4) 45(1) 
C12 6881(3) 8193(1) 8692(3) 31(1) O110 8207(2) 7043(1) 7832(2) 36(1) 
O12 6429(2) 8004(1) 8217(2) 37(1) N110 6200(3) 7017(1) 7423(3) 29(1) 
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Supplementary Table S10b. Atomic coordinates ( x 104) and equivalent  isotropic displacement 
parameters (Å2x 103) for -4aa truncation of xanthomonin I.  U(eq) is defined as one third of  the trace of 
the orthogonalized Uij tensor. 
 x y z U(eq)  x y z U(eq) 
C110 7740(3) 7271(1) 7913(3) 27(1) O119 6302(3) 4690(1) 6885(3) 59(1) 
C210 6698(3) 7297(1) 7528(3) 33(1) N119 6682(3) 4514(1) 4344(3) 34(1) 
O111 8941(2) 8059(1) 8304(2) 33(1) C119 6741(4) 4662(1) 6110(4) 41(1) 
N111 8093(2) 7517(1) 8323(3) 28(1) C219 6281(3) 4475(1) 5316(4) 39(1) 
C111 9472(3) 7850(1) 8556(3) 27(1) C319 6464(5) 4142(1) 5523(5) 54(1) 
C211 9070(3) 7542(1) 8724(3) 31(1) C519 7152(4) 4244(1) 3971(4) 44(1) 
O112 12300(3) 8381(1) 7922(3) 52(1) C4A19 7277(8) 4068(2) 4911(9) 43(2) 
N112 10427(3) 7884(1) 8729(3) 28(1) C4B19 6661(14) 4000(3) 4560(11) 70(4) 
C112 11718(3) 8174(1) 7910(4) 33(1) O120 7645(2) 5391(1) 6488(2) 36(1) 
C212 10911(3) 8171(1) 8652(3) 31(1) N120 7623(3) 4766(1) 5970(3) 33(1) 
C312 11287(4) 8280(1) 9642(4) 40(1) C120 8365(3) 5231(1) 6527(3) 30(1) 
C412 10486(3) 8407(1) 10246(3) 34(1) C220 8242(3) 4897(1) 6717(3) 34(1) 
C512 10290(4) 8708(1) 10215(4) 46(1) C320 9189(4) 4722(1) 6828(3) 37(1) 
C612 9532(5) 8829(1) 10749(5) 55(1) C420 9091(5) 4396(1) 7085(5) 62(2) 
C712 8989(4) 8647(2) 11313(4) 55(2) C520 10093(6) 4253(2) 7081(5) 74(2) 
C812 9175(4) 8346(1) 11344(4) 48(1) C620 8620(6) 4350(2) 8048(9) 107(4) 
C912 9914(4) 8226(1) 10811(3) 41(1) O121 10645(2) 5516(1) 5143(2) 35(1) 
O113 11300(2) 7774(1) 5381(2) 39(1) N121 9264(3) 5333(1) 6413(3) 32(1) 
N213 14610(3) 7774(1) 7582(4) 48(1) C121 10162(3) 5712(1) 5530(3) 26(1) 
N113 11730(3) 7951(1) 7278(3) 29(1) C221 9484(3) 5650(1) 6358(3) 29(1) 
C113 12094(3) 7890(1) 5568(3) 32(1) C321 9950(4) 5758(1) 7306(3) 38(1) 
C213 12502(3) 7915(1) 6595(3) 30(1) O122 10722(2) 6570(1) 3654(2) 32(1) 
O313 13405(3) 7627(1) 8528(3) 50(1) N122 10207(3) 5998(1) 5284(3) 30(1) 
C313 13094(3) 7629(1) 6828(4) 37(1) C122 10278(3) 6351(1) 3945(3) 27(1) 
C413 13725(3) 7674(1) 7715(4) 37(1) C222 10809(3) 6113(1) 4533(3) 31(1) 
O114 13013(2) 7442(1) 3967(2) 41(1) O123 8050(2) 6628(1) 4735(2) 33(1) 
N114 12670(3) 7984(1) 4870(3) 36(1) N123 9340(3) 6304(1) 3764(2) 27(1) 
C114 12397(3) 7612(1) 3608(3) 34(1) C123 8125(3) 6690(1) 3881(3) 26(1) 
C214 12368(4) 7940(1) 3870(3) 36(1) O223 7959(2) 5812(1) 549(2) 33(1) 
C314 12998(5) 8119(1) 3184(4) 49(1) C223 8732(3) 6506(1) 3196(3) 26(1) 
C414 12829(7) 8450(1) 3339(5) 75(2) C323 8016(3) 6326(1) 2547(3) 28(1) 
C514 14054(5) 8036(2) 3240(5) 66(2) C423 8501(3) 6100(1) 1909(3) 29(1) 
O115 12362(3) 7104(1) 975(2) 47(1) C523 7836(3) 5880(1) 1393(3) 27(1) 
N115 11774(3) 7517(1) 2918(3) 32(1) O124 5852(2) 6932(1) 5351(2) 30(1) 
C115 12557(4) 7156(1) 1823(3) 36(1) O324 7391(4) 8083(1) 3095(5) 82(2) 
C215 11774(3) 7202(1) 2577(3) 35(1) N124 7587(3) 6911(1) 3490(2) 27(1) 
C315 10755(4) 7162(1) 2167(4) 40(1) C124 6186(3) 6870(1) 4555(3) 26(1) 
C415 10490(4) 7467(1) 1785(4) 41(1) O224 6139(4) 7845(1) 2435(3) 64(1) 
C515 10918(4) 7680(1) 2540(4) 40(1) C224 6948(3) 7073(1) 4118(3) 28(1) 
O116 15647(3) 6814(1) 1783(3) 46(1) C324 6506(3) 7336(1) 3582(3) 32(1) 
N116 13463(3) 7177(1) 2169(3) 38(1) C424 7287(4) 7572(1) 3383(4) 40(1) 
C116 14787(3) 6851(1) 1624(3) 35(1) C524 6867(5) 7846(1) 2935(4) 49(1) 
O216 14158(2) 6634(1) 1474(3) 43(1) O125 5907(2) 6030(1) 3340(2) 28(1) 
C216 14320(4) 7154(1) 1577(4) 41(1) N125 5898(2) 6632(1) 4053(2) 25(1) 
O117 7841(2) 5162(1) 1712(3) 41(1) C125 5827(3) 6100(1) 4205(3) 25(1) 
N117 7141(3) 5756(1) 1918(3) 28(1) C225 4270(3) 6388(1) 4068(3) 30(1) 
C117 6999(3) 5219(1) 1876(3) 31(1) C325 3736(3) 6109(1) 4410(4) 41(1) 
C217 6542(3) 5513(1) 1565(3) 31(1) C425 3726(3) 6674(1) 4304(4) 35(1) 
O118 6073(2) 4973(1) 4214(2) 35(1) C525 3458(4) 6715(1) 5359(4) 44(1) 
N118 6408(3) 5035(1) 2347(3) 33(1) C625 5326(3) 6391(1) 4461(3) 26(1) 
C118 6468(3) 4758(1) 3839(3) 32(1) O126 8041(2) 5871(1) 4367(3) 37(1) 
C218 6748(3) 4762(1) 2788(3) 34(1) N126 6139(2) 5930(1) 4916(2) 25(1) 
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Supplementary Table S10c. Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for -4aa truncation of xanthomonin I.  U(eq) is defined as one third of  the trace of 
the orthogonalized Uij tensor. 
 x y z U(eq)  x y z U(eq) 
C126 7568(3) 5642(1) 4373(3) 26(1) C329 13556(3) 5259(1) 5044(4) 38(1) 
C226 6524(3) 5635(1) 4724(3) 27(1) C429 12318(3) 4997(1) 6013(3) 30(1) 
O127 8685(2) 4840(1) 4287(2) 34(1) O130 12573(3) 5416(1) 8829(3) 47(1) 
N127 7885(3) 5383(1) 4065(3) 31(1) N130 12444(3) 4889(1) 7735(3) 34(1) 
C127 9225(3) 5030(1) 3976(3) 28(1) C130 11944(3) 5225(1) 8992(3) 35(1) 
C227 8849(3) 5335(1) 3691(3) 29(1) C230 12100(4) 4905(1) 8728(3) 37(1) 
O128 11954(3) 4484(1) 4910(3) 54(1) C330 12833(4) 4751(1) 9429(4) 46(1) 
N128 10175(3) 4986(1) 3839(3) 29(1) C430 12919(6) 4423(2) 9179(5) 66(2) 
C128 11452(3) 4709(1) 4770(3) 33(1) C530 12552(5) 4794(2) 10473(4) 64(2) 
C228 10631(3) 4699(1) 4024(3) 32(1) O131 12028(2) 5615(1) 11053(2) 41(1) 
C328 10973(4) 4560(1) 3072(4) 40(1) N131 11135(3) 5308(1) 9440(3) 38(1) 
C428 10134(4) 4457(1) 2454(3) 38(1) C131 11689(3) 5756(1) 10350(3) 37(1) 
C528 9707(5) 4638(1) 1749(4) 48(1) C231 10962(4) 5621(1) 9651(4) 45(1) 
C628 8897(5) 4545(2) 1206(4) 63(2) C331 9961(4) 5620(2) 10085(5) 66(2) 
C728 8509(5) 4278(2) 1359(5) 64(2) C531 10291(4) 5123(2) 9631(5) 59(2) 
C828 8911(5) 4089(1) 2052(5) 58(2) C631 9422(8) 5313(3) 9739(9) 39(4) 
C928 9701(4) 4182(1) 2604(4) 47(1) C4A31 9855(7) 5355(2) 10428(8) 47(3) 
O129 11085(2) 5103(1) 7170(2) 37(1) O132 10759(3) 6272(1) 11612(3) 63(1) 
N129 11566(3) 4959(1) 5284(3) 29(1) N132 11877(3) 6042(1) 10193(3) 39(1) 
C129 11882(3) 4999(1) 7027(3) 31(1) C132 11613(3) 6316(1) 11681(4) 39(1) 
O229 13317(3) 5315(1) 4207(3) 54(1) O232 12059(2) 6456(1) 12407(2) 40(1) 
N229 14430(3) 5160(1) 5296(4) 54(1) C232 12339(4) 6230(1) 10921(3) 40(1) 
C229 12861(3) 5291(1) 5860(3) 32(1)      
 
 
Supplementary Table S11a. Bond lengths [Å] and angles [°] for  the -4 aa truncation of xanthomonin I. 
 
O(100)-H(101)  0.9103 OH2-HH2  0.8400 C13-C23  1.516(8) 
O(100)-H(102)  0.9813 C11-O11  1.215(6) C23-C33  1.526(8) 
OH1-C(100)  1.393(8) C11-N22  1.353(6) C23-H23  1.0000 
OH1-H(6)  0.8400 C11-C21  1.527(6) C33-C43  1.489(12) 
C(100)-C(101)  1.559(11) C21-N11  1.455(6) C33-H3A3  0.9900 
C(100)-H(10A)  0.9900 C21-H2A1  0.9900 C33-H3B3  0.9900 
C(100)-H(10B)  0.9900 C21-H2B1  0.9900 C43-C53  1.505(9) 
C(101)-C(102)  1.503(11) N11-C17  1.340(6) C43-H4A3  0.9900 
C(101)-H(10C)  0.9900 N11-H11  0.8800 C43-H4B3  0.9900 
C(101)-H(10D)  0.9900 N22-C22  1.442(6) C53-H5A3  0.9900 
C(102)-C(103)  1.546(13) N22-H22  0.8800 C53-H5B3  0.9900 
C(102)-H(10E)  0.9900 C12-O12  1.238(6) O14-C14  1.242(6) 
C(102)-H(10F)  0.9900 C12-N13  1.330(6) N14-C24  1.468(6) 
C(103)-C(104)  1.555(14) C12-C22  1.514(7) N14-H14  0.8800 
C(103)-H(10G)  0.9900 C22-H2A2  0.9900 C14-N15  1.331(6) 
C(103)-H(10H)  0.9900 C22-H2B2  0.9900 C14-C24  1.532(7) 
C(104)-C(105)  1.552(14) O13-C13  1.238(7) C24-C34  1.532(7) 
C(104)-H(10I)  0.9900 N13-C53  1.468(7) C24-H24  1.0000 
C(104)-H(10J)  0.9900 N13-C23  1.477(7) C34-C44  1.514(8) 
C(105)-OH2  1.465(14) C13-N14  1.327(6) C34-H3A4  0.9900 
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Supplementary Table S11b. Bond lengths [Å] and angles [°] for  the -4 aa truncation of xanthomonin I. 
 
C34-H3B4  0.9900 C48-C58  1.479(8) C812-C912  1.387(8) 
C44-C64  1.527(10) C48-H4A8  0.9900 C812-H812  0.9500 
C44-C54  1.535(11) C48-H4B8  0.9900 C912-H912  0.9500 
C44-H44  1.0000 O19-C19  1.230(5) O113-C113  1.235(6) 
C54-H5A4  0.9800 N19-C29  1.458(6) N213-C413  1.319(7) 
C54-H5B4  0.9800 N19-H19  0.8800 N213-H2A13  0.8800 
C54-H5C4  0.9800 C19-N110  1.333(6) N213-H2B13  0.8800 
C64-H6A4  0.9800 C19-C29  1.534(6) N113-C213  1.453(6) 
C64-H6B4  0.9800 C29-C39  1.540(6) N113-H113  0.8800 
C64-H6C4  0.9800 C29-H29  1.0000 C113-N114  1.338(6) 
C15-O15  1.230(5) C39-C79  1.534(7) C113-C213  1.524(6) 
C15-N16  1.324(6) C39-C59  1.535(8) C213-C313  1.555(7) 
C15-C25  1.540(6) C39-H39  1.0000 C213-H213  1.0000 
C25-N15  1.468(6) C59-C69  1.495(9) O313-C413  1.241(6) 
C25-C35  1.520(6) C59-H5A9  0.9900 C313-C413  1.504(7) 
C25-H25  1.0000 C59-H5B9  0.9900 C313-H3A13  0.9900 
C35-H3A5  0.9800 C69-H6A9  0.9800 C313-H3B13  0.9900 
C35-H3B5  0.9800 C69-H6B9  0.9800 O114-C114  1.239(6) 
C35-H3C5  0.9800 C69-H6C9  0.9800 N114-C214  1.455(6) 
N15-H15  0.8800 C79-H7A9  0.9800 N114-H114  0.8800 
C16-O16  1.234(6) C79-H7B9  0.9800 C114-N115  1.342(6) 
C16-N17  1.343(6) C79-H7C9  0.9800 C114-C214  1.526(7) 
C16-C26  1.506(7) O110-C110  1.221(6) C214-C314  1.535(7) 
N16-C26  1.452(6) N110-C210  1.444(6) C214-H214  1.0000 
N16-H16  0.8800 N110-H110  0.8800 C314-C514  1.504(10) 
C26-H2A6  0.9900 C110-N111  1.335(6) C314-C414  1.524(9) 
C26-H2B6  0.9900 C110-C210  1.527(6) C314-H314  1.0000 
C17-O17  1.241(5) C210-H2A10  0.9900 C414-H4A14  0.9800 
C17-C27  1.520(6) C210-H2B10  0.9900 C414-H4B14  0.9800 
C27-C47  1.528(6) O111-C111  1.237(5) C414-H4C14  0.9800 
C27-H2A7  0.9900 N111-C211  1.451(6) C514-H5A14  0.9800 
C27-H2B7  0.9900 N111-H111  0.8800 C514-H5B14  0.9800 
C47-C57  1.540(6) C111-N112  1.343(6) C514-H5C14  0.9800 
C47-H4A7  0.9900 C111-C211  1.516(6) O115-C115  1.225(6) 
C47-H4B7  0.9900 C211-H2A11  0.9900 N115-C515  1.478(6) 
O37-C67  1.237(5) C211-H2B11  0.9900 N115-C215  1.500(6) 
C57-N17  1.449(6) O112-C112  1.233(6) C115-N116  1.333(7) 
C57-C67  1.538(6) N112-C212  1.462(6) C115-C215  1.537(7) 
C57-H57  1.0000 N112-H112  0.8800 C215-C315  1.515(7) 
C67-N18  1.325(6) C112-N113  1.336(6) C215-H215  1.0000 
N17-H17  0.8800 C112-C212  1.536(6) C315-C415  1.514(7) 
O18-C18  1.240(6) C212-C312  1.538(7) C315-H3A15  0.9900 
N18-C28  1.463(6) C212-H212  1.0000 C315-H3B15  0.9900 
N18-H18  0.8800 C312-C412  1.516(7) C415-C515  1.531(7) 
C18-N19  1.322(6) C312-H3A12  0.9900 C415-H4A15  0.9900 
C18-C28  1.548(7) C312-H3B12  0.9900 C415-H4B15  0.9900 
O28-C58  1.215(7) C412-C512  1.384(8) C515-H5A15  0.9900 
C28-C38  1.513(7) C412-C912  1.392(7) C515-H5B15  0.9900 
C28-H2A8  1.0000 C512-C612  1.409(8) O116-C116  1.212(6) 
O38-C58  1.293(7) C512-H512  0.9500 N116-C216  1.461(6) 
O38-H38  0.8400 C612-C712  1.371(9) N116-H116  0.8800 
C38-C48  1.542(8) C612-H612  0.9500 C116-O216  1.321(6) 
C38-H3A8  0.9900 C712-C812  1.380(10) C116-C216  1.513(7) 
C38-H3B8  0.9900 C712-H712  0.9500 O216-H216  0.8400 
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Supplementary Table S11c. Bond lengths [Å] and angles [°] for  the -4 aa truncation of xanthomonin I. 
 
C216-H2A16  0.9900 C520-H5C20  0.9800 C125-N126  1.317(6) 
C216-H2B16  0.9900 C620-H6A20  0.9800 C125-C625  1.527(6) 
O117-C117  1.219(6) C620-H6B20  0.9800 C225-C425  1.534(6) 
N117-C523  1.342(6) C620-H6C20  0.9800 C225-C325  1.537(7) 
N117-C217  1.452(6) O121-C121  1.241(6) C225-C625  1.544(6) 
N117-H117  0.8800 N121-C221  1.461(6) C225-H225  1.0000 
C117-N118  1.347(6) N121-H121  0.8800 C325-H3A25  0.9800 
C117-C217  1.523(6) C121-N122  1.331(6) C325-H3B25  0.9800 
C217-H2A17  0.9900 C121-C221  1.527(6) C325-H3C25  0.9800 
C217-H2B17  0.9900 C221-C321  1.531(6) C425-C525  1.530(7) 
O118-C118  1.236(6) C221-H221  1.0000 C425-H4A25  0.9900 
N118-C218  1.449(6) C321-H3A21  0.9800 C425-H4B25  0.9900 
N118-H118  0.8800 C321-H3B21  0.9800 C525-H5A25  0.9800 
C118-N119  1.334(6) C321-H3C21  0.9800 C525-H5B25  0.9800 
C118-C218  1.519(7) O122-C122  1.237(5) C525-H5C25  0.9800 
C218-H2A18  0.9900 N122-C222  1.447(6) C625-H625  1.0000 
C218-H2B18  0.9900 N122-H122  0.8800 O126-C126  1.221(5) 
O119-C119  1.254(6) C122-N123  1.330(6) N126-C226  1.458(6) 
N119-C519  1.481(7) C122-C222  1.525(6) N126-H126  0.8800 
N119-C219  1.483(6) C222-H2A22  0.9900 C126-N127  1.325(6) 
C119-N120  1.323(6) C222-H2B22  0.9900 C126-C226  1.533(6) 
C119-C219  1.516(8) O123-C123  1.225(5) C226-H2A26  0.9900 
C219-C319  1.549(8) N123-C223  1.457(5) C226-H2B26  0.9900 
C219-H219  1.0000 N123-H123  0.8800 O127-C127  1.224(6) 
C319-C4A19  1.463(13) C123-N124  1.349(6) N127-C227  1.457(6) 
C319-C4B19  1.515(17) C123-C223  1.529(6) N127-H127  0.8800 
C319-H3A19  0.9900 O223-C523  1.228(5) C127-N128  1.345(6) 
C319-H3B19  0.9900 C223-C323  1.551(6) C127-C227  1.516(6) 
C319-H3A19  0.9900 C223-H223  1.0000 C227-H2A27  0.9900 
C319-H3B19  0.9900 C323-C423  1.518(7) C227-H2B27  0.9900 
C519-C4A19  1.534(12) C323-H3A23  0.9900 O128-C128  1.243(6) 
C519-C4B19  1.540(15) C323-H3B23  0.9900 N128-C228  1.460(6) 
C519-H5A19  0.9900 C423-C523  1.517(6) N128-H128  0.8800 
C519-H5B19  0.9900 C423-H4A23  0.9900 C128-N129  1.340(6) 
C519-H5A19  0.9900 C423-H4B23  0.9900 C128-C228  1.517(7) 
C519-H5B19  0.9900 O124-C124  1.238(5) C228-C328  1.548(6) 
C4A19-H4AA19  0.9900 O324-C524  1.308(8) C228-H228  1.0000 
C4A19-H4AB19  0.9900 O324-H324  0.8400 C328-C428  1.498(8) 
C4B19-H4BA19  0.9900 N124-C224  1.455(6) C328-H3A28  0.9900 
C4B19-H4BB19  0.9900 N124-H124  0.8800 C328-H3B28  0.9900 
O120-C120  1.228(6) C124-N125  1.339(6) C428-C528  1.392(8) 
N120-C220  1.453(6) C124-C224  1.531(6) C428-C928  1.398(8) 
N120-H120  0.8800 O224-C524  1.207(8) C528-C628  1.397(9) 
C120-N121  1.336(6) C224-C324  1.518(6) C528-H528  0.9500 
C120-C220  1.540(7) C224-H224  1.0000 C628-C728  1.339(11) 
C220-C320  1.532(7) C324-C424  1.546(7) C628-H628  0.9500 
C220-H220  1.0000 C324-H3A24  0.9900 C728-C828  1.389(10) 
C320-C420  1.519(7) C324-H3B24  0.9900 C728-H728  0.9500 
C320-H3A20  0.9900 C424-C524  1.493(8) C828-C928  1.382(9) 
C320-H3B20  0.9900 C424-H4A24  0.9900 C828-H828  0.9500 
C420-C620  1.515(13) C424-H4B24  0.9900 C928-H928  0.9500 
C420-C520  1.526(10) O125-C125  1.249(5) O129-C129  1.216(6) 
C420-H420  1.0000 N125-C625  1.464(6) N129-C429  1.443(6) 
C520-H5A20  0.9800 N125-H125  0.8800 N129-H129  0.8800 
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Supplementary Table S11d. Bond lengths [Å] and angles [°] for  the -4 aa truncation of xanthomonin I. 
 
C129-N130  1.333(6) C132-C232  1.524(7) O12-C12-C22 120.8(4) 
C129-C429  1.545(6) O232-H232  0.8400 N13-C12-C22 116.7(4) 
O229-C329  1.226(7) C232-H2A32  0.9900 N22-C22-C12 111.3(4) 
N229-C329  1.326(7) C232-H2B32  0.9900 N22-C22-H2A2 109.4 
N229-H2A29  0.8800 H(101)-O(100)-H(102) 98.2 C12-C22-H2A2 109.4 
N229-H2B29  0.8800 C(100)-OH1-H(6) 109.5 N22-C22-H2B2 109.4 
C229-C329  1.509(7) OH1-C(100)-C(101) 108.8(7) C12-C22-H2B2 109.4 
C229-C429  1.539(6) OH1-C(100)-H(10A) 109.9 H2A2-C22-H2B2 108.0 
C229-H2C29  0.9900 C(101)-C(100)-H(10A) 109.9 C12-N13-C53 125.2(4) 
C229-H2D29  0.9900 OH1-C(100)-H(10B) 109.9 C12-N13-C23 121.9(4) 
C429-H429  1.0000 C(101)-C(100)-H(10B) 109.9 C53-N13-C23 112.2(4) 
O130-C130  1.247(6) H(10A)-C(100)-H(10B) 108.3 O13-C13-N14 121.9(5) 
N130-C230  1.472(6) C(102)-C(101)-C(100) 114.0(9) O13-C13-C23 118.4(5) 
N130-H130  0.8800 C(102)-C(101)-H(10C) 108.7 N14-C13-C23 119.7(4) 
C130-N131  1.345(6) C(100)-C(101)-H(10C) 108.7 N13-C23-C13 117.7(4) 
C130-C230  1.503(7) C(102)-C(101)-H(10D) 108.7 N13-C23-C33 102.1(5) 
C230-C330  1.551(7) C(100)-C(101)-H(10D) 108.7 C13-C23-C33 110.7(5) 
C230-H230  1.0000 H(10C)-C(101)-H(10D) 107.6 N13-C23-H23 108.7 
C330-C430  1.522(9) C(101)-C(102)-C(103) 110.4(12) C13-C23-H23 108.7 
C330-C530  1.523(8) C(101)-C(102)-H(10E) 109.6 C33-C23-H23 108.7 
C330-H330  1.0000 C(103)-C(102)-H(10E) 109.6 C43-C33-C23 104.5(5) 
C430-H4A30  0.9800 C(101)-C(102)-H(10F) 109.6 C43-C33-H3A3 110.9 
C430-H4B30  0.9800 C(103)-C(102)-H(10F) 109.6 C23-C33-H3A3 110.9 
C430-H4C30  0.9800 H(10E)-C(102)-H(10F) 108.1 C43-C33-H3B3 110.9 
C530-H5A30  0.9800 C(102)-C(103)-C(104) 130.0(17) C23-C33-H3B3 110.9 
C530-H5B30  0.9800 C(102)-C(103)-H(10G) 104.8 H3A3-C33-H3B3 108.9 
C530-H5C30  0.9800 C(104)-C(103)-H(10G) 104.8 C33-C43-C53 104.7(6) 
O131-C131  1.247(6) C(102)-C(103)-H(10H) 104.8 C33-C43-H4A3 110.8 
N131-C531  1.461(8) C(104)-C(103)-H(10H) 104.8 C53-C43-H4A3 110.8 
N131-C231  1.462(7) H(10G)-C(103)-H(10H) 105.8 C33-C43-H4B3 110.8 
C131-N132  1.332(7) C(105)-C(104)-C(103) 123(2) C53-C43-H4B3 110.8 
C131-C231  1.510(7) C(105)-C(104)-H(10I) 106.5 H4A3-C43-H4B3 108.9 
C231-C331  1.521(8) C(103)-C(104)-H(10I) 106.5 N13-C53-C43 102.9(5) 
C231-H231  1.0000 C(105)-C(104)-H(10J) 106.5 N13-C53-H5A3 111.2 
C331-C4A31  1.295(13) C(103)-C(104)-H(10J) 106.5 C43-C53-H5A3 111.2 
C331-C631  1.639(14) H(10I)-C(104)-H(10J) 106.5 N13-C53-H5B3 111.2 
C331-H3A31  0.9900 OH2-C(105)-C(104) 104(2) C43-C53-H5B3 111.2 
C331-H3B31  0.9900 C(105)-OH2-HH2 109.5 H5A3-C53-H5B3 109.1 
C331-H3A31  0.9900 O11-C11-N22 123.4(4) C13-N14-C24 122.0(4) 
C331-H3B31  0.9900 O11-C11-C21 121.3(4) C13-N14-H14 119.0 
C531-C631  1.483(14) N22-C11-C21 115.3(4) C24-N14-H14 119.0 
C531-C4A31  1.647(11) N11-C21-C11 108.8(3) O14-C14-N15 123.6(4) 
C531-H5A31  0.9900 N11-C21-H2A1 109.9 O14-C14-C24 118.3(4) 
C531-H5B31  0.9900 C11-C21-H2A1 109.9 N15-C14-C24 118.1(4) 
C531-H5A31  0.9900 N11-C21-H2B1 109.9 N14-C24-C34 112.0(4) 
C531-H5B31  0.9900 C11-C21-H2B1 109.9 N14-C24-C14 108.7(4) 
C631-H6A31  0.9900 H2A1-C21-H2B1 108.3 C34-C24-C14 115.5(4) 
C631-H6B31  0.9900 C17-N11-C21 123.7(4) N14-C24-H24 106.7 
C4A31-H4AA31  0.9900 C17-N11-H11 118.1 C34-C24-H24 106.7 
C4A31-H4AB31  0.9900 C21-N11-H11 118.1 C14-C24-H24 106.7 
O132-C132  1.197(6) C11-N22-C22 121.7(4) C44-C34-C24 115.2(5) 
N132-C232  1.456(7) C11-N22-H22 119.1 C44-C34-H3A4 108.5 
N132-H132  0.8800 C22-N22-H22 119.1 C24-C34-H3A4 108.5 
C132-O232  1.328(6) O12-C12-N13 122.4(4) C44-C34-H3B4 108.5 
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Supplementary Table S11e. Bond lengths [Å] and angles [°] for  the -4 aa truncation of xanthomonin I. 
 
C24-C34-H3B4 108.5 C17-C27-H2A7 108.7 O19-C19-N110 122.7(4) 
H3A4-C34-H3B4 107.5 C47-C27-H2A7 108.7 O19-C19-C29 120.2(4) 
C34-C44-C64 108.8(6) C17-C27-H2B7 108.7 N110-C19-C29 117.1(4) 
C34-C44-C54 113.0(5) C47-C27-H2B7 108.7 N19-C29-C19 107.2(3) 
C64-C44-C54 112.2(6) H2A7-C27-H2B7 107.6 N19-C29-C39 111.9(4) 
C34-C44-H44 107.5 C27-C47-C57 114.0(3) C19-C29-C39 110.2(4) 
C64-C44-H44 107.5 C27-C47-H4A7 108.7 N19-C29-H29 109.2 
C54-C44-H44 107.5 C57-C47-H4A7 108.7 C19-C29-H29 109.2 
C44-C54-H5A4 109.5 C27-C47-H4B7 108.7 C39-C29-H29 109.2 
C44-C54-H5B4 109.5 C57-C47-H4B7 108.7 C79-C39-C59 112.6(4) 
H5A4-C54-H5B4 109.5 H4A7-C47-H4B7 107.6 C79-C39-C29 110.0(4) 
C44-C54-H5C4 109.5 N17-C57-C67 109.4(3) C59-C39-C29 112.9(4) 
H5A4-C54-H5C4 109.5 N17-C57-C47 110.8(4) C79-C39-H39 107.0 
H5B4-C54-H5C4 109.5 C67-C57-C47 106.4(3) C59-C39-H39 107.0 
C44-C64-H6A4 109.5 N17-C57-H57 110.1 C29-C39-H39 107.0 
C44-C64-H6B4 109.5 C67-C57-H57 110.1 C69-C59-C39 117.0(5) 
H6A4-C64-H6B4 109.5 C47-C57-H57 110.1 C69-C59-H5A9 108.0 
C44-C64-H6C4 109.5 O37-C67-N18 120.1(4) C39-C59-H5A9 108.0 
H6A4-C64-H6C4 109.5 O37-C67-C57 121.3(4) C69-C59-H5B9 108.0 
H6B4-C64-H6C4 109.5 N18-C67-C57 118.4(4) C39-C59-H5B9 108.0 
O15-C15-N16 123.0(4) C16-N17-C57 124.8(4) H5A9-C59-H5B9 107.3 
O15-C15-C25 122.5(4) C16-N17-H17 117.6 C59-C69-H6A9 109.5 
N16-C15-C25 114.5(4) C57-N17-H17 117.6 C59-C69-H6B9 109.5 
N15-C25-C35 110.0(4) C67-N18-C28 117.7(4) H6A9-C69-H6B9 109.5 
N15-C25-C15 108.3(4) C67-N18-H18 121.1 C59-C69-H6C9 109.5 
C35-C25-C15 111.2(4) C28-N18-H18 121.1 H6A9-C69-H6C9 109.5 
N15-C25-H25 109.1 O18-C18-N19 123.3(4) H6B9-C69-H6C9 109.5 
C35-C25-H25 109.1 O18-C18-C28 119.9(4) C39-C79-H7A9 109.5 
C15-C25-H25 109.1 N19-C18-C28 116.6(4) C39-C79-H7B9 109.5 
C25-C35-H3A5 109.5 N18-C28-C38 109.0(4) H7A9-C79-H7B9 109.5 
C25-C35-H3B5 109.5 N18-C28-C18 110.8(4) C39-C79-H7C9 109.5 
H3A5-C35-H3B5 109.5 C38-C28-C18 111.9(4) H7A9-C79-H7C9 109.5 
C25-C35-H3C5 109.5 N18-C28-H2A8 108.4 H7B9-C79-H7C9 109.5 
H3A5-C35-H3C5 109.5 C38-C28-H2A8 108.4 C19-N110-C210 120.2(4) 
H3B5-C35-H3C5 109.5 C18-C28-H2A8 108.4 C19-N110-H110 119.9 
C14-N15-C25 124.0(4) C58-O38-H38 109.5 C210-N110-H110 119.9 
C14-N15-H15 118.0 C28-C38-C48 111.4(4) O110-C110-N111 123.5(4) 
C25-N15-H15 118.0 C28-C38-H3A8 109.3 O110-C110-C210 121.9(4) 
O16-C16-N17 123.4(4) C48-C38-H3A8 109.3 N111-C110-C210 114.6(4) 
O16-C16-C26 120.4(4) C28-C38-H3B8 109.3 N110-C210-C110 114.2(4) 
N17-C16-C26 116.2(4) C48-C38-H3B8 109.3 N110-C210-H2A10 108.7 
C15-N16-C26 123.4(4) H3A8-C38-H3B8 108.0 C110-C210-H2A10 108.7 
C15-N16-H16 118.3 C58-C48-C38 111.1(5) N110-C210-H2B10 108.7 
C26-N16-H16 118.3 C58-C48-H4A8 109.4 C110-C210-H2B10 108.7 
N16-C26-C16 114.7(4) C38-C48-H4A8 109.4 H2A10-C210-H2B10 107.6 
N16-C26-H2A6 108.6 C58-C48-H4B8 109.4 C110-N111-C211 123.8(4) 
C16-C26-H2A6 108.6 C38-C48-H4B8 109.4 C110-N111-H111 118.1 
N16-C26-H2B6 108.6 H4A8-C48-H4B8 108.0 C211-N111-H111 118.1 
C16-C26-H2B6 108.6 O28-C58-O38 122.4(5) O111-C111-N112 122.6(4) 
H2A6-C26-H2B6 107.6 O28-C58-C48 125.1(5) O111-C111-C211 121.5(4) 
O17-C17-N11 122.5(4) O38-C58-C48 112.5(5) N112-C111-C211 115.9(4) 
O17-C17-C27 121.2(4) C18-N19-C29 123.1(4) N111-C211-C111 110.7(4) 
N11-C17-C27 116.3(4) C18-N19-H19 118.4 N111-C211-H2A11 109.5 
C17-C27-C47 114.1(3) C29-N19-H19 118.4 C111-C211-H2A11 109.5 
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Supplementary Table S11f. Bond lengths [Å] and angles [°] for  the -4 aa truncation of xanthomonin I. 
 
N111-C211-H2B11 109.5 C413-C313-C213 110.5(4) C415-C315-H3B15 111.0 
C111-C211-H2B11 109.5 C413-C313-H3A13 109.5 C215-C315-H3B15 111.0 
H2A11-C211-H2B11 108.1 C213-C313-H3A13 109.5 H3A15-C315-H3B15 109.0 
C111-N112-C212 122.3(4) C413-C313-H3B13 109.5 C315-C415-C515 104.2(4) 
C111-N112-H112 118.9 C213-C313-H3B13 109.5 C315-C415-H4A15 110.9 
C212-N112-H112 118.9 H3A13-C313-H3B13 108.1 C515-C415-H4A15 110.9 
O112-C112-N113 124.1(4) O313-C413-N213 122.5(5) C315-C415-H4B15 110.9 
O112-C112-C212 118.7(4) O313-C413-C313 120.7(4) C515-C415-H4B15 110.9 
N113-C112-C212 117.1(4) N213-C413-C313 116.8(4) H4A15-C415-H4B15 108.9 
N112-C212-C112 113.3(4) C113-N114-C214 119.2(4) N115-C515-C415 102.8(4) 
N112-C212-C312 111.2(4) C113-N114-H114 120.4 N115-C515-H5A15 111.2 
C112-C212-C312 111.3(4) C214-N114-H114 120.4 C415-C515-H5A15 111.2 
N112-C212-H212 106.9 O114-C114-N115 120.8(4) N115-C515-H5B15 111.2 
C112-C212-H212 106.9 O114-C114-C214 121.7(4) C415-C515-H5B15 111.2 
C312-C212-H212 106.9 N115-C114-C214 117.3(4) H5A15-C515-H5B15 109.1 
C412-C312-C212 112.3(4) N114-C214-C114 110.6(4) C115-N116-C216 123.9(4) 
C412-C312-H3A12 109.1 N114-C214-C314 111.6(4) C115-N116-H116 118.0 
C212-C312-H3A12 109.1 C114-C214-C314 110.1(4) C216-N116-H116 118.0 
C412-C312-H3B12 109.1 N114-C214-H214 108.2 O116-C116-O216 124.3(5) 
C212-C312-H3B12 109.1 C114-C214-H214 108.2 O116-C116-C216 123.1(4) 
H3A12-C312-H3B12 107.9 C314-C214-H214 108.2 O216-C116-C216 112.6(4) 
C512-C412-C912 118.7(5) C514-C314-C414 112.8(6) C116-O216-H216 109.5 
C512-C412-C312 119.8(5) C514-C314-C214 113.7(5) N116-C216-C116 112.8(4) 
C912-C412-C312 121.5(5) C414-C314-C214 109.5(5) N116-C216-H2A16 109.0 
C412-C512-C612 120.8(5) C514-C314-H314 106.8 C116-C216-H2A16 109.0 
C412-C512-H512 119.6 C414-C314-H314 106.8 N116-C216-H2B16 109.0 
C612-C512-H512 119.6 C214-C314-H314 106.8 C116-C216-H2B16 109.0 
C712-C612-C512 119.5(6) C314-C414-H4A14 109.5 H2A16-C216-H2B16 107.8 
C712-C612-H612 120.3 C314-C414-H4B14 109.5 C523-N117-C217 122.7(4) 
C512-C612-H612 120.3 H4A14-C414-H4B14 109.5 C523-N117-H117 118.6 
C612-C712-C812 120.1(5) C314-C414-H4C14 109.5 C217-N117-H117 118.6 
C612-C712-H712 119.9 H4A14-C414-H4C14 109.5 O117-C117-N118 123.4(4) 
C812-C712-H712 119.9 H4B14-C414-H4C14 109.5 O117-C117-C217 121.5(4) 
C712-C812-C912 120.6(5) C314-C514-H5A14 109.5 N118-C117-C217 115.0(4) 
C712-C812-H812 119.7 C314-C514-H5B14 109.5 N117-C217-C117 109.4(3) 
C912-C812-H812 119.7 H5A14-C514-H5B14 109.5 N117-C217-H2A17 109.8 
C812-C912-C412 120.3(5) C314-C514-H5C14 109.5 C117-C217-H2A17 109.8 
C812-C912-H912 119.8 H5A14-C514-H5C14 109.5 N117-C217-H2B17 109.8 
C412-C912-H912 119.8 H5B14-C514-H5C14 109.5 C117-C217-H2B17 109.8 
C413-N213-H2A13 120.0 C114-N115-C515 126.0(4) H2A17-C217-H2B17 108.2 
C413-N213-H2B13 120.0 C114-N115-C215 121.6(4) C117-N118-C218 122.4(4) 
H2A13-N213-H2B13 120.0 C515-N115-C215 111.5(4) C117-N118-H118 118.8 
C112-N113-C213 122.4(4) O115-C115-N116 122.8(5) C218-N118-H118 118.8 
C112-N113-H113 118.8 O115-C115-C215 122.7(4) O118-C118-N119 121.3(4) 
C213-N113-H113 118.8 N116-C115-C215 114.5(4) O118-C118-C218 121.4(4) 
O113-C113-N114 121.4(4) N115-C215-C315 102.9(4) N119-C118-C218 117.2(4) 
O113-C113-C213 122.2(4) N115-C215-C115 110.3(4) N118-C218-C118 109.1(4) 
N114-C113-C213 116.3(4) C315-C215-C115 113.0(4) N118-C218-H2A18 109.9 
N113-C213-C113 111.0(4) N115-C215-H215 110.2 C118-C218-H2A18 109.9 
N113-C213-C313 110.3(4) C315-C215-H215 110.2 N118-C218-H2B18 109.9 
C113-C213-C313 108.4(4) C115-C215-H215 110.2 C118-C218-H2B18 109.9 
N113-C213-H213 109.0 C415-C315-C215 103.8(4) H2A18-C218-H2B18 108.3 
C113-C213-H213 109.0 C415-C315-H3A15 111.0 C118-N119-C519 125.9(4) 
C313-C213-H213 109.0 C215-C315-H3A15 111.0 C118-N119-C219 119.7(4) 
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Supplementary Table S11g. Bond lengths [Å] and angles [°] for  the -4 aa truncation of xanthomonin I. 
 
C519-N119-C219 113.5(4) C320-C220-C120 115.0(4) C122-C222-H2A22 109.4 
O119-C119-N120 123.9(5) N120-C220-H220 107.0 N122-C222-H2B22 109.4 
O119-C119-C219 118.4(4) C320-C220-H220 107.0 C122-C222-H2B22 109.4 
N120-C119-C219 117.4(4) C120-C220-H220 107.0 H2A22-C222-H2B22 108.0 
N119-C219-C119 115.9(4) C420-C320-C220 116.2(5) C122-N123-C223 123.2(4) 
N119-C219-C319 102.8(4) C420-C320-H3A20 108.2 C122-N123-H123 118.4 
C119-C219-C319 110.0(4) C220-C320-H3A20 108.2 C223-N123-H123 118.4 
N119-C219-H219 109.3 C420-C320-H3B20 108.2 O123-C123-N124 120.0(4) 
C119-C219-H219 109.3 C220-C320-H3B20 108.2 O123-C123-C223 122.6(4) 
C319-C219-H219 109.3 H3A20-C320-H3B20 107.4 N124-C123-C223 117.0(4) 
C4A19-C319-C219 103.7(5) C620-C420-C320 112.5(6) N123-C223-C123 108.6(3) 
C4B19-C319-C219 106.2(6) C620-C420-C520 110.8(5) N123-C223-C323 109.8(3) 
C4A19-C319-H3A19 111.0 C320-C420-C520 108.8(6) C123-C223-C323 107.1(3) 
C219-C319-H3A19 111.0 C620-C420-H420 108.2 N123-C223-H223 110.4 
C4A19-C319-H3B19 111.0 C320-C420-H420 108.2 C123-C223-H223 110.4 
C219-C319-H3B19 111.0 C520-C420-H420 108.2 C323-C223-H223 110.4 
H3A19-C319-H3B19 109.0 C420-C520-H5A20 109.5 C423-C323-C223 114.0(4) 
C4B19-C319-H3A19 110.5 C420-C520-H5B20 109.5 C423-C323-H3A23 108.8 
C219-C319-H3A19 110.5 H5A20-C520-H5B20 109.5 C223-C323-H3A23 108.8 
C4B19-C319-H3B19 110.5 C420-C520-H5C20 109.5 C423-C323-H3B23 108.8 
C219-C319-H3B19 110.5 H5A20-C520-H5C20 109.5 C223-C323-H3B23 108.8 
H3A19-C319-H3B19 108.7 H5B20-C520-H5C20 109.5 H3A23-C323-H3B23 107.7 
N119-C519-C4A19 99.7(6) C420-C620-H6A20 109.5 C523-C423-C323 116.3(4) 
N119-C519-C4B19 101.5(7) C420-C620-H6B20 109.5 C523-C423-H4A23 108.2 
N119-C519-H5A19 111.8 H6A20-C620-H6B20 109.5 C323-C423-H4A23 108.2 
C4A19-C519-H5A19 111.8 C420-C620-H6C20 109.5 C523-C423-H4B23 108.2 
N119-C519-H5B19 111.8 H6A20-C620-H6C20 109.5 C323-C423-H4B23 108.2 
C4A19-C519-H5B19 111.8 H6B20-C620-H6C20 109.5 H4A23-C423-H4B23 107.4 
H5A19-C519-H5B19 109.6 C120-N121-C221 122.5(4) O223-C523-N117 122.2(4) 
N119-C519-H5A19 111.5 C120-N121-H121 118.8 O223-C523-C423 121.1(4) 
C4B19-C519-H5A19 111.5 C221-N121-H121 118.8 N117-C523-C423 116.6(4) 
N119-C519-H5B19 111.5 O121-C121-N122 123.4(4) C524-O324-H324 109.5 
C4B19-C519-H5B19 111.5 O121-C121-C221 122.6(4) C123-N124-C224 117.8(3) 
H5A19-C519-H5B19 109.3 N122-C121-C221 113.9(4) C123-N124-H124 121.1 
C319-C4A19-C519 107.8(7) N121-C221-C121 110.7(3) C224-N124-H124 121.1 
C319-C4A19-H4AA19 110.1 N121-C221-C321 110.5(4) O124-C124-N125 122.2(4) 
C519-C4A19-H4AA19 110.1 C121-C221-C321 109.7(4) O124-C124-C224 119.7(4) 
C319-C4A19-H4AB19 110.1 N121-C221-H221 108.7 N125-C124-C224 118.2(3) 
C519-C4A19-H4AB19 110.1 C121-C221-H221 108.7 N124-C224-C324 109.9(3) 
H4AA19-C4A19-H4AB19 108.5 C321-C221-H221 108.7 N124-C224-C124 111.8(3) 
C319-C4B19-C519 104.9(9) C221-C321-H3A21 109.5 C324-C224-C124 112.8(4) 
C319-C4B19-H4BA19 110.8 C221-C321-H3B21 109.5 N124-C224-H224 107.3 
C519-C4B19-H4BA19 110.8 H3A21-C321-H3B21 109.5 C324-C224-H224 107.3 
C319-C4B19-H4BB19 110.8 C221-C321-H3C21 109.5 C124-C224-H224 107.3 
C519-C4B19-H4BB19 110.8 H3A21-C321-H3C21 109.5 C224-C324-C424 110.6(4) 
H4BA19-C4B19-H4BB19 108.8 H3B21-C321-H3C21 109.5 C224-C324-H3A24 109.5 
C119-N120-C220 124.4(4) C121-N122-C222 124.3(4) C424-C324-H3A24 109.5 
C119-N120-H120 117.8 C121-N122-H122 117.9 C224-C324-H3B24 109.5 
C220-N120-H120 117.8 C222-N122-H122 117.9 C424-C324-H3B24 109.5 
O120-C120-N121 123.2(4) O122-C122-N123 123.6(4) H3A24-C324-H3B24 108.1 
O120-C120-C220 119.2(4) O122-C122-C222 120.1(4) C524-C424-C324 112.3(5) 
N121-C120-C220 117.7(4) N123-C122-C222 116.2(4) C524-C424-H4A24 109.1 
N120-C220-C320 110.3(4) N122-C222-C122 111.2(3) C324-C424-H4A24 109.1 
N120-C220-C120 110.0(4) N122-C222-H2A22 109.4 C524-C424-H4B24 109.1 
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Supplementary Table S11h. Bond lengths [Å] and angles [°] for  the -4 aa truncation of xanthomonin I. 
 
C324-C424-H4B24 109.1 C126-N127-H127 118.0 C329-N229-H2B29 120.0 
H4A24-C424-H4B24 107.9 C227-N127-H127 118.0 H2A29-N229-H2B29 120.0 
O224-C524-O324 123.3(6) O127-C127-N128 123.4(4) C329-C229-C429 110.0(4) 
O224-C524-C424 123.2(5) O127-C127-C227 121.5(4) C329-C229-H2C29 109.7 
O324-C524-C424 113.4(6) N128-C127-C227 115.1(4) C429-C229-H2C29 109.7 
C124-N125-C625 123.5(3) N127-C227-C127 110.5(4) C329-C229-H2D29 109.7 
C124-N125-H125 118.3 N127-C227-H2A27 109.6 C429-C229-H2D29 109.7 
C625-N125-H125 118.3 C127-C227-H2A27 109.6 H2C29-C229-H2D29 108.2 
O125-C125-N126 122.6(4) N127-C227-H2B27 109.6 O229-C329-N229 122.7(5) 
O125-C125-C625 119.5(4) C127-C227-H2B27 109.6 O229-C329-C229 122.1(5) 
N126-C125-C625 117.9(4) H2A27-C227-H2B27 108.1 N229-C329-C229 115.1(5) 
C425-C225-C325 112.4(4) C127-N128-C228 121.6(4) N129-C429-C229 110.5(4) 
C425-C225-C625 112.4(4) C127-N128-H128 119.2 N129-C429-C129 110.5(4) 
C325-C225-C625 110.6(4) C228-N128-H128 119.2 C229-C429-C129 108.9(4) 
C425-C225-H225 107.0 O128-C128-N129 123.2(4) N129-C429-H429 108.9 
C325-C225-H225 107.0 O128-C128-C228 119.0(4) C229-C429-H429 108.9 
C625-C225-H225 107.0 N129-C128-C228 117.7(4) C129-C429-H429 108.9 
C225-C325-H3A25 109.5 N128-C228-C128 113.9(4) C129-N130-C230 118.6(4) 
C225-C325-H3B25 109.5 N128-C228-C328 110.4(4) C129-N130-H130 120.7 
H3A25-C325-H3B25 109.5 C128-C228-C328 111.0(4) C230-N130-H130 120.7 
C225-C325-H3C25 109.5 N128-C228-H228 107.1 O130-C130-N131 118.8(5) 
H3A25-C325-H3C25 109.5 C128-C228-H228 107.1 O130-C130-C230 120.8(4) 
H3B25-C325-H3C25 109.5 C328-C228-H228 107.1 N131-C130-C230 120.3(4) 
C525-C425-C225 115.8(4) C428-C328-C228 111.5(4) N130-C230-C130 109.1(4) 
C525-C425-H4A25 108.3 C428-C328-H3A28 109.3 N130-C230-C330 110.2(4) 
C225-C425-H4A25 108.3 C228-C328-H3A28 109.3 C130-C230-C330 111.9(4) 
C525-C425-H4B25 108.3 C428-C328-H3B28 109.3 N130-C230-H230 108.5 
C225-C425-H4B25 108.3 C228-C328-H3B28 109.3 C130-C230-H230 108.5 
H4A25-C425-H4B25 107.4 H3A28-C328-H3B28 108.0 C330-C230-H230 108.5 
C425-C525-H5A25 109.5 C528-C428-C928 116.7(5) C430-C330-C530 111.4(5) 
C425-C525-H5B25 109.5 C528-C428-C328 122.0(5) C430-C330-C230 110.3(5) 
H5A25-C525-H5B25 109.5 C928-C428-C328 121.1(5) C530-C330-C230 111.3(5) 
C425-C525-H5C25 109.5 C428-C528-C628 121.6(6) C430-C330-H330 107.9 
H5A25-C525-H5C25 109.5 C428-C528-H528 119.2 C530-C330-H330 107.9 
H5B25-C525-H5C25 109.5 C628-C528-H528 119.2 C230-C330-H330 107.9 
N125-C625-C125 107.1(3) C728-C628-C528 120.1(6) C330-C430-H4A30 109.5 
N125-C625-C225 112.5(3) C728-C628-H628 119.9 C330-C430-H4B30 109.5 
C125-C625-C225 109.9(3) C528-C628-H628 119.9 H4A30-C430-H4B30 109.5 
N125-C625-H625 109.1 C628-C728-C828 120.5(6) C330-C430-H4C30 109.5 
C125-C625-H625 109.1 C628-C728-H728 119.8 H4A30-C430-H4C30 109.5 
C225-C625-H625 109.1 C828-C728-H728 119.8 H4B30-C430-H4C30 109.5 
C125-N126-C226 120.6(4) C928-C828-C728 119.7(6) C330-C530-H5A30 109.5 
C125-N126-H126 119.7 C928-C828-H828 120.1 C330-C530-H5B30 109.5 
C226-N126-H126 119.7 C728-C828-H828 120.1 H5A30-C530-H5B30 109.5 
O126-C126-N127 124.3(4) C828-C928-C428 121.3(6) C330-C530-H5C30 109.5 
O126-C126-C226 121.8(4) C828-C928-H928 119.3 H5A30-C530-H5C30 109.5 
N127-C126-C226 113.9(4) C428-C928-H928 119.3 H5B30-C530-H5C30 109.5 
N126-C226-C126 112.9(3) C128-N129-C429 123.2(4) C130-N131-C531 127.0(5) 
N126-C226-H2A26 109.0 C128-N129-H129 118.4 C130-N131-C231 120.1(4) 
C126-C226-H2A26 109.0 C429-N129-H129 118.4 C531-N131-C231 112.2(4) 
N126-C226-H2B26 109.0 O129-C129-N130 122.3(4) O131-C131-N132 123.5(5) 
C126-C226-H2B26 109.0 O129-C129-C429 121.6(4) O131-C131-C231 121.8(5) 
H2A26-C226-H2B26 107.8 N130-C129-C429 116.0(4) N132-C131-C231 114.6(4) 
C126-N127-C227 124.0(4) C329-N229-H2A29 120.0 N131-C231-C131 114.3(4) 
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Supplementary Table S11i. Bond lengths [Å] and angles [°] for  the -4 aa truncation of xanthomonin I. 
 
N131-C231-C331 103.4(5) N131-C531-C4A31 93.8(6) C331-C4A31-H4AA31 110.3 
C131-C231-C331 110.0(4) N131-C531-H5A31 109.7 C531-C4A31-H4AA31 110.3 
N131-C231-H231 109.7 C631-C531-H5A31 109.7 C331-C4A31-H4AB31 110.3 
C131-C231-H231 109.7 N131-C531-H5B31 109.7 C531-C4A31-H4AB31 110.3 
C331-C231-H231 109.7 C631-C531-H5B31 109.7 H4AA31-C4A31-H4AB31 108.6 
C4A31-C331-C231 105.1(7) H5A31-C531-H5B31 108.2 C131-N132-C232 122.2(4) 
C231-C331-C631 107.2(6) N131-C531-H5A31 113.0 C131-N132-H132 118.9 
C231-C331-H3A31 110.3 C4A31-C531-H5A31 113.0 C232-N132-H132 118.9 
C631-C331-H3A31 110.3 N131-C531-H5B31 113.0 O132-C132-O232 125.3(5) 
C231-C331-H3B31 110.3 C4A31-C531-H5B31 113.0 O132-C132-C232 124.4(5) 
C631-C331-H3B31 110.3 H5A31-C531-H5B31 110.4 O232-C132-C232 110.3(4) 
H3A31-C331-H3B31 108.5 C531-C631-C331 98.8(7) C132-O232-H232 109.5 
C4A31-C331-H3A31 110.7 C531-C631-H6A31 112.0 N132-C232-C132 110.2(4) 
C231-C331-H3A31 110.7 C331-C631-H6A31 112.0 N132-C232-H2A32 109.6 
C4A31-C331-H3B31 110.7 C531-C631-H6B31 112.0 C132-C232-H2A32 109.6 
C231-C331-H3B31 110.7 C331-C631-H6B31 112.0 N132-C232-H2B32 109.6 
H3A31-C331-H3B31 108.8 H6A31-C631-H6B31 109.7 C132-C232-H2B32 109.6 
N131-C531-C631 110.0(7) C331-C4A31-C531 107.0(7) H2A32-C232-H2B32 108.1 
 
 
Supplementary Table S12a. Anisotropic displacement parameters (Å
2
x 10
3
) for the -4 aa truncation of xanthomonin I.  
The anisotropic displacement factor exponent takes the form:  -2
2
[ h
2
 a*
2
U
11
 + ...  + 2 h k a* b* U
12
 ]. 
 
 U11 U22  U33 U23  U11 U22  U33 U23 
O(100) 36(2)  34(2) 25(1)  1(1) C22 33(2)  33(2) 33(2)  2(2) 
OH1 38(2)  100(3) 49(2)  10(2) O13 82(3)  80(3) 44(2)  10(2) 
C(100) 80(5)  103(6) 70(5)  -16(4) N13 34(2)  29(2) 39(2)  1(2) 
C(101) 129(8)  126(7) 114(7)  -25(6) C13 38(3)  38(2) 39(3)  11(2) 
C(102) 155(11)  113(7) 131(9)  -31(6) C23 31(2)  44(3) 47(3)  13(2) 
C(103) 190(16)  109(9) 310(20)  -2(11) C33 91(5)  39(3) 66(4)  16(3) 
C(104) 350(30)  340(30) 330(20)  160(20) C43 110(6)  40(3) 75(5)  9(3) 
C(105) 430(30)  370(30) 233(16)  158(18) C53 51(3)  33(2) 50(3)  -4(2) 
OH2 108(6)  87(5) 257(11)  28(6) O14 27(2)  39(2) 38(2)  3(2) 
OW1 37(2)  46(2) 31(2)  0(2) N14 31(2)  35(2) 29(2)  4(2) 
OW2 43(2)  53(2) 67(2)  -4(2) C14 33(2)  38(2) 18(2)  0(2) 
OW3 53(2)  50(2) 71(3)  -2(2) C24 38(3)  33(2) 27(2)  5(2) 
OW4 34(2)  43(2) 58(2)  -4(2) C34 43(3)  40(3) 39(2)  2(2) 
OW5 33(2)  65(2) 43(2)  11(2) C44 64(4)  43(3) 59(3)  0(3) 
OW6 33(2)  42(2) 35(2)  2(2) C54 100(6)  63(4) 76(5)  29(4) 
OW7 42(2)  52(2) 47(2)  8(2) C64 87(5)  52(4) 91(5)  -14(4) 
OW8 41(2)  74(3) 45(2)  20(2) C15 28(2)  35(2) 23(2)  0(2) 
OW15 52(2)  98(3) 45(2)  17(2) O15 43(2)  38(2) 28(2)  1(1) 
OW23 41(2)  164(6) 78(3)  4(4) C25 29(2)  35(2) 26(2)  1(2) 
C11 31(2)  33(2) 25(2)  -5(2) C35 37(2)  39(2) 27(2)  -1(2) 
O11 31(2)  35(2) 58(2)  5(2) N15 28(2)  33(2) 28(2)  1(2) 
C21 30(2)  33(2) 25(2)  2(2) C16 26(2)  35(2) 27(2)  -4(2) 
N11 32(2)  33(2) 23(2)  -2(2) O16 32(2)  45(2) 42(2)  9(2) 
N22 32(2)  38(2) 28(2)  4(2) N16 29(2)  35(2) 27(2)  0(2) 
C12 22(2)  33(2) 39(2)  1(2) C26 23(2)  43(3) 30(2)  -1(2) 
O12 35(2)  40(2) 36(2)  4(2) C17 26(2)  28(2) 23(2)  0(2) 
 
  
 S53 
 
Supplementary Table S12b. Anisotropic displacement parameters (Å
2
x 10
3
) for the -4 aa truncation of xanthomonin I.  
The anisotropic displacement factor exponent takes the form:  -2
2
[ h
2
 a*
2
U
11
 + ...  + 2 h k a* b* U
12
 ]. 
 
 U11 U22  U33 U23  U11 U22  U33 U23 
O17 33(2)  37(2) 20(1)  2(1) C114 32(2)  39(2) 30(2)  -4(2) 
C27 23(2)  32(2) 27(2)  1(2) C214 36(2)  38(2) 33(2)  -6(2) 
C47 27(2)  31(2) 23(2)  -1(2) C314 66(4)  42(3) 39(3)  -5(2) 
O37 38(2)  45(2) 21(1)  1(1) C414 123(6)  43(3) 59(4)  -2(3) 
C57 27(2)  32(2) 23(2)  1(2) C514 66(4)  84(5) 50(3)  -4(3) 
C67 29(2)  28(2) 27(2)  0(2) O115 52(2)  57(2) 32(2)  2(2) 
N17 26(2)  30(2) 26(2)  2(2) N115 33(2)  30(2) 33(2)  1(2) 
O18 42(2)  61(2) 23(2)  -8(2) C115 42(3)  34(2) 32(2)  4(2) 
N18 31(2)  34(2) 23(2)  -2(2) C215 39(3)  28(2) 38(2)  2(2) 
C18 29(2)  41(2) 25(2)  -2(2) C315 35(3)  36(2) 50(3)  3(2) 
O28 59(3)  141(5) 43(2)  -1(3) C415 37(3)  38(3) 47(3)  -1(2) 
C28 28(2)  42(2) 24(2)  -7(2) C515 37(3)  40(3) 42(3)  3(2) 
O38 45(2)  101(4) 48(2)  -3(2) O116 33(2)  44(2) 60(2)  -1(2) 
C38 42(3)  47(3) 36(2)  -2(2) N116 33(2)  45(2) 35(2)  3(2) 
C48 51(3)  67(4) 39(3)  2(3) C116 34(3)  38(2) 32(2)  1(2) 
C58 46(3)  48(3) 46(3)  -3(3) O216 34(2)  40(2) 55(2)  0(2) 
O19 31(2)  51(2) 23(2)  -2(1) C216 36(3)  43(3) 45(3)  6(2) 
N19 27(2)  37(2) 23(2)  -3(2) O117 32(2)  41(2) 49(2)  4(2) 
C19 18(2)  39(2) 30(2)  -1(2) N117 31(2)  28(2) 27(2)  -2(2) 
C29 24(2)  39(2) 24(2)  2(2) C117 34(2)  31(2) 29(2)  -2(2) 
C39 30(2)  47(3) 40(3)  5(2) C217 27(2)  36(2) 30(2)  3(2) 
C59 33(3)  51(3) 60(3)  7(3) O118 33(2)  35(2) 36(2)  0(2) 
C69 42(3)  47(3) 87(5)  -6(3) N118 27(2)  36(2) 35(2)  3(2) 
C79 26(2)  51(3) 58(3)  -5(3) C118 25(2)  31(2) 39(2)  1(2) 
O110 29(2)  35(2) 44(2)  1(2) C218 34(2)  29(2) 38(2)  -2(2) 
N110 28(2)  38(2) 22(2)  1(2) O119 44(2)  95(3) 40(2)  1(2) 
C110 26(2)  35(2) 20(2)  9(2) N119 34(2)  28(2) 40(2)  6(2) 
C210 27(2)  35(2) 35(2)  5(2) C119 34(3)  52(3) 36(2)  10(2) 
O111 27(2)  39(2) 33(2)  2(1) C219 30(2)  43(3) 43(3)  15(2) 
N111 20(2)  34(2) 30(2)  2(2) C319 62(4)  43(3) 57(3)  17(3) 
C111 23(2)  38(2) 21(2)  2(2) C519 46(3)  31(2) 56(3)  4(2) 
C211 27(2)  37(2) 29(2)  5(2) C4A19 38(6)  33(5) 58(7)  11(5) 
O112 54(2)  39(2) 63(2)  -16(2) C4B19 102(12)  38(6) 68(9)  14(6) 
N112 26(2)  28(2) 28(2)  3(2) O120 31(2)  40(2) 38(2)  -5(2) 
C112 29(2)  28(2) 42(3)  0(2) N120 28(2)  42(2) 29(2)  6(2) 
C212 28(2)  32(2) 32(2)  -4(2) C120 32(2)  38(2) 21(2)  3(2) 
C312 34(3)  52(3) 35(2)  -9(2) C220 36(2)  39(3) 28(2)  4(2) 
C412 34(2)  42(3) 28(2)  -6(2) C320 43(3)  37(2) 31(2)  2(2) 
C512 55(3)  41(3) 41(3)  -7(2) C420 77(4)  36(3) 72(4)  11(3) 
C612 60(4)  47(3) 58(3)  -17(3) C520 104(6)  55(4) 63(4)  7(3) 
C712 43(3)  75(4) 48(3)  -29(3) C620 70(5)  82(5) 170(10)  84(7) 
C812 45(3)  65(4) 34(3)  -7(3) O121 38(2)  34(2) 33(2)  -1(1) 
C912 49(3)  44(3) 30(2)  -4(2) N121 29(2)  32(2) 36(2)  3(2) 
O113 29(2)  52(2) 36(2)  -3(2) C121 25(2)  29(2) 25(2)  0(2) 
N213 26(2)  64(3) 55(3)  4(2) C221 29(2)  31(2) 28(2)  2(2) 
N113 22(2)  36(2) 28(2)  1(2) C321 44(3)  42(3) 27(2)  0(2) 
C113 26(2)  35(2) 35(2)  -4(2) O122 28(2)  30(2) 38(2)  1(1) 
C213 27(2)  31(2) 32(2)  -5(2) N122 28(2)  32(2) 29(2)  0(2) 
O313 36(2)  72(3) 42(2)  7(2) C122 24(2)  33(2) 23(2)  -5(2) 
C313 33(2)  38(2) 41(3)  -8(2) C222 23(2)  37(2) 33(2)  5(2) 
C413 29(2)  36(2) 46(3)  0(2) O123 31(2)  43(2) 24(2)  5(1) 
O114 38(2)  43(2) 41(2)  -6(2) N123 24(2)  31(2) 27(2)  9(2) 
N114 32(2)  43(2) 32(2)  -8(2) C123 21(2)  30(2) 26(2)  3(2) 
 
Supplementary Table S12c. Anisotropic displacement parameters (Å
2
x 10
3
) for the -4 aa truncation of xanthomonin I.  
The anisotropic displacement factor exponent takes the form:  -2
2
[ h
2
 a*
2
U
11
 + ...  + 2 h k a* b* U
12
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 U11 U22  U33 U23  U11 U22  U33 U23 
O223 37(2)  37(2) 25(2)  1(1) C428 43(3)  36(2) 34(2)  -9(2) 
C223 26(2)  30(2) 23(2)  3(2) C528 70(4)  40(3) 35(3)  -7(2) 
C323 26(2)  30(2) 28(2)  4(2) C628 84(5)  60(4) 44(3)  -18(3) 
C423 25(2)  34(2) 30(2)  1(2) C728 60(4)  68(4) 62(4)  -34(4) 
C523 25(2)  31(2) 27(2)  4(2) C828 62(4)  50(3) 62(4)  -21(3) 
O124 29(2)  38(2) 23(1)  -3(1) C928 59(3)  43(3) 40(3)  -9(2) 
O324 99(4)  34(2) 115(4)  5(2) O129 26(2)  49(2) 34(2)  0(2) 
N124 28(2)  31(2) 22(2)  -1(2) N129 27(2)  28(2) 31(2)  -1(2) 
C124 21(2)  32(2) 24(2)  0(2) C129 29(2)  31(2) 31(2)  0(2) 
O224 83(3)  52(2) 56(2)  15(2) O229 55(2)  70(3) 38(2)  10(2) 
C224 30(2)  30(2) 23(2)  -4(2) N229 38(2)  63(3) 64(3)  7(3) 
C324 38(2)  30(2) 30(2)  0(2) C229 28(2)  34(2) 35(2)  1(2) 
C424 55(3)  32(2) 32(2)  0(2) C329 33(3)  35(2) 47(3)  -1(2) 
C524 63(4)  39(3) 46(3)  4(3) C429 27(2)  34(2) 30(2)  -1(2) 
O125 25(2)  36(2) 24(2)  1(1) O130 33(2)  53(2) 55(2)  -6(2) 
N125 23(2)  30(2) 22(2)  1(2) N130 25(2)  44(2) 33(2)  2(2) 
C125 20(2)  30(2) 24(2)  3(2) C130 28(2)  46(3) 32(2)  1(2) 
C225 24(2)  33(2) 32(2)  -1(2) C230 35(2)  46(3) 31(2)  5(2) 
C325 26(2)  39(3) 59(3)  -5(2) C330 41(3)  57(3) 39(3)  9(3) 
C425 25(2)  36(2) 45(3)  -1(2) C430 77(4)  69(4) 53(3)  15(3) 
C525 36(3)  44(3) 54(3)  -5(3) C530 76(4)  78(4) 38(3)  12(3) 
C625 26(2)  29(2) 23(2)  2(2) O131 36(2)  57(2) 31(2)  5(2) 
O126 28(2)  31(2) 53(2)  1(2) N131 35(2)  49(2) 31(2)  0(2) 
N126 25(2)  30(2) 21(2)  -1(2) C131 34(2)  51(3) 24(2)  -1(2) 
C126 23(2)  32(2) 21(2)  4(2) C231 44(3)  53(3) 37(3)  -9(2) 
C226 25(2)  28(2) 27(2)  1(2) C331 26(3)  98(5) 73(4)  -39(4) 
O127 28(2)  38(2) 37(2)  1(2) C531 48(3)  67(4) 62(4)  15(3) 
N127 22(2)  33(2) 37(2)  -2(2) C631 24(6)  58(8) 35(7)  -7(6) 
C127 26(2)  35(2) 23(2)  -6(2) C4A31 37(5)  52(6) 51(7)  -5(5) 
C227 24(2)  39(2) 26(2)  1(2) O132 31(2)  98(3) 60(2)  -31(2) 
O128 51(2)  40(2) 70(3)  -12(2) N132 37(2)  50(2) 29(2)  3(2) 
N128 25(2)  32(2) 31(2)  -3(2) C132 32(3)  46(3) 39(3)  -3(2) 
C128 29(2)  32(2) 39(2)  -2(2) O232 33(2)  51(2) 34(2)  -6(2) 
C228 30(2)  31(2) 37(2)  -2(2) C232 33(2)  57(3) 32(2)  -1(2) 
C328 38(3)  43(3) 38(3)  -8(2)      
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Supplementary Table S13a. Hydrogen coordinates (Å x 104) and isotropic displacement parameters  
(Å2 x 10 3) for the -4 aa truncation of xanthomonin I. 
 x  y  z  U(eq)  x  y  z  U(eq) 
H(101) 8905 6433 6531 47 H3A8 6237 5735 9167 50 
H(102) 8862 6496 5522 47 H3B8 7046 5504 8836 50 
H(6) 4381 7679 9473 94 H4A8 5609 5615 7406 63 
H(10A) 4693 7928 11178 102 H4B8 6074 5302 7711 63 
H(10B) 3641 7840 10749 102 H19 6274 6323 8885 35 
H(10C) 4877 8253 9765 148 H29 5202 6558 7332 35 
H(10D) 3765 8190 9491 148 H39 4675 6601 9318 47 
H(10E) 4385 8478 11227 159 H5A9 4396 6114 8826 57 
H(10F) 3277 8431 10888 159 H5B9 3396 6276 9038 57 
H(10G) 3659 8906 10501 243 H6A9 3092 6322 7373 88 
H(10H) 3518 8727 9530 243 H6B9 3206 5983 7692 88 
H(10I) 5331 8950 10188 410 H6C9 4079 6148 7179 88 
H(10J) 5142 8787 9188 410 H7A9 3662 6821 7650 67 
HH2 4561 9310 7800 227 H7B9 4127 7016 8507 67 
H2A1 6872 7346 11484 35 H7C9 3196 6814 8694 67 
H2B1 6263 7354 10484 35 H110 6067 6946 6845 35 
H11 7401 7067 9815 35 H2A10 6330 7424 7970 39 
H22 6173 7810 9959 39 H2B10 6702 7397 6893 39 
H2A2 7831 8157 9858 40 H111 7711 7673 8353 34 
H2B2 6817 8303 10133 40 H2A11 9492 7394 8420 37 
H23 6096 8519 7305 49 H2B11 9066 7501 9424 37 
H3A3 7173 8958 6746 78 H112 10775 7728 8895 33 
H3B3 6463 8991 7643 78 H212 10409 8317 8424 37 
H4A3 7920 9110 8340 90 H3A12 11597 8113 9992 49 
H4B3 8487 8866 7720 90 H3B12 11786 8434 9548 49 
H5A3 8335 8602 9095 54 H512 10672 8834 9828 55 
H5B3 7336 8765 9363 54 H612 9398 9036 10719 66 
H14 8200 8175 7186 38 H712 8482 8728 11683 66 
H24 8116 8145 5188 39 H812 8795 8221 11734 58 
H3A4 9891 8225 6251 49 H912 10031 8018 10831 49 
H3B4 9854 8134 5140 49 H2A13 14998 7810 8080 58 
H44 9137 8678 5884 66 H2B13 14812 7805 6994 58 
H5A4 9285 8555 3874 119 H113 11254 7821 7275 34 
H5B4 8781 8838 4345 119 H213 12943 8090 6639 36 
H5C4 8288 8518 4426 119 H3A13 12645 7462 6932 45 
H6A4 10861 8584 4828 114 H3B13 13504 7579 6276 45 
H6B4 10837 8654 5957 114 H114 13224 8072 5015 43 
H6C4 10495 8900 5192 114 H214 11684 8011 3788 43 
H25 8885 7206 6105 36 H314 12762 8072 2514 59 
H3A5 9351 7260 4481 51 H4A14 13212 8563 2883 112 
H3B5 9899 6983 4970 51 H4B14 13026 8503 3999 112 
H3C5 10461 7290 4828 51 H4C14 12140 8494 3235 112 
H15 9909 7737 6018 36 H5A14 14127 7826 3087 99 
H16 10020 6810 6546 37 H5B14 14312 8074 3892 99 
H2A6 11282 6974 8036 38 H5C14 14412 8155 2777 99 
H2B6 11570 6714 7315 38 H215 11887 7064 3133 42 
H2A7 9320 6686 10800 33 H3A15 10739 7013 1644 49 
H2B7 9366 6924 9950 33 H3B15 10306 7100 2673 49 
H4A7 7892 6705 9274 32 H4A15 9778 7490 1724 49 
H4B7 8007 6447 10060 32 H4B15 10776 7501 1148 49 
H57 9451 6277 9361 33 H5A15 11109 7871 2243 48 
H17 9313 6768 8148 33 H5B15 10452 7720 3054 48 
H18 7870 5975 9283 35 H116 13551 7205 2792 45 
H2A8 7379 5802 7489 38 H216 14447 6471 1506 65 
H38 3698 5317 8298 97 H2A16 14800 7305 1794 49 
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Supplementary Table S13b. Hydrogen coordinates (Å x 104) and isotropic displacement parameters 
(Å2 x 10 3) for the -4 aa truncation of xanthomonin I. 
 x  y  z  U(eq)  x  y  z  U(eq) 
H2B16 14134 7199 900 49 H3B25 3738 6106 5115 62 
H117 7044 5825 2501 34 H3C25 4065 5932 4173 62 
H2A17 6485 5521 854 37 H4A25 4131 6845 4114 43 
H2B17 5884 5529 1827 37 H4B25 3123 6681 3904 43 
H118 5791 5082 2389 39 H5A25 3119 6904 5435 67 
H2A18 7461 4747 2741 40 H5B25 4049 6714 5765 67 
H2B18 6455 4590 2447 40 H5C25 3035 6552 5552 67 
H219 5567 4513 5285 46 H625 5324 6412 5178 31 
H3A19 6636 4109 6211 65 H126 6115 5994 5513 31 
H3B19 5886 4021 5349 65 H2A26 6106 5537 4231 32 
H3A19 7028 4117 5970 65 H2B26 6503 5515 5320 32 
H3B19 5890 4050 5816 65 H127 7490 5230 4087 37 
H5A19 7783 4289 3680 53 H2A27 9297 5489 3948 35 
H5B19 6730 4139 3495 53 H2B27 8825 5352 2980 35 
H5A19 7862 4247 4094 53 H128 10530 5134 3633 35 
H5B19 7019 4219 3272 53 H228 10121 4565 4282 39 
H4AA19 7281 3852 4773 52 H3A28 11351 4708 2714 48 
H4AB19 7898 4121 5239 52 H3B28 11403 4389 3220 48 
H4BA19 6049 3934 4238 84 H528 9972 4828 1635 58 
H4BB19 7094 3826 4641 84 H628 8622 4672 726 76 
H120 7850 4755 5385 40 H728 7954 4216 993 76 
H220 7895 4877 7337 41 H828 8643 3897 2146 69 
H3A20 9538 4736 6215 45 H928 9955 4055 3096 56 
H3B20 9597 4819 7332 45 H129 11162 5107 5171 34 
H420 8677 4298 6577 75 H2A29 14868 5133 4855 65 
H5A20 10034 4040 7204 111 H2B29 14573 5123 5905 65 
H5B20 10507 4344 7584 111 H2C29 12390 5451 5709 39 
H5C20 10383 4284 6452 111 H2D29 13224 5346 6458 39 
H6A20 7944 4416 8004 160 H429 12787 4829 5971 36 
H6B20 8969 4466 8543 160 H130 13009 4809 7612 41 
H6C20 8644 4140 8219 160 H230 11466 4799 8757 45 
H121 9741 5205 6368 39 H330 13482 4844 9344 55 
H221 8866 5761 6240 35 H4A30 13201 4403 8542 100 
H3A21 10535 5641 7452 56 H4B30 12274 4332 9173 100 
H3B21 9490 5733 7827 56 H4C30 13336 4324 9662 100 
H3C21 10123 5968 7247 56 H5A30 12426 5005 10591 97 
H122 9846 6124 5599 36 H5B30 13083 4726 10901 97 
H2A22 10998 5949 4102 37 H5C30 11967 4679 10600 97 
H2B22 11408 6198 4826 37 H231 10945 5737 9037 54 
H123 9073 6143 3999 33 H3A31 9585 5794 9857 79 
H223 9141 6638 2795 32 H3B31 10017 5628 10796 79 
H3A23 7552 6222 2961 34 H3A31 9921 5770 10602 79 
H3B23 7640 6466 2133 34 H3B31 9456 5663 9586 79 
H4A23 8870 6208 1418 35 H5A31 10409 5007 10228 70 
H4B23 8974 5986 2310 35 H5B31 10180 4982 9094 70 
H324 7126 8230 2823 123 H5A31 10465 4928 9912 70 
H124 7622 6955 2875 32 H5B31 9857 5098 9059 70 
H224 7356 7154 4662 33 H6A31 8985 5235 10234 47 
H3A24 5989 7424 3971 39 H6B31 9056 5338 9122 47 
H3B24 6210 7267 2965 39 H4AA31 9161 5313 10531 56 
H4A24 7624 7625 3997 47 H4AB31 10212 5335 11051 56 
H4B24 7773 7487 2950 47 H132 11716 6119 9629 47 
H125 6061 6618 3446 30 H232 11646 6516 12797 59 
H225 4299 6375 3350 36 H2A32 12595 6411 10614 48 
H3A25 3066 6113 4159 62 H2B32 12890 6123 11231 48 
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Supplementary Table S14a. Torsion angles [°] for the -4 aa truncation of xanthomonin I. 
 
OH1-C(100)-C(101)-C(102) -170.7(10) C47-C57-C67-O37 110.0(4) O112-C112-N113-C213 6.4(7) 
C(100)-C(101)-C(102)-C(103) 175.8(13) N17-C57-C67-N18 175.6(4) C212-C112-N113-C213 -174.6(4) 
C(101)-C(102)-C(103)-C(104) -65(3) C47-C57-C67-N18 -64.6(5) C112-N113-C213-C113 -126.3(4) 
C(102)-C(103)-C(104)-C(105) -176(2) O16-C16-N17-C57 -2.5(7) C112-N113-C213-C313 113.5(5) 
C(103)-C(104)-C(105)-OH2 -91(4) C26-C16-N17-C57 176.9(4) O113-C113-C213-N113 -32.3(6) 
O11-C11-C21-N11 -53.1(5) C67-C57-N17-C16 -109.8(4) N114-C113-C213-N113 151.6(4) 
N22-C11-C21-N11 126.3(4) C47-C57-N17-C16 133.2(4) O113-C113-C213-C313 89.0(5) 
C11-C21-N11-C17 88.9(5) O37-C67-N18-C28 -3.1(6) N114-C113-C213-C313 -87.1(5) 
O11-C11-N22-C22 2.8(7) C57-C67-N18-C28 171.6(4) N113-C213-C313-C413 -73.3(5) 
C21-C11-N22-C22 -176.5(4) C67-N18-C28-C38 176.5(4) C113-C213-C313-C413 164.9(4) 
C11-N22-C22-C12 127.6(4) C67-N18-C28-C18 -60.0(5) C213-C313-C413-O313 86.9(6) 
O12-C12-C22-N22 1.4(6) O18-C18-C28-N18 143.2(4) C213-C313-C413-N213 -91.0(5) 
N13-C12-C22-N22 -179.8(4) N19-C18-C28-N18 -40.7(5) O113-C113-N114-C214 -2.2(7) 
O12-C12-N13-C53 -178.8(4) O18-C18-C28-C38 -95.0(5) C213-C113-N114-C214 173.9(4) 
C22-C12-N13-C53 2.4(6) N19-C18-C28-C38 81.1(5) C113-N114-C214-C114 -69.3(5) 
O12-C12-N13-C23 10.8(7) N18-C28-C38-C48 -177.8(4) C113-N114-C214-C314 167.8(4) 
C22-C12-N13-C23 -168.0(4) C18-C28-C38-C48 59.4(6) O114-C114-C214-N114 -33.8(6) 
C12-N13-C23-C13 -77.8(6) C28-C38-C48-C58 -140.6(5) N115-C114-C214-N114 151.1(4) 
C53-N13-C23-C13 110.7(5) C38-C48-C58-O28 -17.1(9) O114-C114-C214-C314 89.9(6) 
C12-N13-C23-C33 160.8(5) C38-C48-C58-O38 162.4(5) N115-C114-C214-C314 -85.2(5) 
C53-N13-C23-C33 -10.7(5) O18-C18-N19-C29 -6.0(7) N114-C214-C314-C514 60.6(6) 
O13-C13-C23-N13 175.5(5) C28-C18-N19-C29 178.1(4) C114-C214-C314-C514 -62.5(6) 
N14-C13-C23-N13 -5.5(7) C18-N19-C29-C19 -118.8(4) N114-C214-C314-C414 -66.4(7) 
O13-C13-C23-C33 -67.8(7) C18-N19-C29-C39 120.2(5) C114-C214-C314-C414 170.4(6) 
N14-C13-C23-C33 111.2(6) O19-C19-C29-N19 -70.7(5) O114-C114-N115-C515 170.0(4) 
N13-C23-C33-C43 29.4(6) N110-C19-C29-N19 108.5(4) C214-C114-N115-C515 -14.8(7) 
C13-C23-C33-C43 -96.6(6) O19-C19-C29-C39 51.3(5) O114-C114-N115-C215 2.1(7) 
C23-C33-C43-C53 -37.9(7) N110-C19-C29-C39 -129.5(4) C214-C114-N115-C215 177.2(4) 
C12-N13-C53-C43 176.9(5) N19-C29-C39-C79 179.2(4) C114-N115-C215-C315 156.5(4) 
C23-N13-C53-C43 -11.9(6) C19-C29-C39-C79 60.0(5) C515-N115-C215-C315 -13.0(5) 
C33-C43-C53-N13 30.4(7) N19-C29-C39-C59 -54.1(5) C114-N115-C215-C115 -82.7(5) 
O13-C13-N14-C24 3.1(8) C19-C29-C39-C59 -173.3(4) C515-N115-C215-C115 107.7(4) 
C23-C13-N14-C24 -175.9(4) C79-C39-C59-C69 62.1(6) O115-C115-C215-N115 -112.3(5) 
C13-N14-C24-C34 104.9(5) C29-C39-C59-C69 -63.3(6) N116-C115-C215-N115 68.3(5) 
C13-N14-C24-C14 -126.4(5) O19-C19-N110-C210 -2.7(6) O115-C115-C215-C315 2.3(7) 
O14-C14-C24-N14 63.3(5) C29-C19-N110-C210 178.1(4) N116-C115-C215-C315 -177.2(4) 
N15-C14-C24-N14 -118.6(4) C19-N110-C210-C110 70.7(5) N115-C215-C315-C415 31.7(5) 
O14-C14-C24-C34 -169.9(4) O110-C110-C210-N110 23.3(6) C115-C215-C315-C415 -87.2(5) 
N15-C14-C24-C34 8.2(6) N111-C110-C210-N110 -157.8(4) C215-C315-C415-C515 -39.3(5) 
N14-C24-C34-C44 -65.8(6) O110-C110-N111-C211 -0.2(6) C114-N115-C515-C415 -179.7(4) 
C14-C24-C34-C44 169.2(4) C210-C110-N111-C211 -179.1(4) C215-N115-C515-C415 -10.7(5) 
C24-C34-C44-C64 175.7(5) C110-N111-C211-C111 144.2(4) C315-C415-C515-N115 30.4(5) 
C24-C34-C44-C54 -59.0(7) O111-C111-C211-N111 14.4(6) O115-C115-N116-C216 3.3(8) 
O15-C15-C25-N15 -7.1(6) N112-C111-C211-N111 -167.8(4) C215-C115-N116-C216 -177.2(4) 
N16-C15-C25-N15 172.0(4) O111-C111-N112-C212 1.3(6) C115-N116-C216-C116 -100.0(6) 
O15-C15-C25-C35 113.9(5) C211-C111-N112-C212 -176.5(4) O116-C116-C216-N116 -130.1(5) 
N16-C15-C25-C35 -67.0(5) C111-N112-C212-C112 -120.5(4) O216-C116-C216-N116 49.9(6) 
O14-C14-N15-C25 4.6(6) C111-N112-C212-C312 113.2(4) C523-N117-C217-C117 92.9(5) 
C24-C14-N15-C25 -173.3(4) O112-C112-C212-N112 -165.3(4) O117-C117-C217-N117 -52.8(6) 
C35-C25-N15-C14 100.9(5) N113-C112-C212-N112 15.7(6) N118-C117-C217-N117 126.6(4) 
C15-C25-N15-C14 -137.4(4) O112-C112-C212-C312 -39.0(6) O117-C117-N118-C218 6.3(7) 
O15-C15-N16-C26 1.0(7) N113-C112-C212-C312 141.9(4) C217-C117-N118-C218 -173.0(4) 
C25-C15-N16-C26 -178.0(4) N112-C212-C312-C412 -77.6(5) C117-N118-C218-C118 126.1(4) 
C15-N16-C26-C16 129.9(5) C112-C212-C312-C412 155.0(4) O118-C118-C218-N118 -4.6(6) 
O16-C16-C26-N16 151.4(4) C212-C312-C412-C512 -92.5(6) N119-C118-C218-N118 176.6(4) 
N17-C16-C26-N16 -28.0(6) C212-C312-C412-C912 85.2(6) O118-C118-N119-C519 180.0(4) 
C21-N11-C17-O17 9.0(6) C912-C412-C512-C612 0.4(8) C218-C118-N119-C519 -1.3(7) 
C21-N11-C17-C27 -170.7(4) C312-C412-C512-C612 178.3(5) O118-C118-N119-C219 11.8(6) 
O17-C17-C27-C47 137.3(4) C412-C512-C612-C712 0.6(9) C218-C118-N119-C219 -169.4(4) 
N11-C17-C27-C47 -43.1(5) C512-C612-C712-C812 -0.9(9) C118-N119-C219-C119 -74.5(6) 
C17-C27-C47-C57 170.8(3) C612-C712-C812-C912 0.2(9) C519-N119-C219-C119 115.9(5) 
C27-C47-C57-N17 -55.6(5) C712-C812-C912-C412 0.8(8) C118-N119-C219-C319 165.5(4) 
C27-C47-C57-C67 -174.5(4) C512-C412-C912-C812 -1.2(7) C519-N119-C219-C319 -4.0(5) 
N17-C57-C67-O37 -9.7(6) C312-C412-C912-C812 -178.9(5) O119-C119-C219-N119 164.2(5) 
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Supplementary Table S14b. Torsion angles [°] for the -4 aa truncation of xanthomonin I. 
 
N120-C119-C219-N119 -21.4(7) C323-C423-C523-N117 -44.9(5) O128-C128-N129-C429 3.7(7) 
O119-C119-C219-C319 -79.9(6) O123-C123-N124-C224 1.4(6) C228-C128-N129-C429 -179.9(4) 
N120-C119-C219-C319 94.5(5) C223-C123-N124-C224 175.4(3) C429-C229-C329-O229 90.4(6) 
N119-C219-C319-C4A19 24.1(7) C123-N124-C224-C324 172.8(4) C429-C229-C329-N229 -88.2(5) 
C119-C219-C319-C4A19 -99.8(7) C123-N124-C224-C124 -61.1(5) C128-N129-C429-C229 130.4(4) 
N119-C219-C319-C4B19 -17.1(9) O124-C124-C224-N124 151.5(4) C128-N129-C429-C129 -108.9(5) 
C119-C219-C319-C4B19 -141.1(9) N125-C124-C224-N124 -28.9(5) C329-C229-C429-N129 -76.9(5) 
C118-N119-C519-C4A19 174.7(6) O124-C124-C224-C324 -84.0(5) C329-C229-C429-C129 161.5(4) 
C219-N119-C519-C4A19 -16.5(7) N125-C124-C224-C324 95.6(4) O129-C129-C429-N129 -34.0(6) 
C118-N119-C519-C4B19 -146.0(8) N124-C224-C324-C424 -69.0(5) N130-C129-C429-N129 148.3(4) 
C219-N119-C519-C4B19 22.8(8) C124-C224-C324-C424 165.5(4) O129-C129-C429-C229 87.6(5) 
C4B19-C319-C4A19-C519 62.8(10) C224-C324-C424-C524 -174.9(4) N130-C129-C429-C229 -90.1(5) 
C219-C319-C4A19-C519 -36.2(9) C324-C424-C524-O224 -28.5(7) O129-C129-N130-C230 -2.3(7) 
N119-C519-C4A19-C319 32.5(9) C324-C424-C524-O324 154.9(5) C429-C129-N130-C230 175.4(4) 
C4B19-C519-C4A19-C319 -63.9(12) O124-C124-N125-C625 -12.8(6) C129-N130-C230-C130 -59.9(5) 
C4A19-C319-C4B19-C519 -60.8(10) C224-C124-N125-C625 167.6(4) C129-N130-C230-C330 176.9(4) 
C219-C319-C4B19-C519 31.4(12) C325-C225-C425-C525 53.6(6) O130-C130-C230-N130 -47.7(6) 
N119-C519-C4B19-C319 -32.4(11) C625-C225-C425-C525 -72.0(5) N131-C130-C230-N130 134.6(4) 
C4A19-C519-C4B19-C319 58.7(10) C124-N125-C625-C125 -130.6(4) O130-C130-C230-C330 74.5(6) 
O119-C119-N120-C220 6.8(8) C124-N125-C625-C225 108.6(4) N131-C130-C230-C330 -103.1(5) 
C219-C119-N120-C220 -167.3(4) O125-C125-C625-N125 -62.0(5) N130-C230-C330-C430 -62.3(6) 
C119-N120-C220-C320 120.5(5) N126-C125-C625-N125 119.6(4) C130-C230-C330-C430 176.2(5) 
C119-N120-C220-C120 -111.5(5) O125-C125-C625-C225 60.4(5) N130-C230-C330-C530 173.6(5) 
O120-C120-C220-N120 59.1(5) N126-C125-C625-C225 -118.0(4) C130-C230-C330-C530 52.1(6) 
N121-C120-C220-N120 -120.9(4) C425-C225-C625-N125 -60.9(5) O130-C130-N131-C531 175.2(5) 
O120-C120-C220-C320 -175.6(4) C325-C225-C625-N125 172.6(4) C230-C130-N131-C531 -7.1(7) 
N121-C120-C220-C320 4.4(6) C425-C225-C625-C125 179.9(4) O130-C130-N131-C231 5.5(7) 
N120-C220-C320-C420 -59.0(6) C325-C225-C625-C125 53.4(5) C230-C130-N131-C231 -176.8(4) 
C120-C220-C320-C420 175.8(4) O125-C125-N126-C226 -5.3(6) C130-N131-C231-C131 -64.3(6) 
C220-C320-C420-C620 -61.7(7) C625-C125-N126-C226 173.0(4) C531-N131-C231-C131 124.6(5) 
C220-C320-C420-C520 175.2(5) C125-N126-C226-C126 78.6(5) C130-N131-C231-C331 176.2(5) 
O120-C120-N121-C221 8.4(7) O126-C126-C226-N126 7.7(6) C531-N131-C231-C331 5.1(6) 
C220-C120-N121-C221 -171.6(4) N127-C126-C226-N126 -170.9(3) O131-C131-C231-N131 -37.6(7) 
C120-N121-C221-C121 -134.4(4) O126-C126-N127-C227 0.9(7) N132-C131-C231-N131 147.0(4) 
C120-N121-C221-C321 104.0(5) C226-C126-N127-C227 179.6(4) O131-C131-C231-C331 78.1(7) 
O121-C121-C221-N121 -17.5(5) C126-N127-C227-C127 144.6(4) N132-C131-C231-C331 -97.2(6) 
N122-C121-C221-N121 164.4(4) O127-C127-C227-N127 14.4(6) N131-C231-C331-C4A31 24.3(7) 
O121-C121-C221-C321 104.6(5) N128-C127-C227-N127 -167.1(4) C131-C231-C331-C4A31 -98.1(7) 
N122-C121-C221-C321 -73.5(5) O127-C127-N128-C228 2.2(6) N131-C231-C331-C631 -21.0(8) 
O121-C121-N122-C222 0.9(6) C227-C127-N128-C228 -176.2(4) C131-C231-C331-C631 -143.4(7) 
C221-C121-N122-C222 178.9(4) C127-N128-C228-C128 -121.0(4) C130-N131-C531-C631 -155.6(7) 
C121-N122-C222-C122 139.7(4) C127-N128-C228-C328 113.4(5) C231-N131-C531-C631 14.7(8) 
O122-C122-C222-N122 142.5(4) O128-C128-C228-N128 -172.7(4) C130-N131-C531-C4A31 164.5(6) 
N123-C122-C222-N122 -38.4(5) N129-C128-C228-N128 10.7(6) C231-N131-C531-C4A31 -25.1(6) 
O122-C122-N123-C223 0.5(6) O128-C128-C228-C328 -47.4(6) N131-C531-C631-C331 -25.5(9) 
C222-C122-N123-C223 -178.6(4) N129-C128-C228-C328 136.0(4) C4A31-C531-C631-C331 47.3(7) 
C122-N123-C223-C123 -102.2(4) N128-C228-C328-C428 -71.4(5) C4A31-C331-C631-C531 -65.3(8) 
C122-N123-C223-C323 140.9(4) C128-C228-C328-C428 161.4(4) C231-C331-C631-C531 28.6(9) 
O123-C123-C223-N123 -12.9(5) C228-C328-C428-C528 92.6(6) C231-C331-C4A31-C531 -41.6(8) 
N124-C123-C223-N123 173.4(3) C228-C328-C428-C928 -83.0(6) C631-C331-C4A31-C531 57.8(8) 
O123-C123-C223-C323 105.7(4) C928-C428-C528-C628 -1.3(8) N131-C531-C4A31-C331 42.1(8) 
N124-C123-C223-C323 -68.1(4) C328-C428-C528-C628 -177.1(5) C631-C531-C4A31-C331 -73.8(10) 
N123-C223-C323-C423 -54.6(5) C428-C528-C628-C728 0.4(9) O131-C131-N132-C232 -12.3(7) 
C123-C223-C323-C423 -172.3(4) C528-C628-C728-C828 -0.7(10) C231-C131-N132-C232 162.9(4) 
C223-C323-C423-C523 169.4(4) C628-C728-C828-C928 1.8(10) C131-N132-C232-C132 -76.5(6) 
C217-N117-C523-O223 6.2(6) C728-C828-C928-C428 -2.7(9) O132-C132-C232-N132 -9.9(8) 
C217-N117-C523-C423 -171.0(4) C528-C428-C928-C828 2.4(7) O232-C132-C232-N132 172.2(4) 
C323-C423-C523-O223 137.9(4) C328-C428-C928-C828 178.3(5)   
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Supplementary Table S15. Hydrogen bonds for the -4 aa truncation of xanthomonin I [Å and °]. 
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
 O(100)-H(101)...O37 0.91 1.68 2.582(4) 171.1 
 O(100)-H(102)...O123 0.98 1.66 2.608(4) 162.2 
 O(100)-H(102)...N123 0.98 2.69 3.292(5) 120.2 
 OH1-H(6)...N213#1 0.84 2.69 3.347(7) 136.3 
 OH1-H(6)...O313#1 0.84 1.87 2.700(6) 167.8 
 OH2-HH2...OW11 0.84 2.14 2.777(13) 132.6 
 OH2-HH2...OW21 0.84 2.07 2.64(2) 125.2 
 N11-H11...O19 0.88 2.10 2.800(5) 135.5 
 N22-H22...OH1 0.88 2.07 2.936(6) 169.1 
 N14-H14...O111 0.88 1.91 2.770(5) 164.8 
 N15-H15...O113 0.88 2.14 2.858(5) 138.3 
 N16-H16...O(100) 0.88 1.88 2.740(5) 164.8 
 N17-H17...O110 0.88 2.01 2.834(5) 156.5 
 N18-H18...O223#2 0.88 1.91 2.782(5) 172.9 
 O38-H38...O130#1 0.84 1.79 2.561(6) 151.4 
 O38-H38...N130#1 0.84 2.69 3.199(6) 120.0 
 N19-H19...OW1 0.88 2.10 2.949(5) 160.8 
 N110-H110...O124 0.88 2.09 2.932(5) 159.8 
 N111-H111...O12 0.88 2.32 3.178(5) 165.2 
 N112-H112...OW8 0.88 1.98 2.854(5) 171.2 
 N213-H2A13...O12#3 0.88 2.16 2.837(5) 132.8 
 N213-H2B13...OW3 0.88 2.18 3.027(7) 161.8 
 N113-H113...O15 0.88 1.99 2.800(5) 152.5 
 N114-H114...OW2 0.88 2.16 3.028(6) 169.0 
 N116-H116...O114 0.88 2.10 2.852(5) 142.7 
 O216-H216...OW6 0.84 1.81 2.648(5) 172.7 
 N117-H117...O125 0.88 2.18 2.915(5) 140.2 
 N118-H118...OW5 0.88 2.04 2.920(5) 174.4 
 N120-H120...O127 0.88 1.97 2.809(5) 158.7 
 N121-H121...O129 0.88 2.19 2.894(5) 136.9 
 N122-H122...O(100) 0.88 1.88 2.729(5) 161.6 
 N123-H123...O126 0.88 1.96 2.793(5) 158.1 
 O324-H324...OW14 0.84 1.97 2.778(14) 161.4 
 O324-H324...OW16 0.84 1.87 2.638(14) 151.7 
 O324-H324...OW30 0.84 2.41 3.24(4) 170.7 
 N124-H124...O17#4 0.88 1.99 2.777(5) 148.7 
 N125-H125...O116#1 0.88 2.53 3.270(5) 142.7 
 N126-H126...O18 0.88 1.92 2.798(5) 175.4 
 N127-H127...O118 0.88 2.28 3.120(5) 158.9 
 N128-H128...OW15 0.88 2.03 2.894(6) 165.2 
 N129-H129...O121 0.88 1.98 2.818(5) 159.4 
 N229-H2A29...O118#3 0.88 2.04 2.878(6) 159.5 
 N130-H130...OW23 0.88 2.12 2.988(7) 167.2 
 N132-H132...O16 0.88 2.01 2.844(5) 159.0 
 O232-H232...O122#2 0.84 1.78 2.613(5) 169.0 
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Supporting Information 
  
 Supporting figure 1 – heat stability of (a) caulonodin IV and (b) caulonodin VI, heat and 
carboxypeptidase stability of (c) caulonodin V and (d) caulonodin VII shown as UV traces 
and mass signals measured on the low-resolution HPLC-MS system 
Supporting figure 2 – heat stable 
mutants of (a) caulonodin IV, 
(b) caulonodin VI and (c) caulonodin 
VII shown as total ion current (TIC), 
extracted ion current (EIC) and UV 
traces measured on the high-resolution 
HPLC-MS system 
 
  
 Supporting figure 3 – 3D fold predictions of the caulonodins (a) IV, (b) V, (c) VI and (d) VII 
in a schematic representation based on the plug mutants; aa involved in the formation of the 
macrolactam ring shown in red, other aa of the ring shown in yellow, aa in the tail shown in 
blue, plug aa shown in green.  
 Supporting figure 4 – 1H  NMR  spectra  of  caulonodin  V  in  H2O/D2O (9:1) at variable 
temperatures in the range from 10.6 to 6.6 ppm 
 
  
 Supporting figure 5 – 2D 1H NOESY spectrum of caulonodin V at 300 ms mixing time 
  
 Supporting figure 6 – Quality of the structure determination. Ramachandran Plot of the 15 
minimum energy structures showing all residues in most favored and additionally allowed 
regions. 
  
 Supporting figure 7 – 1H  NMR  spectra  of  caulonodin  VI  in  H2O/D2O (9:1) at variable 
temperatures in the range from 10.0 to 6.7 ppm; labeling according to signal assignments at 
288 and 300 K; circles denote side chain NH2 of N11 and Q12.  
 Supporting figure 8 – 2D 1H NOESY spectrum of caulonodin VI at 300 ms mixing time  
 Supporting figure 9 – Multiple alignments using the gonnet protein weight matrix of (a) all 
seven caulonodin precursors and (b) the four chromosomal precursors; coloring according to 
similarity from red for identical and orange to yellow and white for different; arrow marks 
proteolytic cleavage site between leader and core peptide 
  
 Supporting figure 10 – Alignment of the 27 leader peptides from the 30 known, functional 
lasso peptide biosynthetic gene clusters, wherein the motif was identified using the MEME 
algorithm; leader peptide of caulonodin V marked with a blue arrow, of rhodanodin with a red 
arrow 
  
Supporting table 1 – Oligonucleotide primers 
name sequence 
CK31_198x_A1_NdeI_FP GGATTAC CAT ATG ACC CCG ATC CAA TCC AAG TTC TGC CTT 
CTG 
CK31_198x_C_XhoI_RP ATAT CTC GAG TCA TGA GAC CCT GAG CTT GGC TTC CCA GG 
CK31_2238_A1_NdeI_FP GGATTAC CAT ATG AAT ACG CTC AAG ACC CGG CTG ATC CG 
CK31_2241_C_XhoI_RP ATAT CTC GAG TTA GGC GCC GCG CGC TTC CCA G 
CK31_198xB_SLIM_FPS CTT TGG CTC GCC CAG GAC GTC CAT GC 
CK31_198xB_rbs_SLIM_FPL AGAGGAGAAATTAACC ATG CCC CTT TGG CTC GCC CAG GAC 
GTC CAT GC 
CK31_198xA2_SLIM_RPS TTA GGG CCA GTA GGT CTG CGA GCT CAT G 
CK31_198xA2_rbs_SLIM_RPL GGG CAT GGTTAATTTCTCCTCT TTA GGG CCA GTA GGT CTG CGA 
GCT CAT G 
CK31_198xA2Del_SLIM_RPS TCA GGC GAA GTA GTA TTG GCT GAC GAG ACC 
CK31_198xA2Del_SLIM_RPL GGG CAT GGTTAATTTCTCCTCT TCA GGC GAA GTA GTA TTG GCT 
GAC GAG ACC 
CK31_198xA1Del_SLIM_FPS ATG ACT CAA GTC TCT CCC TCG CCC CTG C 
CK31_198xA1Del_SLIM_FPL CTT TAA GAA GGA GAT ATA CAT ATG ACT CAA GTC TCT CCC 
TCG CCC CTG C 
CK31_bothA1Del_SLIM_RPS TTA AAC AAA ATT ATT TCT AGA GGG GAA TTG TTA TCC GCT 
CAC 
CK31_bothA1Del_SLIM_RPL ATG TAT ATC TCC TTC TTA AAG TTA AAC AAA ATT ATT TCT 
AGA GGG GAA TTG TTA TCC GCT CAC 
CK31_22xxB_SLIM_FPS CTA ACC TGG CGG CCC GGC GTT CAC 
CK31_22xxB_SLIM_FPL AGAGGAGAAATTAACC ATG ACG CTA ACC TGG CGG CCC GGC 
GTT CAC 
CK31_22xxA2_SLIM_RPS TCA GTC CCA ACG GCG AAC CAT GTT GGG C 
CK31_22xxA2_SLIM_RPL CGT CAT GGTTAATTTCTCCTCT TCA GTC CCA ACG GCG AAC CAT 
GTT GGG C 
CK31_22xxA2Del_SLIM_RPS TCA GGC CGG GTC GTA CCG CTT GAT CTG 
CK31_22xxA2Del_SLIM_RPL GGG CAT GGTTAATTTCTCCTCT TCA GGC CGG GTC GTA CCG CTT 
GAT CTG 
CK31_22xxA1Del_SLIM_FPS ATG ACG ACT CCC AAG TTT CGA CTG ATC CGT CTG 
CK31_22xxA1Del_SLIM_FPL CTT TAA GAA GGA GAT ATA CAT ATG ACG ACT CCC AAG TTT 
CGA CTG ATC CGT CTG 
198xA12_SLIM_FPS TGA AGA GGA GAA ATT AAC CAT GCC CCT TTG GCT C 
1984A1_SLIM_RPS GAG ACC TTC CTT GAT GGT GCC GAC ATC GAA G 
1984A1_Y15A_FPL GTC AGC CAA GCC TAC TTC GCC TGA AGA GGA GAA ATT AAC 
CAT GCC CCT TTG GCT C 
1984A1_Y15A_RPL GGC GAA GTA GGC TTG GCT GAC GAG ACC TTC CTT GAT GGT 
GCC GAC ATC GAA G 
1984A1_Y16A_FPL GTC AGC CAA TAC GCC TTC GCC TGA AGA GGA GAA ATT AAC 
CAT GCC CCT TTG GCT C 
1984A1_Y16A_RPL GGC GAA GGC GTA TTG GCT GAC GAG ACC TTC CTT GAT GGT 
GCC GAC ATC GAA G 
1984A1_F17A_FPL GTC AGC CAA TAC TAC GCC GCC TGA AGA GGA GAA ATT AAC 
CAT GCC CCT TTG GCT C 
1984A1_F17A_RPL GGC GGC GTA GTA TTG GCT GAC GAG ACC TTC CTT GAT GGT 
GCC GAC ATC GAA G 
1984A1_Y15W_FPL GTC AGC CAA TGG TAC TTC GCC TGA AGA GGA GAA ATT AAC 
CAT GCC CCT TTG GCT C 
1984A1_Y15W_RPL GGC GAA GTA CCA TTG GCT GAC GAG ACC TTC CTT GAT GGT 
GCC GAC ATC GAA G 
1984A1_Y16W_FPL GTC AGC CAA TAC TGG TTC GCC TGA AGA GGA GAA ATT AAC 
CAT GCC CCT TTG GCT C 
1984A1_Y16W_RPL GGC GAA CCA GTA TTG GCT GAC GAG ACC TTC CTT GAT GGT 
GCC GAC ATC GAA G 
1984A1_F17W_FPL GTC AGC CAA TAC TAC TGG GCC TGA AGA GGA GAA ATT AAC 
CAT GCC CCT TTG GCT C 
name sequence 
1984A1_F17W_RPL GGC CCA GTA GTA TTG GCT GAC GAG ACC TTC CTT GAT GGT 
GCC GAC ATC GAA G 
198xA2_SLIM_RPS CAT GGA CTC CCG CAG ACC GGA GTC G 
198xA2_T15A_FPL AGC TCG CAG GCC TAC TGG CCC TGA AGA GGA GAA ATT AAC 
CAT GCC CCT TTG GCT C 
198xA2_T15A_RPL GGG CCA GTA GGC CTG CGA GCT CAT GGA CTC CCG CAG ACC 
GGA GTC G 
198xA2_Y16A_FPL AGC TCG CAG ACC GCC TGG CCC TGA AGA GGA GAA ATT AAC 
CAT GCC CCT TTG GCT C 
198xA2_Y16A_RPL GGG CCA GGC GGT CTG CGA GCT CAT GGA CTC CCG CAG ACC 
GGA GTC G 
198xA2_Y16F_FPL AGC TCG CAG ACC TTC TGG CCC TGA AGA GGA GAA ATT AAC 
CAT GCC CCT TTG GCT C 
198xA2_Y16F_RPL GGG CCA GAA GGT CTG CGA GCT CAT GGA CTC CCG CAG ACC 
GGA GTC G 
198xA2_W17A_FPL AGC TCG CAG ACC TAC GCG CCC TGA AGA GGA GAA ATT AAC 
CAT GCC CCT TTG GCT C 
198xA2_W17A_RPL GGG CGC GTA GGT CTG CGA GCT CAT GGA CTC CCG CAG ACC 
GGA GTC G 
198xA2_W17F_FPL AGC TCG CAG ACC TAC TTC CCC TGA AGA GGA GAA ATT AAC 
CAT GCC CCT TTG GCT C 
198xA2_W17F_RPL GGG GAA GTA GGT CTG CGA GCT CAT GGA CTC CCG CAG ACC 
GGA GTC G 
198xA2_W17Y_FPL AGC TCG CAG ACC TAC TAC CCC TGA AGA GGA GAA ATT AAC 
CAT GCC CCT TTG GCT C 
198xA2_W17Y_RPL GGG GTA GTA GGT CTG CGA GCT CAT GGA CTC CCG CAG ACC 
GGA GTC G 
CK31_223xA12_SLIM2_FPS TGA AGA GGA GAA ATT AAC CAT GAC GCT AAC CTG GC 
CK31_2238_SLIM2_RPS CTG GTT GGT TTC CGG GAG AAG CAC CCC G 
CK31_2238_K14A_FPL ATC GCG CGG TAC GAC CCG GCC TGA AGA GGA GAA ATT AAC 
CAT GAC GCT AAC CTG GC 
CK31_2238_K14A_RPL GGC CGG GTC GTA CCG CGC GAT CTG GTT GGT TTC CGG GAG 
AAG CAC CCC G 
CK31_2238_R15A_FPL ATC AAG GCG TAC GAC CCG GCC TGA AGA GGA GAA ATT AAC 
CAT GAC GCT AAC CTG GC 
CK31_2238_R15A_RPL GGC CGG GTC GTA CGC CTT GAT CTG GTT GGT TTC CGG GAG 
AAG CAC CCC G 
CK31_2238_Y16A_FPL ATC AAG CGG GCC GAC CCG GCC TGA AGA GGA GAA ATT AAC 
CAT GAC GCT AAC CTG GC 
CK31_2238_Y16A_RPL GGC CGG GTC GGC CCG CTT GAT CTG GTT GGT TTC CGG GAG 
AAG CAC CCC G 
CK31_2238_K14W_FPL ATC TGG CGG TAC GAC CCG GCC TGA AGA GGA GAA ATT AAC 
CAT GAC GCT AAC CTG GC 
CK31_2238_K14W_RPL GGC CGG GTC GTA CCG CCA GAT CTG GTT GGT TTC CGG GAG 
AAG CAC CCC G 
CK31_2238_R15W_FPL ATC AAG TGG TAC GAC CCG GCC TGA AGA GGA GAA ATT AAC 
CAT GAC GCT AAC CTG GC 
CK31_2238_R15W_RPL GGC CGG GTC GTA CCA CTT GAT CTG GTT GGT TTC CGG GAG 
AAG CAC CCC G 
CK31_2238_Y16W_FPL ATC AAG CGG TGG GAC CCG GCC TGA AGA GGA GAA ATT AAC 
CAT GAC GCT AAC CTG GC 
CK31_2238_Y16W_RPL GGC CGG GTC CCA CCG CTT GAT CTG GTT GGT TTC CGG GAG 
AAG CAC CCC G  
CK31_2239_SLIM_RPS GGG CTC GGG GAA CAC GTC CCC GAT CC 
CK31_2239_R14A_FPL AAC ATG GTT GCC CGT TGG GAC TGA AGA GGA GAA ATT AAC 
CAT GAC GCT AAC CTG GC 
CK31_2239_R14A_RPL GTC CCA ACG GGC AAC CAT GTT GGG CTC GGG GAA CAC GTC 
CCC GAT CC 
CK31_2239_R14W_FPL AAC ATG GTT TGG CGT TGG GAC TGA AGA GGA GAA ATT AAC 
CAT GAC GCT AAC CTG GC 
name sequence 
CK31_2239_R14W_RPL GTC CCA ACG CCA AAC CAT GTT GGG CTC GGG GAA CAC GTC 
CCC GAT CC 
CK31_2239_R15A_FPL AAC ATG GTT CGC GCT TGG GAC TGA AGA GGA GAA ATT AAC 
CAT GAC GCT AAC CTG GC 
CK31_2239_R15A_RPL GTC CCA AGC GCG AAC CAT GTT GGG CTC GGG GAA CAC GTC 
CCC GAT CC 
CK31_2239_R15K_FPL AAC ATG GTT CGC AAA TGG GAC TGA AGA GGA GAA ATT AAC 
CAT GAC GCT AAC CTG GC 
CK31_2239_R15K_RPL GTC CCA TTT GCG AAC CAT GTT GGG CTC GGG GAA CAC GTC 
CCC GAT CC 
CK31_2239_R15W_FPL AAC ATG GTT CGC TGG TGG GAC TGA AGA GGA GAA ATT AAC 
CAT GAC GCT AAC CTG GC 
CK31_2239_R15W_RPL GTC CCA CCA GCG AAC CAT GTT GGG CTC GGG GAA CAC GTC 
CCC GAT CC 
CK31_2239_W16A_FPL AAC ATG GTT CGC CGT GCG GAC TGA AGA GGA GAA ATT AAC 
CAT GAC GCT AAC CTG GC 
CK31_2239_W16A_RPL GTC CGC ACG GCG AAC CAT GTT GGG CTC GGG GAA CAC GTC 
CCC GAT CC 
CK31_2239_W16Y_FPL AAC ATG GTT CGC CGT TAC GAC TGA AGA GGA GAA ATT AAC 
CAT GAC GCT AAC CTG GC 
CK31_2239_W16Y_RPL GTC GTA ACG GCG AAC CAT GTT GGG CTC GGG GAA CAC GTC 
CCC GAT CC 
CK31_2239_W16F_FPL AAC ATG GTT CGC CGT TTC GAC TGA AGA GGA GAA ATT AAC 
CAT GAC GCT AAC CTG GC 
CK31_2239_W16F_RPL GTC GAA ACG GCG AAC CAT GTT GGG CTC GGG GAA CAC GTC 
CCC GAT CC 
198xA2_SLIM_RING_FPS TCC GGT CTG CGG GAG TCC ATG AGC TC 
198xA2_SLIM_RING_RPS ATC GAG GGC GCG CCC GAC ACG 
198xA2_S1G_FP CTG ACC CGT GGG ATC GGC GAC TCC GGT CTG CGG GAG TCC 
ATG AGC TC 
198xA2_S1G_RP GTC GCC GAT CCC ACG GGT CAG ATC GAG GGC GCG CCC GAC 
ACG 
198xA2 _S1A_FP CTG ACC CGT GCG ATC GGC GAC TCC GGT CTG CGG GAG TCC 
ATG AGC TC 
198xA2 _S1A_RP GTC GCC GAT CGC ACG GGT CAG ATC GAG GGC GCG CCC GAC 
ACG 
198xA2 _S1C_FP CTG ACC CGT TGC ATC GGC GAC TCC GGT CTG CGG GAG TCC 
ATG AGC TC 
198xA2 _S1C_RP GTC GCC GAT GCA ACG GGT CAG ATC GAG GGC GCG CCC GAC 
ACG 
198xA2 _S1F_FP CTG ACC CGT TTC ATC GGC GAC TCC GGT CTG CGG GAG TCC 
ATG AGC TC 
198xA2 _S1F_RP GTC GCC GAT GAA ACG GGT CAG ATC GAG GGC GCG CCC GAC 
ACG 
198xA2_S1V_FP CTG ACC CGT GTG ATC GGC GAC TCC GGT CTG CGG GAG TCC 
ATG AGC TC 
198xA2_S1V_RP GTC GCC GAT CAC ACG GGT CAG ATC GAG GGC GCG CCC GAC 
ACG 
198xA2_S1T_FP CTG ACC CGT ACG ATC GGC GAC TCC GGT CTG CGG GAG TCC 
ATG AGC TC 
198xA2_S1T_RP GTC GCC GAT CGT ACG GGT CAG ATC GAG GGC GCG CCC GAC 
ACG 
CK31_2238_SLIM1_FPS GTG CTT CTC CCG GAA ACC AAC CAG ATC AAG C 
CK31_2238_SLIM1_RPS GCG CTT GGC CGA GCC GAA ACG G 
CK31_2238_A1G_FPL CTG ACC CGC GGC GGC ACC GGG GTG CTT CTC CCG GAA ACC 
AAC CAG ATC AAG C 
CK31_2238_A1G_RPL CCC GGT GCC GCC GCG GGT CAG GCG CTT GGC CGA GCC GAA 
ACG G 
CK31_2238_A1S_FPL CTG ACC CGC TCC GGC ACC GGG GTG CTT CTC CCG GAA ACC 
AAC CAG ATC AAG C 
name sequence 
CK31_2238_A1S_RPL CCC GGT GCC GGA GCG GGT CAG GCG CTT GGC CGA GCC GAA 
ACG G 
CK31_2238_A1C_FPL CTG ACC CGC TGC GGC ACC GGG GTG CTT CTC CCG GAA ACC 
AAC CAG ATC AAG C 
CK31_2238_A1C_RPL CCC GGT GCC GCA GCG GGT CAG GCG CTT GGC CGA GCC GAA 
ACG G 
CK31_2238_A1F_FPL CTG ACC CGC TTC GGC ACC GGG GTG CTT CTC CCG GAA ACC 
AAC CAG ATC AAG C 
CK31_2238_A1F_RPL CCC GGT GCC GAA GCG GGT CAG GCG CTT GGC CGA GCC GAA 
ACG G 
CK31_2238_A1V_FPL CTG ACC CGC GTC GGC ACC GGG GTG CTT CTC CCG GAA ACC 
AAC CAG ATC AAG C 
CK31_2238_A1V_RPL CCC GGT GCC GAC GCG GGT CAG GCG CTT GGC CGA GCC GAA 
ACG G 
CK31_2238_A1T_FPL CTG ACC CGC ACC GGC ACC GGG GTG CTT CTC CCG GAA ACC 
AAC CAG ATC AAG C 
CK31_2238_A1T_RPL CCC GGT GCC GGT GCG GGT CAG GCG CTT GGC CGA GCC GAA 
ACG G 
198xLeaderDel1_RtH_RP CAT ATG TAT ATC TCC TTC TTA AAG TTA AAC AAA ATT ATT TCT 
AGA GGG GAA TTG 
198xLeaderDel1_RtH_FP CTG CGG CTC ATC CGT GTC GGG CG 
198xLeaderDel12_RtH_FP GGG CGC GCC CTC GAT CTG ACC CG 
198xLeaderDel123_RtH_FP ACC CGT TCG ATC GGC GAC TCC GGT CTG 
198xLeaderDel2FPS CTC GAT CTG ACC CGT TCG ATC GGC GAC 
198xLeaderDel2RPS AGA GAC TTG AGT CAT ATG TAT ATC TCC TTC TTA AAG TTA 
AAC AAA ATT ATT TC 
198xLeaderDel2FPL CCC TCG CCC GGG CGC GCC CTC GAT CTG ACC CGT TCG ATC 
GGC GAC 
198xLeaderDel2RPL GGC GCG CCC GGG CGA GGG AGA GAC TTG AGT CAT ATG TAT 
ATC TCC TTC TTA AAG TTA AAC AAA ATT ATT TC 
198xLeaderDel3FPS ATC GGC GAC TCC GGT CTG CGG GAG TCC 
198xLeaderDel3RPS GAG CCG CAG GGG CGA GGG AGA GAC TTG 
198xLeaderDel3FPL ATC CGT GTC ACC CGT TCG ATC GGC GAC TCC GGT CTG CGG 
GAG TCC 
198xLeaderDel3RPL CGA ACG GGT GAC ACG GAT GAG CCG CAG GGG CGA GGG AGA 
GAC TTG 
198xLeaderBlock1 SLIM FPS GAT CTG ACC CGT TCG ATC GGC GAC TCC 
198xLeaderBlock1 SLIM RPS CCG CAG GGG CGA GGG AGA GAC TTG 
198xLeaderLIVAtoRRRR FPL CGC CGT CGT CGC GGG CGC CGT CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
198xLeaderLIVAtoRRRR RPL GAG ACG GCG CCC GCG ACG ACG GCG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198xLeaderLIVAtoEEEE FPL GAA GAG CGT GAA GGG CGC GAA CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
198xLeaderLIVAtoEEEE RPL GAG TTC GCG CCC TTC ACG CTC TTC CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_LI-11-12toRR FPL CGC CGT CGT GTC GGG CGC GCC CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
198x_LI-11-12toRR RPL GAG GGC GCG CCC GAC ACG ACG GCG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_LI-11-12toEE FPL GAA GAG CGT GTC GGG CGC GCC CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
198x_LI-11-12toEE RPL GAG GGC GCG CCC GAC ACG CTC TTC CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_LI-11-12toQQ FPL CAA CAG CGT GTC GGG CGC GCC CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
198x_LI-11-12toQQ RPL GAG GGC GCG CCC GAC ACG CTG TTG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_VA-9-6toRR FPL CTC ATC CGT CGC GGG CGC CGT CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
name sequence 
198x_VA-9-6toRR RPL GAG ACG GCG CCC GCG ACG GAT GAG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_VA-9-6toEE FPL CTC ATC CGT GAA GGG CGC GAA CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
198x_VA-9-6toEE RPL GAG TTC GCG CCC TTC ACG GAT GAG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_VA-9-6toQQ FPL CTC ATC CGT CAG GGG CGC CAG CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
198x_VA-9-6toQQ RPL GAG CTG GCG CCC CTG ACG GAT GAG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_V-9R FPL CTC ATC CGT CGC GGG CGC GCC CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
198x_V-9R RPL GAG GGC GCG CCC GCG ACG GAT GAG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_V-9E FPL CTC ATC CGT GAA GGG CGC GCC CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
198x_V-9E RPL GAG GGC GCG CCC TTC ACG GAT GAG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_A-6R FPL CTC ATC CGT GTC GGG CGC CGT CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
198x_A-6R RPL GAG ACG GCG CCC GAC ACG GAT GAG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_A-6E FPL CTC ATC CGT GTC GGG CGC GAA CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
198x_A-6E RPL GAG TTC GCG CCC GAC ACG GAT GAG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_G-8F FPL CTC ATC CGT GTC TTC CGC GCC CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
198x_G-8F RPL GAG GGC GCG GAA GAC ACG GAT GAG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_G-8R FPL CTC ATC CGT GTC CGT CGC GCC CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
198x_G-8R RPL GAG GGC GCG ACG GAC ACG GAT GAG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_G-8E FPL CTC ATC CGT GTC GAA CGC GCC CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
198x_G-8E RPL GAG GGC GCG TTC GAC ACG GAT GAG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_G-8A FPL CTC ATC CGT GTC GCG CGC GCC CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
198x_G-8A RPL GAG GGC GCG CGC GAC ACG GAT GAG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_G-8V FPL CTC ATC CGT GTC GTG CGC GCC CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TC 
198x_G-8V RPL GAG GGC GCG CAC GAC ACG GAT GAG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_G-8P FPL CTC ATC CGT GTC CCG CGC GCC CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
198x_G-8P RPL GAG GGC GCG CGG GAC ACG GAT GAG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_R-10A FPL CTC ATC GCT GTC GGG CGC GCC CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
198x_R-10A RPL GAG GGC GCG CCC GAC AGC GAT GAG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_R-10F FPL CTC ATC TTT GTC GGG CGC GCC CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
198x_R-10F RPL GAG GGC GCG CCC GAC AAA GAT GAG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198x_R-10E FPL CTC ATC GAA GTC GGG CGC GCC CTC GAT CTG ACC CGT TCG 
ATC GGC GAC TCC 
name sequence 
198x_R-10E RPL GAG GGC GCG CCC GAC TTC GAT GAG CCG CAG GGG CGA GGG 
AGA GAC TTG 
198xLeaderBlock 2SLIM FPS TCC GGT CTG CGG GAG TCC ATG AGC TC 
198xLeaderBlock 2SLIM RPS GGC GCG CCC GAC ACG GAT GAG C 
198xR-1A_ FPL CTC GAT CTG ACC GCC TCG ATC GGC GAC TCC GGT CTG CGG 
GAG TCC ATG AGC TC 
198xR-1A_ RPL GTC GCC GAT CGA GGC GGT CAG ATC GAG GGC GCG CCC GAC 
ACG GAT GAG C 
198xR-1Q_ FPL CTC GAT CTG ACC CAG TCG ATC GGC GAC TCC GGT CTG CGG 
GAG TCC ATG AGC TC 
198xR-1Q_ RPL GTC GCC GAT CGA CTG GGT CAG ATC GAG GGC GCG CCC GAC 
ACG GAT GAG C 
198xR-1N_ FPL CTC GAT CTG ACC AAC TCG ATC GGC GAC TCC GGT CTG CGG 
GAG TCC ATG AGC TC 
198xR-1N_ RPL GTC GCC GAT CGA GTT GGT CAG ATC GAG GGC GCG CCC GAC 
ACG GAT GAG C 
198xR-1K_ FPL CTC GAT CTG ACC AAG TCG ATC GGC GAC TCC GGT CTG CGG 
GAG TCC ATG AGC TC 
198xR-1K_ RPL GTC GCC GAT CGA CTT GGT CAG ATC GAG GGC GCG CCC GAC 
ACG GAT GAG C 
198xR-1H_ FPL CTC GAT CTG ACC CAC TCG ATC GGC GAC TCC GGT CTG CGG 
GAG TCC ATG AGC TC 
198xR-1H_ RPL GTC GCC GAT CGA GTG GGT CAG ATC GAG GGC GCG CCC GAC 
ACG GAT GAG C 
198xR-1F_ FPL CTC GAT CTG ACC TTC TCG ATC GGC GAC TCC GGT CTG CGG 
GAG TCC ATG AGC TC 
198xR-1F_ RPL GTC GCC GAT CGA GAA GGT CAG ATC GAG GGC GCG CCC GAC 
ACG GAT GAG C 
198xR-1E_ FPL CTC GAT CTG ACC GAA TCG ATC GGC GAC TCC GGT CTG CGG 
GAG TCC ATG AGC TC 
198xR-1E_ RPL GTC GCC GAT CGA TTC GGT CAG ATC GAG GGC GCG CCC GAC 
ACG GAT GAG C 
198xT-2A_ FPL CTC GAT CTG GCC CGT TCG ATC GGC GAC TCC GGT CTG CGG 
GAG TCC ATG AGC TC 
198xT-2A_ RPL GTC GCC GAT CGA ACG GGC CAG ATC GAG GGC GCG CCC GAC 
ACG GAT GAG C 
FP_Rhothi_Leader_SLIM GGA GTA TTG CCC ATC GGC AAT GAG TTC ATG GGC CAC G 
RP_Rhothi_Leader_SLIM GAG CTC GAT GAC ATC GTC CTG CGC GTT GCT G 
FPTail_Rhothi_S-8G_SLIM GGC GTC GCC AGT GTC GAG ACC AAA GGA GTA TTG CCC ATC 
GGC AAT GAG TTC ATG GGC CAC G 
RPTail_Rhothi_S-8G_SLIM TTT GGT CTC GAC ACT GGC GAC GCC GAG CTC GAT GAC ATC 
GTC CTG CGC GTT GCT G 
Introduced restriction enzyme sites are underlined; introduced ribosomal binding sites are shown in italics; 
introduced mutations are shown in bold 
  
Supporting table 2 – M9 Vitamin Mix 
component amount 
biotin 0.2 g 
choline chloride 1.0 g 
disodium adenosine 5’-triphosphate 0.3 g 
folic acid 1.0 g 
myo-inositol 2.0 g 
nicotinamide 1.0 g 
panthothenic acid 1.0 g 
pyridoxal hydrochloride 1.0 g 
riboflavin 0.1 g 
thiamine 1.0 g 
H2O ad 300 mL 
10 M NaOH were added to the resulting suspension until everything was 
dissolved. The solution was then sterile filtered and stored at 4°C 
 
  
Supporting Table 3 – Tail sequences of the caulonodins with possible plug residues 
highlighted 
peptide 14 15 16 17 18 19 
caulonodin IV Q Y Y F A - 
caulonodin V Q T Y W P - 
caulonodin VI K R Y D P A 
caulonodin VII R R W D - - 
Positions picked for mutation in bold black, most likely plugs in red 
 
 
  
Supporting Table 4 – Production amounts of all constructed caulonodin and rhodanodin 
mutants; mutant numbering according to figure 1a, positive numbers for mutations in the core 
peptide, negative numbers for mutations in the leader peptide. 
lasso peptide mutant relative production to 
corresponding wild type in % 
heat stable 
caulonodin IV WT 100 ± 15 no 
Y15A 49 ± 2 no 
Y15W 167 ± 12 no 
Y16A 14.3 ± 0.7 no 
Y16W 84 ± 6 no 
F17A not detected - 
F17W 132 ± 9 yes 
caulonodin V WT 100 ± 23 no 
S1G 4.0 ± 0.3 - 
S1A 132.2 ± 1.6 - 
S1C detected - 
S1V detected - 
S1T detected - 
S1F detected - 
T15A 2.7 ± 0.1 - 
Y16A detected - 
Y16F detected - 
W17A detected - 
W17F detected - 
W17Y 8.5 ± 0.6 - 
Del1 7.8 ± 0.5 - 
Del2 detected - 
Del3 detected - 
Del12 not detected - 
Del123 not detected - 
L-12R_I-11R_V-9R_A-6R not detected - 
L-12E_I-11E_V-9E_A-6E not detected - 
L-12R_I-11R 0.3 ± 0.1 - 
L-12E_I-11E 0.4 ± 0.1 - 
L-12Q_I-11Q 7.6 ± 0.1 - 
V-9R_A-6R not detected - 
V-9E_A-6E not detected - 
V-9Q_A-6Q not detected - 
R-10A 97.8 ± 1.8 - 
R-10F 71.2 ± 1.5 - 
R-10E 63.0 ± 1.4 - 
V-9E 2.0 ± 0.1 - 
V-9R 3.6 ± 0.2 - 
G-8A detected - 
lasso peptide mutant relative production to 
corresponding wild type in % 
heat stable 
G-8F 6.0 ± 0.5 - 
G-8E 4.7 ± 0.1 - 
G-8V 0.5 ± 0.1 - 
G-8R not detected - 
G-8P 0.3 ± 0.1 - 
A-6E detected - 
A-6R detected - 
T-2A detected - 
R-1A 80 ± 15 - 
R-1F 1.0 ± 0.1 - 
R-1E 33 ± 14 - 
R-1Q 84 ± 3 - 
R-1N 62 ± 12 - 
R-1K 90 ± 8 - 
R-1H 15.7 ± 1.0 - 
caulonodin VI WT 100 ± 7 no 
A1G 7.1 ± 0.5 - 
A1S 122 ± 30 - 
A1C detected - 
A1V detected - 
A1T 1.3 ± 0.1 - 
A1F detected - 
K14A 38 ± 6 no 
K14W 22.9 ± 1.4 no 
R15A 6.1 ± 0.5 no 
R15W 2.0 ± 0.1 yes 
Y16A detected - 
Y16W 99 ± 14 no 
caulonodin VII WT 100 ± 29 no 
R14A 29.7 ± 0.6 no 
R15A 0.8 ± 0.1 no 
R15K 123 ± 5 no 
R15W detected yes 
W16A not detected - 
W16F detected - 
W16Y 73 ± 12 no 
rhodanodin WT 100 - 
S-8G 1460 - 
 
 
  
Supporting table 5 – Chemical shift Assignment of 1H  signals  (ppm)  of  caulonodin  V  in  
H2O/D2O (9:1) at 298 K 
aa NH ĮH ȕH others 
Ser1 7.075 4.560 4.190; 3.995 / 
Ile2 9.084 4.891 2.509 ȖCH3: 1.159 
ȖCH2: 1.478; 1.342 
įCH3: 1.151 
Gly3 8.702 4.528; 3.664 / / 
Asp4 8.973 5.155 3.082 / 
Ser5 7.600 3.240 3.821 / 
Gly6 8.185 4.651; 3.701 / / 
Leu7 9.406 4.841 2.089 ȖCH: 2.044 
įCH3: 1.244; 1.172 
Arg8 8.872 4.007 1.863; 1.737 ȖCH2: 1.700; 1.513 
įCH2: 3.170; 3.132 
İNH: 7.140 
Glu9 7.989 3.386 1.485; 1.327 ȖCH2: 1.225 
Ser10 7.854 4.691 4.200; 4.008 / 
Met11 8.900 4.574 2.304 ȖCH2: 2.894; 2.763 
İCH3: 2.290 
Ser12 8.305 4.730 4.078; 3.969 / 
Ser13 7.671 4.653 4.013; 3.871 / 
Gln14 8.921 4.488 2.039 ȖCH2: 2.494 
İNH2: 7.649; 6.992 
Thr15 7.468 4.643 4.204 ȖCH3: 1.221 
Tyr16 8.058 5.136 3.033; 2.165 2. 6H: 6.787 
3. 5H: 6.787 
Trp17 9.350 5.488 3.731; 3.293 2H: 7.176; 4H: 7.941 
5H: 7.278; 6H: 7.434 
7H: 7.779; NH: 10.401 
Pro18 / 4.774 2.516; 2.355 ȖCH2: 2.267; 2.468 
įCH2: 4.483; 4.351 
 
  
Supporting table 6 – Structural statistics for the family of 15 structures selected to represent 
the structure of caulonodin V in H2O/D2O (9:1) 
Restraining Constraints Constraints Violations 
Total: 166 Distance violations, >0.5 Å: 0 
distance, i=j: 79 RMS deviations: 0.02 Å 
distance, |i-j|=1: 35 Dihedral violations, > 5°: 0 
distance, |i-j|>1: 22 RMS deviation: 1.8° 
dihedral: 22 Average pairwise RMS deviation (Ile2-Trp17) 
hydrogen bond: 0 Backbone atoms: 0.06 Å 
Constraints/residue: 9.2 All heavy atoms: 0.45 Å 
 
 
 
  
Supporting table 7 – Chemical shift Assignment of 1H  signals  (ppm)  of  caulonodin  VI  in  
H2O/D2O (9:1) at 288 K 
aa NH ĮH ȕH others 
Ala1 7.654 4.426 1.617 / 
Gly2 8.608 4.576; 4.602   
Thr3 7.695 4.623 4.437 ȖCH3: 1.358 
Gly4 7.700 3.844; 4.524   
Val5 7.960 4.829 2.516 ȖCH3: 0.964; 1.008 
Leu6 8.027 4.289 amb.* ȖCH2: amb. 
įCH3: 1.038; 1.078 
Leu7 8.962 5.131 amb. ȖCH2 amb. 
įCH3: 0.911; 1.096 
Pro8 / 4.776 amb. Amb. 
Glu9 8.790 4.586 2.242 ȖCH2: 2.275; 2.424 
Thr10 8.659 4.293 4.146 ȖCH3: 1.444 
Asn11 amb. amb. amb. amb. 
Gln12 8.252 4.384 2.340; 2.547 ȖCH2: 2.505; 2.575 
İNH2: amb. 
Ile13 8.412 4.494 amb. ȖCH2: amb. 
ȖCH3: 1.120; įCH3: 1.056 
Lys14 7.989 4.756 amb. ȖCH2: amb.; įCH2: amb. 
İCH2: 3.162; İNH3+: 7.825 
Arg15 8.521 5.593 amb. ȖCH2: amb. 
įCH2: 3.077; 3.479 
NH: 7.143 
Tyr16 9.772 4.727 3.135; 3.183 2, 6H: 7.027 
3, 5H: 6.825 
Asp17 8.959 5.363 amb.  
Pro18 / 4.693 amb. amb. 
Ala19 8.825 4.532 1.644  
*amb. = ambiguous 
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ABSTRACT: Integrins moderate diverse important functions in the human body and are promising targets in cancer therapy. 
Hence, the selective inhibition of specific integrins is of great medicinal interest. Here, we report the optimization of a grafted 
lasso peptide, yielding MccJ25(RGDF), which is a highly potent and selective inhibitor of the v3 integrin. Furthermore, its 
elucidated structure was employed in a molecular dynamics approach, revealing information about the integrin binding mode 
and selectivity profile of MccJ25(RGDF). 
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Experimental Procedures 
 
Generation, Production and Isolation of MccJ25 Variants. Oligonucleotide primers were 
purchased from Sigma Aldrich. E. coli TOP10 was used for the generation of the mutants, while 
E. coli BL21(DE3) was used for the heterologous expression. Both strains were obtained from 
Invitrogen. Phusion polymerase was purchased from New England Biolabs. For confirming the 
correct incorporation of the desired mutations, DNA dideoxy sequencing was performed by GATC 
Biotech. Variants of the plasmid pTUC202
1
 were generated by employing site-directed 
ligase-independent mutagenesis (SLIM)
2, 3
 using the oligonucleotide primers shown in 
Supplementary Table S1. Initial screens of the production of the new MccJ25 variants were done in 
100 mL M63 minimal medium (13.6 g/L KH2PO4, 2 g/L (NH4)2SO4, 1 g/L bacto casamino acids, 
1 mL/L MgSO4 solution (2 M), pH = 7.0; after autoclaving 5 mL/L glucose solution (40% w/v), 
0.2 mL/L biotin solution (10 mg/L) and 0.2 mL/L thiamine solution (10 mg/mL) were added) 
containing 17 g/mL chloramphenicol that was inoculated to an OD600 of 0.01 with LB overnight 
cultures containing the same antibiotic. After fermentation for 1 day at 37 °C, the cells were 
harvested by centrifugation. Supernatants were collected and applied to solid phase extraction using 
XAD16 resin (Sigma Aldrich, ~4 g/L culture supernatant). After the addition of the XAD16 resin, 
the supernatant was stirred for 1 h at room temperature. Subsequently, the resin was removed by 
filtration, washed with water and eluted with pure MeOH (100 mL/L of the initial culture volume). 
Solvent was evaporated at 40 °C under reduced pressure and the dried extracts were each 
resuspended in 1 mL of 50% MeOH. These extracts were cleared by centrifugation and analyzed  
with an LTQ-FT ultra instrument (Thermo Fisher Scientific) connected to a microbore 1100 HPLC 
system (Agilent) using 100 L of extract for each measurement. For detection the UV absorption at 
215 nm was recorded. Separation was achieved using a CC 125/2 Nucleosil 300-8 C18 column 
(Macherey-Nagel) applying the following gradient of water/0.1% trifluoroacetic acid (solvent A) 
and MeCN/0.1% trifluoroacetic acid (solvent B) at a column temperature of 40 °C and a flow rate 
of 0.2 mL/min: holding 2% B for 2 min, followed by a linear increase from 2% to 30% B in 18 min, 
a subsequent linear increase from 30% to 95% B in 15 min and holding 95% B for additional 2 min. 
In both cases, the predicted masses corresponding to the full length lasso peptides were detected. 
Subsequent large scale fermentation and isolation of the novel MccJ25 variants was then performed 
under the tested conditions. After XAD16 extraction, MccJ25 variants were purified by two rounds 
of preparative HPLC (microbore 1100 HPLC system (Agilent) with a VP 250/21 Nucleodur C18 
Htec 5 m column (Macherey-Nagel) at room temperature and a flow rate of 18 mL/min). 
For the first round, the following gradient of water/0.05% formic acid (solvent A) and 
S4 
 
MeOH/0.04% formic acid (solvent B) was used: Linear increase from 40% to 55% B in 30 min, 
followed by a linear increase from 55% to 95% B in 2 min and holding 95% B for an additional 
3 min. The observed retention times were 25.0 min for MccJ25(FRGD) and 27.0 min for 
MccJ25(RGDF). The pooled fractions of each variant were evaporated at 40 °C under reduced 
pressure and reapplied to a second round of purification using the following gradient of water/0.1% 
trifluoroacetic acid (solvent C) and MeCN/0.1% trifluoroacetic acid (solvent D): Linear increase 
from 20% to 40% D in 30 min, followed by a linear increase from 40% to 95% D in 2 min and 
holding 95% D for additional 3 min. The observed retention times were 26.5 min for 
MccJ25(FRGD) and 25.5 min for MccJ25(RGDF). Pure MccJ25(FRGD) was obtained with a yield 
of 0.2 mg/L culture, while pure MccJ25(RGDF) could be isolated with a yield of 4.6 mg/L culture. 
MccJ25(RGD) was produced, isolated and purified as previously described.
4
 The purity of the 
isolated compounds was assessed by using a microbore 1100 HPLC system (Agilent) coupled with 
a 1100 series MSD (Hewlett-Packard). For this, a sample of each compound was separated over an 
EC 125/2 Nucleodur 100 3 C18ec column and checked for impurities. In all instances, the LC MS 
analysis showed the compounds to have a purity that was equal to or even exceeding 95%.  
 
Assessment of the In Vitro Integrin Inhibition by ELISA. The inhibiting activity and selectivity 
of the tested antagonists were determined by using ELISAs based on previously reported methods 
with some optimizations.
5, 6
 
Human integrins αvβ3 and αvβ5 were purchased from Millipore, αIIbβ3 from Enzyme Research 
Laboratories, α5β1 and αvβ3 from R&D Systems. Vitronectin was purchased from Millipore, 
fibronectin from Sigma Aldrich, fibrinogen from Calbiochem and LAP protein from R&D Systems. 
For the integrins αvβ3 and αvβ5 the binding was visualized using a mouse anti-human integrin α-V 
monoclonal antibody for the αv subunit (MAB 1978 purchased from Chemicon) while for α5β1 and 
αIIbβ3 antibodies from BD Biosciences were used (mouse anti-human CD49e for α5β1, mouse 
anti-human CD41b for αIIbβ3). In all cases, anti-mouse IgG-peroxidase from Sigma Aldrich was 
used as secondary antibody, containing a peroxidase conjugate that was employed for the 
visualization and quantification. Peroxidase development was performed by using the substrate 
solution 3,3,5,5’-tetramethylethylenediamine (TMB) from Seramun Diagnostic GmbH and by 
adding 3 M H2SO4 to stop the reaction. 
The absorbance (450, 492 nm) was recorded with a POLARstar Galaxy plate reader (BMG 
Labtechnologies). Every concentration was analyzed in duplicate and the resulting inhibition curves 
were analyzed using OriginPro 7.5G software. The turning point of these curves describes the IC50 
value. Each plate contained either cilengitide or tirofiban as reference compounds.
7, 8
 
Blocking and binding steps were performed with TS buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 
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1 mM CaCl2, 1 mM MgCl2, and 1 mM MnCl2) containing 1% BSA (TSB buffer). After the 
incubation time, washing steps were done with PBST buffer (10 mM Na2HPO4, pH 7.5, 150 mM 
NaCl, and 0.01% Tween20). 
For the αvβ3 assays, a flat-bottom 96-well ELISA plate (from Brand) was coated overnight with 
100 µL of vitronectin (2 µg/mL) in carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) at a 
temperature of 4 °C. After removing the solutions from the plate, the wells were blocked for 1 h at 
room temperature with 150 μL TSB buffer per well. The plate was subsequently washed three times 
with 200 μL PBST buffer per well. Afterward, 4.0 μg/mL of the soluble integrin αvβ3 and a serial 
dilution of the different compounds and a cilengitide control were incubated in the coated wells for 
2 h at room temperature. After washing three times, the plate was treated with each 100 μL of the 
primary antibody (MAB1978, diluted 1:500 in TSB buffer, 1.0 μg/mL) and 100 μL of the secondary 
antibody (anti-mouse IgG-peroxidase, diluted 1:385 in TSB buffer, 2.0 μg/mL) per well for 1 h at 
room temperature. After this treatment, the plate was washed three times and the binding was then 
visualized using TMB. For this substrate, the oxidation reaction was performed for only 5 min and 
the absorbance was measured at 450 nm. IC50 determination was done as explained above. 
For the αvβ5 assays, an appropriate 96-well ELISA plate was coated overnight with 100 µL of 
vitronectin (5 µg/mL) in TS buffer at a temperature of 4 °C. After removing the solutions from the 
plate, the wells were blocked for 1 h at room temperature with 150 μL TSB buffer per well. Plates 
were then washed three times with 200 μL PBST buffer per well. Subsequently, 3.0 μg/mL of the 
soluble integrin αvβ5 and a serial dilution of the different compounds and a cilengitide control were 
incubated in the coated wells for 1 h at room temperature. After washing three times, the plate was 
treated with each 100 μL of the primary antibody (MAB1978, diluted 1:500 in TSB buffer, 
1.0 μg/mL) and 100 μL of the secondary antibody (anti-mouse IgG-peroxidase, diluted 1:770 in 
TSB buffer, 1.0 μg/mL) per well for 1 h at room temperature. Then, the plate was treated with TMB 
and the absorbance was measured as previously described. 
For the α5β1 assays, the flat-bottom 96-well ELISA plate was coated overnight at 4 °C with 100 μL 
of fibronectin (0.5 μg/mL) in carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6). The 
plates were subsequently blocked for 1 h at room temperature with 150 μL TSB buffer per well. 
Afterward, 1.0 μg/mL of the soluble integrin α5β1 and a serial dilution of the different compounds 
and a cilengitide control were incubated in the coated wells for 1 h at room temperature. After 
washing three times, the plate was treated with each 100 μL of the primary antibody (CD49e, 
diluted 1:500 in TSB buffer, 1.0 μg/mL) and 100 μL of the secondary antibody (anti-mouse 
IgG-peroxidase, diluted 1:385 in TSB buffer, 2.0 μg/mL) per well for 1 h at room temperature. After 
this treatment, the plate was washed three times and the binding was visualized with TMB as 
described above. Then, the absorbance was measured at 450 nm and the IC50 values were 
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determined as mentioned before. 
For the αIIbβ3 assays, a flat-bottom 96-well ELISA plate was coated overnight at 4 °C with 100 μL 
of fibronogen (10.0 μg/mL) in carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6). After 
the plates were blocked for 1 h at room temperature with 150 μL TSB buffer per well, 2.5 μg/mL of 
the soluble integrin αIIbβ3 and a serial dilution of the different compounds and a cilengitide as well  
as a tirofiban control were incubated in the coated wells for 1 h at room temperature. The plate was 
then washed three times and subsequently treated with each 100 μL of the primary antibody 
(CD41b, diluted 1:250 in TSB buffer, 2.0 μg/mL) and 100 μL of the secondary antibody 
(anti-mouse IgG-peroxidase, diluted 1:770 in TSB buffer, 1.0 μg/mL) per well for 1 h at room 
temperature. The binding was visualized as described before. 
 
Optimization of MccJ25(RGDF) Production. For production optimization, M63 and M9 minimal 
medium (17.1 g/L Na2HPO4∙12 H2O, 3 g/L KH2PO4, 0.5 g/L NaCl, 1 g/L NH4Cl, 1 mL/L MgSO4 
solution (2 M), 0.2 mL/L CaCl2 solution (0.5 M), pH = 7.0, after autoclaving 10 mL/L glucose 
solution (40% w/v) and 0.2 mL/L vitamin mix (Supplementary Table S2) were added), containing 
17 g/mL chloramphenicol, were tested. For quantification, fermentations were performed in 
500 mL M63 medium for 1 day at 37 °C, in 500 mL M9 medium for 1 day at 37 °C and in 100 mL 
M9 medium for 3 days at 37 °C. Supernatants of these fermentations were extracted as described 
above. The dried extracts were resuspended in 7.5 mL of 40% MeOH, cleared by centrifugation and 
then applied to purification by two rounds of preparative HPLC as described above. In this way, 
pure MccJ25(RGDF) could be obtained in yields of 4.6 mg/L (M63 medium, 1 day at 37 °C), 
10.8 mg/L (M9 medium, 1 day at 37 °C) and 13.5 mg/L (M9 medium, 3 days at 37 °C) culture. 
 
NMR Structure Elucidation of MccJ25(RGDF). The sample for the NMR measurements 
contained 7.0 mg of MccJ25(RGDF) in 250 L of methanol-d3. Spectra were recorded on a Bruker 
Avance 600 MHz spectrometer equipped with an inverse triple resonance 
1
H/
13
C/
15
N probe with 
z-gradient. The sample was filled into a Wilmad 3 mm tube obtained from Rototec Spintec. 
Temperature effects on the structure were surveyed by recording 
1
H spectra at variable 
temperatures. For sequential assignment, DQF-COSY, TOCSY, and NOESY spectra
9-12
 were 
recorded at 298 and 303 K. TOCSY spectra were recorded with a mixing time of 140 ms. NOESY 
spectra were taken with mixing times of 100 and 300 ms. Solvent suppression was fulfilled by using 
excitation sculpting with gradients for DQF-COSY, TOCSY, and NOESY experiments.
13
 1D spectra 
were acquired with 65536 data points, while 2D spectra were collected using 4096 points in the F2 
dimension and 512 increments in the F1 dimension. For 2D spectra 32 transients were used. 
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Relaxation delay was 3.0 s. Chemical shifts were referenced to solvent signal. All spectra were 
processed with Bruker TOPSPIN 3.1. NOE cross-peaks were further analyzed within the program 
Sparky.
14
 
The assignment of 
1
H chemical shifts was fulfilled by using 
1
H – 1H homonuclear correlation 
spectra.
15
 Thus, a combination of DQF-COSY (Supplementary Figure S4) and NOESY 
(Supplementary Figure S5) produced sequential assignments (i.e. all H and NH and their sequence 
in the backbone), and a combination of DQF-COSY and TOCSY (Supplementary Figure S6) 
resulted in assignments of the side chains (Supplementary Table S3). NOE cross-peaks observed in 
the 100 ms mixing time NOESY spectrum at 298 K were assigned and a list of peak volumes was 
obtained within Sparky. On the basis of the peak volumes of the available geminal protons of the 
glycine residues at positions 1, 2, 4, and 13, a manual distance calibration was carefully done with a 
reference distance of 1.78 Å.
16
 The NOE peak volumes were thus converted into distances and used 
as distance upper limits for structure calculation within the program package CYANA 2.1.
17
 
Furthermore, an internal linkage for the isopeptide bond was realized by putting a distance 
constraint of 1.33 Å between the nitrogen atom of Gly1 and the C of Glu8. In this way, 154 
distance constraints were obtained; 58 for the backbone, 35 for long-range interactions and 96 for 
the side chains. Hence, there was an average of 7.0 distance constraints per residue. With the vicinal 
coupling constants 
3
JHNH

, which were measured directly from the amide proton signals in the 1D 
1
H NMR spectra, torsion angles  were calculated on the basis of the Karplus equation optimized 
for  in peptides.16, 18, 19 The conformations of the side chains were established carefully,16, 19, 20 and 
only unambiguous ones were included: His5, Glu8, Phe10, Arg12, and Phe15 with t
2
g
3
, Val6 and 
Asp14 with g
2
t
3
, and Tyr9 and Ser
18
 with g
2
g
3
. For t
2
g
3
, g
2
t
3
, and g
2
g
3
 conformations around the 
C-C bond, the torsion angle 1 was constrained in the range of -60  15°, 180  15°, and 
60  15°, respectively. 
The above mentioned constraints were used in the simulated annealing protocol for the CYANA 2.1 
calculation. The calculation started with 50 random conformers and the resulting structures were 
engineered by the program package Sybyl 7.3 to include the covalent linkage between the nitrogen 
of Gly1 and C of Glu8, followed by an energy minimization using the TRIPOS force field within 
Sybyl 7.3. Thus, on the basis of low energies and minimal violations of the experimental data, a 
family of 15 structures was chosen. These 15 energy-minimized conformers show an average root-
mean-square deviation (RMSD) for the backbone of 0.06 Å and were kept to represent the solution 
structure of the grafted lasso peptide MccJ25(RGDF) (Supplementary Table S4). The quality of 
these structures was evaluated using the program PROCHECK.
21
 The structure has been deposited 
to RCSB Protein Data Bank, with the accession code 2MMT. 
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Molecular Modelling. First, a manual docking of the MccJ25(RGDF) averaged NMR structure in 
the crystal structure of the αvβ3 integrin in complex with cilengetide (PDB code: 1L5G) was 
accomplished. Specifically, we superimposed the coordinates of the Cα carbons within the RGDF 
motif in MccJ25(RGDF) with the corresponding atoms in cilengetide, which was then removed 
from the complex. Subsequently, to mimic the typical interaction pattern of RGD integrin ligands,
22
 
the side chains of Arg12 and Asp14 in the lasso peptide were properly optimized to interact with 
(αv)-Asp218 and with the metal ion at the MIDAS, respectively. The obtained complex was then 
submitted to an over 100-ns MD simulation with NAMD 2.9,
23
 using the ff99SBildn Amber force 
field parameters.
24, 25
 Prior to the MD simulations, the co-crystallized Mn
2+
 ions in the receptor 
were replaced with the more physiologically relevant Mg
2+
 ions, which were also used in the 
biochemical assays. For these ions, we used the parameters recently developed by Allnér and 
co-workers,
26
 which favour an octahedral coordination geometry. The parameters for the isopeptide 
bond between the terminal amine group of Gly1 and the carboxylic side chain of Glu8 in the lasso 
peptide were generated with Antechamber.
27
 Initially, charges were computed using the restrained 
electrostatic potential (RESP) fitting procedure.
28
 The ESP was first calculated by means of the 
Gaussian09 package
29
 using a 6-31G* basis set at Hartree-Fock level of theory, and then the RESP 
charges were obtained by a two-stages fitting procedure using Antechamber.
27
 Missing bonds, 
angles, torsion and improper torsion angle parameters were then generated using the same program. 
The complex was then solvated in a 10.0 Å layer cubic water box using the TIP3P water model 
parameters.
30
 Neutrality was ensured by adding six further Mg
2+
 ions. A 12 Å cutoff (switched at 
10.0 Å) was used for atom pair interactions. The long-range electrostatic interactions were 
computed by means of the particle mesh Ewald (PME) method using a 1.0 Å grid spacing in 
periodic boundary conditions. The RATTLE algorithm
31
 was applied to constrain bonds involving 
hydrogen atoms, and thus an integration 2 fs time step interval could be used. The system was 
minimized and heated up to 300 K while putting harmonic constraints, which were gradually 
released along the thermalization process. The Mg
2+
 ions and their coordination shells were further 
equilibrated for 5 ns during which harmonic constraints of 0.5 kcal/mol were applied to these ions 
and the surrounding residues. Production runs were then performed under NPT conditions at 1 atm 
and 300 K. 
 
Tube Formation Assays. The tube formation assay was performed as previously described.
32
 
Briefly, Matrigel
TM
 (BD Discovery Labware, Bedford, MA) was filled into ‘µ-slide Angiogenesis’ 
chambers (IBIDI, Martinsried, Germany) and incubated at 37 °C. HUVECs were purchased from 
Promocell (Heidelberg, Germany). 12,000 HUVECs were added and stimulated with the respective 
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amount of each compound or left untreated as control reaction. After 16 h, images were taken on a 
Axiovert 200 microscope (Zeiss). The images were analyzed with the tube formation module of 
Wimasis (Munich, Germany). This software is programmed to recognize tubular structures and to 
analyze the area covered by tubes, tube length and network complexity (number of nodes). All 
experiments were done in triplicates (see Supplementary Table S5). 
 
Cell Adhesion Assays. 12,000 HUVECs per well were pipetted into 96-well plates and treated with 
either cilengitide, MccJ25(RGD) or MccJ25(RGDF) at concentrations of 3, 10 or 30 M. In a 
control reaction, the HUVECs were not further treated at all. After subsequent 15 min in a cell 
culture incubator, the plates were washed twice with warm PBS (37 °C). Then, the firmly adherent 
cells were fixed and stained with a crystal violet solution (0.5% crystal violet in 20% methanol). 
After washing and air drying, the bound dye was eluted from the cells with 0.1 M sodium citrate in 
50% ethanol and absorbance was determined at 540 nm with a Sunrise plate reader (TECAN).  
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Supplementary Tables 
 
Supplementary Table S1. Oligonucleotide primers for the generation of the MccJ25 variants via 
site-directed ligase-independent mutagenesis. SLIM overhangs are underlined. Introduced 
mutations are highlighted in bold. 
name sequence 
mcjA_SLIM_FP TTC TAT GGC TGA TAT TCT GAA AGA AGA ACT CTG 
mcjA_SLIM_RP CTC AGG CAC ATG TCC TGC ACC ACC 
mcjA_SLIM_FRGD_Tail_FP TAT TTT TTC CGC GGC GAT ACA CCT ATA TCT TTC TAT GGC TGA TAT 
TCT GAA AGA AGA ACT CTG 
mcjA_SLIM_FRGD_Tail_RP AGA TAT AGG TGT ATC GCC GCG GAA AAA ATA CTC AGG CAC ATG TCC 
TGC ACC ACC 
mcjA_SLIM_RGDF_Tail_FP TAT TTT GTG CGC GGC GAT TTT CCT ATA TCT TTC TAT GGC TGA TAT 
TCT GAA AGA AGA ACT CTG 
mcjA_SLIM_RGDF_Tail_RP AGA TAT AGG AAA ATC GCC GCG CAC AAA ATA CTC AGG CAC ATG TCC 
TGC ACC ACC 
 
 
Supplementary Table S2. M9 Vitamin Mix. 
component amount 
choline chloride 1.0 g 
folic acid 1.0 g 
pantothenic acid 1.0 g 
nicotinamide 1.0 g 
myo-inositol 2.0 g 
pyridoxal hydrochloride 1.0 g 
thiamine 1.0 g 
riboflavin 0.1 g 
disodium adenosine 5'-triphosphate 0.3 g 
biotin 0.2 g 
 ad 300 mL ddH2O
a
 
a
10 M NaOH was slowly added to the resulting suspension until everything was dissolved (pH ~12). 
Afterward the solution was sterile filtered and stored at 4 °C until needed. 
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Supplementary Table S3. 
1
H chemical shifts of MccJ25(RGDF) in methanol-d3 at 298 K. 
AA NH HA HB Others AA NH HA HB Others 
Gly1  7.952 4.229 
3.544 
  Arg12 8.361 4.144 1.885 
1.802 
CH2: 1.625; 1.669 
CH2: 3.203 
NH: 7.410 
Gly2 9.027 4.208 
3.877 
  Gly13 8.492 4.071 
3.541 
  
Ala3 8.543 4.655 1.307  Asp14 8.253 4.663 2.751 
2.648 
 
Gly4 7.776 4.060 
3.493 
  Phe15 8.212 4.936 2.971 
3.203 
H2,6: 7.300; H3,5: 7.300 
His5 7.362 4.710 3.259 
2.920 
H2: 8.710; H4: 7.370 Pro16  4.451 1.891 
1.748 
CH2: 2.070; 1.957 
CH2: 3.868; 3.569 
Val6 8.703 4.687 1.746 CH3: 1.098; 0.848 Ile17 7.820 4.388 1.870 CH3: 0.877 
CH2: 1.454 
CH3: 1.121 
Pro7  4.238 1.807 
1.613 
CH2: 2.200; 1.965 
CH2: 4.130; 3.796 
Ser18 7.415 4.405 4.048 
3.860 
 
Glu8 8.288 4.347 1.764 
1.652 
CH2: 2.002; 1.858 Phe19 8.832 5.442 2.582 
2.539 
H2,6: 6.863; H3,5: 7.060 
Tyr9 7.476 4.498 2.908 
2.675 
H2,6: 6.926; H3,5: 6.618 Tyr20 9.509 4.934 3.024 
2.983 
H2,6: 6.966; H3,5: 6.715 
Phe10 8.093 4.795 2.941 
2.764 
H2,6: 7.020; H3,5: 7.150 Gly21 8.623 3.856   
Val11 8.218 4.237 2.082 CH3: 0.942; 0.942      
 
Supplementary Table S4. Structural statistics for the family of 15 structures selected to represent 
the solution structure of MccJ25(RGDF). 
restraining constraints constraint violations 
total: 183 distance violations, >0.5 Å: 0 
distance, i=j: 78 RMS deviations: 0.02 Å 
distance, i-j=1: 41 dihedral violations, > 5°: 0 
distance, i-j>1: 35 RMS deviation: 1.6° 
dihedral: 29 average pairwise RMS deviation (Gly
2
-Tyr
20
) 
hydrogen bond: 0 backbone atoms: 0.06 Å 
constraints/residue: 8.7 all heavy atoms: 0.40 Å 
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Supplementary Table S5a.  Observed area covered by tubes in the tube formation assays. 
compound concentration experiment 1 experiment 2 experiment 3 mean 
none (control) - 26 22 18 22.0 ±  3.3 
cilengtide 3 M 17 13 11 13.7 ± 2.5 
 10 M 17 12 12 13.7 ± 2.4 
 30 M 12 14 10 12.0 ± 1.6 
MccJ25(RGD) 3 M 17 18 13 16.0 ± 2.2 
 10 M 16 15 11 14.0 ± 2.2 
 30 M 13 14 14 13.7 ± 0.5 
MccJ25(RGDF) 3 M 18 15 13 15.3 ± 2.1 
 10 M 14 14 10 12.7 ± 1.9 
 30 M 14 13 9 12.0 ± 2.2 
 
Supplementary Table S5b. Observed tube length in the tube formation assays. 
compound concentration experiment 1 experiment 2 experiment 3 mean 
none (control) - 12883 10852 9116 10950 ± 1539 
cilengtide 3 M 9241 7443 6321 7668 ± 1203 
 10 M 8463 6943 5898 7101 ± 1053 
 30 M 8542 8645 5284 7490 ± 1561 
MccJ25(RGD) 3 M 9419 10522 7080 9007 ± 1435 
 10 M 9285 7575 6447 7769 ± 1167 
 30 M 7600 7438 6023 7020 ± 708 
MccJ25(RGDF) 3 M 10167 8643 6402 8404 ± 1546 
 10 M 8513 7214 5927 7218 ± 1056 
 30 M 7209 7467 5280 6652 ± 976 
 
Supplementary Table S5c. Number of branching points observed in the tube formation assays. 
compound concentration experiment 1 experiment 2 experiment 3 mean 
none (control) - 68 49 43 53.3 ± 10.7 
cilengtide 3 M 33 24 25 27.3 ± 4.0 
 10 M 29 19 20 22.7 ± 4.5 
 30 M 28 33 11 24.0 ± 9.4 
MccJ25(RGD) 3 M 42 48 25 38.3 ± 9.7 
 10 M 46 33 17 32.0 ± 11.9 
 30 M 30 31 14 25.0 ± 7.8 
MccJ25(RGDF) 3 M 48 43 21 37.3 ± 11.7 
 10 M 38 24 18 26.7 ± 8.4 
 30 M 27 27 20 24.7 ± 3.3 
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Supplementary Table S5d. Inhibition of cell adhesion of HUVECs relative to a control reaction. 
compound concentration experiment 1 experiment 2 experiment 3 mean 
none (control) - 99.4 92.8 107.8 100.0 ± 6.1 
cilengtide 3 M 53.3 55.6 61.7 56.9 ± 3.5 
 10 M 50.6 51.7 54.4 52.2 ± 1.6 
 30 M 53.3 50.6 50.6 51.5 ± 1.3 
MccJ25(RGD) 3 M 76.1 77.8 75.6 76.5 ± 0.9 
 10 M 58.9 65.0 62.8 62.2 ± 2.5 
 30 M 60.0 53.3 61.7 58.3 ± 3.6 
MccJ25(RGDF) 3 M 96.7 83.9 90.6 90.4 ± 5.2 
 10 M 72.2 70.6 75.0 72.6 ± 1.8 
 30 M 65.0 62.2 71.7 66.3 ± 4.0 
 
Supplementary Figures 
 
 
Supplementary Figure S1. (A) The averaged rmsd plot of the Cα carbons within the RGDF motif in MccJ25(RGDF) 
during the production MD run. Prior to the rmsd calculations, trajectory frames were aligned using the coordinates of 
the Cα carbons of the secondary structural elements of the αvβ3 integrin. (B) Time evolution of the distances between 
representative atoms of the amino acids involved in the key MccJ25(RGDF)/αvβ3 interactions described in the main 
text: Asp14 Cγ–Mg2+ ion at the MIDAS (red plot); Arg12 Cζ–(αv)-Asp218 Cγ (black plot); Arg12 Cζ–(αv)-Thr212 Cβ 
(green plot). 
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Supplementary Figure S2. Comparison between the binding poses of MccJ25(RGDF) and cilengetide at the αvβ3 
integrin. The lasso peptide is shown as green cartoon and sticks, while cilengetide is depicted as yellow sticks. The αv 
and β3 receptor subunits are represented as light red and blue surface, respectively. The metal ion at the MIDAS is 
shown as a purple sphere. The crystal structure of the v3 integrin employed in the MD simulation was obtained from 
the protein data bank (PDB code 1L5G). 
 
 
 
Supplementary Figure S3. Superposition between the α5β1 receptor and the αvβ3 integrin in complex with 
MccJ25(RGDF). The lasso peptide is shown as green cartoon and sticks. The α5β1 and αvβ3 (PDB code 1L5G) 
receptors (only key substitutions) are represented as gray and transparent magenta Connolly surfaces, respectively. In 
both receptors, residues important for selectivity are highlighted as sticks. The metal ion at the MIDAS is shown as a 
purple sphere. 
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Supplementary Figure S4. Fingerprint region of the DQF-COSY spectrum of MccJ25(RGDF) in methanol-d3 at 
298 K. 
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Supplementary Figure S5. Section of the NOESY spectrum of MccJ25(RGDF) in methanol-d3 at 298 K and with a 
mixing time of 300 ms. 
 
 
Supplementary Figure S6. Section of the TOCSY spectrum of MccJ25(RGDF) in methanol-d3 at 298 K and with a 
mixing time of 140 ms. 
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